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ABSTRACT 
 
The complex and multifaceted nature of Alzheimer’s pathology has significantly hindered the 
discovery and development of viable therapeutics, let alone the cause and initiation of the disease. Over the 
past century, what was known as the ‘one drug, one target’ approach has only recently shifted to the 
multifunctional ideology. By investing, discovering and developing therapeutic options with multi-
targeting capabilities, not only would patient outcomes improve, but the road to multi-targeting therapeutics 
can help shed new light on Alzheimer’s disease (AD) pathogenesis. In order to undertake the 
multifunctional ideology, viable and interconnecting targets need to be identified.  
As such, the work presented herein employed computer-aided drug design (CADD) to develop 
bicyclic small-molecules against three key targets of AD pathology – the cholinesterases (AChE and 
BuChE), amyloid-β (Aβ) aggregation and reactive oxygen species (ROS) generation. A chemical library of 
~ 140 derivatives, based on a quinazoline (Qnz) or a pyridopyrimidine (Ppd) ring scaffold, was generated to 
gather structure-activity relationship (SAR) data in the target-specific assays with the goal of identifying 
lead multi-targeting candidates for future optimization and pre-clinical assessment. Specifically:  
 
Chapter one provides the background information and literature survey with respect to the statistics of 
AD, the current hypotheses with a keen focus on cholinergic dysfunction and amyloid toxicity, and an 
overview of the interconnectivity observed with each of the hypotheses put forth in relation to disease 
pathology and progression.  
 
Chapter two surveys the utility of the quinazoline and pyridopyrimidine scaffolds in medicinal 
chemistry and ties that with previously utilized templates and those found in marketed therapies to develop 
a AD-specific hypothesis bearing a multi-targeting focus. From that survey and hypothesis, a chemical 
design and development plan was generated to yield the sought-after chemical derivatives.  
 
 
 
	   iv	  
Chapter three is dedicated to the design, development and evaluation of the first series of compounds, 
which were based on a Qnz-scaffold and featured a dimethoxybenzylamine group at the C4-position (2-
substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines). This series contained 13 derivatives with 
varying functional groups at the C2-position. The general observations from this collection revealed the 
lack of inhibitory activity toward BuChE and Aβ42, while AChE and Aβ40 targeting were considered 
moderate. The most active AChEI and ROS scavenger across the research program was discovered within 
this series. This chapter also included the bulk of synthetic and biochemical assessment 
protocols/methodologies.  
 
Chapter four describes the design, development and evaluation of 2-substituted-N-benzylquinazolin-
4-amines. This was primarily a measure of the 3,4-dimethoxy moiety’s validity in dual-ChE targeting and 
anti-amyloid aggregation potential. This series also contained 12 derivatives with varying functional groups 
at the C2-position as well as one regioisomer. The general observations from this collection revealed on par 
activities toward AChE inhibition with slight improvements toward BuChE inhibition for some derivatives. 
In addition, the overall Aβ40/42 inhibitory profiles were also improved, although the ROS scavenging 
derivative was not as potent compared to its dimethoxy counterpart. That said, the first nanomolar Aβ40 
inhibitor was identified within this series so was the first low-mid micromolar Aβ42 aggregation inhibitor.  
 
Chapter five describes the design, development and evaluation of 2-substituted-N-(3,4-
dimethoxyphenethyl)-quinazolin-4-amines. This was primarily a measure of the additional methylene 
group’s validity in dual-ChE targeting and anti-amyloid aggregation potential. This was a larger series with 
12 derivatives carrying the same functional groups at the C2-position as those in Chapters 3 and 4, a 
regioisomer and an additional 12 derivatives. These additional derivatives explored the addition of a 
chlorine atom on the Qnz-scaffold at three positions (C6-, C7-, or C8-) with the top 4 C2-groups to expand 
the SAR data. With respect to Chapter 3 counterparts, the general observations from this collection 
revealed on par activities toward AChE inhibition with slight improvements toward BuChE inhibition for 
some derivatives. Mixed outcomes were observed with respect to Aβ40/42 targeting capacities, while the 
weakest ROS scavenger was identified within this series of derivatives. More so, the outcomes of the 
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chloroquinazoline counterparts were not as promising as anticipated with respect to dual ChE and dual 
Aβ40/42 targeting, although some exceptions do apply. Interestingly, this series revealed some of the first 
potent and dual, non-selective Aβ aggregation inhibitors, along with the selectivity toward Aβ42 with 8-
chloro-based quinazoline derivatives.  
 
Chapter six describes the design, development and evaluation of 2-substituted-N-
phenethylquinazolin-4-amines. This elicited a dual measure of the validity of the 3,4-dimethoxy moiety as 
well as the additional methylene linker in dual-ChE targeting and anti-amyloid aggregation potential with 
respect to the counterparts in Chapters 4 and 5. This series included the original 12 functional groups at the 
C2-position, two regioisomers and the additional 12 chloroquinazoline-based derivatives. With respect to 
Chapter 4 and 5 counterparts, the general observations from this collection revealed on par activities toward 
AChE inhibition with significant improvements toward BuChE inhibition for some derivatives. Mixed 
outcomes were observed with respect to Aβ40/42 targeting capacities, while the ROS scavenger within this 
series was more potent compared to its counterparts in Chapters 4 and 5. More so, the outcomes of the 
chloroquinazoline counterparts were more promising with respect to dual ChE and dual Aβ40/42 targeting, 
when compared to those in Chapter 5. Besides revealing some potent and dual, non-selective Aβ 
aggregation inhibitors, the most potent BuChEI was identified within this series. 
 
Chapter seven describes the design, development and evaluation of 2,4-disubstituted 
pyridopyrimidines as rational counterparts to leading derivatives from Chapters 5 and 6. This series 
included 10 derivatives and was developed to assess iron chelation potential and assess Qnz vs. Ppd. SAR 
data. The derivatives here did not impart significant improvements toward AChE, but as expected, were 
inactive toward BuChE. Activity toward Aβ40 was of mixed outcomes, while improvements toward Aβ42 
inhibition were observed.  Lastly, chelation capacity was considered weak to moderate at best.  
 
Chapter eight describes the design, development and evaluation of monosubstituted quinazoline-2,4-
diamines to further investigate the regioisomeric impact on Aβ40/42 targeting as an expansion on two 
isomeric pairs from Chapters 4 and 6. This series discussed 30 isomeric derivatives (15 C2-amino, and 15 
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C4-amino) in comparison to the previously disclosed isomers. The general observations from this 
collection revealed that C2-amino-based isomers were more effective at targeting Aβ40 (compared to their 
C4-amino isomers), while the opposite was true with respect to Aβ42. The most potent Aβ40 aggregation 
inhibitor across the collective library was identified within this Chapter.  
 
Chapter nine provides closing conclusions and a future works/outlook plan. 
 
 
 
* Graphical Abstract 
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CHAPTER 1 
  Background on Alzheimer’s Disease   
 
1.1. Introduction 
 
We are all unique – not only by virtue of our genetic makeup, but also by way of our neuronal 
framework and networking. Individuality has much to do with what one projects on the exterior as it is with 
what they captivate within. A life’s worth of memories and experiences define our cognitive fingerprint and 
elicit one of our fabrics of humanity. While cancer is portrayed as a hijacker of a cell’s proliferation 
mechanisms, Alzheimer’s disease (AD) can be painted, as a hijacker of one’s conscious and subconscious 
mind – an eraser of a substantial aspect of your self-being.  
With initial documentation of its pathology dating back to 1907,1, 2 a growing prevalence and a lack of 
viable cures or therapeutic options, AD has manifested a strong socioeconomic holding and an 
overwhelming healthcare burden on communities across the globe. To appreciate the severity of this 
neurodegenerative disorder, consider the following: (a) According to the World Health Organization 
(WHO), nearly 48 million people worldwide are living with AD and that number is anticipated to escalate 
to about 76 million by 2030; (b) In Canada alone, the Alzheimer’s Society of Canada estimates the 
combined annual direct and indirect costs associated with AD to be upwards of $33 billion; (c) In the 
United States, the Alzheimer’s Association estimates that a new patient develops AD every 67 seconds and 
(d) the dollar amount spent on AD research accounts for less than 0.4% of the amount spent on the 
disease’s presumed “treatment”.3-5 
The challenges of tackling the AD dilemma are inclusive, with the lack of early detection and an 
overall miscomprehension of disease pathology being chief culprits. With the former, the onset of dementia 
symptoms typically point to a lost opportunity for any level of successful intervention as progression is 
well underway, while the latter simply points to the overall complexity of the neuroscience field and its ties 
with the normal aging process that can mask early-warning signs of dementia.6-8 As it stands now, an 
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Alzheimer’s diagnosis is ominously a death-sentence – no cure, no viable treatments and a losing uphill 
battle. 
In a general sense, AD is the progressive loss of brain mass, due to neuronal cell death, that presents in 
the form of dementia, loss of cognitive, and eventually, motor function. Patients lose memory recall 
capability, the ability to perform typical daily tasks, the ability to connect and interact with surrounding 
environments and, ultimately, symptoms of depression and isolation surface leading to poorer health 
status.9-11 AD patients typically succumb to death as a result of various infections, rather than a direct cause 
of dementia insults.12 While AD generally afflicts elderly populations worldwide, it is not a gender-specific 
disorder and a number of genetic pre-dispositions expand its outreach to middle-aged patients as well.13-17   
The road to understanding AD pathology has been charted with more of a retrosynthetic (or reverse 
discovery) tactic – starting with the end outcomes and backtracking to potential causes of said outcomes. In 
fact, back in 1906, the post-mortem discovery of dense proteinaceous deposits in the brain of what is now 
known as the first AD patient, established one of the quintessential hallmarks of AD pathology.1, 2, 18, 19 
Further classified as amyloid plaques (originating from the Aβ peptide) and neurofibrillary tangles (NFTs, 
originating from the tau peptide), these proteinaceous deposits still captivate a substantial amount of 
research focus in AD.20-23 Clinical assessments also linked the observed regression in cognitive ability with 
the decline of acetylcholine (ACh, a cholinergic neurotransmitter) levels in the brains of AD patients.9, 24-26 
From these conclusions, amongst many others, a number of disease hypotheses were put forth in an attempt 
to explain disease progression and to identify potential interventions. Primary hypotheses included 
cholinergic dysfunction,9, 24-26 amyloid-β,16, 20, 27-30 tau protein28, 31-37 and the multipronged reactive oxygen 
species (ROS),38-40 with the foremost being the oldest and most fruitful at generating marketed AD 
therapeutics (e.g. Aricept™, Reminyl™ and Exelon™). That said, AD is still a cureless disorder and the 
aforementioned therapeutics merely offer symptomatic relief without targeting neither disease initiation nor 
progression.24, 41, 42 
Therein lies one of the significant setbacks toward curing AD. It was not until recently that the 
research community was devoting most of its efforts with the “one-drug, one target” ideology.  It is that 
ideology that generated currently marketed therapeutics but then again, they are not true treatments. With a 
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disease as complex and as misunderstood as AD, a multidimensional approach does not simply become an 
option but rather a mandate. By shifting focus toward multi-targeting and multifunctional therapeutics, not 
only are better outcomes anticipated but it could also be argued that through the development and discovery 
of such candidates, new light could be shone on the pathological framework.43-50 
The good news is that this paradigm shift is well underway as more and more research endeavors are 
charting the relatively untested waters of multi-targeting agents as potentially being the next generation of 
AD treatment options.  
	  
1.2. The Cholinergic Dysfunction Hypothesis 
 
One of the key factors of maintaining a vehicle in motion is having enough gasoline flowing to the 
engine – a similar principle applies to cholinergic function and in that scenario, the cholinergic “gasoline” 
is ACh. As one of the oldest hypotheses put forth to explain the clinical assessments tied with deteriorating 
cognitive ability, the cholinergic dysfunction premise is centered on ACh, its generation, actions in the 
CNS and metabolism.  
 
1.2.1. Cholinergic Neurotransmission  	  
There are a number of critical players that collectively contribute to the functionality of the cholinergic 
system. The neurotransmitter ACh is synthesized from acetyl-CoA and recycled choline by choline 
acetyltransferase (ChAT) and is stored in vesicles, which are released from the presynaptic neurons upon 
depolarization from a stimulus. Upon ACh release, it binds to nicotinic (nAChR) or muscarinic 
acetylcholine receptors (mAChR) to elicit the appropriate physiological response and the remaining ACh 
molecules are rapidly hydrolyzed by the cholinesterases (AChE or BuChE) to acetic acid (AcOH) and 
choline (a substrate for the choline transporters on the presynaptic neurons) (Figure 1).9, 26, 51 
 	   4 
Under typical circumstances, the activity of the cholinesterases (ChEs) is a security measure against 
neuronal overstimulation. Chemical nerve agents, for example, induce overstimulation of the cholinergic 
system by paralyzing the ChEs, leading to an overwhelming concentration of ACh in the synapse.52  
 
 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of cholinergic neurotransmission mediated by acetylcholine (ACh). *Not drawn to 
scale. 
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Transferring that concept to AD pathology, as the number of ACh-producing neurons are declining, 
developing reversible ChE inhibitors was meant to restore or maintain the ACh levels in the synapse of AD 
patients to alleviate some of the memory deficits – a symptom, not a cause of AD. 
 
1.2.2. The Cholinesterase (ChE) Enzymes	  
 
While the cholinesterases play a number of diverse physiological roles, in the context of AD and the 
cholinergic dysfunction hypothesis, they primarily function to eliminate unbound ACh in the cholinergic 
synapse by hydrolyzing the neurotransmitter to acetic acid and choline, which is recycled back to pre-
synaptic neurons. While the ChE isoforms (AChE/BuChE) only share about 50% sequence identity, their 
structure homology is relatively similar.53, 54 Moreover, the ACh hydrolysis mechanism is shared and relies 
on the presence of a catalytic triad (serine, histidine and glutamic acid) with the serine hydroxyl group 
acting as the nucleophile. Upon binding of ACh, a tetrahedral intermediate is formed, where its eventual 
collapse releases choline leaving an acetylated serine residue, which is rapidly hydrolyzed back to the 
active state (Figure 2).55-57 
Due to their active site variances (discussed later), their substrate specificity is unique. While AChE is 
capable of hydrolyzing ACh at near diffusion limits, BuChE is not as fast but it has a larger substrate pool. 
These variances also translate to the design of cholinesterase inhibitors (ChEIs) and explain the difficulty of 
successfully developing a dual, potent and non-selective ChEI.58-60 A brief examination of previously and 
currently marketed ChE-based AD therapeutics, demonstrates that none are ideal with respect of effectively 
targeting both ChEs and at possessing multi-targeting capabilities (Figure 3).  
The concept of dual-ChE targeting has more to do with disease progression than simply a mere 
ambition. Moreover, the overall distribution and arrangements of the ChEs in and outside of the CNS play a 
role in their implications with AD.  
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Figure 2: Hydrolysis mechanism of ACh via the ChE catalytic triad – serine, histidine and glutamic acid. Residue 
numbering reflects that of human AChE (hAChE). 
 
 
Figure 3: Comparison of first-generation and currently marketed ChEIs.  	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1.2.2.1. Acetylcholinesterase (AChE)	  
 
As the primary cholinesterase, AChE represents the prime target with respect to the cholinergic 
dysfunction hypothesis. In humans, this hydrolase is encoded by a single gene (ACHE), located on 
chromosome 7, which takes on two major forms based on alternative splicing. On the surface of 
erythrocytes, AChE is present as a dimer anchored to GPI (glycophosphatidylinositol), while in the CNS it 
is present as a tetramer that is either anchored to PRiMA (proline-rich membrane anchor) at the synapses or 
to ColQ (AChE-associated collagen) at the neuromuscular junctions.54, 61 
 
	  
 
Figure 4: Active site outline of hAChE (1B41) showcasing the catalytic triad (green), acyl pocket (turquoise), anionic 
pocket (purple) and peripheral anionic site (PAS, red). Hydrogen atoms were removed to enhance clarity. 
 
With respect to the core of this ChE, its active site is located at the bottom of a 20Å gorge that is lined 
with aromatic residues (tryptophan and tyrosine) at the entry site creating a bottleneck-like conformation 
that is believed to contribute to AChE’s specificity. The active site’s catalytic triad (green residues in 
Figure 4) work in tandem to hydrolyze ACh once bound and stabilized by the anionic pocket (primarily 
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composed of W86, purple). The phenylalanine residues of the acyl pocket (F295 and F297, turquoise 
residues) are essential for stabilizing the tetrahedral intermediate formed as a result of the nucleophilic 
attack on the ACh ester carbonyl. The discovery of a secondary “back-door” channel was believed to aid in 
the displacement of water molecules, which are crucial for hydrolyzing the acetylated serine residue and 
further attest to the astonishing ACh hydrolysis rates observed.54, 57, 58, 62-66 
Another noteworthy mention regarding AChE is what is typically referred to as a peripheral anionic 
site (PAS) that is comprised of a number of tryptophan and tyrosine resides (more importantly W286, red 
residue).62, 67, 68 The PAS, part of the active site gorge entry, has been well documented to act as a seeding 
facilitator for Aβ-peptides to form higher-order aggregates and highly toxic AChE-Aβ complexes.69, 70 The 
elevated toxicity from these complexes is a result of their close proximity to many post- and pre-synaptic 
membrane proteins by virtue of the anchorage of the synaptic AChE isoform via PRiMA. Those findings 
gated the focus of ChE inhibitor development toward drug candidates featuring PAS-binding moieties – 
these candidates, which greatly focused on tacrine-based hybrids, were generally referred to as bivalent 
inhibitors (Figure 5).71-79  
 
Figure 5: Comparison of active-site bound vs. dual-binding/bivalent inhibitors (yellow) of hAChE (PBD ID: 1B41). 
Hydrogen atoms were removed to enhance clarity. The PAS highlighted with Trp286 (red) and the active site 
highlighted with Trp86 (purple). 
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The downside of this approach is that to achieve bivalent binding, while maintaining strong inhibition 
at the catalytic triad, meant that these hybrid candidates were large in size and very hydrophobic in nature, 
which explains why no such hybrid/bivalent candidates ever made it through preclinical studies.  
 
 
1.2.2.2. Butyrylcholinesterase (BuChE)	  
 
Unlike AChE, this pseudocholinesterase (secondary ChE) is typically not the primary target within the 
general cholinergic dysfunction hypothesis. That being said, it is still capable of hydrolyzing ACh and it 
does hold a relatively important ranking with respect to later stages of AD progression.  
A single gene located on chromosome 3 encodes for this pseudocholinesterase and, just like AChE, 
alternative splicing yields various forms. With its wider distribution throughout the body – present in 
plasma, liver and the CNS – and more substrate capacity, BuChE has been suggested to play more of a 
general hydrolase with some detoxifying roles like the hydrolysis of cocaine and scopolamine. In plasma, 
BuChE is presented as a soluble tetramer while a combination of both soluble dimers/tetramers can be 
found in association with glial and neuronal cells.54, 80  
The overall architecture of BuChE resembles many aspects found in AChE; however, a number of key 
differences do exist. Although the enzyme’s catalytic triad is also 20 Å below the enzyme surface, the entry 
to that gorge is far less restrictive as the degree of aromatic residues in that region is far less than what is 
found in AChE. While the anionic pocket also contains a tryptophan residue (W82, purple, Figure 6), the 
acyl pocket region consists of non-aromatic residues (L286-V288) that account for BuChE’s wider 
substrate pool. With a less hindered gorge entry and acyl domain, the overall volume capacity of BuChE is 
approximately 200Å3 larger compared with AChE. Although BuChE is lacking a PAS at its gorge entry, 
some studies suggested its association with neurotoxic aggregates as part of an inflammatory response, 
although the underlying details are not known.58, 59, 62, 81, 82 
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Figure 6: Active site outline of hBuChE (1P0I) showcasing the catalytic triad (green), acyl pocket (turquoise), anionic 
pocket (purple) and entry site (red). Hydrogen atoms were removed to enhance clarity. 	  
Under typical circumstances, AChE is the principle ACh-degrading enzyme. However, as the 
neuronal cholinergic mass shrinks with AD progression, the abundance of AChE declines and that is when 
BuChE’s presence in the CNS sparks to take-on ACh metabolism. This increase in BuChE levels may not 
necessarily be an up regulation of its expression but merely a result of an inflammatory response as CNS-
derived BuChE is typically associated with glial cells. That shift in the ChE ratio with disease progression 
constitutes the mandate of developing dual ChEIs in an effort to better manage patient symptoms at various 
stages of AD.83, 84 
 
1.2.3. Hypothesis Summary 
 
The cholinergic dysfunction hypothesis is one of the oldest ever put forth to describe the pathology of 
AD. All factors considered, however, this hypothesis merely outlines the cause of dementia symptoms but 
not necessarily the roots of disease initiation. Other pathological routes are compromising the integrity of 
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the cholinergic branch thus shrinking the neuronal mass occurs, which disrupts the neuronal framework, 
reduces ACh-producing neurons and collectively, yields the dementia outcomes observed, amongst other 
symptoms.   
That said, the ChEs are still considered valuable targets for developing the next generation of anti-
dementia medications but more so, should be part of any well-rounded multi-targeting research platform as 
they are implicated in other hypotheses of the AD pathogenesis tree (Figure 7). 
 
 
Figure 7: Summary of cholinergic dysfunction in AD progression. 	  
1.3. The Amyloid-β (Aβ) Hypothesis 
 
If the cholinergic dysfunction hypothesis were to be portrayed as a DeLorean DMC-12, then the Aβ-
hypothesis could be depicted as the Camaro contrast – the DeLorean was a star in its prime but now, it’s 
more of a figurative/collectable icon, and while the Camaro had its followers and fan club back then, it 
went off-grid for a while but recently made a stunning return and re-gained the attention of old and new 
fans. 
What truly primes the Aβ-hypothesis is its intricate manifestation and interplay within the AD 
pathogenesis hierarchy. Unlike the cholinergic dysfunction hypothesis, Aβ-specific pathology has the 
potential, on some level, of mitigating the upstream consequences leading to neuronal cell death. The 
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hypothesis itself is centered on the 40–42 amino acid-long amyloid- β (Aβ) peptide, its generation, 
function, metabolism and off-course neurotoxic potentials, but before the main event, let’s highlight the 
origin story.  
	  
1.3.1. Amyloid Precursor Protein (APP) 
 
As the name suggests, the amyloid precursor protein (APP) is the parent peptide from which Aβ is 
released, under a specific metabolic sequence discussed in the proceeding section. The highly-conserved 
gene encoding for APP is located on chromosome 21 and, with various splicing arrangements, the 
translated peptide can vary largely from ~ 365–770 amino acids in length with three particular isoforms 
(APP695, APP751 and APP770) holding stronger interests in neuronal synapses.29, 85, 86 A noteworthy mention 
regarding those three isoforms, both APP751 and APP770 contain a KPI (Kunitz Protease Inhibitor) domain, 
while APP695 (the most predominant form expressed in neurons) lacks said domain.85, 86 While the primary 
role of APP is not fully understood, a number of key roles like cell adhesion, neurite growth and iron 
transport, to name a few, have been proposed.29, 87, 88  
The APP, as shown in Figure 8, has a larger extracellular (N-terminal) domain as compared to its 
intracellular (C-terminal) domain. The N-terminal domain is comprised of the E1, containing a conserved 
metal binding motif and a growth factor-like domain, and E2 domains. The KPI domain, again only found 
in the larger APP isoforms, divides the E1 and E2 domains and two key glycosylation sites are located 
downstream of the E2 domain. With respect to the amyloid-β placement within APP, a larger component of 
its sequence exists extracellularly with ~ 30% of the sequence being embedded within the transmembrane 
domain.16, 17, 86, 89-92  
Mutations within the APP gene, specifically those surrounding the amyloid sequence domain, can 
promote or exacerbate the development of AD by increasing the overall production of Aβ-peptides. The 
well characterized Swedish, Flemish, Dutch, Florida and London APP mutations (Figure 8) do in fact alter 
APP processing pathways in AD-favourable mechanisms. On the other hand, a rare mutation identified 
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within Icelandic communities has been shown to steer APP metabolism away from pathological Aβ-peptide 
production.93, 94 These mutations don’t include other factors such as Down’s syndrome (trisomy 21) and 
Presenilin-1 and -2 (PS1, PS2) mutations that are also linked to disrupting the APP processing balance.16, 89, 
90  
 
 
Figure 8: Schematic of APP structure and currently identified mutations that enhance or hinder AD pathology via the 
amyloid-β hypothesis. Numbering is based on APP770 isoform. *Not drawn to scale. 	  
1.3.2. APP Metabolism and Processing Pathways 
 
As with countless biological system synergies, when harmony and homeostasis are disturbed, 
undesirable consequences arise in multifaceted manners. The affiliation of APP with the amyloid-β 
hypothesis is not a direct correlation per se but more of a disruption in the metabolism of APP that result in 
a shift toward AD pathogenesis.  
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In a general context, one of two primary secretase enzymes dictate the fate of APP metabolism, while 
a third is simply solicited to “finish the job” or in other words, is influenced by the actions of upstream 
secretases. The alpha-gamma duo (α-secretase and γ-secretase) constitutes the non-amyloidogenic, non-
pathological metabolic stream, while the beta-gamma duo (β-secretase and γ-secretase) elicits 
amyloidogenic (Aβ-release) metabolic outcomes (Figure 9).90, 95, 96 If things were simply presented as 
above, then the solution becomes quite straightforward – disable the beta-gamma duo, or just β-secretase 
for that matter and no Aβ is formed, right? 
 
 
Figure 9: Schematic of APP metabolism via the non-amyloidogenic route (left) or the amyloidogenic route (right). 
*Not drawn to scale. 
 
Unfortunately, it is not quite as simple as it may appear. While APP is strongly predicted to engage in 
a number of neuronal functions, it is under a constitutive secretory pathway due to its short half-life and 
ongoing secretase-based metabolism.86 Of its two metabolic fates, the non-amyloidogenic processing route 
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(via α- and γ-secretase) is the most dominant form under typical circumstances. That process, initiated by 
α-secretase, cleaves APP near the surface of the membrane (between K687 and L688 – APP770 numbering) 
generating a large soluble peptide (sAPPα) and an 83-amino acid C-terminal fragment (CTF83), while 
disrupting Aβ-fragment sequence.97-99 The resulting CTF83 is processed by γ-secretase releasing the APP 
intracellular C-terminal domain (AICD) and a small 3kD peptide (p3) (Figure 9).17, 86, 89, 90 On the other 
hand, the amyloidogenic metabolism of APP, via of β- and γ-secretase, is of greater interest with respect to 
AD pathology as the full Aβ1-40 /42 peptide is liberated with significant potential of inducing neurotoxic 
outcomes. The β-site APP cleaving enzyme (BACE or β-secretase) severs APP further upstream compared 
to the α-secretase cleavage site. The bond cleavage between M671 and D672 (APP770 numbering) generates 
a large soluble peptide (sAPPβ) and a 99-amino acid C-terminal fragment (CTF99). At this point, the full 
Aβ-fragment sequence is still within the CTF99 fragment and it's the action of γ-secretase (between 
A713/W714 or V711/I712) that releases the AICD with the undisrupted Aβ1-42 or Aβ1-40 peptide, 
respectively (Figure 9).17, 100-103 
Putting aside the consequences of Aβ-peptide alone for now, let’s briefly examine the outcomes 
related to the other metabolites of APP. For starters, the sAPPα fragment from the non-amyloidogenic 
pathway has been reported to enact neuroprotective benefits (via some regulatory roles with kinases like 
CDK5 and GSK-3β),85, 104, 105 modulate/restrict the activity of β-secretase106 and support neuronal 
plasticity.95, 98, 107, 108 The role of the truncated Aβ-peptide (p3, released from CTF83), however, is a bit of 
mystery. While it does not aggregate in an Aβ-type fashion, some studies have shown that p3 is capable of 
forming deposits/lesions, inducing apoptosis and inflammatory cytokines,95, 109 while others, 
acknowledging those roles, also suggesting some potential modulation of the full length Aβ-peptide itself 
via p3.110 With respect to the sAPPβ fragment from the amyloidogenic pathway, it is surprisingly not as well 
characterized or studied as its alpha-relative. It may possess some level of a neurotrophic factor but it is far-
less active compared to sAPPα;95 however, other reports showcase it as not being a neuroprotective entity at 
all.85 Lastly, the AICD (a highly conserved APP domain and a shared proteolytic product of both APP 
metabolic pathways) is believed to act as a transcriptional regulator as it is transported to the nucleus after 
CTF83/99 processing via γ-secretase.111 A number of studies have implicated the AICD with pro-apoptotic 
mechanisms, activation of GSK-3β transcription, other pro-AD pathologies111-114 but also some anti-Aβ 
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activities,115 which points to a knowledge gap regarding the full discourse of APP metabolism. The AICD 
also contains a key threonine residue (T668) that is susceptible to phosphorylation. The phosphorylation 
state of this residue also plays an important role in APP localization and its ability to interact with different 
adaptor proteins. As such, it is not surprising to observe high levels of phosphorylated T668-APP in AD 
patients compared to healthy/control groups suggesting a role for this residue in AD pathology.86, 114 
As it looks, the APP has a lot more going on besides simply carrying the Aβ–fragment and there is a 
lot more to be discovered about its regulation, its function as a whole and the function of its metabolites.  
 
1.3.3.  The Aβ Peptide: Structure, Function and Clearance  
 
Now that the origins of the Aβ-peptide have been described, it’s time to hone in on the primary target 
that defines and captivates the amyloid-β hypothesis.  
The final processing of CTF99 by γ-secretase can release Aβ-fragments ranging from 34 to 43 amino 
acids long, with the Aβ40 being the more commonly liberated product and Aβ42 being the most toxic 
form.116 The native peptide, despite its size, contains a number of important domains that implicate it in AD 
pathology.  
 
 
Figure 10: Amyloid-β sequence showcasing the metal-binding domain and amyloidogenic cores.  
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The metal-binding domain, consisting of three histidine residues (H6, H13 and H14; marked in blue in 
Figure 10), is known to coordinate with copper and iron metals – an interaction that is documented as a key 
contributor to the increase in the redox chemistry within the brain that generates ROS.117-120 Besides the 
metal-binding domain, the Aβ-peptide contains a number of hydrophobic domains that naturally drive its 
aggregation propensity. The KLVFFA domain, shown in red in Figure 10, is one of the most studied 
domains on the Aβ-sequence as it is the driver of oligomer formation – the early stages of aggregation that 
produce the most toxic form of Aβ.121, 122 Downstream of the KLVFFA region, closer to the C-terminal end, 
exists a larger stretch of hydrophobic domains (Figure 10) that are implicated in the higher-order 
aggregates of Aβ that facilitate the maturation of oligomers to protofibrils.123, 124 
It’s noteworthy that the Aβ-peptide itself, as a stand-alone monomer, is not toxic. In fact, non-AD 
patients produce Aβ on a regular basis, especially considering that the amyloidogenic APP pathway is 
active in non-AD patients as well. Under typical physiological conditions (and with proper regulatory 
control), Aβ-peptide concentrations hover around the picomolar (pM) scale with rate of clearance roughly 
at 1.1-fold higher than the rate of generation.125, 126 At that concentration, the monomeric peptide serves a 
number of physiological functions, supported by neuronal culturing work, including neuronal support/ 
growth and ties to glucose metabolism.127-129 
A big piece of the puzzle here has to deal with post-production handling and clearance of Aβ-
peptides. Upon its release, is either engaged in one of its physiological functions, targeted by a variety of 
peptidases for degradation or trafficked outside of the brain’s extracellular space. With respect to enzymatic 
degradation, neprilysin and insulin-degrading enzyme (both being zinc-binding proteases) are some of the 
more commonly affiliated peptidases. Transport of soluble Aβ-peptides out of the interstitial fluid can 
occur by bulk flow or by receptor-mediated efflux across the blood-brain barrier (BBB) into the 
bloodstream. The former, is a very slow process that accounts for 10-15%, while receptor-mediated efflux 
can occur via lipoprotein receptor-related protein (LRP) or ATP-binding cassette transporter p-glycoprotein 
(p-gp).130-132  
Under normal conditions and circumstances, the Aβ-peptide is being produced at physiologically 
relevant rates and concentrations and is either cleared via peptidase- or microglial-degradation or removed 
out of the extracellular space, across the BBB, to the bloodstream. As mentioned earlier, the amyloid 
 	   18 
hypothesis is based on the disruption in the management of Aβ-peptide production and post-production 
handling. A complex cascade of biochemical events occurs where the ratio of Aβ-peptide production to its 
clearance is hindered, resulting in a growing population of Aβ monomeric species. It is noteworthy that 
most amyloid-degrading enzymes (ADEs) were reported to have decreased levels of activity/expression in 
aging and AD brains, while the efflux mechanisms become greatly compromised with the increased Aβ-
peptide load. The situation gets worse with the presence of receptor for advanced glycation end products 
(RAGE) as it works against efflux mechanisms by funneling Aβ from the blood stream into the brain’s 
extracellular space.131, 132 It is that offset in regulatory balance that alters Aβ-peptide structure and behavior 
charting a path toward neurotoxic outcomes and engaging in positive feedback loops that propagate disease 
progression and downstream pathogenesis (Figure 11). 
 
 
 
Figure 11: Reduction of amyloid-β degradation (via peptidase activity) and clearance mechanisms (via efflux 
receptors) propagating AD pathogenesis by increasing the amyloid-β load in the extracellular space. *Not drawn to 
scale. 
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1.3.4. Aβ Aggregation and Toxicity Mechanisms 
 
It is not quite clear whether an event upstream of Aβ production sparks the imbalance between 
production and clearance pathways resulting in higher Aβ concentrations in the brain or if it is Aβ alone 
that disrupts that delicate balance, in a positive feedback manner, to propagate itself. A large part of the 
uncertainty here (and elsewhere along the pathology tree) has to do with the complex feedback mechanisms 
that regulate every aspect of this hypothesis, from APP to APP metabolites including Aβ itself and the 
downstream pathways.  
Nonetheless, by glancing at the right-hand side of Figure 11, it is evident that the degradation and 
clearance mechanisms are crumbling and the concentration of Aβ has exceeded the physiological picomolar 
range. While concentration has a key role to play in the aggregation pathway, it is not a stand-alone 
contributor. The native Aβ-peptide takes on a helix-kink-helix arrangement that is initiated and maintained 
by the activity of molecular chaperons (e.g. heat-shock protein 70 – Hsp70). The regulatory activities of 
molecular chaperones, along with that of the ubiquitin-proteasome system, are crucial to ensuring an 
aggregate-free environment. Unfortunately, both of these mechanisms face the same fate as the ADEs and 
efflux receptors, which quintessentially generate the “perfect storm” of AD amyloidosis that starts with the 
misfolding of the native Aβ-peptide (Figure 12).133-136 
At this point, the misfolded Aβ monomer, while non-toxic, has a very high propensity of self-
association (self-induced aggregation) and that is when the floodgates of neurotoxicity are open. Recall that 
PAS pocket in AChE (Section 1.2.2.1) – It is a strong primer for misfolded Aβ monomer self-association as 
it provides a seeding location for the aggregation process. While self-induced and PAS-induced 
aggregation toward higher-order structures follow similar mechanisms, the Aβ monomer can also undergo 
a metal-ion induced misfolding arrangement, as seen in Figure 12, that is as problematic as the other 
conformations. Misfolded Aβ-peptides maintain their random coil structures by undergoing a number of 
hydrophobic, salt-bridge and coordinating (metal-ion arrangements only) interactions that stabilize the 
conformation and facilitate the downstream aggregation and toxicity pathways.38, 39, 118 It is not a surprise to 
see the susceptibility of Aβ-peptide to metal-induced misfolding, considering it has a metal-binding domain 
(Figure 10). Under disease-conditions, the unfolded monomer utilizes its tri-histidine-based metal-binding 
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domain, along with the D1 residue, to coordinate with free copper, iron or zinc metals (Figure 12) and that 
plays a crucial role in stabilizing that complex.119, 120, 137 On the other hand, non metal-ion based Aβ random 
coils are stabilized by a salt-bridge formed between D23 and K28 and a number of hydrophobic and 
stacking interactions between the 16-KLVFF-20 region and the C-terminal region (32-IGLMVGGVVIA-
42) of the peptide.138 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Schematic of progressive decline in the management of amyloid-β structural conformation from the stable 
helix-kink-helix arrangement to the misfolded random coil, with or without the influence of metal-ions. The blue-
dotted lines represent the essential salt bridges and hydrophobic interactions that stabilize the random coil, while the 
purple dotted lines represent those coordinated with the metal-ion. *Not drawn to scale. 
 
The path from a single misfolded monomer to higher-order aggregates can undoubtedly be described 
as an intricate dance of biochemical and biophysical interplay. There are a number of critical aggregate 
forms pertaining to the Aβ hierarchy, each with unique structural features and varying neurotoxicity 
impacts. One of the initial steps to furthering the aggregation pathway is the collapse of the stabilizing 
interactions within the misfolded monomer in favour of the dimeric stabilizing interactions.139 This 
turnover switch occurs with both metal-bound and metal-free Aβ monomers (as shown in Figure 13) and is 
essentially, the first amyloidogenic structure in this process, which has been reported to be energetically 
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favourable compared to the native form.119, 120, 137, 140, 141 This dimeric structure is considered the smallest 
seeding point in the pathway, which makes way for other misfolded monomers to join in and the evolution 
of the small molecular weight oligomers arise. This is, typically, where the metal-bound and metal-free 
aggregation path similarities end as the presence of metal-ions (like copper, iron and zinc) prevents the 
formation of downstream aggregate forms and the population is left as a large complex of size-variable 
oligomers (Figure 13). These Aβ-metal complexes contribute to the pro-inflammatory and pro-toxicity 
pathways in AD via redox chemistry and the increase in ROS generation.38, 118, 120, 142, 143 
 
 
Figure 13: Schematic of the downstream aggregation pathways of misfolded amyloid-β. Both aggregation pathways 
lead to plaque deposits but with different morphologies and pathological characteristics. *Not drawn to scale. 
 
 Metal-free oligomers, on the other hand, continue to grow and elongate to form protofilaments. These 
structures can be pictured of as a growing stack of unidirectional horseshoes that average about 4-5 nm in 
thickness and are rich in parallel β-sheet formation.144, 145 As the population of protofilaments increases, the 
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structures can propagate to form antiparallel β-sheet dimeric, trimeric, tetrameric, pentameric and 
oligomeric forms (as pictured in Figure 13). While protofilaments can be seen as relatively short and 
straight structures under transmission electron microscopy (TEM), higher-order aggregates display 
intriguing twist-form morphology, resulting in banding patterns observed under microscopy, (Figure 14) 
with a hollow-core ranging from ~ 1–5 nm internal diameter.146-150  
  
 
 
 
 
 
 
Figure 14: Transmission electron micrograph of an amyloidogenic peptide (closely related to amyloid-β) displaying 
the transformation of two protofilaments (A) into a dimeric-isoform (B) with the red triangles pointing to the banding 
pattern. The tetrameric form (C) is showcasing thicker banding indicated by the alternating white/black triangles. The 
morphological assessment during early-stage aggregation showcases the ~ 4–5 nm wide oligomeric structures 
represented above as “cross-sections” of protofilament (A). 
 
 
As mentioned earlier, the various aggregate isoforms elicit a wide range of neurotoxic mechanisms, 
although it has been well documented that the oligomeric forms of Aβ, such as the amyloid-derived 
diffusible ligands (ADDLs), are the most toxic.151-155 Besides acting as seed points for higher-order 
aggregates, these oligomers have been shown to disrupt cell membrane integrity via pore formation, 
interfere with ion channels and other membrane-bound receptors, enhance ROS generation, impact 
downstream regulation of gene expression, impede mitochondrial function, induce a positive feedback loop 
back to amyloidogenic APP metabolic regulation and more. On the other hand, higher-order aggregates are 
still problematic as the resulting amyloid plaques disrupt signal transduction and contribute to the 
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inflammatory responses, although their direct neurotoxicity impact is lower compared to oligomers and 
ADDLs.27, 110, 126, 156-169 
 
1.3.5. Aβ Targeting Strategies  
 
While the intricate layers centered on the amyloid cascade are still being peeled, what is currently 
known offers a diverse platform of intervening potentials for drug discovery and therapeutic developments. 
The common factor with these upstream or downstream interventions is the Aβ-peptide itself. 
 
1.3.5.1. Upstream of Aβ Production 
 
Recalling the biological mechanisms leading up to the release of the Aβ-peptide (Section 1.3.2), one 
can easily identify BACE-1 and/or γ-secretase as primary upstream targets for the management or 
reduction of Aβ-peptide production. In fact, these targets have taken the therapeutic spotlight for a few 
years, leading to the development of a number of small-molecule or peptidomimtic clinical candidates.10, 73, 
102, 170-180 While those candidates showcased potential at the pre-clinical, and some even at the early clinical 
stages, most ended up failing in late-stage clinical studies. While these were devastating outcomes, they 
painted a clear picture regarding the role of the secretases (especially γ-secretase) that extends beyond APP 
processing. Selectivity was also a concern, considering that β-secretase has two isoforms (BACE-1/2) and a 
number of other aspartate proteases, like the cathepsins, that are susceptible to eliciting side effects with 
inappropriate targeting. That said, BACE-1 and γ-secretase still hold a substantial mainstay and therapeutic 
interest that pharmaceutical companies are pursuing novel candidates at various stages of R&D and more 
so, on formulating properly structured clinical trials to assess validity.181-185 Interestingly, the reinvestment 
in these targets has been paralleled with a re-boost in Aβ-based research from both academia and pharma as 
well. This further exemplifies the strong connection between AD pathology and progression with this 
peptide and cascade as a whole. 
What about non-secretase based approaches? It does not come as a surprise that the intertwining 
complexity of AD signals a number of indirect approaches to the upstream interventions tied to the Aβ-
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peptide. For starters, cholinesterase inhibitors have been shown to bi-directionally modulate APP 
processing.186, 187 This is both an interesting and crucial find considering that current medication regimens 
are based primarily on cholinesterase inhibition. This modulation could be a result of some level of direct 
or indirect agonistic or antagonistic activity on the secretases. Additionally, certain AChR have been shown 
to steer APP processing toward the non-amyloidogenic pathway, increasing the release of the 
neuroprotective sAPPα.98, 188 A great example of these interactions can be depicted with galantamine 
(Reminyl™) – a weak cholinesterase inhibitor with positive modulation of APP processing in addition to 
its agonistic properties on nAChRs and reported inhibition of Aβ-aggregation.189, 190 
It is also noteworthy that the Aβ-peptide itself elicits feedback loops on its release (Figure 15) and that 
is a primer for the large collective effort directed at the downstream interventions discussed below.29, 95, 110, 
158, 191 
 
 
Figure 15: Schematic overview of upstream interventions utilized to modulate amyloid-β production. 
 
 
1.3.5.2. Downstream of Aβ Production 
 
The strategies handling the post-release of the Aβ-peptide outnumber upstream interventions. While 
discussing each potential strategy is beyond the scope of this thesis, these downstream interventions can 
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generally be grouped as strategies toward the modulation of Aβ-peptide behavior or the modulation of Aβ-
prone targets. The primary focus moving forward with this section will be the modulation of Aβ-peptide 
behavior as it is a direct and well-studied approach. 
Recalling to Section 1.3.4, the case was made to distinguish the toxicity implications along the Aβ-
aggregation pathway – If plotted, it would look something like the inlay in Figure 16.136, 155, 192 As such, it is 
not a surprise to come across varying opinions on which strategy (pro- or anti-aggregation of Aβ-peptide) is 
most effective. The reality is, neither is perfect as a stand-alone strategy because in both cases, a saturation 
limit will be met and the efficacy of treatment, on either end, will diminish.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Schematic comparison of the varying toxicity impact (cell death) with progressive amyloid-β aggregation. 
 
The pro-aggregation approach is based on accelerating the aggregation process of the peptide, beyond 
the oligomer stage, to minimize neuronal exposure to the ADDLs and cell-damaging oligomers.193, 194 The 
case for a pro-aggregation strategy plays out like this: a) higher order aggregates and plaques will 
eventually form because an anti-aggregation treatment is not viable long-term, b) and once formed, plaques 
are generally localized entities and act as sponges for free-flowing oligomers and c) this strengths the case 
of using plaque-specific anti-bodies to engage the immune response as a scavenger of these aggregate 
deposits.152, 153, 195 The issues against this strategy look like this: a) the success rate of developing a brain-
penetrable anti-body are low, b) not to mention that by the time dense plaques have formed, disease 
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progression is far beyond repair, c) and along with mid- to advanced-stage disease progression, patients are 
likely to be immune-compromised, and lastly d) by that stage, any trace of Aβ-clearance activity will very 
likely crumble as a result of the overload. On the other hand, the anti-aggregation approach is based on 
preventing the oligomerization of the peptide significantly to minimize neuronal exposure to the ADDLs 
and cell-damaging oligomers but to also reduce plaque load and the associated inflammatory responses.11, 
196-199 The case for an anti-aggregation strategy plays out like this: a) stabilizing the monomer or even the 
misfolded monomer long enough can reduce the rate of oligomerization, b) and by elongating the lag-
phase, cellular responses may be able to clear, correct or digest the misfolded monomers, or c) allow for 
other non-toxic structures to form reducing the positive-feedback loop elicited by Aβ, ADDLs and 
oligomeric entities. The issues against this strategy are solely based on challenges tied to the treatment’s 
therapeutic window, half-life and overall long-term viability. In addition to those strategies, a 
combinational approach has started to flourish in the research community. Some groups have reported 
aggregation-modifiers as potential therapeutic strategies. The concept there is based on small-molecules 
that bind to the misfolded monomers and induce a non-typical aggregation scheme that shuttles these 
misfolded monomers away from neurotoxic pathways.193, 200, 201 The concern here lies with the fate of these 
supposedly non-toxic, non-typical aggregates – could they not disrupt other cellular processes downstream? 
(Figure 17) 
 
 
Figure 17: Schematic overview of downstream interventions utilized to modulate amyloid-β behavior and impact. 
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Collectively, it is quite clear that downstream interventions are not suitable as stand-alone strategies. 
That said, what is a common feature amongst these downstream strategies, besides the Aβ-peptide itself, is 
the need for one-on-one interactions between a particular molecule and Aβ. The interesting factor here 
though, is that these interactions are distinctive on the molecular level – while the end result is more 
plaques or less plaques, the road to that conclusion is specific. This phenomenon is attributed to the multi-
stage aggregation process of Aβ. As showcased in Figure 13, there are multiple “access” points for a given 
molecule to potentially interact and even similar molecules in a chemical library might behave differently 
along the aggregation process. Where a molecule that binds early on in the aggregation process could delay 
or reduce oligomer formation, another that binds favourably at the oligomer/fibril domains could delay or 
reduce fibril formation.  
 
 
Figure 18: Commonly utilized small-molecule probes/dyes used in studying and tracking of amyloid-β aggregation in 
in vitro and staining studies. These compounds undergo free-rotation in solution, but once bound to amyloid their 
rotation capacity is restricted, attributing to their spectral red shifts. 
 
The preferential binding or interactions of molecules with varying forms of Aβ constitute one the 
largest research areas in this subclass of AD research. The ability of researchers to assess molecular 
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interactions with Aβ, has led the way of a number of critical findings about AD and other amyloid-based 
diseases, like Parkinson’s disease. One of the simplest and most common approaches to these studies is 
based on small-molecule probes or dyes, like Thioflavin-T/S (ThT/ThS) and Congo red (CR), which 
undergo spectrophotometric changes upon binding to amyloidogenic peptides/aggregates (Figure 18).202-205 
 
 
Figure 19: Schematic overview of a typical ThT-monitored kinetic plot of amyloid-β aggregation without (black) or 
with a multi-mode aggregation inducer (red) or a multi-mode aggregation inhibitor (blue). The lag phase starts at t = 0 
and ends at the start of the aggregation slope. The aggregation rate is indicative of how fast oligomers and 
protofilaments are forming. The saturation phase is the end point where fibrils are the dominant form (usually 
corroborated by AFM/TEM). R.F.U = Relative Fluorescence Units. 
 
 
While not perfect (due to specificity concerns), these probes have become essential in in vitro 
screening efforts to study molecular interactions with Aβ and also for amyloid staining in tissue samples. 
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While the histological applications are mainly qualitative, the dyes’ spectrophotometric red shifts 
(fluorescence or absorbance based) are used to indirectly quantify the initiation, rate and extent of β-
sheet/amyloid formation in solutions, in relation to assay controls. While these aggregation kinetic studies 
are typically corroborated with secondary experiments, like AFM (atomic force microscopy), TEM or 
circular dichroism (CD) spectroscopy, they have been favourably exploited to classify the modulation 
impact of molecular entities on Aβ-aggregation (Figure 19).206-210 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: A brief listing of aromatic, conjugated ring systems that modulate amyloid-β aggregation. Blue-coded 
compounds belong to the anti-aggregatory grouping, while red-coded compounds belong to the pro-aggregatory 
grouping. 
 
 
In a practical sense, developing aggregation modulators for the Aβ40 isoform is easier when compared 
to Aβ42, considering its slower misfolding and aggregation kinetic rates.147, 211, 212 These properties offer a 
larger window of opportunity for chemical candidates to interact with the Aβ40 isoform along the 
aggregation path. That said, it would be inappropriate to assume that any given Aβ42 modulator would also 
impact Aβ40 aggregation in a similar fashion. Due to the nature of these peptides, the traditional 
pharmacophore development approach has not been very successful as there is no defined active site and 
this exemplifies the diverse interactions that could modulate the aggregation process. A number of Aβ-
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modulation platforms are based on naturally-sourced, phenolic compounds such as curcumin  (a component 
of the spice turmeric), resveratrol (a phytoalexin found in grapes and berries), epigallocatechin-3-gallate 
(EGCG, a catechin-based antioxidant found in tea) and more.121, 213-222 In addition, synthetic dyes, like 
orange G and methylene blue, are also used as pharmacological tools in drug discovery due to their anti-
aggregation properties (Figure 20).199, 223 
 
 
1.3.6. Hypothesis Summary 
 
In contrast to the cholinergic dysfunction hypothesis, the amyloid cascade is not only more intricate, 
but is also more upstream along the pathological roadmap (Figure 21). This mainstay hypothesis is centered 
on the production, function, regulation and behavior of a single peptide. The Aβ-peptide, along with its 
precursor (APP), are physiologically relevant in the maintenance and function of the central nervous 
system, so complete eradication is not a viable approach. As highlighted earlier, the pathology attributed to 
Aβ is a consequence of the disruption and collapse of the mechanisms that regulate and maintain its 
positive, non-pathological outputs. The significance of this hypothesis in modern AD research is that the 
causation of this regulatory collapse in Aβ checkpoints is not fully comprehensible. 
With our current knowledge and understanding of Aβ’s upstream and downstream origins and 
impacts, a thorough and multidimensional approach is needed.204 A critical aspect to a viable, long-term 
solution is the advancement of early-detection screening, considering that the manifestation of the amyloid 
hypothesis is not abrupt – it is a slow and progressive indication. Along with ongoing early-detection, a 
therapeutic strategy aimed at reducing the rate of Aβ production, while stabilizing the peptide to avoid 
misfolding-derived neurotoxicity is an asset. 
Considering the collective discussion thus far, it would seem that a multi-mode Aβ-aggregation 
modulator, possessing some cholinesterase activity, is the key to a successful therapeutic strategy.69, 224, 225 
Unfortunately, the AD puzzle is far more complex than that. A critical piece to the proper placement of the 
various pathological events comes from post-mortem analyses, where AD patients’ brains were showcasing 
large variances in the amount of amyloid plaques. This indicates that while Aβ is a major player in the 
 	   31 
pathology of AD, its overall placement along the pathology timeline is more upstream. In addition, the 
number of toxic implications of ADDLs and oligomers exemplify the sheer destructive power of this 
cascade, which charters the path to a host of secondary hypothesis and mechanisms that further drive 
disease progression.162, 167 As such, the critical aspect becomes the balance between amyloidogenic and 
non-amyloidogenic metabolism as it is directly related to the delicate balance between production and 
clearance of amyloid-β.  
 	  
	  
Figure 21: A brief recap of the amyloid cascade along with potential intervention sites. 	  	  
1.4. Other Factors in AD Pathology 
 
The multifaceted nature of AD pathogenesis is grounded by the principle of neuronal cell death leading 
to the onset of dementia symptoms. While cholinergic dysfunction is a consequence, not cause, of neuronal 
cell death, implications tied to the amyloid cascade, and many other factors, are responsible for said 
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neuronal cell death. What starts out in a localized branch of the CNS, spreads over time in prion-like 
fashion to other areas of the brain.145, 226 
Although the primary focus of this thesis is linked to the cholinergic and amyloid hypotheses, it is 
important to address other key factors in AD pathology. Due to their impact and connectivity to the 
amyloid cascade, the principles of the tau and inflammatory hypotheses are briefly discussed below. 
 
 
1.4.1. Tauopathy 
 
If the baseline of the amyloid cascade had a relative, it would be tauopathy. This aggregation-based 
hypothesis is centered on the causation, formation and consequences of neurofibrillary tangles (NFTs), 
which are the amyloid plaque equivalent in this cascade.  
Similar to the extracellular amyloid plaques, intracellular NFTs cause significant damage to the neuron 
by hindering regulatory and metabolic processes and destabilizing the cell’s cytoskeletal framework along 
the way. These NFTs are comprised of hyperphosphorylated tau proteins that originate from the native, 
microtubule-associated tau (τ) proteins. Just as APP and Aβ are vital to neuronal function, tau proteins are 
crucial to maintaining neuronal integrity and axon stability and function.32, 227 Comparable to the imbalance 
between Aβ production and clearance that fosters the amyloid cascade, the imbalance between tau kinases 
and phosphatases results in the increased rate of tau phosphorylation, which forms the basis of the 
tauopathy cascade.33, 34 The excessive phosphorylation of tau (hyperphosphorylation) weakens its affinity to 
the neuronal microtubule assemblies and as they start to dissociate, the cellular cytoskeleton is 
compromised and the hyperphosphorylated tau monomers under amyloidogenic aggregation in a very 
similar fashion to that observed in Aβ.31, 228 As a matter of fact, a few studies based on the amyloidogenic 
KLVFFA core of Aβ are often mirrored with the VQIVYK amyloidogenic core of tau. These 
amyloidogenic hexapeptide domains serve as a high-throughput screening model since the results are 
generally translatable and the screening costs are much lower.210, 229-231 
The collapse of the neuronal cytoskeleton, combined with the persistent observations of NFTs and 
brain shrinkage in postmortem analysis point to tauopathy as more of a downstream pathological 
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mechanism, as compared to the amyloid cascade. As a matter of fact, a growing number of studies 
implicate the amyloid cascade with tauopathy, even though tauopathy-induced cellular damage has positive 
feedback input into the amyloid cascade.36, 37, 162, 204, 228, 232, 233 Yet again, literature would demonstrate a 
collection of upstream and downstream intervention strategies for tauopathy,35, 234-236 but unlike the amyloid 
cascade, downstream interventions upon tau hyperphosphorylation or NFT formation would not be 
therapeutically viable considering the extent of neurotoxicity in place at that stage. That said, it is safe to 
assume that interventions upstream of tau hyperphosphorylation are worthy as those are typically based on 
restoring the balance of kinase and phosphatase activity, although that is not without challenge, or are 
based on upstream/downstream interventions within the amyloid cascade (discussed earlier).  
 
 
 
Figure 22: A brief summary of the tau cascade along with potential intervention sites. 
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The challenge with regulating or restoring the balance of tau phosphorylation has to do with the type of 
kinases involved in that process. Developing inhibitors or modulators of GSK-3β or Cdk5 is not the 
challenge per se, but having site-specific activity is as these kinases are well dispersed throughout the body 
and carry substantially critical activities – A potent, non-site specific inhibitor of GSK-3β for example 
could wreak havoc on healthy cellular functions.104, 237, 238 Overall, it is best to target as far upstream as 
possible and with respect to tauopathy, dealing with the amyloid cascade could alleviate the need to focus 
on tau-related pathogenesis (Figure 22).22, 105, 239  
 
 
1.4.2. Inflammation 
 
The concept of an appropriate and physiological inflammatory response compared to ongoing and 
longer onset inflammation linked to disease initiation and progression is not a novel one. A large proportion 
of disorders, like heart disease, diabetes and cancer, include an inflammatory component and 
neurodegenerative diseases are no different.  
With respect to AD, while the cascades discussed thus far seem to have a general placement along the 
pathology timeline, inflammation is a bit different. There are a few ideas that suggest the entire pathology 
timeline starts out with ongoing inflammatory responses, while others hypothesize that inflammation is a 
key component throughout the pathology timeline. Considering the causes of inflammation are vast, it 
could be that both schools of thought are correct – Where inflammation is a key initiator and continues to 
promote disease progression.240 As such, the inflammatory hypothesis for AD is not well defined because 
anything from an infection, brain trauma or metabolic dysfunction could set the tone for ongoing or 
unsuppressed inflammation, especially in older adults. It is well documented that amyloid species (like Aβ 
and NFTs) induce inflammation but it is not far-fetched that further upstream inflammatory responses 
could offset the balance tied to Aβ production/ clearance and/or tau kinase/phosphatase activity.109, 241, 242  
One of the primary culprits identified under the inflammatory umbrella is the N-methly-D-aspartate 
(NMDA) receptor. Elevated levels of glutamate result in the over-activation of NMDA receptors leading to 
a large influx of Ca2+ ions and this leads to excitotoxicity and neuronal degeneration.243-245 Another 
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potential target, which is also implicated in Parkinson’s disease, is the monoamine oxidase family of 
enzymes (MAO A/B). Along with the generation of peroxide radicals as part of their mechanistic activity, 
recent studies have reported elevated levels of MAO activity in AD patients. The elevated levels of MAO 
could be a response to the diminishing cholinergic mass or attributed to an increase in monoamine 
substrates. Regardless of the cause, that increased MAO activity contributes to the reduction of key 
neurotransmitters, like serotonin, leading to elevated depression levels in AD patients.246-248 In addition, the 
oxygenase enzymes, COX-1/2 and 12-/15-LOX, along with the TNF-α cytokine have been implicated with 
pro-inflammatory mechanisms in AD.249-253 
It is without a doubt that inflammation plays a significant role here to the point that it is considered a 
given. That said, literature wouldn’t necessarily showcase research platforms solely targeting inflammatory 
responses in neurodegenerative diseases as that has much to do with the large umbrella/tent that the 
inflammation casts on everyday life. Alternatively, research efforts tend to be more targeted at the specific 
causes of inflammation – The upstream intervention strategy (Figure 23).254 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: A brief schematic of the ubiquitous role and presence of inflammation along the pathology timeline of AD. 
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1.5. Chapter Conclusion 
 
The mechanisms and cascades outlining AD pathology are not linearly associated as summarized in 
Figure 24. The collective research conducted over the past 100+ years has revealed a number of key 
hypotheses, a small handful of marketed treatments and countless failed clinical trials.  	  	  	  	  	  	  	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: A schematic and basic overview of the complexity tying the various cascades and mechanisms together 
contributing to AD pathology. 
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While it would seem that there is much left to uncover with respect to AD pathology, a few primary 
take home messages from this chapter include: a) the fact that cholinergic dysfunction, while not directly 
implicated in neuronal cell death, has been linked to patients’ dementia symptoms, b) not to mention that 
the amyloid cascade has and continues to be a high-ranking culprit due to its vast downstream implications 
and lastly c) the mandate for a multipronged strategy, primarily based on amyloid targeting, to inflict the 
most positive outcomes in the ‘global’ perspective of AD pathology was built.  
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CHAPTER 2 
  Rationale Behind the Utilization of the Quinazoline Ring Scaffold for Designing 
Novel AD Therapies   
 
2.1. Quinazoline Survey 
 
Heterocyclic ring scaffolds function as effective templates for multiple disease platforms and industry 
research pipelines. In a broad sense, these scaffolds are sought after for their known biological properties, 
applications and potential to afford novel therapeutics.  
From microorganisms to plants and marine animals, nature hosts a variety of bioactive quinazoline 
and related heterocylics (Figure 25). Selectively produced by yeast (C. lipolytica) and found in a few plant 
species, tryptanthin, an indolequinazoline, has been reported for its anti-inflammatory and antimicrobial 
properties.255 The Aspergillus genus of fungi are a source of multi-cyclic quinazolines, like sclerotigenin, 
circumdatin F and asperlicin C, with varying biological profiles.256, 257 Initially isolated from D. febrifuga, 
the quinazoline alkaloid (+)-febrifugine has been documented for its antimalarial properties. The vasicine-
related alkaloid, deoxypeganine is isolated from J. adhatoda and has a wide-range of biological activity 
including substance abuse/ dependence and Alzheimer’s disease.258 On the marine front, fumiquinazoline K 
is isolated from the soft coral fungus A. fumigatus, while the Russian brown algae L. sachalinensis is a 
known source of the carnequinazolines B and C.259  
 
 
 
 
 
 
 
 
 
Figure 25: Naturally-occurring quinazoline and quinazolinone alkaloids. 
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As a privileged scaffold, the quinazoline ring system (along with its close relatives and bioisosteres) 
have seen numerous oncological,260-264 microbial,265-268 inflammatory,269-271 anti-obesity 272-274 and 
neurological 73, 275-281 applications ranging from early-development to successful marketed therapies as 
showcased below (Figure 26).257, 282-287 These quinazoline and quinazoline-like derivatives truly exemplify 
the diversity, broad utility and therapeutic potential of these scaffolds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: A collection of marketed, in-development and patented quinazoline and related derivatives. Structures 
featuring the quinazoline or quinazolinone rings are indicated with red, whereas those featuring the pyridopyrimidine or 
related rings are indicated with blue. 
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The synthetic roadmap to bioactive quinazoline molecules is strategically diverse to allow for the 
design and development of diverse compound libraries for the acquisition of comprehensive structure-
activity relationship (SAR) data – A brief overview of these multi-approach synthetic routes are showcased 
below in Scheme 1 (metal-free methods)257, 264, 269, 272, 288-291, Scheme 2 (catalyst-dependent methods)290, 292-
294 and Scheme 3 (microwave or ultrasound-aided methods).257, 290, 293, 295 It is noteworthy that some of these 
methods are translatable to related heterocyclic derivatives including pyridopyrimdines and quinolones. 
 
 
Scheme 1a  
 
 
aReagents and conditions: Highlighting a few metal-free synthetic routes toward quinazoline-based derivative. (a) 
Urea, pressure tube, 150–160 °C, 3–4 h.; (b) POCl3, base, 0–115 °C, 5–18 h.; (c) POCl3, TEA, THF, 0°C; (d) NaH, 
DMF, 0 °C; (e) Ammonium acetate, 110 °C; (f) Ammonium acetate, DMAP, EtOH, 40 °C; (g) Guanidine carbonate, 
DMA, 140 °C, 8 h; (h) DMSO, dry air, 120 °C; (i) DMSO, open flask, 100 °C; (j) DMSO, TsOH, DTBP, 100 °C, 20 h.; 
(k) DIPEA, DCM, 20 °C, 2 h; (l) Water, carbon dioxide, 160 °C; (m) Pyridine, benzoyl chloride; (n) Hydrazine 
hydrate, EtOH; (o) AcOH, EtOH; (p) Water, tripotassium phosphate, 100 °C; (q) AcOH, 100 °C. 
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Scheme 2a 
 
 
aReagents and conditions: Highlighting a few catalyst/metal-dependant synthetic routes toward quinazoline-based 
derivatives. (a) PhI(OAc)2, toluene, 140 °C; (b) AgBF4, [Cp*RhCl2]2, DCE, 50 °C, 5 h.; (c) Pivalic acid, tripotassium 
phosphate, copper iodide, 1,2-DCB, 110 °C, 18 h; (d) Copper iodide, cesium carbonate, MeCN, 90 °C, 24 h; (e) TiCl4-
Zn, THF; (f) Toluene, amine, 100°C; (g) Pd(OAc)2, silver carbonate, isocyanide; (h) Cyanamide, dry MeOH, sodium t-
butoxide, NBS, 0–50 °C, 12 h; (i) Amine, MeOH, iron/hydrochloric acid, r.t.–60 °C, 3 h; (j) CuFe2O4, NPs, water, air 
80 °C; (k) Pd(OAc)2, BuPAd2, potassium carbonate, carbon monoxide, DMSO, water. 
 
 
Scheme 3a 
 
 
 
aReagents and conditions: Highlighting a few microwave or ultrasound-assisted synthetic routes toward quinazoline-
based derivatives. (a) p-TsOH, DMA, MW; (b) Ultrasound; (c) Guanidine carbonate, potassium carbonate, MW 140 
°C, 20 min. 
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2.2. Template Design 
 
With its medicinal/pharmaceutical advantage, prior exploitation in AD therapeutics279, 296-298 and 
diverse synthetic approaches, the platform of this thesis is based on utilizing the quinazoline ring scaffold 
to design novel, multi-targeting candidates focused on the modulation of Aβ-aggregation and the dual 
targeting of the ChE enzymes. The results of the author’s prior work with a disubstituted pyrimidine ring 
scaffold has shown that the presence of a C4 3,4-dimethoxybenzylamine substituent provided bivalent 
inhibition of AChE. The lead molecule (Pyr-lead) exhibited dual ChE inhibition and anti-Aβ aggregation 
properties (AChE IC50 = 9.9 µM, BuChE IC50 = 11.4 µM, Percent inhibition of AChE-induced Aβ 
aggregation = 59.3%, percent inhibition of self-induced Aβ aggregation = 17.4% at 100 µM)299 and the 
collective data from those studies influenced the design strategy showcased below (Figure 27). 
As seen in the left-panel of Figure 27, the combination of the pyrimidine ring scaffold, the 
benzylpiperidine pharmacophore from donepezil and a 3,4-dimethoxybenzylamine at the C4-position 
resulted in a true bivalent ligand (Pyd-lead) that extends past donepezil for stronger interactions at the PAS 
of AChE (W286). When the pyrimidine scaffold was replaced with a quinazoline (Qnz-version), it became 
evident that the majority of the ligand was binding at and beyond the PAS in AChE (W286). While the 
benzylpiperidine pharmacophore was binding within the active site gorge, it was not exhibiting favourable 
or comparable interactions as donepezil or Pyd-lead (W86). The preliminary molecular modeling studies 
suggested the radical downsizing of the functional groups at the C2-position of the quinazoline scaffold 
with minor linker extensions at the C4-positions to be favourable. The binding interactions observed with 
the Qnz ligand, in the right-panel of Figure 27, support the ChE-targeting design strategy of employing 
smaller functional groups at the C2-position while maintaining aromatic amines at the C4-position with 1-2 
methylene unit linkers.  
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Figure 27: Summary of the design strategy leading to the disubstituted quinazoline template featuring a smaller group 
at the C2-position to effectively generate bivalent inhibitors. 
 
 
In addition to dual cholinesterase targeting, the chosen scaffold design is hypothesized to effectively 
target and modulate Aβ-aggregation. With its planar and bicyclic nature, the quinazoline scaffold offers 
similar characteristics seen with the effective Aβ-aggregation modulator orange G, which contains a planar 
naphthalene scaffold. While the core template may offer intercalating or stacking interactions within the 
amyloid backbone structures, the nature, size and electrostatic properties of the functional groups at the C2 
 	   44 
and C4-positions will play a critical role in varying the extent of anti-aggregation potential across the 
multiple domains of the dimeric and fibril structures of Aβ. Additional activity parameters, such as metal 
chelation and ROS scavenging, are also factored in the design strategy to meet the overall objective of 
developing multi-targeting candidates.  
Prime focus on the incorporation of Lipinski’s rules was accomplished by monitoring ClogP values 
(around the 3–6 range), maintaining molecular weights under 500 Da and limiting hydrogen-bonding 
acceptors (equal to or under 8) and donors (equal to or under 5) (Figure 28).  
 
 
Figure 28: Overview of proposed SAR optimization on the quinazoline derivatives including template modifications. 
 
 
2.3. Synthesis of quinazoline core template 
 
In order to synthesize C2- and C4-substituted quinazoline libraries, nucleophilic aromatic substitution 
(NAS) reactions were utilized on chloro-substituted quinazoline or pyrido[3,2-d]pyrimidine intermediates 
(Figure 29).  
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Figure 29: Retrosynthetic pathway to the key di- or trichloroquinazoline and dichloropyrido[3,2-d]pyrimidine 
intermediates. 
 
For these applications, the synthesis of 2,4-dichloroquinazoline (2,4-DCQ) began with the 
condensation of anthranilic acid (2-aminobenzoic acid) with excess urea to form quinazoline-2,4-diol.264, 
289, 300 In the proceeding step, the quinazoline-2,4-diol was converted to the 2,4-dichloroquinazoline via a 
quinazoline-2,4-diyl-bis(phosphorodichloridate) intermediate.301  
 
 
 
Figure 30:  Reaction mechanisms for the cyclization and chlorination of 2-aminobenzoic acid to generate 2,4-DCQ. 
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These steps are easily transferable to afford the 2,4,6-, 2,4,7-, or 2,4,8-trichloroquinazoline or 2,4-
dichloropyrido[3,2-d]pyrimidine intermediates required to synthesize sought-after quinazoline or 
pyrido[3,2-d]pyrimidine compound libraries. The reaction mechanisms for these known protocols are 
showcased in Figure 30 and the proton NMR spectral shifts for these intermediates are compared in 
Appendix I. The assessment of the proton spectral shift changes with chlorine placements and the change 
from quinazoline (Qnz) to pyrido[3,2-d]pyrimidine (Ppd), offered some insight into the chemical nature of 
these intermediates. 
 
2.4. Target Quinazoline Library 
 
The research program was broadly divided into two phases. The first was centered on the quinazoline 
scaffold, while the second was primarily based on chloroquinazolines and pyrido[3,2-d]pyrimidines. In 
phase one, a wide array of SAR data was acquired to lay the foundation for the phase two where further 
SAR optimization was accomplished. The following is the complete list of quinazoline and pyrido[3,2-
d]pyrimidine compound libraries synthesized: 
 
______________________________________________________________________________________ 
 
1. N-(3,4-Dimethoxybenzyl)quinazolin-4-amines (Chapter 3 – 14 derivatives) 
2. N-Benzylquinazolin-4-amines + 1 regioisomer (Chapter 4 – 14 derivatives) 
3. N-(3,4-Dimethoxyphenethyl)quinazolin-4-amines + 1 regioisomer + N-(3,4-Dimethoxyphenethyl) 
chloroquinazolin-4-amines (Chapter 5 – 29 derivatives) 
4. N-Phenethylquinazolin-4-amines + 2 regioisomers + N-Phenethylchloroquinazolin-4-amines  
(Chapter 6 – 30 derivatives) 
5. 2,4-Disubstituted Pyrido[3,2-d]pyrimidines (Chapter 7 – 10 derivatives) 
6. Isomeric 2,4-Diaminoquinazolines (Chapter 8 – 30 derivatives) 
______________________________________________________________________________________ 
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In total, the thesis encompasses the design, development and biological screening of 127 quinazoline 
derivatives (Figure 31) with extensive SAR data for targeting the ChEs, amyloid aggregation and secondary 
interests such as metal chelation and ROS scavenging.  
 
 
 
Figure 31:  Outline of target derivatives in this research program. 
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CHAPTER 3 
  Development and Evaluation of N-(3,4-dimethoxybenzyl)quinazolin-4-amines as 
Dual ChE and Aβ Aggregation Inhibitors   
 
 * Chapter banner 
  
3.1. Introduction 
 
With an initial design strategy based on the Pyd-lead and the preliminary ligand (Qnz-version, Figure 
27), this series features a group of derivatives bearing the 3,4-dimethoxybenzylamine group at the C4-
position of the quinazoline scaffold. A combination of EWGs and EDGs was utilized to investigate and 
understand the role of steric and electrostatic properties in the biological profile outcomes.  
This chapter discusses the synthesis and development of target derivatives  (refer to the chapter banner 
above) along with the acquisition and assessment of the SAR data toward dual ChE and Aβ40/42 
aggregation inhibition. A brief summary is provided prior to the listing of experimental data and 
methodology. 
 
3.2. Hypothesis 
 
With respect to this series of derivatives, the presence of a 3,4-dimethoxyphenyl substituent at the C4 
position of the quinazoline ring scaffold was predicted to provide bivalent AChE inhibition with binding to 
both the catalytic and PAS of AChE. It was anticipated that this structural feature may work in favour with 
respect to the modulation of amyloid aggregation by interacting with monomeric species to prevent or 
hinder the dimerization and further oligomerization. 
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On the other hand, the selection of C2-groups offers wider postulations. The presence of an azide 
group, for example, may not be favourable in most scenarios due to its rigid conformation. In addition, the 
hydrophobic pockets of BuChE are likely to reject polar derivatives, although those derivatives might be 
capable of targeting AChE effectively. The alkylamines are strongly predicted to benefit BuChE inhibition, 
while effectively targeting AChE and modulating amyloid aggregation. 
 
3.3. Results and Discussions 
 
The proceeding sub-chapter describes the synthetic route to desired derivatives (8–15) along with 
biological assessments in the cholinesterase assay, to obtain inhibition concentrations to reduce 50% 
enzyme activity (IC50 values), and the amyloid-β aggregation assay to investigate aggregation kinetics and 
establish end-point IC50 or percent inhibition values. Select derivatives were assessed for ROS scavenging 
in the DPPH (2,2-diphenyl-1-picrylhydrazyl) assay. Finally, computational studies using the Discovery 
Studio software suite were performed to evaluate the acquired SAR data using the ChE X-ray structures 
and amyloid models.  
 
 
3.3.1. Synthesis 
 
As described earlier in Chapter 2, the synthesis of target derivatives stems from 2,4-
dichloroquinazoline (4, Scheme 4). This key intermediate was obtained from the reduction of 2-
nitrobenzoic acid (1a) or methyl-2-nitrobenzoate to the corresponding amine (2a or 2b),302 followed by the 
cyclization with urea yielding the quinazoline-2,4-dione (3) and final chlorination with POCl3 to provide 
2,4-DCQ (4, Scheme 4). The reaction mechanisms pertaining to these steps were also discussed in Chapter 
2.  
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Scheme 4a  
 
 
 
 
 
aReagents and conditions: Synthetic route toward the 2,4-dichloroquinazoline intermediate. (a) Pd/C, hydrazine 
hydrate, EtOH, 80–85 °C, 2 h; (b) Urea, 150–155 °C, pressure vial, oil bath, 2 h; (c) POCl3, toluene, N,N-
diethylaniline, POCl3, 0–105 °C, reflux, 14–16 h. 
 
 
In the first coupling reaction, the 3,4-dimethoxybenzylamine group was added to the C4-position of 
2,4-dichloroquinazoline (2,4-DCQ). This NAS reaction required moderate refluxing (3-4 h) in ethanol with 
an organic base, like diisopropylethylamine (DIPEA) to yield 2-chloro-N-(3,4-dimethoxybenzyl) 
quinazolin-4-amine (5, Scheme 5, 80–85% yield).299, 303  
 
Scheme 5a  
 
 
 
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 5-7. (a) 3,4-dimethoxybenzylamine, 
DIPEA, EtOH, reflux, 4 h; (b) 4-amino-1-benzylpiperidine, DIPEA, 1,4-dioxane, 160–165 °C, pressure vial, oil bath, 6 
h.; (c) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h. 
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Besides being a derivative of interest, 5 also played the role of “intermediate” for a number of 
compounds downstream. The coupling of 5 with 4-amino-1-benzylpiperidine via NAS, under harsh 
conditions, generated N2-(1-benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)quinazoline-2,4-diamine (6, 
Scheme 5, ~ 50% yield), which was screened for dual ChE and amyloid-β aggregation inhibition during the 
initial design phase (Qnz-version, Chapter 2).299 The C2-position SAR was explored initially by a 
dechlorination reaction to obtain N-(3,4-dimethoxybenzyl)quinazolin-4-amine (7, Scheme 5, ~ 45% yield) 
via the Pd/C and hydrazine-driven dehalogenation reaction.304 The general reaction mechanism pertaining 
to NAS reactions is briefly outlined in Figure 32, while the Pd/C and hydrazine-driven dehalogenation 
mechanism is showcased in Figure 33. 
 
 
Figure 32: Mechanism for NAS reactions on the quinazoline scaffold. Coupling at the C2-position requires harsher 
conditions compared to C4-based coupling. 
 
 
 
 
 
 
 
 
 
 
Figure 33: Mechanism for hydrazine and Pd/C driven dehalogenation via oxidative addition, β-hydrogen elimination 
and reductive elimination.  
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Further utilization of 5 was demonstrated with the nucleophilic addition of hydrazoic acid (via sodium 
azide) at the C2-position, under reflux conditions in ethanol and acetic acid, to yield 2-azido-N-(3,4-
dimethoxybenzyl) quinazolin-4-amine (8, Scheme 6, ~ 90% yield).305, 306 In addition to acting as a stand-
alone derivative, the azide-based derivative was later utilized in the generation of the C2-amino derivative 
(9, Scheme 6, N4-(3,4-dimethoxybenzyl)quinazoline-2,4-diamine) as an alternate method to the copper(I) 
oxide approach. The initial approach of direct coupling using ammonia to 5, via the copper (I) oxide and 
DMEDA-ligand complex (Figure 34), proved to be inefficient.307-311 With yields only reaching ~ 35%, the 
alternate approach of reducing 8 to 9, via Pd/C and hydrazine, was acknowledged as an easier and higher-
yielding (~80%) route, even when compared to the attempted triphenylphosphine approach to azide 
cleavage (Staudinger reaction). It is noteworthy that experimental attempts were made to convert 9 to 8, via 
the diazo intermediate generated with sodium nitrite and hydrochloric acid, but outcomes were a mixture of 
8 and 10 (4-((3,4-dimethoxybenzyl)amino)quinazolin-2-ol) (Figure 35).305 An effective approach to 
generating 10 was developed by heating 5 in formic acid and potassium formate under reflux overnight 
(Scheme 6, yield ~ 65%). The reaction mechanisms pertaining to the synthesis of the azide and the C2-
hydroxyl derivatives are showcased in Figures 35 and 36; respectively. 
 
Scheme 6a   
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 8-10. (a) Sodium azide, EtOH, 
acetic acid, 90–95 °C, 2 h; (b) Cu2O, K2CO3, DMEDA, ethylene glycol, ammonium hydroxide, pressure vial, oil bath, 
105 °C, 24 h; (c) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h; (d) HCl, sodium nitrite, sodium azide, 0 °C–r.t., 1 h; (e) 
potassium formate, formic acid, 120–125 °C, 14–16 h. 
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Figure 34: Copper-DMEDA complex mediating the amination of 2-chloro-N4-substituted quinazoline derivatives using 
ammonium hydroxide. 
 
 
 
 
Figure 35: Reaction mechanism toward the generation and reduction of 2-azido-N4-substituted quinazoline derivatives. 
 
 
δ+ 
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Figure 36: Reaction mechanism toward the generation of N4-substituted quinazoline-2-ol derivatives using formic acid 
and potassium formate. 
 
 
The development of C2-carbonyl based derivatives began with the displacement of the C2-chlorine of 
5 with urea under high temperature and pressure conditions. The NAS reaction yielded derivative 11 
(Scheme 7, 1-(4-((3,4-dimethoxybenzyl)amino)quinazolin-2-yl)urea, ~ 45-50% yield) along with derivative 
9 (yield ~ 50%) as the hydrolyzed-urea product.305 To enhance the SAR within the carbonyl-based 
derivatives, glycinamide was coupled to 5, via a NAS reaction, to provide derivative 12 (Scheme 7, 2-((4-
((3,4-dimethoxybenzyl)amino)quinazolin-2-yl)amino)acetamide, yield ~55%).299 Interestingly, efforts to 
replicate the urea-coupling approach with other functional groups, like acetamide or methyl carbamate, 
proved unsuccessful. A replacement route to C2-acetamide was developed by refluxing 9 with acetyl 
chloride in acetic acid and 1,4-dioxane to yield N-(4-((3,4-dimethoxybenzyl)amino)quinazolin-2-
yl)acetamide (13, Scheme 7, yield ~ 40%).312 The acetylation of 9, via a nucleophilic attack on the acyl 
chloride, is showcased in Figure 37. 
 
 
Scheme 7a  
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 11-13. (a) Urea, 1,4-dioxane, 
pressure vial, 160–165 °C, 24 h.; (b) glycinamide, DBU, 1,4-dioxane, pressure vial, 150–155 °C, 4 h.; (c) acetyl 
chloride, acetic acid, 1,4-dioxane, 120 °C, 24 h. 
 	   55 
 
 
 
 
Figure 37: Reaction mechanism toward the generation of N4-substituted quinazoline-2-acetamide derivatives using 
acetyl chloride and acetic acid. 
 
 
The introduction of alkyl moieties at the C2-position of the quinazoline scaffold was established by 
coupling 5 with various alkylamines (methyl, ethyl, propyl, isopropyl and cycloproply), under previously 
discussed NAS conditions, to generate derivatives 14-18 (Scheme 8, ~ 60-70% yield).288, 313, 314 
 
Scheme 8a – Synthetic routes toward quinazoline-based derivatives 14-18. 
 
 
 
 
 
 
aReagents and conditions: (a) Primary amine (R1 = Me, Et, n-Pr, i-Pr or c-Pr), DIPEA, 1,4-dioxane, pressure vial 
150–155 °C, 2 h. 
 
 
3.3.2. Cholinesterase 
 
The ability of 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (5–18) to target the 
cholinesterases (hAChE/hBuChE) was assessed (Table 1) using the hallmark DTNB method for 
cholinesterase inhibition.315 This standard assay was run in triplicate, along with assay controls (Figure 38) 
and blanks, using six concentrations for the drug candidates (1, 2.5, 5, 10, 25, 50 µM) and the data was 
processed as an average IC50 value of two to three independent experiments.  
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Figure 38: Standards utilized in the DTNB cholinesterase screening protocol. The broad inhibition window ensures 
representable and reliable data at both ends of the inhibition spectrum. 
 
 
Table 1: Cholinesterase inhibition data for 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (5–18). 
 
 
 
 
Derivative R-Grp 
ChE IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
hAChE hBuChE 
5 Cl 3.0 ± 0.2 > 50 – 3.75 213.6 1:5 
6 1-BnPpd* 2.1 ± 0.1 8.3 ± 0.9 0.25 5.65 400.2 2:7 
7 H 2.8 ± 0.2 > 50 – 1.84 199.6 1:5 
8 N3 8.3 ± 0.7 > 50 – 4.41 262.7 1:7 
9 H 2.6 ± 0.2 > 50 – 2.98 209.5 3:6  
10 OH 7.7 ± 0.9 > 50 – 3.61 248.3 2:6 
11 CONH2 8.6 ± 0.6 > 50 – 3.01 269.2 4:8 
12 CH2CONH2 7.4 ± 0.8 > 50 – 2.59 289.1 4:8 
13 COMe 8.5 ± 0.6 > 50 – 2.53 277.8 2:7 
14 Me 7.3 ± 0.5 30.5 ± 4.0 0.24 3.80 218.8 2:6 
15 Et 6.3 ± 0.4 25.0 ± 1.2  0.25 4.33 232.8 2:6 
16 n-Pr 5.6 ± 0.4 30.4 ± 1.7 0.19 4.86 245.5 2:6 
17 i-Pr 6.8 ± 0.5 29.8 ± 2.0 0.23 4.64 243.8 2:6 
18 c-Pr 7.2 ± 0.6 29.8 ± 2.5 0.24 4.38 241.8 2:6 
Donepezil – 0.03 ± 0.002 3.6 ± 0.4 0.01 4.59 321.7 0:4 
Tacrine – 0.16 ± 0.01 0.04 ± 0.001 4.00 3.27 165.6 2:2 
Galantamine – 2.6 ± 0.6 > 50 – 1.18 239.4 1:4 
Rivastigmine – 6.5 ± 0.5 > 10 – 2.10 226.3 0:4 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. 
bSelectivity index is calculated as (hAChE IC50)  ÷ (hBuChE IC50). cClogP values were determined using ChemDraw 
Professional 15.0. dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design 
software, BIOVIA Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding 
acceptors. *1-BnPpd = 1-benzylpiperidine. 
 
 	   57 
Examination of Table 1 quickly pointed out the overall weak or no ability of this series to target 
BuChE (with the exception of 6). On the other hand, AChE inhibition ranged from 2 to 9 µM placing these 
derivatives at level playing field with marketed compounds, galantamine and rivastigmine. Starting out 
with the secondary intermediate (5), the C2-chlorine based derivative was equipotent to galantamine in 
AChE (IC50 = 3.0 µM) but was ineffective toward BuChE. Recalling back to Section 2.2, it was interesting 
to observe derivative 6 (with a C2-aminobenzylpiperidine group) as being the most potent AChEI (IC50 = 
2.1 µM) in this series, despite its not-so-favourable binding mode within the enzyme. More so, it was the 
most potent (albeit most active) BuChEI (IC50 = 8.3 µM) in the grouping surpassing rivastigmine’s activity. 
Another interesting observation came from the equipotent profiles of 5 and 7 despite the significant change 
in steric and electrostatic properties at the C2-position. 
As predicated earlier, the hindrance associated with the azide functionality did not serve ChE targeting 
as seen with 8. Compared to the C2-unsubstituted derivative (7), 8 was roughly 3-fold less active toward 
AChE (IC50 = 8.3 µM) and was completely ineffective toward BuChE. Upon reduction of that azide 
however, AChE activity was restored as seen with derivative 9 (IC50 = 2.6 µM). Yet again, the observation 
of equipotent activity amongst C2-chlorine, C2-hydrogen and C2-amino derivatives might suggest that 
sterics, more so than electrostatic properties, are more important to ChE targeting with this series. This 
suggestion was quickly withdrawn with the results observed from 10 (IC50 = 7.7 µM), which was roughly 
3-fold less active toward AChE compared to the amine-based bioisostere. While a small difference, NMR-
studies indicated a considerable variance in the acidity of the protons at the C2-position and that would 
point to a big difference in the electrostatic properties between 9 and 10. 
With respect to the carbonyl-based series, derivatives 11 – 13 exhibited similar activity toward AChE 
and it was not a surprise to see them as ineffective toward BuChE. Of the three, the C2-glycinamide 
derivative (12, IC50 = 7.4 µM) was first at nearly 0.9-fold more potent compared to the urea (11, IC50 = 8.6 
µM) and acetamide (13, IC50 = 8.5 µM) derivatives toward AChE.   
The introduction of alkylamines at the C2-position established some level of BuChE inhibition, albeit 
it weak (IC50 ~ 30 µM), while AChE activity ranged from IC50 5.6–7.3 µM. Increasing the length of the 
alkyl chain, from methyl (14) to ethyl (15) to propyl (16), resulted in roughly 1.1-fold incremental 
improvements in AChE potency (IC50 = 7.3 to 6.3 to 5.6 µM; respectively). Increasing the sterics, but not 
 	   58 
necessarily the molecular volumes, of the propyl chain in 17 (isopropyl) and 18 (cyclopropyl) reduced 
potency roughly 1.2-fold in both cases (IC50 ~ 7 µM). 
In summary, 14 derivatives were assessed for dual cholinesterase activity, of which derivative 6 (N2-
(1-benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)quinazoline-2,4-diamine) was identified as the best dual, 
selective ChEI. This series proved to be ineffective toward BuChE, while providing a decent range of 
AChE activity IC50 < 10 µM (Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Cholinesterase metrics for fourteen 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (5–18). 
 
 
 
3.3.3. Amyloid-β Aggregation 
 
The ability of 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (5-18) to modulate the 
aggregation kinetics of amyloid-β was assessed (Table 2) using the standard ThT-binding method for β-
sheet aggregation monitoring.47, 203, 215, 222, 281, 316-318 This crucial assay was run in triplicate, along with assay 
controls (Figure 40) and blanks, using three concentrations for the drug candidates (1, 5, 25 µM) and the 
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data was processed as an average IC50 value or percent inhibition (P.I) at 25 µM of two to three 
independent experiments. Select derivatives were analyzed to establish aggregation kinetic plots to 
investigation potential modes of action in comparison to assay controls. 
 
 
 
 
 
Figure 40: Standards utilized in the ThT-binding assay for β-sheet aggregation monitoring. 
 
 
Table 2: Amyloid-β (Aβ40/42) inhibition data for 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (5–18). 
 
 
 
 
Derivative R-Grp 
Amyloid-β IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
Aβ40 Aβ42 
5 Cl 18% 16% – 3.75 213.6 1:5 
6 1-BnPpd* 2.3 ± 0.5 27% – 5.65 400.2 2:7 
7 H 31% 20% – 1.84 199.6 1:5 
8 N3 7.2 ± 1.5 NA – 4.41 262.7 1:7 
9 H 8.4 ± 1.7 34% – 2.98 209.5 3:6  
10 OH 7.8 ± 1.2 NA – 3.61 248.3 2:6 
11 CONH2 8.3 ± 1.2 40% – 3.01 269.2 4:8 
12 CH2CONH2 NA NA – 2.59 289.1 4:8 
13 COMe 3.1 ± 0.4 NA – 2.53 277.8 2:7 
14 Me 36% 31% – 3.80 218.8 2:6 
15 Et 35% 30% – 4.33 232.8 2:6 
16 n-Pr 1.7 ± 0.3 NA – 4.86 245.5 2:6 
17 i-Pr NA NA – 4.64 243.8 2:6 
18 c-Pr 8.3 ± 1.6 20% – 4.38 241.8 2:6 
Curcumin – 3.3 ± 0.45 9.9 ± 0.4 0.33 4.59 302.1 2:6 
Resveratrol – 1.1 ± 0.1 15.3 ± 1.9 0.07 2.83 187.2 3:3 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). bSelectivity 
index is calculated as (Aβ40 IC50)  ÷ (Aβ42 IC50). cClogP values were determined using ChemDraw Professional 15.0. 
dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design software, BIOVIA 
Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding acceptors. *1-
BnPpd = 1-benzylpiperidine. 
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Examination of Table 2 quickly pointed out the overall ability of this series to dually target Aβ 
aggregation (9 out of 14 derivatives as dual inhibitors). Inhibitory activity toward Aβ40 was more 
promising compared to Aβ42 and only two derivatives were completely inactive toward either species (12 
and 17). When compared to assay controls, none of these derivatives matched curcumin’s or resveratrol’s 
activity toward Aβ42; however, three met or surpassed the activity observed by curcumin on Aβ40 
aggregation.  
Starting out with the compound (5), the C2-chlorine based derivative was a weak inhibitor of Aβ40/42 
aggregation (P.I at 25 µM was 16%).  The presence of a C2-aminobenzylpiperidine group in 6 improved 
Aβ42 activity by roughly 1.7-fold (P.I at 25 µM was 27%), while inhibition of Aβ40 was remarkably 
improved and was in between resveratrol and curcumin profiles (IC50 = 2.3 µM). The proposed linearity 
and sterics associated with 6 are likely in play, especially considering the profile of 7 (C2-hydrogen) that 
exhibited a dramatic loss toward Aβ40 activity (P.I at 25 µM was 30%), while relatively maintaining Aβ42 
activity (P.I at 25 µM was 20%).       
Despite initial anticipations regarding the azide functionality, it was disappointing to uncover 
derivative 8’s moderate activity toward Aβ40 (IC50 = 7.3 µM) and ineffectiveness toward Aβ42. The 
reduction of that azide restored some level Aβ42 activity (9, P.I at 25 µM was 34%), while furthering the 
decline in Aβ40 activity (9, IC50 = 8.4 µM). Interestingly, comparing 6 and 9 suggested stronger 
interactions between the C2-amino group of 9 and Aβ42, while the bulkiness of 6 along with the slower 
aggregation rate of Aβ40, allowed for stronger inhibitory interactions. Replacement of the amino group in 9 
with a hydroxyl group in 10 resulted in similar activity toward Aβ40 (IC50 = 7.8 µM) and inactivity toward 
Aβ42 – an equipotent profile with azide-based derivative 8. 
With respect to the carbonyl-based derivatives, C2-urea-containing derivative 11 exhibited equipotent 
activity toward Aβ40 and Aβ42 as 9 (C2-amino), while the gylcinamide derivative (12) was inactive on 
both fronts – Very interesting observation based on an additional methylene group at the C2-position. The 
acetamide derivative (13) on the other hand, while inactive toward Aβ42, it was roughly 3-fold more potent 
toward Aβ40 (IC50 = 3.1 µM) compared to its urea bioisostere (11) and amino-based derivative (9). 
The introduction of alkylamines at the C2-position established some interesting SAR. With either a 
methyl or an ethyl chain, derivatives 14 and 15 exhibited weak and equipotent dual activity toward Aβ40 
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and Aβ42 with P.I at 25 µM roughly at 34%). An additional methylene group in 16 (C2 = propylamine) 
provided the most potent activity toward Aβ40 (IC50 = 1.7 µM), while becoming ineffective toward Aβ42. 
Interestingly, the isopropyl isomer of 16 was totally ineffective toward either species of Aβ, while the 
cyclopropyl-based derivative (18) provided activity toward Aβ40 similar to 9 and 11 (IC50 = 8.3 µM), while 
restoring some Aβ42 activity (P.I at 25 µM was 20%) compared to its other isomers 16 and 17. 
In summary, 14 derivatives were assessed for dual Aβ-aggregation activity, of which derivative 16 
(N4-(3,4-dimethoxybenzyl)-N2-propylquinazoline-2,4-diamine) was identified the most potent Aβ40 
aggregation inhibitor (IC50 = 1.7 µM). While most derivatives in this series were ineffective or weak 
inhibitors toward Aβ42, derivative 11 (1-(4-((3,4-dimethoxybenzyl)amino)quinazolin-2-yl)urea) was 
identified the most active aggregation inhibitor (P.I at 25 µM was 40%) (Figure 41). 
 
 
 
 
 
 
\ 
 
 
 
 
Figure 41: Amyloid-β metrics for fourteen 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (5-18). 
 
 
The aggregation kinetic assessment of Aβ40 with or without series-leading derivatives is showcased 
in Figure 42 (due to the lack of promising data with Aβ42, kinetic assessments were not conducted for this 
series). As observed with resveratrol (Panel A), derivatives 6 and 16 (Panels B and C; respectively) exhibit 
concentration-dependent inhibition of Aβ40 aggregation. Both managed to showcase multi-type modulation 
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of the aggregation process, although they were not necessarily stabilizing the monomeric structure as seen 
with resveratrol (specifically at 25 µM). This was concluded based on the lag phase timeline that matches 
the Aβ40-alone curve. Nonetheless, across the three concentrations tested, both derivatives managed to 
reduce the rate of oligomerization (seen by the decreased slopes between the 10-15 hour mark) and lower 
the total amyloid load at the experiment’s conclusion. In both cases, percent reduction in amyloid load (at 
the 1:1 ratio) surpassed the 50% mark. Based on the overall kinetic plots, it is evident that derivatives 6 and 
16 act upon Aβ40 primarily at the very early stages of oligomerization. 
 
 
 
 
 
 
 
 
 
 
Figure 42: ThT-monitored kinetics of Aβ40 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of resveratrol on the aggregation kinetics of 5 µM 
Aβ40. Panel (B): Impact of 1, 5 or 25 µM of N2-(1-benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)quinazoline-2,4-
diamine (6) on the aggregation kinetics of 5 µM Aβ40. Panel (C): Impact of 1, 5 or 25 µM of N4-(3,4-
dimethoxybenzyl)-N2-propylquinazoline-2,4-diamine (16) on the aggregation kinetics of 5 µM Aβ40.  
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3.3.4. Antioxidant Capacity 
 
The ability of select 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (9 and 10) to 
neutralize ROS was assessed using a DPPH-scavenging assay.216, 319-321 This simple assay was run in 
triplicate (at 50 µM of test compound), along with assay controls (Figure 43), blanks and the data was 
processed as an average percent DPPH-scavenging at 50 µM of two independent experiments.  
 
 
 
 
 
 
 
 
 
Figure 43: Standards utilized in the DPPH-scavenging along with the data for selective derivatives (9 and 10). 
 
 
As phenolics are typically good antioxidants, especially when connected to conjugated systems, it was 
no surprise to observe the effectiveness of 10 at scavenging the DPPH radical. Its observed antioxidant 
capacity was roughly halfway in-between the capacities of resveratrol and trolox (Figure 43). While the 
amino bioisostere (9) is also conjugated, it was ineffective at DPPH-scavenging, which was expected 
considering the weaker potential of amines at displaying antioxidant capacity.  
 
3.3.5. Molecular Modeling 
 
The utilization of computational software is not only useful in structure-based drug design, it is also 
employed to understand and corroborate the acquired SAR data. The assessment of ligand-receptor 
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interactions was conducted between leading (or comparable) derivatives from the 2-substituted-N-(3,4-
dimethoxybenzyl)-quinazolin-4-amine series (5–18) and the cholinesterase or amyloid targets of interest.  
 
3.3.5.1. Cholinesterase 
 
Based on the acquired anti-ChE data, presented in Table 1, the docking interactions of 6 and 9 were 
investigated in hAChE (PBD: 1B41) and superimposed in Figure 44, along with the docking interactions of 
6 and 9 in hBuChE (PBD: 1P0I). 
 
 
 
 
 
 
 
 
 
Figure 44: Superimposition of docking structures. Panel (A): Binding modes of 6 (red) and 9 (green) in the active site 
of hAChE (PDB ID: 1B41). Panel (B): Binding modes of 6 (red) and 9 (green) in the active site of hBuChE (PDB ID: 
1P0I). Hydrogens removed to enhance visibility. Black-dashed lines indicate hydrogen-bonding interactions.  
 
 
As observed in Panel A, the quinazoline scaffold of 6 was equidistantly oriented between the acyl 
pocket (F295/F297) and the anionic pocket (W86) at roughly 6 Å. The scaffold was also about 5 Å from 
the catalytic triad of hAChE (S203, E334 and H447). The derivative’s C4-dimethoxyphenyl ring was 
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stacked parallel to W86 with close interactions roughly at 4–5 Å. The benzylpiperidine pharmacophore was 
pointed toward the PAS (W286), where the piperidine ring was oriented parallel to the acyl pocket (~ 7 Å) 
and the phenyl ring was stacked parallel to W286 at roughly 5–6 Å. Unlike the proposed binding 
orientation discussed in Chapter 2, the interactions here was collected after a wider assessment of the 
binding sphere identified within hAChE. In contrast, derivative 9 exhibited a more localized binding mode 
within the catalytic site as observed with its approximate distance to W286 at roughly 11 Å. The 
quinazoline scaffold was stacked against W86 at roughly 4–5 Å; however, the stacking was not favourably 
parallel to the indole ring of W86. The derivative’s C4-dimethoxy phenyl ring was oriented toward the 
catalytic triad and sitting roughly at 6–7 Å from S203 and H447. 
With respect to BuChE binding, as observed in Panel B, both derivative 6 and 9 bind with their 
quinazoline scaffold roughly 12 Å from A277. The scaffolds were perpendicularly stacked against the acyl 
pocket (L286–V288) at roughly 4–5 Å. Both derivatives’ C4-dimethoxyphenyl ring were stacked parallel 
or semi-parallel to W82 with close interactions roughly at 5–6 Å, while one methoxy oxygen in 9 
underwent hydrogen-bonding interactions with W82’s indole NH  (~ 3 Å). The benzylpiperidine 
pharmacophore in 6 underwent a folding arrangement with the rest of the ligand to point toward W82, 
allowing for hydrogen-bonding interactions between S286 carbonyl oxygen and 6’s C2-NH (~ 2.8 Å). In 
contrast, the C2-amino group of 9 underwent hydrogen-bonding interactions with S203’s hydroxyl group 
and H447’s imidazole ring (~ 2.6–3 Å). 
 
 
3.3.5.2. Amyloid-β 
 
Based on the acquired anti-Aβ data, presented in Table 2, the docking interactions of 6 and 16 were 
investigated in both a dimeric and fibril model of Aβ (Aβ9-40 – PDB 2LMN)322 with superimpositions 
showcased in Figure 45.  
In the dimer model (Panel A), the quinazoline scaffold of 6 was stacked parallel to I32–G33 roughly 
at 5–6 Å, compared to the perpendicular placement of 16’s quinazoline scaffold between A21–G22 and 
I32–G33 on the opposite end (~ 7–8 Å). The C4-dimethoxyphenyl ring of 6 was stacked between F19/F20 
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of monomer 1 (~ 4–5 Å), while the benzyl ring of the C2-functionality was stacked between D23 and G29 
of monomer 2 (~ 4–5 Å). With its larger volume, it was interesting to note the same planar arrangement of 
the quinazoline scaffold, the dimethoxyphenyl ring and the C2-benzyl ring as opposed to the piperidine 
ring, which was oriented in a perpendicular plane to the other ring systems. In addition, derivative 6 was 
capable of full interactions with both monomeric structures in the dimer spanning other regions outside of 
the hairpin loop domain. With 16, the C4-dimethoxy phenyl ring was stacked parallel between D23 and 
A30 (~ 4 Å), while its C2-proply chain was pointed toward F19/F20 (~ 4–6 Å). 
 
 
 
 
 
Figure 45: Superimposition of docking structures. Panel (A): Binding modes of 6 (red) and 16 (turquoise) in the Aβ 
(Aβ9-40 – PDB 2LMN) dimer model or fibril model [Panel (B)]. Hydrogens removed to enhance visibility. Amino acid 
labels to be used as a general guide as space restrictions limited complete and accurate labeling of both structures. 
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and exhibited close interactions with M35 and V36 roughly at 6 Å, compared to the parallel arrangement of 
16’s quinazoline scaffold against L34 and M35 (~ 4–5 Å). Both derivatives had their C4-dimethoxyphenyl 
rings inserted into the steric zipper domain with placement between the M35 residues roughly at 6 Å. The 
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benzylpiperidine pharmacophore in 6 extended to the second dimeric pair forming an anti-parallel V-
shaped arrangement at the hairpin loop domain (N27–I31 ~ 6–8 Å). The propyl chain of 16 pointed inward 
at I32-L34 roughly at 5–6 Å). 
 
 
3.4. Summary 
 
Briefly, of the 14 derivatives in this series, all but one proved to be ineffective at targeting BuChE and 
to a certain extent Aβ42 aggregation. Nonetheless, the series showcased a strong DPPH-radical scavenger 
in 10 and a resveratrol-equivalent Aβ40 inhibitor in 16. More so, 6 proved to be a good dual ChEI with 
good Aβ40 inhibitory potential at equivalent targeting potency with AChE inhibition (Figure 46).  
 
 
 
Figure 46: Cumulative chapter summary of 2-substituted-N-(3,4-dimethoxybenzyl)-quinazolin-4-amines (5–18). 
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3.5. Experimental 
 
3.5.1. Chemistry 
 
General Information. All the reagents and solvents were reagent grade purchased from various vendors 
(Acros Organics, Sigma-Aldrich, and Alfa Aesar, USA) with a minimum purity of 95% and were used 
without further purification. Melting points (mp) were determined using a Fisher-Johns apparatus and are 
uncorrected. Reaction progress was monitored by UV using thin-layer chromatography (TLC) using Merck 
60F254 silica gel plates. Column chromatography was performed with Merck silica gel 60 (230−400 mesh) 
with 5:1 EtOAc:MeOH as the solvent system unless otherwise specified. Proton (1H NMR) and carbon (13C 
NMR) spectra were performed on a Bruker Avance (at 300 and 75 MHz; respectively) spectrometer using 
DMSO-d6. Coupling constants (J values) were recorded in hertz (Hz) and the following abbreviations were 
used to represent multiplets of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. 
Carbon multiplicities (C, CH, CH2 and CH3) were assigned by DEPT 90/135 experiments. High-resolution 
mass spectrometry (HRMS) was determined using a Thermo Scientific Q-Exactive Orbitrap mass 
spectrometer (positive mode, ESI), Department of Chemistry, University of Waterloo. Compound purity 
(roughly 95% or over) was determined using an Agilent 1100 series HPLC equipped with an analytical 
column (Agilent Zorbax Eclipse XDB-C8 column, 4.6 x 150 mm, 5 µm particle size) running 50:50 
Water:ACN with 0.1% TFA at a flow rate of 1.0-1.5 mL/min or an Agilent 6100 series single quad LCMS 
equipped with an Agilent 1.8 µm Zorbax Eclipse Plus C18 (2.1 x 50 mm) running 50:50 Water:ACN with 
0.1% FA with a flow rate of 0.5mL/min. All the final compounds exhibited ≥ 95% purity. 
 
General procedure for the synthesis of compounds 2a or 2b.314 In a 100 mL RBF, 5 g of 1a or 1b 
(27.62–29.94 mmol) was dissolved in 30 mL of argon-degassed ethanol followed by the addition of 10 mol. 
% of Pd/C (2.76–2.99 mmol) and 1.5 eq. of hydrazine hydrate (41.44–44.91 mmol). Solution was refluxed 
at 80–85 °C for 2 h. Upon reaction completion, the hot ethanol solution was passed through dense cotton 
packing in a 60 mL syringe by washing with ethanol (20 mL x 3). The combined ethanol fractions were 
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concentrated in vacuo and purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the 
eluent. Yield ranged from 80–85%.  
 
General procedure for the synthesis of compound 3.289, 323 In a 100 mL round pressure vial, 8–9 g 
of urea was heated at 150–155 °C till it melted. To the liquid urea solution 0.1 eq. of 2a or 2b (~ 2 g, 13.23-
14.59 mmol) was added. The pressure vial was sealed and heated at 150–155 °C for 2 h and cooled to room 
temperature before adding ~ 50 mL of water and re-heating at 100–105 °C for 1 h. Upon cooling to room 
temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and washed brine solution (40 mL x 
3). The combined aqueous layers were washed with ~ 25 mL of EtOAc. The combined EtOAc layers were 
dried over MgSO4 and the EtOAc was removed in vacuo to yield a solid product that did not require further 
purification. Yield ranged from 75–85%.  
 
General procedure for the synthesis of 4.289, 323 In a 250 mL RBF, 5 g of 3 (30.84 mmol) was 
suspended in 25 mL of anhydrous toluene and allowed to stir on an ice bath. To this, 5 eq. of POCl3 
(154.18 mmol) was added in small aliquots followed by the slow addition of 5 eq. of DEA (154.18 mmol). 
The solution was kept on the ice bath for 10 min before moving to room temperature and allowed to stir for 
1 h prior to refluxing at 105–110 °C for 14–16 h. Upon cooling to room temperature, the reaction mixture 
was added in small aliquots to a double-ice-water bath while stirring. The quenching solution was left 
stirring at room temperature for 5 h before vacuum filtering the yellowish-grey precipitate. The precipitate 
was stirred for 1 h in a saturated NaHCO3 solution and then was re-filtered. This neutralization process was 
carried out 2–3 times until the bicarbonate solution maintains a neutral to slight basic pH. The final 
precipitate was dissolved in DCM and purified by a silica gel column chromatography using 100% DCM as 
the eluent to afford white to light grey solid. 
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2,4-Dichloroquinazoline (4). Yield: 80% (4.91 g, 24.77 mmol). Mp 117–119 °C; 1H NMR (DMSO-d6, 300 
MHz) δ 8.20 (d, J = 8.4 Hz, 1 H), 8.08 (td, J = 7.8 Hz, 1.4 Hz, 1 H), 7.94 (d, J = 8.4 Hz, 1 H), 7.81 (td, J = 
7.5 Hz, 1.2 Hz, 1 H).  
 
General procedure for the synthesis of 2-chloro-N-substituted-quinazolin-4-amines.303, 305  To a 
30 mL solution of ethanol in a 100 mL round-bottom flask on ice, 5 g of 4 (25.13 mmol) was added 
followed by slow addition of 1.3 eq. (32.66 mmol) of the corresponding primary amine. Contents were 
stirred on an ice bath while 2.0 eq. of diisopropyl-ethylamine (DIPEA, 50.25 mmol) was added in drop 
wise fashion. The solution was then heated at 80–85 °C under reflux for 3–4 h. The reaction contents were 
cooled to room temperature and precipitated residues were vacuum-filtered with ethyl acetate (EtOAc) 
rinses. The organic supernatant was concentrated in vacuo followed by two rounds of liquid-liquid 
extraction using EtOAc and saturated brine solution (40–50 mL each respectively). The combined organic 
layers were dried over MgSO4, evaporated in vacuo and purified (1–2 times) using silica gel column 
chromatography with 5:1 EtOAc:MeOH as the elution solvent. Final compounds were white to beige solids 
with yields ranging from 70-90%.  
 
2-Chloro-N-(3,4-dimethoxybenzyl)-quinazolin-4-amine (5). Yield: 90% (7.41 g, 22.50 mmol). Mp: 195–
197 °C. 1H NMR (300 MHz, DMSO-d6) δ 9.17 (t, 5.7 Hz 1H), δ 8.25 (d, J = 8.1 Hz, 1H), δ 7.74 (t, J = 7.6 
Hz, 1H), δ 7.57 (d, J = 8.1 Hz, 1H), δ 7.47 (t, J = 7.6 Hz, 1H), δ 7.03 (s, 1H), δ 6.89–6.83 (m, 2H), δ 4.62 
(d, J = 5.7 Hz, 2H), δ 3.70 (s, 3H), δ 3.68 (s, 3H). HRMS (ESI) m/z calcd for C17H16ClN3O2 [M + H]+ 
330.0931, found 330.0953. Purity: 97.9% 
 
General procedure for the synthesis of compound 6.299 In a 50 mL pressure vial (PV), 0.25 g of 5 
(0.76 mmol) was dissolved in 5 mL of 1,4-dioxane followed by the addition of 4 eq. (3.03 mmol) of 4-
amino-1-benzylpiperidine and 5 eq. of DIPEA (3.78 mmol). Pressure vial was sealed and stirred in an oil 
bath at 160–165 °C for 6 h. Upon completion and cooling to room temperature, the reaction mixture was 
diluted with ~ 40 mL of EtOAc and washed two to three times with equal volumes of brine solution. The 
combined aqueous layers were washed with ~ 25 mL of EtOAc. The combined EtOAc layers were dried 
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over MgSO4 and the organic solvent was removed in vacuo to yield a solid product which was purified by 
silica gel column chromatography using 9:1 acetone:MeOH solvent system. 
 
N2-(1-Benzylpiperidin-4-yl)-N4-(3,4-dimethoxybenzyl)quinazoline-2,4-diamine (6). Yield: 42% (0.15 g, 
0.32 mmol); Mp 127–129 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.96 (d, J = 8.2 Hz, 1H), δ 7.42 (t, J = 7.8 
Hz, 1H), δ 7.28–7.20 (m, 7H), δ 7.02–6.98 (m, 2H), δ 6.85–6.80 (m, 2H), 6.65 (br s, 1H), δ 4.58 (d, J = 5.0 
Hz, 2H), δ 3.70–3.66 (m, 6H), δ 3.46 (s, 2H), δ 2.77–2.70 (m, 3H), δ 2.04–2.00 (m, 2H), δ 1.78–1.73 (m, 
2H), δ 1.47–1.44 (m, 2H). HRMS (ESI) m/z calcd for C29H34N5O2 [M + H]+ 485.2634, found 485.2705. 
Purity: 98.7% 
 
General procedure for the synthesis of N4-substituted-quinazolin-4-amines. In a 50 mL round 
bottom flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was dissolved 
in 20 mL of anhydrous ethanol. While stirring on ice, 10 mol. % of 10% Pd/C was added to reaction 
mixture followed by the drop-wise addition of 1.3 eq. of hydrazine hydrate. Solution was stirred on ice for 
5 min before refluxing for 2 h at 80–85 °C. Upon completion and cooling to room temperature, the reaction 
mixture was passed through a tightly-packed cotton-filled syringe that has been pre-rinsed with ethanol, to 
remove the Pd/C catalyst. A 30 mL aliquot of ethanol was used to rinse the syringe. The combined ethanol 
solutions were evaporated in vacuo, diluted in EtOAc (20 mL) and washed 25 mL x 2 with equal volumes 
of brine solution. The combined aqueous layers were washed with 15 mL of EtOAc. The combined EtOAc 
layers were dried over MgSO4, before removing the EtOAc in vacuo to yield a solid or semi-solid crude 
product that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH solvent system. 
Final compounds were white to pale yellow solids with yields ranging from 40–47%. 
 
N-(3,4-Dimethoxybenzyl)quinazolin-4-amine (7). Yield 47% (0.21 g, 0.71 mmol); Mp 187–189 °C. 1H 
NMR (300 MHz, DMSO-d6): δ 8.69 (br s, 1H), δ 8.42 (s, 1H), δ 8.25 (d, J = 6.0 Hz, 1H), δ 7.71 (t, J = 9.0 
Hz, 1H), δ 7.64 (d, J = 6.0 Hz, 1H), δ 7.45 (t, J = 9.0 Hz, 1H), δ 6.99 (s, 1H), δ 6.84 (s, 2H), δ 4.67 (d, J = 
6.0 Hz, 2H), δ 3.68 (s, 3H), δ 3.67 (s, 3H). HRMS (ESI) m/z calcd for C17H18N3O2 [M + H]+ 296.1321, 
found 296.1392. Purity: 97.3% 
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General procedure for the synthesis of 2-azido-N-substituted-quinazolin-4-amine.305 In a 50 mL 
RBF, 2-chloro-N-substituted-quinazolin-4-amine (~1.86 mmol), 1.1 eq. NaN3 (2.05 mmol), 4:1 EtOH (20 
mL) and glacial acetic acid (5 mL) were combined and refluxed at 90–95 °C for 2 h with stirring. After 
cooling, the solution was vacuum-filtered to afford white solids at yields ranging from 80–85%. 
 
2-Azido-N-(3,4-dimethoxybenzyl)quinazolin-4-amine (8). Yield 80% (0.41 g, 1.21 mmol); Mp 253–255 
°C. 1H NMR (300 MHz, DMSO-d6): δ 9.34 (br s, 1H), δ 8.52 (d, J = 8.2 Hz, 1H), δ 8.32 (d, J = 8.3 Hz, 
1H), δ 7.99 (t, J = 8.0 Hz, 1H), δ 7.73 (t, J = 8.0 Hz, 1H), δ 7.05 (s, 1H), δ 6.93–6.85 (m, 2H), δ 4.74 (d, J 
= 3.0 Hz, 2H), δ 3.71 (s, 3H), δ 3.67 (s, 3H). HRMS (ESI) m/z calcd for C17H16N6O2 [M + H]+ 337.1335, 
found 337.1407. Purity: 98.5% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2,4-diamine.305  
Method 1A: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was added along with 20 mol. % of CuI. To that, a mixture of 1,4-dioxane (5 mL) and 30% aqueous 
ammonia (15 mL) was added at room temperature. The pressure vial was sealed tightly and partially 
submerged in silicone oil heating at 130–135 °C. Contents were stirred in the pressure vial for 24 h (Note: 
in the event of pressure leakage, the contents were cooled to room temperature and additional aqueous 
ammonia, (10 mL) was added, sealed and heating was carried on through the 24 h period). The reaction 
contents were cooled to room temperature and the solution was diluted with 25 mL EtOAc, washed with 
saturated brine solution (10 mL x 3), and the aqueous layer was neutralized with dilute HCl, and then re-
extracted with 15 mL EtOAc. The organic layers were combined, dried over MgSO4, evaporated in vacuo 
and purified using silica gel column chromatography with 5:1 EtOAc:MeOH as an initial elution solvent 
followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine). Final compounds were obtained as 
white to beige solids with final yields ranging from 20-25%.  
 
Method 1B: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was dissolved and gently heated in 5 mL ethylene glycol. To that, 20 mol. % of Cu2O and DMEDA 
were added followed by 20 eq. K2CO3 and finally, 40 eq. of 30% aqueous ammonia solution (~15-20 mL). 
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The pressure vial was sealed tightly, partially submerged in silicone oil and heated at 100–105 °C. Contents 
were stirred in the pressure vial for 24 h. After the reaction contents were cooled to room temperature, the 
solution was diluted with 50 mL EtOAc, washed with saturated brine solution (25 mL x 3) and the aqueous 
layer was neutralized with dilute HCl, and then re-extracted with 25 mL EtOAc. The residue formed was 
dissolved in methanol (20–25 mL). The EtOAc layers were dried over MgSO4 and evaporated in vacuo. 
The methanol fraction was dried with molecular sieves before evaporating the methanol in vacuo. Both 
EtOAc and methanol fractions were combined and purified using silica gel column chromatography with 
5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH with 1% TEA 
(triethylamine). Final compounds were obtained as white to beige solids with yields ranging from 35-40%.  
 
Method 2: In a 50 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) 
was combined with 6 eq. urea (22.32 mmol) and diluted with 10 mL of anhydrous 1,4-dioxane. The 
pressure vial was sealed tightly and partially submerged in silicone oil heating at 160–165 °C. Contents 
were stirred in the pressure vial for 24 h. Once the reaction contents were cooled to room temperature, the 
solution was diluted with 20–25 mL EtOAc. The contents were washed three times with 20 mL saturated 
brine solution and the aqueous layers were re-extracted twice with 20 mL EtOAc. The organic layers were 
combined, dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography 
with 5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA 
(triethylamine). Final compounds were obtained as white to light beige solids with yields ranging from 50-
55%. 
 
Method 3: In a 50 mL round-bottom flask, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) was 
combined with 1.1 eq. NaN3 (4.09 mmol), before diluting with 4:1 EtOH (20 mL) and glacial acetic acid (5 
mL). Flask contents were stirred under reflux at 90–95 °C for 2 h. After cooling the reaction mixture, 10 
mol. % of Pd/C (10%) was added followed by slow addition of 1.5 eq. of hydrazine hydrate (5.58 mmol). 
Flask contents were stirred under reflux at 90–95 °C for an additional two hrs. Once complete, the warm 
solution was passed through a large, tightly packed cotton syringe with the aid of additional EtOH washes 
(2 x 20 mL). The ethanolic mixture was evaporated in vacuo. Final compounds were obtained as white to 
beige solids with yields ranging from 80–85%. 
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N4-(3,4-Dimethoxybenzyl)quinazolin-2,4-diamine (9). Yield 80% (0.75 g, 2.43 mmol);. Mp: 205-207 °C. 
1H NMR (300 MHz, DMSO-d6) δ 8.28 (br s, 1H), δ 7.95 (d, J = 7.9 Hz, 1H), δ 7.44 (t, J = 7.7 Hz, 1H), δ 
7.15 (d, J = 7.7 Hz, 1H), δ 7.02–6.99 (m, 2H), δ 6.84-6.77 (m, 2H), δ 6.06 (br s, 2H), δ 4.59 (d, J = 5.0 Hz, 
2H), δ 3.69 (s, 3H), δ 3.67 (s, 3H). HRMS (ESI) m/z calcd for C17H18N4O2 [M + H]+ 311.1508, found: 
311.1502. 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-ols. In a 50 mL round bottom 
flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was combined with 1.3 
eq. of potassium formate (1.89–2.41 mmol) then dissolved in 20 mL of formic acid. Solution was refluxed 
for 14–16 h at 120–125 °C. Upon completion and cooling to room temperature, the reaction mixture was 
diluted with ~ 30 mL of brine solution, ~ 50 mL of saturated NaHCO3 solution before extracting with ~ 25 
mL (x 3) of EtOAc and washed with 25 mL (x 3) parts of brine solution. The combined aqueous layers 
were washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 before 
removing the EtOAc in vacuo to yield a solid product that generally did not require additional purification. 
Additional purification as required, was accomplished by silica gel column chromatography using 5:1 
EtOAc:MeOH as the eluent. The compounds were obtained as white solids with yields ranging from 58–
70%. 
 
4-((3,4-Dimethoxybenzyl)amino)quinazolin-2-ol (10). Yield 70% (0.33 g, 1.06 mmol); Mp 202–204 °C. 
1H NMR (300 MHz, DMSO-d6): δ 10.61 (br s, 1H), δ 8.65 (t, J = 5.7 Hz, 1H), δ 8.02 (d, J = 8.1 Hz, 1H), δ 
7.49 (t, J = 7.5 Hz, 1H), δ 7.11–7.05 (m, 1H), δ 6.98 (s, 1H), δ 6.88–6.85 (m, 2H), δ 4.58 (d, J = 5.6 Hz, 
2H), δ 3.70 (s, 3H), δ 3.68 (s, 3H). HRMS (ESI) m/z calcd for C17H18N3O3 [M + H]+ 312.1270, found 
312.1342. Purity: 99.9% 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-urea.305 In a pressure vial, 0.5 
g of 2-chloro-N-substituted-quinazolin-4-amine (~1.85 mmol) was mixed with 6 eq. urea (~11.2 mmol) and 
10 mL of anhydrous 1,4-dioxane, sealed tightly and heated at 160–165 °C in an oil bath for 24 h. After 
cooling to room temperature, the solution was diluted with 20 mL EtOAc, washed three times with 20 mL 
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brine solution; the aqueous layers were extracted twice with 20 mL EtOAc. The combined organic layers 
were dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography using a 
combination of 5:1 EtOAc:MeOH and 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine) to afford target 
compounds as white solids with yields ranging from 45–50% and the hydrolyzed amine compounds as off 
white solids with yields ranging from 50–55%.  
 
1-(4-((3,4-Dimethoxybenzyl)amino)quinazolin-2-yl)urea (11). Yield 45% (0.24 g, 0.68 mmol); Mp 263–
265 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.06 (br s, 1H), δ 8.80 (br s, 2H), δ 8.11 (d, J = 8.2 Hz, 1H), δ 
7.59 (t, J = 7.5 Hz, 1H), δ 7.44 (d, J = 8.2 Hz, 1H), δ 7.23 (t, J = 7.3 Hz, 1H), δ 7.06 (br s, 1H), δ 6.95–6.82 
(m, 3H), δ 4.60 (d, J = 5.7 Hz, 2H), δ 3.71 (s, 3H), δ 3.67 (s, 3H). HRMS (ESI) m/z calcd for C18H20N5O3 
[M + H]+ 354.1488, found 354.1560. Purity: 95.5% 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-glycinamide.299 In a 50 mL 
pressure vial, 0.25 g of 2-chloro-N-substituted-quinazolin-4-amine (~ 0.83 mmol) was combined with 3 eq. 
(~ 2.50-mmol) of glycinamide.HCl then dissolved in 5 mL of 1,4-dioxane followed by the addition of 5 eq. 
of DBU (~ 4.15 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 4 h. Upon 
completion and cooling to room temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and 
washed 25 mL (x 3) brine solution. The combined aqueous layers were washed with ~ 25 mL of EtOAc. 
The combined EtOAc layers were dried over MgSO4 and EtOAc was removed in vacuo to yield solid that 
was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the eluent to afford target 
compounds as pale yellow to brown solids with yields ranging between 52–58%. 
 
2-((4-((3,4-Dimethoxybenzyl)amino)quinazolin-2-yl)amino)acetamide (12). Yield 54% (0.15 g, 0.41 
mmol); Mp 164–166 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.33 (br s, 1H), δ 8.02 (d, J = 8.2 Hz, 1H), δ 
7.47 (t, J = 7.5 Hz, 1H), δ 7.23 (d, J = 8.4 Hz, 2H), δ 7.09–7.03 (m, 2H), δ 6.96 (br s, 1H), δ 6.91–6.82 (m, 
2H), δ 6.65 (br s, 1H), δ 4.60 (d, J = 5.6 Hz, 2H), δ 3.98 (d, J = 7.1 Hz, 2H), δ 3.70 (s, 3H), δ 3.68 (s, 3H). 
HRMS (ESI) m/z calcd for C19H22N5O3 [M + H]+ 368.1644, found 368.1719. Purity: 99.4%  
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General procedure for the synthesis of N4-substituted-quinazolin-2-acetamide.312 In a 50 mL 
round bottom flask (RBF), 0.5 g of N4-substituted-quinazolin-2,4-diamine (1.54–2.00 mmol) was dissolved 
in 15 mL of 1,4-dioxane and 10 mL of glacial acetic acid/acetyl chloride combination (4:1 ratio). Solution 
was refluxed for 24 h at 90–95 °C. Upon completion and cooling to room temperature, the reaction mixture 
was diluted with ~ 30 mL of brine solution, ~ 30 mL of concentrated NaHCO3 solution before extracting 
with ~ 25 mL (x 3) of EtOAc and washed with 25 mL (x 2) brine solution. The combined aqueous layers 
were washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 and the 
organic solvent was removed in vacuo to yield a solid product that generally did not require additional 
purification. Purification was carried out as required, by silica gel column chromatography using 5:1 
EtOAc:MeOH as the eluent to afford target compounds as white solids with yields ranging from 35–42%. 
 
N-(4-((3,4-Dimethoxybenzyl)amino)quinazolin-2-yl)acetamide (13). Yield 55% (0.31 g, 0.88 mmol); 
Mp 263–265 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.88 (br s, 1H), δ 8.67 (br s, 1H), δ 8.24 (d, J = 8.0 Hz, 
1H), δ 7.64 (t, J = 7.2 Hz, 1H), δ 7.58 (d, J = 9.0 Hz, 1H), δ 7.26 (t, J = 6.0 Hz, 1H), δ 6.87–6.78 (m, 3H), δ 
4.63 (d, J = 6.0 Hz, 2H), δ 3.69 (s, 3H), δ 3.67 (s, 3H), δ 2.24 (s, 3H). ESI-MS m/z calcd for C19H21N4O3 
[M + H]+ 353.15, found 353.17. Purity: 99.1% 
 
General procedure for the synthesis of N4-substituted-N2-alkyl-quinazolin-2,4-diamine.299, 313 In a 
50 mL pressure vial (PV), 0.25 g of 2-chloro-N-substituted-quinazolin-4-amine (~ 0.83 mmol) was 
combined with 2 eq. (~ 1.66 mmol) of primary amine (methyl-, ethyl-, n-propyl-, isopropyl- or 
cyclopropylamine) then dissolved in 5 mL of 1,4-dioxane followed by the addition of 3 eq. of DIPEA (~ 
2.40 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 2 h. Upon completion and 
cooling to room temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and washed with 
brine solution (25 mL x 2). The combined aqueous layer was washed with ~ 25 mL of EtOAc. The 
combined EtOAc layers were dried over MgSO4 before removing EtOAc in vacuo to yield a solid product 
that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the eluent to afford pale 
yellow to brown solids yielding at 55–70%. 
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N4-(3,4-Dimethoxybenzyl)-N2-methylquinazoline-2,4-diamine (14). Yield 68% (0.33 g, 1.02 mmol); Mp 
199–201 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.23 (br s, 1H), δ 8.01 (d, J = 8.0 Hz, 1H), δ 7.41 (t, J = 
7.2 Hz, 1H), δ 7.21 (m, 2H), δ 6.95 (t, J = 6.0 Hz, 1H), δ 6.84–6.80 (m, 2H), δ 6.50 (br s, 1H), δ 4.58 (d, J 
= 6.0 Hz, 2H), δ 3.68 (s, 3H), δ 3.66 (s, 3H), δ 2.77 (d, J = 4.5 Hz, 3H). HRMS (ESI) m/z calcd for 
C18H21N4O2 [M + H]+ 325.1586, found 325.1659. Purity: 97.6%  
 
N4-(3,4-Dimethoxybenzyl)-N2-ethylquinazoline-2,4-diamine (15). Yield 67% (0.36 g, 1.06 mmol); Mp 
186–188 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.25 (br s, 1H), δ 7.95 (d, J = 8.0 Hz, 1H), δ 7.41 (t, J = 
7.2 Hz, 1H), δ 7.20–7.18 (m, 1H), δ 7.00–6.95 (m, 2H), δ 6.84–6.72 (m, 2H), δ 6.40 (br s, 1H), δ 4.59 (d, J 
= 6.0 Hz, 2H), δ 3.68 (s, 3H), δ 3.66 (s, 3H), δ 3.24–3.19 (m, 2H), δ 1.06 (t, J = 7.0 Hz, 3H). HRMS (ESI) 
m/z calcd for C19H23N4O2 [M + H]+ 339.1743, found 339.1817. Purity: 98.8% 
 
N4-(3,4-Dimethoxybenzyl)-N2-propylquinazoline-2,4-diamine (16). Yield 65% (0.34 g, 0.97 mmol); Mp 
156–158 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.20 (br s, 1H), δ 7.90 (d, J = 8.0 Hz, 1H), δ 7.40 (t, J = 
7.2 Hz, 1H), δ 7.15 (d, J = 9.0 Hz, 1H), δ 7.05–6.95 (m, 2H), δ 6.82-6.74 (m, 2H), δ 6.50 (br s, 1H), δ 4.58 
(d, J = 6.0 Hz, 2H), δ 3.68 (s, 3H), δ 3.66 (s, 3H), δ 3.24–3.19 (m, 2H), δ 1.46 (q, J = 7.0 Hz, 2H), δ 0.80 (t, 
J = 7.0 Hz, 3H). HRMS (ESI) m/z calcd for C20H25N4O2 [M + H]+ 353.1899, found 353.1927. Purity: 
98.9% 
 
N4-(3,4-Dimethoxybenzyl)-N2-isopropylquinazoline-2,4-diamine (17). Yield 68% (0.36 g, 1.02 mmol); 
Mp 177–179 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.21 (br s, 1H), δ 7.95 (d, J = 8.0 Hz, 1H), δ 7.39 (t, J 
= 7.2 Hz, 1H), δ 7.20 (d, J = 9.0 Hz, 1H), δ 7.02–6.95 (m, 2H), δ 6.84–6.72 (m, 2H), δ 6.20 (br s, 1H), δ 
4.58 (d, J = 6.0 Hz, 2H), δ 4.10–4.05 (m, 1H), δ 3.68 (s, 3H), δ 3.66 (s, 3H), δ 1.07 (d, J = 6.0 Hz, 6H). 
HRMS (ESI) m/z calcd for C20H25N4O2 [M + H]+ 353.1899, found 353.1926. Purity: 98.6% 
 
N2-Cyclopropyl-N4-(3,4-dimethoxybenzyl)quinazoline-2,4-diamine (18). Yield 70% (0.37 g, 1.06 
mmol); Mp 201–203 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.20 (br s, 1H), δ 7.85 (d, J = 8.0 Hz, 1H), δ 
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7.40 (t, J = 7.2 Hz, 1H), δ 7.20 (d, J = 9.0 Hz, 1H), δ 7.00–6.97 (m, 2H), δ 6.84-6.70 (m, 2H), δ 6.60 (br s, 
1H), δ 4.59 (d, J = 6.0 Hz, 2H), δ 3.67 (s, 3H), δ 3.66 (s, 3H), δ 2.46–2.42 (m, 1H), δ 0.63–0.58 (m, 2H), δ 
0.48–0.41 (m, 2H). HRMS (ESI) m/z calcd for C20H23N4O2 [M + H]+ 351.1743, found 351.1816. Purity: 
98.2% 
 
 
3.5.2. Biological Screening 
 
3.5.2.1. Human Cholinesterase (hChE) Assay299, 313 
 
The inhibition profile of quinazoline derivatives was evaluated using the Ellman (DTNB) reagent.315 
Human AChE and BuChE enzymes were obtained from Sigma-Aldrich, St. Louis, MO, USA (AChE 
product number C0663 and BuChE product number B4186 respectively). The cholinesterase inhibitors 
tacrine (item number 70240, Cayman Chemical Company, Ann Arbor, MI), donepezil (product number 
D6821, Sigma-Aldrich, St. Louis, MO), galantamine (product number G1660, Sigma-Aldrich, St. Louis, 
MO) and rivastigmine (product number SML0881, Sigma-Aldrich, St. Louis, MO) were used as reference 
agents. Quinazoline derivative stock solutions were prepared in DMSO (maximum 1% v/v in final wells) 
and diluted in buffer solution (50 mM Tris.HCl, pH 8.0, 0.1 M NaCl, 0.02 M MgCl2.6H2O). Then 160 µL 
of 5,5’-dithiobis(2-nitrobenzoic acid) (1.5 mm DTNB), 50 µL of hAChE (0.22 U/mL in 50 mM Tris.HCl, 
pH 8.0, 0.1% w/v bovine serum albumin, BSA) or 50 µL of hBuChE (0.12 U/mL in 50 mM Tris.HCl, pH 
8.0, 0.1% w/v BSA) were added to 96–well plates after which 10 µL each of quinazoline derivatives (final 
concentration range 0.1–50 µM) were added and incubated for 5 min. Then 30 µL of either 
acetylthiocholine iodide (15 mM AThCl prepared in ultra pure water) or S-butyrylthiocholine iodide (15 
mM BThCI prepared in ultra pure water) were added.  
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Figure 47: Principles of the DTNB-assay for assessing ChE inhibition by target quinazoline derivatives.  
 
The absorbance was measured at different time intervals (0, 60, 120, 180, 240 and 300 s) using a 
wavelength of 412 nm. The inhibitory concentration (IC50 values) was calculated from the concentration–
inhibition dose response curve on a logarithmic scale. The results were expressed as average values based 
on two to three independent experiments run in triplicate measurements. 
 
 
3.5.2.2. Amyloid-β (Aβ) Aggregation Assay317 
 
The ability of quinazoline-based derivatives to inhibit Aβ-aggregation kinetics was determined using a 
ThT-binding fluorescence assay. These assays were conducted in Costar, black-surround, clear-bottom 
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384–well plates with frequent shaking (30 sec. of linear shaking at 730 cpm every 5 minutes) and constant 
heating at 37 °C for 24 h. The ThT excitation/emission was measured at 440 nm/490 nm and readings were 
taken every 5 minutes using a BioTek Synergy H1 microplate reader. Quinazoline stock solutions were 
prepared in DMSO and diluted to 10x in 215 mM phosphate buffer at pH 7.4. Abeta.HFIP samples (Aβ40 
or Aβ42, rPeptide, Bogart, USA) were dissolved in 1% ammonium hydroxide, sonicated at room 
temperature for 5 minutes then diluted to 50 µM in 215 mM phosphate buffer (pH 7.4). A 15 µM ThT stock 
solution was prepared with 50 mM glycine and adjusted to pH 7.4. The assay was carried out by adding 44 
µL ThT, 20–35 µL buffer, 1 µL DMSO (for background and controls only) followed by the addition of 8 
µL of 10x compound dilutions (1–25 µM concentration range). An end point reading was conducted to 
evaluate potential test compound interference with ThT-fluorescence before adding 8 µL of Aβ40 or Aβ42 
stock solutions (5 µM final concentration). Plates were sealed with a transparent plate film before initiating 
the assay. RFU values were corrected for ThT-interference before calculating end point percent inhibitions 
or IC50 values and obtaining the aggregation kinetic plots. Data presented was an average of triplicate 
reading for two-three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: Principles of the ThT assay for assessing Aβ-aggregation inhibition by target quinazoline derivatives.  
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3.5.2.3. DPPH Scavenging Assay324 
 
The ability of select quinazolines to scavenge the DPPH radical was utilized as a measure of 
antioxidant capacity, compared to trolox as the assay control. Quinazoline stock solutions were prepared in 
anhydrous methanol (500 µM) and the DPPH solution was also prepared in anhydrous methanol (56 µM). 
The addition sequence was carried out in a 96–well clear, flat bottom plate as follows: 90 µL DPPH, 10 µL 
test compound solution (50 µΜ) final concentration. Control solutions contained 90 µL anhydrous 
methanol and 10 µL test compound whereas DPPH control contained 90 µL of DPPH, and 10 µL 
anhydrous methanol. This readings were taken initially at 517 nm with 30 sec. shaking (double orbital at 
530 cpm) prior to the 1 h, light restrictive, incubation period at room temperature after which readings were 
taken again at 517 nm after another round of 30 sec shaking (double orbital at 530 cpm) using a BioTek 
Synergy H1 microplate reader. The results were expressed as percentage inhibition and the data presented 
was an average of triplicate reading (for two independent experiments). 
 
 
 
 
 
 
 
 
 
 
 
Figure 49: Principles of the DPPH-scavenging assay for assessing antioxidant capacity for select quinazolines.  
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3.5.3. Computational Chemistry299, 313, 317, 324 
 
The molecular docking studies were conducted using Discovery Studio 4.0 (Structure-Based-Design 
program) from BIOVIA Inc. San Diego, USA. Select quinazolines derivatives were built and minimized 
using the small molecules module in Discovery Studio. X-ray coordinates of human cholinesterases were 
obtained from the protein data bank (hAChE PBD ID: 1B41 and hBuChE PDB ID: 1P0I) and prepared 
using the macromolecules module in Discovery Studio. Ligand binding sites were defined by selecting a 12 
Å radius sphere for AChE and 15 Å radius sphere for BuChE. The molecular docking was performed using 
the receptor-ligand interactions module in Discovery Studio. The LibDock algorithm was used to find the 
most appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. For amyloid-β docking studies, the NMR solution structure of Aβ fibrils were 
obtained from the protein data bank (PDB ID: 2LMN). Aβ dimer and Aβ fibril assemblies were built using 
the macromolecules module in Discovery Studio. Ligand binding site was defined by selecting a 15 Å 
radius sphere for both Aβ assemblies. Molecular docking was performed using the receptor-ligand 
interactions module in Discovery Studio, where the LibDock algorithm was used to find the most 
appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. 
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CHAPTER 4 
  Development and Evaluation of N-benzylquinazolin-4-amines as Dual ChE and 
Aβ Aggregation Inhibitors   
 
 
* Chapter banner   
  
4.1. Introduction 
 
The dimethoxybenzyl series (see Chapter 3) provided good insight into the requirements and 
restrictions toward the dual targeting of the ChEs and Aβ aggregation. While the presence of the 
benzylpiperidine moiety in 6 proved beneficial to that series, further exploration of the smaller C2-groups 
was desired. A new aspect is briefly introduced in this Chapter and that is the evaluation of a 
monosubstituted quinazoline-2,4-diamine regioisomer (Chapter 8 contains a larger degree of SAR 
pertaining to the regioisomer assessment). 
This chapter highlights the synthesis and development of target derivatives (refer to the chapter 
banner above) along with the acquisition and assessment of the SAR data. For the most part, the synthetic 
approaches and mechanisms here have been previously discussed in Chapter 3. A brief summary is 
provided prior to the listing of experimental data and methodology. 
 
4.2. Hypothesis 
 
With respect to this series, the absence of the 3,4-dimethoxy moiety should reduce structural 
hindrance at the C4-position; however, the limited points of rotation connecting the phenyl ring and the 
quinazoline scaffold still exist. While the absence of the 3,4-dimethoxy moiety might benefit ChE targeting 
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(especially BuChE), it may reduce potential hydrogen bonding with Aβ structures impacting the 
modulation of amyloid aggregation. 
On the other hand, continuing with the existing selection of C2-groups offers an opportunity to 
evaluate and compare the impact of the 3,4-dimethoxy moiety at the C4-position. Previous predications 
hold true with entities like the azide and carbonyl-based groups with respect to their inability to target 
BuChE. The reduced sterics at the C4-position, combined with alkylamines at the C2-posiiton, are 
predicted to improve BuChE inhibition, while effectively targeting AChE and modulating amyloid 
aggregation.  
Lastly, the regioisomer comparison is likely to produce split observations with regards to dual ChE 
and amyloid aggregation targeting, primarily due to the conformational differences that each isomer takes 
on in the target of interest.  
 
4.3. Results and Discussions 
 
The proceeding sub-chapter discusses new synthetic methodology, while briefly highlighting 
previously-established routes to desired derivatives. Biological assessments in the cholinesterase and 
amyloid-β aggregation assay (to obtain IC50 values and/or investigation aggregation kinetics) are conducted. 
Aggregate load is corroborated via transmission electron microscopy in amyloid morphology screening and 
select derivatives were assessed for ROS scavenging in the DPPH assay. Computational studies were 
performed in the ChE X-ray structures and amyloid models to evaluate the acquired SAR data.  
 
4.3.1. Synthesis 
 
As similarly described in Chapter 3, initial coupling in this series utilized 2,4-DCQ (4), to add the 
unsubstituted benzylamine group to the C4-position of the quinazoline scaffold, via a NAS reaction, to 
yield N-(benzyl)-2-chloroquinazolin-4-amine (19, Scheme 9, 80–85% yield).299, 303 The C2-unsubstituted 
derivative (N-benzylquinazolin-4-amine, 20, Scheme 9, ~ 45% yield) was also synthesized via the Pd/C and 
hydrazine-driven dehalogenation reaction.304  
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Scheme 9a  
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 19 and 20. (a) Benzylamine, DIPEA, 
EtOH, reflux, 4 h; (b) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h. 
 
 
Scheme 10a  
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 21-23. (a) Sodium azide, EtOH, 
acetic acid, 90–95 °C, 2 h; (b) Cu2O, K2CO3, DMEDA, ethylene glycol, ammonium hydroxide, pressure vial, oil bath, 
105 °C, 24 h; (c) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h; (d) HCl, sodium nitrite, sodium azide, 0 °C–r.t., 1 h; (e) 
potassium formate, formic acid, 120–125 °C, 14–16 h. 
 
 
Synthesis of 2-azido-N-benzylquinazolin-4-amine (21, Scheme 10, ~ 90% yield) was accomplished as 
previously described utilizing sodium azide,305, 306 while the generation of the C2-amino derivative (22, 
Scheme 10, N4-benzylquinazoline-2,4-diamine) was primarily conducted using the azide reduction 
approach via Pd/C and hydrazine.305 The effective formate/formic acid approach was utilized to generate 23 
(4-(benzylamino)quinazolin-2-ol, Scheme 10, yield ~ 65%).  
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Scheme 11a  
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 22 and 22-iso. (a) Guanidine 
carbonate, DMA, 150–155 °C, 14–16 h; (b) Sodium hydride, DMSO, benzyl bromide, 0 °C–r.t., 14 h; (c) DMA, 
potassium or cesium carbonate, benzyl bromide 80–85 °C, 5 h. 
 
 
Scheme 12a  
 
 
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 24-31. (a) Urea, 1,4-dioxane, 
pressure vial, 160–165 °C, 24 h.; (b) glycinamide, DBU, 1,4-dioxane, pressure vial, 150–155 °C, 4 h.; (c) acetyl 
chloride, acetic acid, 1,4-dioxane, 120 °C, 24 h.; (d) Primary amine (R1 = Me, Et, n-Pr, i-Pr or c-Pr), DIPEA, 1,4-
dioxane, pressure vial 150–155 °C, 2 h. 
 
 
An alternate route to the synthesis of C2-amino derivatives, along with their C4-amino regioisomers, 
came from the utilization of 2,4-diaminoquinazoline (DAQ, Scheme 11). The generation of DAQ was 
accomplished by condensing 2-fluorobenzonitrile with guanidine carbonate in a similar fashion used to 
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condense urea with 2-aminobenzoic acid (Chapter 2, Figure 30). The selective alkylation of DAQ at the 
C4-position (22) was accomplished by utilizing sodium hydride, at equal equivalence with DAQ, to 
selectively deprotonate the C4-amino group before nucleophilic attack on the aryl bromide. For selective 
alkylation at the C2-position (22-iso) on the other hand, an inorganic quenching base was used and the 
more nucleophilic C2-amino group acted upon the aryl bromide, without deprotonation, to displace the 
halogen.291, 317 The development of both the C2-carbonyl based derivatives 24 (C2 = urea), 25 (C2 = 
glycinamide), 26 (C2 = acetamide) and the C2-alkylamine based derivatives (27–31) (Scheme 12) was 
accomplished as previously described in Chapter 3. 
 
4.3.2. Cholinesterase 
 
The ability of 2-substituted-N-benzylquinazolin-4-amines (19–31) and the C4-amino regiosiomer (22-
iso) to target the cholinesterases (hAChE/hBuChE) was assessed using the DTNB method as described in 
Chapter 3 (Table 3).315  
Examination of Table 3 generally pointed to the overall ability of most derivatives within this series to 
target BuChE. While anti-BuChE activity was not necessarily promising, it did support the hypothesis 
regarding the reduced sterics and polarity associated with this series and how that would benefit BuChE 
targeting overall. With respect to AChE targeting, IC50 values ranged from 5 to 14 µM and benzyl-based 
derivatives were, generally, less potent compared to their 3,4-dimethoxybenzyl counterparts (Chapter 3, 
Table 1). 
Starting out with the C2-chlorine based derivative, 19 was roughly 2.5-fold less potent toward AChE 
(IC50 = 7.5 µM) compared to 5 and it was also ineffective toward BuChE. Dechlorination of 19 slightly 
improved AChE targeting by roughly 1.3-fold (20, IC50 = 5.8 µM); however it was also 2-fold less potent 
compared to its dimethoxybenzyl counterpart (7, Chapter 3). As expected, 20 was also ineffective toward 
BuChE. The azide functionality in this series (21) was more detrimental to AChE targeting, resulting in the 
least active AChEI (IC50 = 14.0 µM), which was also ineffective toward BuChE and roughly 1.8-fold less 
active compared to 8 (the dimethoxybenzyl counterpart, Chapter 3). 
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Table 3: Cholinesterase inhibition data for 2-substituted-N-benzylquinazolin-4-amines (9-31) and the C4-amino 
regiosiomer (22-iso). 
 
 
 
 
Derivative R-Grp 
ChE IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
hAChE hBuChE 
19 Cl 7.5 ± 0.8 > 50 – 4.09 174.5 1:3 
20 H 5.8 ± 0.4 > 50 – 3.33 158.1 1:3 
21 N3 14.0 ± 1.1 > 50 – 4.75 210.6 1:5 
22 H 5.0 ± 0.7 30.1 ± 4.0 0.17 3.32 163.9 3:4  
22-iso – 7.5 ± 0.8 11.6 ± 1.3 0.65 3.32 195.5 3:4  
23 OH 9.8 ± 0.6 > 50 – 3.95 199.6 2:4 
24 CONH2 8.3 ± 0.9 > 50 – 3.35 221.2 4:6 
25 CH2CONH2 7.2 ± 0.7 > 50 – 2.78 241.1 4:6 
26 COMe 7.5 ± 0.5 > 50 – 2.87 228.4 2:5 
27 Me 8.0 ± 0.5 18.8 ± 1.5 0.43 4.14 176.9 2:4 
28 Et 7.5 ± 0.6 15.2 ± 1.0 0.49 4.67 186.5 2:4 
29 n-Pr 7.8 ± 0.9 14.4 ± 0.9 0.54 5.20 205.1 2:4 
30 i-Pr 6.4 ± 0.5 11.7 ± 0.8 0.55 4.98 198.5 2:4 
31 c-Pr 6.6 ± 0.4 22.0 ± 1.6 0.30 4.73 200.9 2:4 
Donepezil – 0.03 ± 0.002 3.6 ± 0.4 0.01 4.59 321.7 0:4 
Tacrine – 0.16 ± 0.01 0.04 ± 0.001 4.00 3.27 165.6 2:2 
Galantamine – 2.6 ± 0.6 > 50 – 1.18 239.4 1:4 
Rivastigmine – 6.5 ± 0.5 > 10 – 2.10 226.3 0:4 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. 
bSelectivity index is calculated as (hAChE IC50)  ÷ (hBuChE IC50). cClogP values were determined using ChemDraw 
Professional 15.0. dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design 
software, BIOVIA Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding 
acceptors. 
 
 
Reducing the azide to yield 22 generated the most active AChEI in this series (IC50 = 5.0 µM), 
although it was 2-fold less potent compared to the dimethoxy counterpart in Chapter 3 (9). That said, 22 
was the first derivative in this series to mildly target BuChE (IC50 ~ 30 µM) – a characteristic not seen with 
9. The assessment of 22’s regiosiomer revealed an interesting observation where 22-iso lost 33 % of AChE 
inhibitory potency (compared to 22), while gaining a 61 % increase in BuChE potency (Table 3). 
Molecular volume (164 Å3 vs. 196 Å3; respectively) and overall conformational changes are likely to 
account for the observed regioisomeric effect. Similar to the bioisosteric comparison in Chapter 3, the C2-
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hydroxy derivative (23, IC50 ~ 10 µM) was roughly 2-fold less potent compared to 22, ineffective toward 
BuChE and less potent toward AChE (~ 1.3-fold) when compared to the dimethoxybenzyl counterpart (10, 
Chapter 3). 
With respect to the carbonyl-based derivatives, similar to those in Chapter 3, derivatives 24–26 
exhibited similar activity toward AChE (IC50 ~ 8 µM) and were also ineffective toward BuChE, 
strengthening the hypothesis that small, carbonyl-based moieties (coupled to the quinazoline scaffold) are 
not suitable to target BuChE.  
The introduction of alkylamines at the C2-position (derivatives 27–31, Table 3) established 
comparable activity toward AChE (IC50 ~ 7.1 µM) as seen with the dimethoxybenzyl counterpart (14–18, 
Chapter 3, IC50 ~ 6.6 µM). That said, the alkylamine-based derivatives in this series were anywhere from 
1.3 to 3-fold more effective at targeting BuChE compared to derivatives 14–18. Another interesting note, 
while 14–18 (Chapter 3) exhibited BuChE activity ranging from 25-30 µM the unsubstituted benzylamine 
counterparts (27–31) exhibited a wider range of BuChE activity (12–22 µM). The ranking of the alkyl side 
chains were: i-Pr > n-Pr > Et > Me > c-Pr. 
 
 
 
 
 
 
 
Figure 50: Cholinesterase metrics for fourteen 2-substituted-N-benzylquinazolin-4-amines (19–31). 
 
 
In summary, 14 derivatives were assessed for dual cholinesterase activity, of which derivative 22 (N4-
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regioisomer (22-iso) was identified as the most active BuChEI (IC50 ~ 12 µM). Generally, this series 
proved to be less effective toward AChE, while maintaining or improving BuChE outlook compared to the 
dimethoxybenzyl series in Chapter 3 (Figure 50). 
 
 
4.3.3. Amyloid-β Aggregation 
 
The ability of 2-substituted-N-benzylquinazolin-4-amines (19–31) and the C4-amino regiosiomer (22-
iso) to modulate the aggregation kinetics of amyloid-β was assessed using the ThT-binding method 
described earlier in Chapter 3 (Table 4). 
Examination of Table 2 demonstrated the overall ability of this series to dually target Aβ aggregation 
(12 out of 14 derivatives as dual inhibitors). In most cases, inhibitory activity toward Aβ40 was improved 
compared to the dimethoxybenzyl counterparts in Chapter 3. Of the 14 derivatives, only two were inactive 
toward Aβ42 (22 and 25) and 25 was also inactive toward Aβ40 – similar observation with the C2-
gylcinamide as seen in Chapter 3. When compared to assay controls, only 22-iso surpassed both curcumin’s 
and resveratrol’s activity toward Aβ42, while 23 was identified as a strong Aβ40 inhibitor that easily 
surpassed both controls’ activity toward Aβ40. In addition, three derivatives (21, 22-iso and 26) were 
potent enough to be placed between resveratrol’s and curcumin’s ranking with respect to Aβ40 aggregation 
inhibition (Table 4). 
Starting out with the C2-chlorine derivative, 19 (IC50 ~ 17 µM) was considered a weak inhibitor of 
Aβ40, although it was more potent compared to its dimethoxybenzyl counterpart (5, Chapter 3, P.I at 25 
µM was 18%). It was also equally weak as 5 toward Aβ42 (P.I at 25 µM was ~ 20%). Dechlorination of 19 
worsened the activity of 20 toward Aβ40, while roughly maintaining the same P.I at 25 µM ~ 25%). When 
compared to 7 (Chapter 3, P.I of Aβ40/42 at 25 µM was ~ 30% and ~ 20%; respectively), 20 was more 
potent by ~ 7% toward both Aβ species. 
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Table 4: Amyloid-β (Aβ40/42) inhibition data for 2-substituted-N-benzylquinazolin-4-amines (19–31) and the C4-
amino regiosiomer (22-iso). 
 
 
 
 
 
Derivative R-Grp 
Amyloid-β IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
Aβ40 Aβ42 
19 Cl 16.7 ± 2.5 22% – 4.09 174.5 1:3 
20 H 37% 27% – 3.33 158.1 1:3 
21 N3 2.6 ± 0.7 37% – 4.75 210.6 1:5 
22 H 4.8 ± 1.1 NA – 3.32 163.9 3:4  
22-iso – 2.2 ± 0.5 8.4 ± 1.1 0.26 3.32 195.5 3:4  
23 OH 0.27 ± 0.02 24% – 3.95 199.6 2:4 
24 CONH2 13.3 ± 2.5 48% – 3.35 221.2 4:6 
25 CH2CONH2 NA NA – 2.78 241.1 4:6 
26 COMe 1.9 ± 0.3 31% – 2.87 228.4 2:5 
27 Me 48% 19% – 4.14 176.9 2:4 
28 Et 7.0 ± 1.4 24% – 4.67 186.5 2:4 
29 n-Pr 5.0 ± 1.0 26% – 5.20 205.1 2:4 
30 i-Pr 4.4 ± 0.8 13% – 4.98 198.5 2:4 
31 c-Pr 5.7 ± 1.1 31% – 4.73 200.9 2:4 
Curcumin – 3.3 ± 0.45 9.9 ± 0.4 0.33 4.59 302.1 2:6 
Resveratrol – 1.1 ± 0.1 15.3 ± 1.9 0.07 2.83 187.2 3:3 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). bSelectivity 
index is calculated as (Aβ40 IC50)  ÷ (Aβ42 IC50). cClogP values were determined using ChemDraw Professional 15.0. 
dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design software, BIOVIA 
Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding acceptors. 
 
 
Unlike the outcome of the azide functionality in Chapter 3, 21 exhibited good activity toward Aβ40 
(IC50 = 2.6 µM, roughly 3-fold more active compared to 8), while providing moderate activity toward Aβ42 
(P.I at 25 µM was ~ 37%). Derivative 21 was the first compound to surpass curcumin’s potency toward 
Aβ40 in the series. Reduction of that azide caused an approximate 2-fold decrease in the activity of 22 
toward Aβ40, while surrendering all inhibitory activity toward Aβ42. When compared to the 
dimethoxybenzyl counterpart (9), 22 was roughly 3-fold more potent toward Aβ40. The regioisomer of 22 
was significantly more active toward Aβ40/42, starting with a 2-fold increase in potency toward Aβ40 (22-
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iso, IC50 = 2.2 µM – stacked between the activities of resveratrol and curcumin) and generating the 
strongest inhibitory activity toward Aβ42 (IC50 = 8.4 µM – surpassed the activities of resveratrol and 
curcumin). Replacement of the amino group in 22 with a hydroxyl group in 23 resulted in a substantial 
improvement to the inhibitory activity toward Aβ40 (IC50 = 270 nM) with mild targeting of Aβ42 (P.I at 25 
µM was 24%) – An equipotent profile with the choline- and hydrogen-based derivatives 19 and 20. When 
compared to its dimethoxybenzyl counterpart, derivative 23 was also roughly 30-fold more active toward 
Aβ40 when compared to 10. 
With respect to the carbonyl-based derivatives, C2-urea-containing derivative 24 exhibited weak to 
moderate activity toward Aβ40 and Aβ42 (IC50 ~ 13 µM and ~ 25 µM; respectively), while the gylcinamide 
derivative (25) was inactive on both fronts – Similar outcome as that observed in Chapter 3. The acetamide 
derivative (26) on the other hand, while weakly active toward Aβ42 (P.I at 25 µM was 31%), it was 
roughly 7-fold more potent toward Aβ40 (IC50 = 1.9 µM) compared to its urea bioisostere (24) and roughly 
3-fold more potent compared to its amino-based derivative (22). 
The introduction of alkylamines at the C2-position established some interesting SAR. With the 
exception of the methyl side chain, other alkyl chains exhibited good to moderate activity toward Aβ40 
(IC50 ~ 5–7 µM). Derivative 27 exhibited a P.I of Aβ40/42 at 25 µM of 48% and 19%; respectively, while 
the ethyl-base derivative (28) improved Aβ40 roughly 4-fold and Aβ42 by 5%. Amongst the propyl-based 
derivatives, ranking with respect to Aβ40 was 30 (isopropyl), 29 (propyl) then 31 (cyclopropyl) and 
interestingly, that ranking is reversed with respect to Aβ42. 
In summary, 14 derivatives were assessed for dual Aβ-aggregation activity, of which derivative 23 (4-
(benzylamino)quinazolin-2-ol) was identified the most potent Aβ40 inhibitor (IC50 = 270 nM). While most 
derivatives in this series were weak to moderate inhibitors of Aβ42, derivative 22-iso (N2-
benzylquinazoline-2,4-diamine) was identified as the most active inhibitor (IC50 ~ 8 µM)  (Figure 51). 
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Figure 51: Amyloid-β metrics for fourteen 2-substituted-N-benzylquinazolin-4-amines (19–31). 
 
 
The aggregation kinetic assessment of Aβ40 with or without series-leading derivatives is showcased 
in Figure 52. As observed with resveratrol (Panel A), derivatives 23 and 26 (Panels B and C; respectively) 
exhibit concentration-dependent inhibition of Aβ40 aggregation. Both managed to showcase multi-type 
modulation of the aggregation process, including significant monomeric structure stabilization (across all 
concentrations) as seen by the extended lag phase timeline as compared to the Aβ40-alone curve. 
Nonetheless, derivative 23 managed to stabilize the monomeric structure, reduce the rate of oligomerization 
and substantially hinder the total amyloid load at the 24-hour mark. At both the 1:1 and 1:5 test ratios, 
derivative 23 prevented significant oligomer formation as witnessed by the low RFU values across the 24 
hour timeline. On the other hand, derivative 26 was very effective at monomeric structure stabilization, but 
did not necessarily reduce the rate of oligomerization. That said, at both the 1:1 and 1:5 test ratios, 
derivative 26 prevented significant fibril formation as witnessed by the lack of a plateau phase in the 
aggregation curves. Based on the overall kinetic plots, it is evident that derivatives 23 and 26 have the 
greatest impact upon Aβ40 at the very early stages of dimerization and oligomerization. 
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The aggregation kinetic assessment of Aβ42 with or without derivative 22-iso is showcased in Figure 
53. Compared to resveratrol (Panel A), derivative 22-iso (Panel B) was effective at reducing the total 
amyloid load at all concentrations tested. In addition, at the 1:1 and 1:5 test ratios, slight stability of the 
monomeric structures was observed as seen by the approximate 2-hour extension in the lag phase timeline 
as compared to the Aβ42-alone curve. Based on the overall kinetic plot, it is evident that derivative 22-iso 
has a minor role in early oligomerization process, but its impact is placed more at the fibrillation stage. 
 
 
 
 
 
 
 
 
 
 
 
Figure 52: ThT-monitored kinetics of Aβ40 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of resveratrol on the aggregation kinetics of 5 µM 
Aβ40. Panel (B): Impact of 1, 5 or 25 µM of 4-(benzylamino)quinazolin-2-ol (23) on the aggregation kinetics of 5 µM 
Aβ40. Panel (C): Impact of 1, 5 or 25 µM of N-(4-(benzylamino)quinazolin-2-yl)acetamide (26) on the aggregation 
kinetics of 5 µM Aβ40.  
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Figure 53: ThT-monitored kinetics of Aβ42 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of resveratrol on the aggregation kinetics of 5 µM 
Aβ42. Panel (B): Impact of 1, 5 or 25 µM of N2-benzylquinazoline-2,4-diamine (22-iso) on the aggregation kinetics of 
5 µM Aβ42. 
 
 
 
4.3.4. Transmission Electron Microscopy (TEM) 
 
The assessment of amyloid morphology at the conclusion of a 24-hour incubation period at 37 °C was 
conducted on leading derivatives. This commonly employed, qualitative technique is used to corroborate 
the quantitative results from the ThT-binding assay.207, 317 Experimental setup included the incubations of 
control and test samples, at 1:1 ratios of 25 µM, in triplicate at 37 °C (with shaking) over a 24-hour 
timeline. Triplicate samples were combined after the incubation period and applied to the copper-mesh 
grids prior to imaging in the TEM. 
As observed in Figure 54, resveratrol was effective at reducing total amyloid load (Panels B and E) 
compared to control samples (Panels A and D). That said, derivative 23 (Panel C) surpassed the inhibitory 
potential of resveratrol against Aβ40, while derivative 22-iso was more effective against Aβ42, compared 
to resveratrol.  
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Figure 54: TEM assessment of Aβ40/42 morphology with or without test compounds at the end of a 24 h, 37 °C 
incubation period at pH 7.4. Panel (A–C): 25 µM Aβ40 alone or at a 1:1 ratio with resveratrol or 4-
(benzylamino)quinazolin-2-ol (23); respectively. Panel (D–F): 25 µM Aβ42 alone or at a 1:1 ratio with resveratrol or 
N2-benzylquinazoline-2,4-diamine (22-iso); respectively. White/black bars represent 500 nm. 
 
 
4.3.5. Antioxidant Capacity 
 
The ability of select 4-(benzylamino)quinazolin-2-ol (23) to neutralize ROS was assessed using the 
previously described DPPH-scavenging assay.216, 319-321  
As a conjugated phenolic compound, it was no surprise to observe the scavenging potential of 23 in the 
DPPH assay. While it was equipotent to resveratrol (~ 42% DPPH-radical scavenging), the absence of the 
dimethoxy moiety at the C4-position impaired its antioxidant capacity by 16%, compared to 10 (Chapter 3). 
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Figure 55: Standards utilized in the DPPH-scavenging along with the data for 4-(benzylamino)quinazolin-2-ol (23). 
 
 
 
4.3.6. Molecular Modeling 
 
The utilization of computational software is not only useful in structure-based drug design, it is also 
employed to understand and corroborate the acquired SAR data. The assessment of ligand-receptor 
interactions was conducted between leading (or comparable) derivatives from the 2-substituted-N-
benzylquinazolin-4-amine series (19-31), including the 22-iso regioisomer, and the cholinesterase or 
amyloid targets of interest.  
 
 
4.3.6.1. Cholinesterase 
 
Based on the acquired anti-ChE data, presented in Table 3, the docking interactions of 20, 22 and 22-
iso were investigated in hAChE (PBD: 1B41) and superimposed in Figure 56, along with the docking 
interactions of 22 and 22-iso in hBuChE (PBD: 1P0I). 
As observed in Panel A, a perfect superimposition of 20 and 22 was observed where the quinazoline 
scaffold was stacked semi-parallel to W86 (~ 4 Å). Binding was deep into the active site as scaffold 
distance to W286 was roughly 14 Å. Both derivatives had their C4-benzyl groups wrap around W86 (~ 4 
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Å), while the C2- groups were directed toward the catalytic triad, allowing for 22 to undergo hydrogen-
bonding interactions with S203’s hydroxyl group. Transitioning to Panel B, the binding of 22-iso was quite 
different compared to its regioisomer. Unlike 22, the overall conformation of 22-iso was more dual site 
binding in hAChE. The quinazoline scaffold was perpendicular to W86 (~ 6–7 Å) and roughly 11 Å from 
W286. The C2-benzyl group was running parallel to the acyl pocket at roughly 5–6 Å where the phenyl 
ring was pointed toward W286 (~ 7 Å). This dual site orientation allowed for the C4-amino group to 
undergo hydrogen-bonding interactions with both S203 and H447 (~ 2.5–3.0 Å). 
 
 
 
 
 
Figure 56: Superimposition of docking structures. Panel (A): Binding modes of 20 (magenta) and 22 (red) in the active 
site of hAChE (PDB ID: 1B41). Panel (B,C): Binding modes of 22 (red) and 22-iso (turquoise) in the active sites of 
hAChE (PDB ID: 1B41) and hBuChE (PDB ID: 1P0I); respectively. Hydrogens removed to enhance visibility. Black-
dashed lines indicate hydrogen-bonding interactions.  
 
 
With respect to regioisomeric comparison in hBuChE, differential binding conformation was observed 
with 22 and 22-iso in Panel C. Both quinazoline scaffolds were roughly 17 Å from A277, but 22’s scaffold 
was stacked parallel between W82 and the catalytic triad (~ 4–5 Å), while 22-iso had its scaffold parallel to 
W82. As a matter of fact, the entire ligand (22-iso) was mainly interacting with W82 (~ 5–6 Å), forming a 
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V-shaped cap over this critical residue. On the other hand, the benzyl group of 22 was directed toward the 
acyl pocket in a perpendicular fashion (~ 5–8 Å), while its C2-amino group was off-centrally placed near 
the catalytic triad with the absence of hydrogen-bonding interactions.  
 
 
4.3.6.2. Amyloid-β 
 
Based on the acquired anti-Aβ data, presented in Table 4, the docking interactions of 22, 22-iso, 23 
and 26 were investigated in both dimeric and fibril model of Aβ (Aβ9-40 – PDB 2LMN)322 with 
superimpositions showcased in Figure 57. In addition, with the appreciation of the strong resonance 
stabilization associated with 23, the binding of its likely resonance structures was superimposed in Figure 
58. 
With respect to regioisomeric comparison in amyloid dimer model, differential binding conformation 
was observed with 22 and 22-iso as shown in Panel A. The quinazoline scaffold of 22 was stacked parallel 
to the A30-I32 region at roughly 5 Å, compared to the parallel stacking against D23-V24 (~ 6 Å) for the 
quinazoline scaffold of 22-iso. Regarding the benzyl groups, derivative 22 had its C4-functionality running 
parallel and toward K28 at roughly 6–7 Å, allowing for hydrogen-bonding interactions with the carboxyl 
side chain of D23 (~ 3.2 Å) and the carbonyl-backbone of V24 (~ 3.5 Å). On the other hand, 22-iso had its 
C2-benzyl group interacting parallel to G29-A30 (~ 5–6 Å), allowing for a hydrogen-bonding interaction 
with the carbonyl-backbone of A30 (~ 3.0 Å). With the amino groups, only derivative 22-iso showcased 
hydrogen-bonding interactions between its C4-amino group and the backbone terminals of I32 (~ 1.8–3.0 
Å). 
Transitioning to Panel B, the binding modes of these bioisosteres (C2-NH2 vs. C2-OH) revealed 
differential conformations that explain the drastic variance in potency. With 23, the quinazoline scaffold 
was stacked parallel to V24-G25 (~ 5–6 Å) and was equidistantly placed between both the upstream and 
downstream stretches of the hairpin loop domain. This placement, resulted in the favourable positioning of 
the C2-OH near key residues in the hairpin loop domain and allowed for multiple hydrogen-bonding 
interactions (N27’s backbone carbonyl at roughly 2.8 Å, S26’s backbone carbonyl at roughly 2.9 Å and 
G29’s backbone amine at roughly 3 Å). Moreover, the ligand’s C4-NH underwent additional hydrogen-
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bonding with D23’s side chain carboxyl group at roughly 3 Å. Lastly, the benzyl moiety was stacked 
against D23-V24 at roughly ~ 5 Å, with the phenyl ring showcasing a perpendicular orientation with the 
peptide chain.  
 
 
 
 
 
 
Figure 57: Superimposition of docking structures. Panels (A–C): Binding modes of 22 (red) and 22-iso (turquoise), 22 
(red) and 23 (green) or 23 (green) and 26 (gold); respectively, in the Aβ (Aβ9-40 – PDB 2LMN) dimer model. or fibril 
model [Panels (D–F)]. Hydrogens removed to enhance visibility. Amino acid labels to be used as a general guide as 
space restrictions limited complete and accurate labeling of all peptide structures. 
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Collectively, these interactions at the hairpin loop domain strongly corroborate the ability of 23 to 
destabilize dimeric and oligomeric structures. For an overview of the resonance-structrue impact on the 
binding mode, see Figure 58. 
Transitioning to Panel C (Figure 57), the first observation was the predominant interactions of 26 with 
the steric zipper domain of the dimeric model. The quinazoline scaffold was stacked perpendicular to A30-
I32 (~ 5 Å), while the C4-benzyl group was running parallel toward K28 (~ 6–7 Å). The C2-acetamide 
group was equidistantly placed parallel between V24 and I32 on the opposing side (~ 4–5 Å). 
 
 
 
 
 
 
 
 
 
Figure 58: Superimposition of docking structures. Panel (A): Binding modes of 23 (red) and its resonance stabilized 
structures (green and yellow/orange) in the Aβ (Aβ9-40 – PDB 2LMN) dimer model or fibril model [Panel (B)]. 
Hydrogens removed to enhance visibility. Amino acid labels to be used as a general guide as space restrictions limited 
complete and accurate labeling of all peptide structures. 
 
 
With respect to the binding modes within the fibril model (Panels D–F, Figure 57), derivatives 22, 22-
iso, 23 and 26 all had their benzyl groups intercalated within the steric zipper domain at roughly 5–6 Å 
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from the quad M35 residues and in a parallel orientation to the peptide chain. All quinazoline scaffolds 
extended outward from the steric zipper domain and were either stacked parallel (23 and 26) or 
perpendicular (22 and 22-iso), with respect to the peptide backbone, to the A30-V36 region of the domain 
(~ 5–6 Å). Individual ligand observations included the hydrogen-bonding interactions between: (a) 22’s 
C4-NH and G33’s backbone carbonyl (2.4 Å), (b) 22-iso’s C4-NH2 and M35’s backbone carbonyl (2.8 Å), 
(c) 22-iso’s C2-NH and G33’s backbone carbonyl (2.2 Å) and (d) 26’s carbonyl and G33’s backbone amine 
(2.8 Å). For an overview of the resonance-structrue impact on the binding mode of 23 in the fibril model, 
see Figure 58, Panel B. 
 
 
4.4. Summary 
 
 
Figure 59: Cumulative chapter summary of 2-substituted-N-benzylquinazolin-4-amines (19–31) and related regio-
isomers. 
 
 
With this benzylamine-based series, an overall improvement in BuChE targeting was observed, 
although that came at the cost of reduced AChE potency. When compared to their dimethoxybenzyl 
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counterparts, the derivatives in this series were more capable of targeting Aβ42, while Aβ40 activity was a 
more of a mixed bag.  
Nonetheless, the series showcased a potent Aβ40 aggregation inhibitor with good antioxidant capacity 
and moderate AChE inhibition in 23. More so, the regioisomer of 22 proved to be a good all-round 
derivative with dual ChE and dual Aβ40/42 inhibitory potential (22-iso, Figure 59).  
 
 
4.5. Experimental 
 
Please note that this subsection includes new and re-listed methodologies from Chapter 3. For 
schematic representation of re-listed methodologies, if applicable, please refer to Chapter 3 – Section 3.5. 
 
4.5.1. Chemistry 
 
General Information. All the reagents and solvents were reagent grade purchased from various vendors 
(Acros Organics, Sigma-Aldrich, and Alfa Aesar, USA) with a minimum purity of 95% and were used 
without further purification. Melting points (mp) were determined using a Fisher-Johns apparatus and are 
uncorrected. Reaction progress was monitored by UV using thin-layer chromatography (TLC) using Merck 
60F254 silica gel plates. Column chromatography was performed with Merck silica gel 60 (230−400 mesh) 
with 5:1 EtOAc:MeOH as the solvent system unless otherwise specified. Proton (1H NMR) and carbon (13C 
NMR) spectra were performed on a Bruker Avance (at 300 and 75 MHz; respectively) spectrometer using 
DMSO-d6. Coupling constants (J values) were recorded in hertz (Hz) and the following abbreviations were 
used to represent multiplets of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. 
Carbon multiplicities (C, CH, CH2 and CH3) were assigned by DEPT 90/135 experiments. High-resolution 
mass spectrometry (HRMS) was determined using a Thermo Scientific Q-Exactive Orbitrap mass 
spectrometer (positive mode, ESI), Department of Chemistry, University of Waterloo. Compound purity 
(roughly 95% or over) was determined using an Agilent 1100 series HPLC equipped with an analytical 
column (Agilent Zorbax Eclipse XDB-C8 column, 4.6 x 150 mm, 5 µm particle size) running 50:50 
Water:ACN with 0.1% TFA at a flow rate of 1.0-1.5 mL/min or an Agilent 6100 series single quad LCMS 
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equipped with an Agilent 1.8 µm Zorbax Eclipse Plus C18 (2.1 x 50 mm) running 50:50 Water:ACN with 
0.1% FA with a flow rate of 0.5mL/min. All the final compounds exhibited ≥ 95% purity. 
General procedure for the synthesis of 2-chloro-N-substituted-quinazolin-4-amines.303, 305  To a 
30 mL solution of ethanol in a 100 mL round-bottom flask on ice, 5 g of 4 (25.13 mmol) was added 
followed by slow addition of 1.3 eq. (32.66 mmol) of the corresponding primary amine. Contents were 
stirred on an ice bath while 2.0 eq. of diisopropyl-ethylamine (DIPEA, 50.25 mmol) was added in drop 
wise fashion. The solution was then heated at 80-85 °C under reflux for 3–4 h. The reaction contents were 
cooled to room temperature and precipitated residues were vacuum-filtered with ethyl acetate (EtOAc) 
rinses. The organic supernatant was concentrated in vacuo followed by two rounds of liquid-liquid 
extraction using EtOAc and saturated brine solution (40–50 mL each respectively). The combined organic 
layers were dried over MgSO4, evaporated in vacuo and purified (1-2 times) using silica gel column 
chromatography with 5:1 EtOAc:MeOH as the elution solvent. Final compounds were white to beige solids 
with yields ranging from 70-90%.  
 
N-Benzyl-2-chloroquinazolin-4-amine (19). Yield: 75% (5.11 g, 19.00 mmol). Mp: 169–171 °C. 1H NMR 
(300 MHz, DMSO-d6) δ 9.24 (t, 6.0 Hz 1H), δ 8.27 (d, J = 6.0 Hz, 1H), δ 7.75 (t, J = 9.0 Hz, 1H), δ 7.59 
(d, J = 6.0 Hz, 1H), δ 7.49 (t, J = 9.0 Hz, 1H), δ 7.34-7.20 (m, 5H), δ 4.72 (d, J = 6.0 Hz, 2H). HRMS (ESI) 
m/z calcd for C15H12ClN3 [M + H]+ 270.0720, found 270.1532. Purity: 98.8% 
 
General procedure for the synthesis of N4-substituted-quinazolin-4-amines. In a 50 mL round 
bottom flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was dissolved 
in 20 mL of anhydrous ethanol. While stirring on ice, 10 mol. % of 10% Pd/C was added to reaction 
mixture followed by the drop-wise addition of 1.3 eq. of hydrazine hydrate. Solution was stirred on ice for 
5 min before refluxing for 2 h at 80–85 °C. Upon completion and cooling to room temperature, the reaction 
mixture was passed through a tightly-packed cotton-filled syringe that has been pre-rinsed with ethanol, to 
remove the Pd/C catalyst. A 30 mL aliquot of ethanol was used to rinse the syringe. The combined ethanol 
solutions were evaporated in vacuo, diluted in EtOAc (20 mL) and washed 25 mL x 2 with equal volumes 
of brine solution. The combined aqueous layers were washed with 15 mL of EtOAc. The combined EtOAc 
 	   105 
layers were dried over MgSO4, before removing the EtOAc in vacuo to yield a solid or semi-solid crude 
product that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH solvent system. 
Final compounds were white to pale yellow solids with yields ranging from 40–47%. 
 
N-Benzylquinazolin-4-amine (20). Yield 45% (0.20 g, 0.85 mmol); Mp 142–145 °C. 1H NMR (300 MHz, 
DMSO-d6): δ 8.84 (t, J = 9.0 Hz, 1H), δ 8.42 (s, 1H), δ 8.26 (d, J = 6.0 Hz, 1H), δ 7.72 (t, J = 6.0 Hz, 1H), 
δ 7.64 (d, J = 6.0 Hz, 1H), δ 7.47 (t, J = 9.0 Hz, 1H), δ 7.31–7.19 (m, 5H), δ 4.71 (d, J = 6.0 Hz, 2H). 
HRMS (ESI) m/z calcd for C15H14N3 [M + H]+ 236.1109, found 236.1181. Purity: 97.9% 
 
 
General procedure for the synthesis of 2-azido-N-substituted-quinazolin-4-amine.305 In a 50 mL 
RBF, 2-chloro-N-substituted-quinazolin-4-amine (~1.86 mmol), 1.1 eq. NaN3 (2.05 mmol), 4:1 EtOH (20 
mL) and glacial acetic acid (5 mL) were combined and refluxed at 90–95 °C for 2 h with stirring. After 
cooling, the solution was vacuum-filtered to afford white solids at yields ranging from 80–85%. 
 
2-Azido-N-benzylquinazolin-4-amine (21). Yield 85% (0.43 g, 1.57 mmol); Mp 224–226 °C. 1H NMR 
(300 MHz, DMSO-d6): δ 9.40 (br s, 1H), δ 8.48 (d, J = 8.2 Hz, 1H), δ 8.29 (d, J = 8.3 Hz, 1H), δ 7.97 (t, J 
= 8.0 Hz, 1H), δ 7.72 (t, J = 8.0 Hz, 1H), δ 7.40–7.21 (m, 5H), δ 4.81 (d, J = 3.0 Hz, 2H). HRMS (ESI) m/z 
calcd for C15H13N6 [M + H]+ 277.1123, found 277.1195. Purity: 96.3% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2,4-diamine.305  
 
Method 1A: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was added along with 20 mol. % of CuI. To that, a mixture of 1,4-dioxane (5 mL) and 30% aqueous 
ammonia (15 mL) was added at room temperature. The pressure vial was sealed tightly and partially 
submerged in silicone oil heating at 130–135 °C. Contents were stirred in the pressure vial for 24 h (Note: 
in the event of pressure leakage, the contents were cooled to room temperature and additional aqueous 
 	   106 
ammonia, (10 mL) was added, sealed and heating was carried on through the 24 h period). The reaction 
contents were cooled to room temperature and the solution was diluted with 25 mL EtOAc, washed with 
saturated brine solution (10 mL x 3), and the aqueous layer was neutralized with dilute HCl, and then re-
extracted with 15 mL EtOAc. The organic layers were combined, dried over MgSO4, evaporated in vacuo 
and purified using silica gel column chromatography with 5:1 EtOAc:MeOH as an initial elution solvent 
followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine). Final compounds were obtained as 
white to beige solids with final yields ranging from 20–25%.  
 
Method 1B: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was dissolved and gently heated in 5 mL ethylene glycol. To that, 20 mol. % of Cu2O and DMEDA 
were added followed by 20 eq. K2CO3 and finally, 40 eq. of 30% aqueous ammonia solution (~ 15–20 mL). 
The pressure vial was sealed tightly, partially submerged in silicone oil and heated at 100-105 °C. Contents 
were stirred in the pressure vial for 24 h. After the reaction contents were cooled to room temperature, the 
solution was diluted with 50 mL EtOAc, washed with saturated brine solution (25 mL x 3) and the aqueous 
layer was neutralized with dilute HCl, and then re-extracted with 25 mL EtOAc. The residue formed was 
dissolved in methanol (20–25 mL). The EtOAc layers were dried over MgSO4 and evaporated in vacuo. 
The methanol fraction was dried with molecular sieves before evaporating the methanol in vacuo. Both 
EtOAc and methanol fractions were combined and purified using silica gel column chromatography with 
5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH with 1% TEA 
(triethylamine). Final compounds were obtained as white to beige solids with yields ranging from 35–40%.  
 
Method 2: In a 50 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) 
was combined with 6 eq. urea (22.32 mmol) and diluted with 10 mL of anhydrous 1,4-dioxane. The 
pressure vial was sealed tightly and partially submerged in silicone oil heating at 160–165 °C. Contents 
were stirred in the pressure vial for 24 h. Once the reaction contents were cooled to room temperature, the 
solution was diluted with 20–25 mL EtOAc. The contents were washed three times with 20 mL saturated 
brine solution and the aqueous layers were re-extracted twice with 20 mL EtOAc. The organic layers were 
combined, dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography 
with 5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA 
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(triethylamine). Final compounds were obtained as white to light beige solids with yields ranging from 50–
55%. 
 
Method 3: In a 50 mL round-bottom flask, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) was 
combined with 1.1 eq. NaN3 (4.09 mmol), before diluting with 4:1 EtOH (20 mL) and glacial acetic acid (5 
mL). Flask contents were stirred under reflux at 90–95 °C for 2 h. After cooling the reaction mixture, 10 
mol. % of Pd/C (10%) was added followed by slow addition of 1.5 eq. of hydrazine hydrate (5.58 mmol). 
Flask contents were stirred under reflux at 90–95 °C for an additional two hrs. Once complete, the warm 
solution was passed through a large, tightly packed cotton syringe with the aid of additional EtOH washes 
(2 x 20 mL). The ethanolic mixture was evaporated in vacuo. Final compounds were obtained as white to 
beige solids with yields ranging from 80–85%. 
 
Method 4: In a 50 mL round-bottom flask, 2,4-diaminoquinazoline* (1 g, 6.24 mmol) was dissolved in 3 
mL DMSO. With stirring and periodic cooling over ice-water, NaH (60%, 0.25 g, 6.24 mmol) was added 
over a 10–15 min. period. After complete addition of NaH, flask was stirred at room temperature with slow, 
dropwise addition of the appropriate alkyl/aryl halide (6.24 mmol) dissolved in 3 mL DMSO. Contents are 
allowed to stir at room temperature overnight (~14 h) before diluting with 20 mL of water and stirring at 
room temperature for 15 min. The mixture is extracted thrice with diethyl ether (40 mL x 3). The combined 
organic layers are washed twice with brine (20 mL x 2). Combined organic layer was dried with MgSO4 
and concentrated in vacuo before purifying with silica gel column chromatography using 5:1 EtOAc/MeOH 
to afford beige to off-white solids at 20–31% yield.  
 
*General procedure for synthesis of 2,4-diaminoquinazoline.291, 317 In a 250 mL round-bottom 
pressure flask, 2-fluorobenzonitrile (4.6 mL, 42.32 mmol) or 2-aminobenzonitrile (5 g, 42.32 mmol) was 
combined with guanidine carbonate (11.43 g, 126.96 mmol) and diluted in 30 mL dimethylacetaminde 
(DMA). Contents are heated in an oil bath at 150 °C for overnight (~14 h) then diluted with 50mL of water 
before extracting thrice with EtOAc (50 mL x 3) and washing with brine (2x 20 mL). Combined organic 
layer was dried with MgSO4 and concentrated in vacuo before purifying with silica gel column 
chromatography using 5:1 EtOAc/MeOH to afford an off-white solid at 80% yield. 1H NMR (300 MHz, 
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DMSO- d6) δ 7.91 (d, J = 7.8 Hz, 1H), δ 7.41 (t, J = 7.8 Hz, 1H), δ 7.21 (br s, 2H), δ 7.15 (d, J = 8.1 Hz, 
1H), δ 6.95 (t, J = 7.2 Hz, 1H), δ 5.91 (br s, 2H). 13C NMR (100 MHz, DMSO- d6) δ 162.45, δ 160.75, δ 
152.52, δ 132.30, δ 124.22, δ 123.52, δ 119.73, δ 110.34. 
 
N4-Benzylquinazolin-2,4-diamine (22). Yield 83% (0.77 g, 3.09 mmol); Mp: 185–187 °C. 1H NMR (300 
MHz, DMSO-d6) δ 8.76 (br s, 1H), 8.06 (d, J = 8.1 Hz, 1H), δ 7.50 (t, J = 8.1 Hz, 1H), δ 7.09-7.36 (m, 6H), 
δ 7.07 (t, J = 7.8 Hz, 1H), δ 6.48 (br s, 2H), δ 4.71 (d, J = 5.9 Hz, 2H). HRMS (ESI) m/z calcd for C15H14N4 
[M + H]+ 251.1296, found: 251.1289. 
 
 
General procedure for synthesis of N2-substituted-quinazoline-2,4-diamines.317 In a 50 mL round-
bottom flask, 2,4-diaminoquinazoline (1 g, 6.24 mmol) was dissolved in 20 mL DMA followed by the 
addition of potassium carbonate (0.85 g, 6.24 mmol) and the appropriate alkyl/aryl halide (6.24 mmol) at 
room temperature. Contents are refluxed at 85 °C for 5 h before diluting with 30 mL of water and stirring at 
R.T for 15 min. The mixture is extracted thrice with EtOAc (50 mL x 3). The combined organic layers are 
washed twice with brine (20 mL x 2). Combined organic layer was dried with MgSO4 and concentrated in 
vacuo before purifying with silica gel column chromatography using 5:1 EtOAc/MeOH to afford beige to 
off-white solids at 14–26% yield. 
 
N2-Benzylquinazoline-2,4-diamine (22-iso). Yield 26% (0.41 g, 1.64 mmol); Mp: 159–161 °C; 1H NMR 
(300 MHz, DMSO-d6): δ 7.95 (d, J = 7.9 Hz, 1H), δ 7.47 (t, J = 7.4 Hz, 2H), δ 7.32–7.14 (m, 6H), δ 7.02 (t, 
J = 7.5 Hz ,1H), δ 4.53 (d, J = 6.3 Hz , 2H). 13C NMR (100 MHz, DMSO-d6) δ 162.75, δ 159.39, δ 141.41, 
δ 133.22, δ 128.54, δ 127.86, δ 127.56, δ 126.82, δ 124.68, δ 124.23, δ 120.87, δ 111.07, δ 44.23. HRMS 
(ESI) calcd for C15H14N4 (M+1) m/z 251.12912, observed 251.12907. 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-ols. In a 50 mL round bottom 
flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was combined with 1.3 
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eq. of potassium formate (1.89–2.41 mmol) then dissolved in 20 mL of formic acid. Solution was refluxed 
for 14–16 h at 120–125 °C. Upon completion and cooling to room temperature, the reaction mixture was 
diluted with ~ 30 mL of brine solution, ~ 50 mL of saturated NaHCO3 solution before extracting with ~ 25 
mL (x3) of EtOAc and washed with 25 mL (x 3) parts of brine solution. The combined aqueous layers were 
washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 before removing 
the EtOAc in vacuo to yield a solid product that generally did not require additional purification. Additional 
purification as required, was accomplished by silica gel column chromatography using 5:1 EtOAc:MeOH 
as the eluent. The compounds were obtained as white solids with yields ranging from 58–70%. 
 
4-(Benzylamino)quinazolin-2-ol (23).  Yield 65% (0.30 g, 1.20 mmol); Mp 198–200 °C. 1H-NMR (300 
MHz, DMSO-d6): δ 10.60 (br s, 1H), δ 8.67 (t, J = 5.7 Hz, 1H), δ 8.47 (d, J = 8.1 Hz, 1H), δ 8.35 (t, J = 7.5 
Hz, 1H), δ 7.31–7.09 (m, 7H), δ 4.66 (d, J = 5.6 Hz, 2H). HRMS (ESI) m/z calcd for C15H14N3O [M + H]+ 
252.1059, found 252.1130. Purity: 99.7% 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-urea.305 In a pressure vial, 0.5 
g of 2-chloro-N-substituted-quinazolin-4-amine (~ 1.85 mmol) was mixed with 6 eq. urea (~ 11.2 mmol) 
and 10 mL of anhydrous 1,4-dioxane, sealed tightly and heated at 160–165 °C in an oil bath for 24 h. After 
cooling to room temperature, the solution was diluted with 20 mL EtOAc, washed three times with 20 mL 
brine solution; the aqueous layers were extracted twice with 20 mL EtOAc. The combined organic layers 
were dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography using a 
combination of 5:1 EtOAc:MeOH and 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine) to afford target 
compounds as white solids with yields ranging from 45–50% and the hydrolyzed amine compounds as off 
white solids with yields ranging from 50–55%.  
 
1-(4-(Benzylamino)quinazolin-2-yl)urea (24). Yield 55% (0.30 g, 1.02 mmol); Mp 214–216 °C. 1H NMR 
(300 MHz, DMSO-d6): δ 9.11 (br s, 1H), δ 8.88 (br s, 1H), δ 8.76 (br s, 1H), δ 8.12 (d, J = 8.2 Hz, 1H), δ 
7.42 (d, J = 8.2 Hz, 1H), δ 7.31–7.26 (m, 2H), δ 7.24–7.20 (m, 5H), δ 6.80 (br s, 1H), δ 4.70 (d, J = 5.7 Hz, 
2H).  HRMS (ESI) m/z calcd for C16H16N5O [M + H]+ 294.1277, found 294.1348. Purity: 95.5%  
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General procedure for the synthesis of N4-substituted-quinazolin-2-glycinamide.299 In a 50 mL 
pressure vial, 0.25 g of 2-chloro-N-substituted-quinazolin-4-amine (~ 0.83 mmol) was combined with 3 eq. 
(~ 2.50 mmol) of glycinamide.HCl then dissolved in 5 mL of 1,4-dioxane followed by the addition of 5 eq. 
of DBU (~ 4.15 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 4 h. Upon 
completion and cooling to room temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and 
washed 25 mL (x 3) brine solution. The combined aqueous layers were washed with ~ 25 mL of EtOAc. 
The combined EtOAc layers were dried over MgSO4 and EtOAc was removed in vacuo to yield solid that 
was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the eluent to afford target 
compounds as pale yellow to brown solids with yields ranging between 52–58%. 
 
2-((4-(Benzylamino)quinazolin-2-yl)amino)acetamide (25). Yield 58% (0.16 g, 0.54 mmol); Mp 161–
163 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.23 (br s, 1H), δ 8.02 (d, J = 8.2 Hz, 1H), δ 7.47 (t, J = 7.5 Hz, 
1H), δ 7.38–7.17 (m, 7H), δ 7.04 (t, J = 7.5 Hz, 1H), δ 6.95 (br s, 1H), δ 6.45 (br s, 1H), δ 4.68 (d, J = 5.5 
Hz, 2H), δ 3.81 (d, J = 5.2 Hz, 2H). HRMS (ESI) m/z calcd for C17H18N5O [M + H]+ 308.1433, found 
308.1506. Purity: 98.8%  
 
General procedure for the synthesis of N4-substituted-quinazolin-2-acetamide.312 In a 50 mL 
round bottom flask (RBF), 0.5 g of N4-substituted-quinazolin-2,4-diamine (1.54–2.00 mmol) was dissolved 
in 15 mL of 1,4-dioxane and 10 mL of glacial acetic acid/acetyl chloride combination (4:1 ratio). Solution 
was refluxed for 24 h at 90–95 °C. Upon completion and cooling to room temperature, the reaction mixture 
was diluted with ~ 30 mL of brine solution, ~ 30 mL of concentrated NaHCO3 solution before extracting 
with ~ 25 mL (x 3) of EtOAc and washed with 25 mL (x 2) brine solution. The combined aqueous layers 
were washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 and the 
organic solvent was removed in vacuo to yield a solid product that generally did not require additional 
purification. Purification was carried out as required, by silica gel column chromatography using 5:1 
EtOAc:MeOH as the eluent to afford target compounds as white solids with yields ranging from 35–42%. 
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N-(4-(Benzylamino)quinazolin-2-yl)acetamide (26). Yield 50% (0.29 g, 0.99 mmol); Mp 219–221 °C. 1H 
NMR (300 MHz, DMSO-d6): δ 9.68 (br s, 1H), δ 8.18 (t, J = 6.0 Hz, 1H), δ 7.95 (d, J = 6.0 Hz, 1H), δ 7.42 
(t, J = 8.4 Hz, 1H), δ 7.34–7.24 (m, 5H), δ 7.18 (d, J = 6.0 Hz, 1H), δ 6.95 (t, J = 6.0 Hz, 1H), δ 4.69 (d, J 
= 6.0 Hz, 2H), δ 2.22 (s, 3H). HRMS (ESI) m/z calcd for C17H17N4O [M + H]+ 293.1324, found 293.1396. 
Purity: 99.9% 
 
General procedure for the synthesis of N4-substituted-N2-alkyl-quinazolin-2,4-diamine.299, 313 In a 
50 mL pressure vial (PV), 0.25 g of 2-chloro-N-substituted-quinazolin-4-amine (~ 0.83 mmol) was 
combined with 2 eq. (~ 1.66 mmol) of primary amine (methyl-, ethyl-, n-propyl-, isopropyl- or 
cyclopropylamine) then dissolved in 5 mL of 1,4-dioxane followed by the addition of 3 eq. of DIPEA (~ 
2.40 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 2 h. Upon completion and 
cooling to room temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and washed with 
brine solution (25 mL x 2). The combined aqueous layer was washed with ~ 25 mL of EtOAc. The 
combined EtOAc layers were dried over MgSO4 before removing EtOAc in vacuo to yield a solid product 
that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the eluent to afford pale 
yellow to brown solids yielding at 55–70%. 
 
 
N4-(Benzyl)-N2-methylquinazoline-2,4-diamine (27). Yield 68% (0.33 g, 1.25 mmol); Mp 139–141 °C. 
1H NMR (300 MHz, DMSO-d6): δ 8.23 (t, J = 6.0 Hz, 1H), δ 7.95 (d, J = 6.0 Hz, 1H), δ 7.55 (t, J = 9.0 Hz, 
1H), δ 7.34–7.20 (m, 6H), δ 6.99 (t, J = 6.0 Hz, 1H), δ 6.53 (br s, 1H), δ 4.66 (d, J = 6.0 Hz, 2H), δ 2.74 (d, 
J = 4.7 Hz, 3H). HRMS (ESI) m/z calcd for C16H17N4 [M + H]+ 265.1375, found 265.1446. Purity: 100.0% 
 
N4-(Benzyl)-N2-ethylquinazoline-2,4-diamine (28). Yield 70% (0.36 g, 1.29 mmol); Mp 130–132 °C. 1H 
NMR (300 MHz, DMSO-d6): δ 8.25 (t, J = 6.0 Hz, 1H), δ 7.96 (d, J = 6.0 Hz, 1H), δ 7.45 (t, J = 9.0 Hz, 
1H), δ 7.36–7.18 (m, 6H), δ 6.99 (t, J = 6.0 Hz, 1H), δ 6.40 (br s, 1H), δ 4.67 (d, J = 6.0 Hz, 2H), δ 3.27–
3.22 (m, 2H), δ 1.03 (t, J = 6.0 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ 159.78, δ 159.57, δ 158.96, δ 
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151.63, δ 139.94, δ 132.33, δ 128.16, δ 127.98, δ 127.34, δ 127.26, δ 126.58, δ 126.23, δ 122.68, δ 119.90, 
δ 43.26, δ 35.25, δ 15.08. HRMS (ESI) m/z calcd for C17H19N4 [M + H]+ 279.1531, found 279.1602. 
Purity: 98.0% 
 
N4-(Benzyl)-N2-propylquinazoline-2,4-diamine (29). Yield 58% (0.31 g, 1.06 mmol); Mp 114–116 °C. 
1H NMR (300 MHz, DMSO-d6): δ 8.21 (t, J = 6.0 Hz, 1H), δ 7.94 (d, J = 6.0 Hz, 1H), δ 7.42 (t, J = 9.0 Hz, 
1H), δ 7.35–7.23 (m, 4H), δ 7.18 (m, 2H), δ 6.95 (t, J = 6.0 Hz, 1H), δ 6.40 (br s, 1H), δ 4.66 (d, J = 6.0 
Hz, 2H), δ 3.14 (q, J = 6.0 Hz, 2H), δ 1.45–1.40 (m, 2H), δ 0.78 (t, J = 7.5 Hz, 3H). HRMS (ESI) m/z calcd 
for C18H21N4 [M + H]+ 293.1688, found 293.1759. Purity: 98.9% 
 
N4-(Benzyl)-N2-isopropylquinazoline-2,4-diamine (30). Yield 67% (0.37 g, 1.27 mmol); Mp 135–137 °C. 
1H NMR (300 MHz, DMSO-d6): δ 8.30 (t, J = 6.0 Hz, 1H), δ 7.90 (d, J = 6.0 Hz, 1H), δ 7.42 (t, J = 9.0 Hz, 
1H), δ 7.35–7.23 (m, 4H), δ 7.20–7.18 (m, 2H), δ 6.90 (t, J = 6.0 Hz, 1H), δ 6.28 (br s, 1H), δ 4.67 (d, J = 
6.0 Hz, 2H), δ 4.13–3.99 (m, 1H), δ 1.05 (d, J = 6.0 Hz, 6H). HRMS (ESI) m/z calcd for C18H21N4 [M + 
H]+ 293.1688, found 293.1759. Purity: 98.1% 
 
N4-(Benzyl)-N2-cyclopropylquinazoline-2,4-diamine (31). Yield 56% (0.30 g, 1.03 mmol); Mp 145–147 
°C. 1H NMR (300 MHz, DMSO-d6): δ 8.25 (t, J = 6.0 Hz, 1H), δ 7.98 (d, J = 6.0 Hz, 1H), δ 7.40 (t, J = 9.0 
Hz, 1H), δ 7.30–7.20 (m, 5H), δ 7.18 (d, J = 6.0 Hz, 1H), δ 6.95 (t, J = 6.0 Hz, 1H), δ 6.45 (br s, 1H), δ 
4.68 (d, J = 6.0 Hz, 2H), δ 2.78–2.66 (m, 1H), δ 0.60 (d, J = 4.8 Hz, 2H), δ 0.45 (d, J = 4.8 Hz, 2H). HRMS 
(ESI) m/z calcd for C18H19N4 [M + H]+ 291.1531, found 291.1603. Purity: 99.6% 
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4.5.2. Biological Screening 
 
4.5.2.1. Human Cholinesterase (hChE) Assay299, 313 
 
The inhibition profile of quinazoline derivatives was evaluated using the Ellman (DTNB) reagent.315 
Human AChE and BuChE enzymes were obtained from Sigma-Aldrich, St. Louis, MO, USA (AChE 
product number C0663 and BuChE product number B4186 respectively). The cholinesterase inhibitors 
tacrine (item number 70240, Cayman Chemical Company, Ann Arbor, MI), donepezil (product number 
D6821, Sigma-Aldrich, St. Louis, MO), galantamine (product number G1660, Sigma-Aldrich, St. Louis, 
MO) and rivastigmine (product number SML0881, Sigma-Aldrich, St. Louis, MO) were used as reference 
agents. Quinazoline derivative stock solutions were prepared in DMSO (maximum 1% v/v in final wells) 
and diluted in buffer solution (50 mM Tris.HCl, pH 8.0, 0.1 M NaCl, 0.02 M MgCl2.6H2O). Then 160 µL 
of 5,5’-dithiobis(2-nitrobenzoic acid) (1.5 mm DTNB), 50 µL of hAChE (0.22 U/mL in 50 mM Tris.HCl, 
pH 8.0, 0.1% w/v bovine serum albumin, BSA) or 50 µL of hBuChE (0.12 U/mL in 50 mM Tris.HCl, pH 
8.0, 0.1% w/v BSA) were added to 96-well plates after which 10 µL each of quinazoline derivatives (final 
concentration range 0.1–50 µM) were added and incubated for 5 min. Then 30 µL of either 
acetylthiocholine iodide (15 mM AThCl prepared in ultra pure water) or S-butyrylthiocholine iodide (15 
mM BThCI prepared in ultra pure water) were added. The absorbance was measured at different time 
intervals (0, 60, 120, 180, 240 and 300 s) using a wavelength of 412 nm. The inhibitory concentration (IC50 
values) was calculated from the concentration–inhibition dose response curve on a logarithmic scale. The 
results were expressed as average values based on two to three independent experiments run in triplicate 
measurements. 
 
4.5.2.2. Amyloid-β (Aβ) Aggregation Assay317 
 
The ability of quinazoline-based derivatives to inhibit Aβ-aggregation kinetics was determined using a 
ThT-binding fluorescence assay. These assays were conducted in Costar, black-surround, clear-bottom 
384-well plates with frequent shaking (30 sec. of linear shaking at 730 cpm every 5 minutes) and constant 
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heating at 37 °C for 24 h. The ThT excitation/emission was measured at 440 nm/490 nm and readings were 
taken every 5 minutes using a BioTek Synergy H1 microplate reader. Quinazoline stock solutions were 
prepared in DMSO and diluted to 10x in 215 mM phosphate buffer at pH 7.4. Abeta.HFIP samples (Aβ40 
or Aβ42, rPeptide, Bogart, USA) were dissolved in 1% ammonium hydroxide, sonicated at room 
temperature for 5 minutes then diluted to 50 µM in 215 mM phosphate buffer (pH 7.4). A 15 µM ThT stock 
solution was prepared with 50 mM glycine and adjusted to pH 7.4. The assay was carried out by adding 44 
µL ThT, 20–35 µL buffer, 1 µL DMSO (for background and controls only) followed by the addition of 8 
µL of 10x compound dilutions (1–25 µM concentration range). An end point reading was conducted to 
evaluate potential test compound interference with ThT-fluorescence before adding 8 µL of Aβ40 or Aβ42 
stock solutions (5 µM final concentration). Plates were sealed with a transparent plate film before initiating 
the assay. RFU values were corrected for ThT-interference before calculating end point percent inhibitions 
or IC50 values and obtaining the aggregation kinetic plots. Data presented was an average of triplicate 
reading for two-three independent experiments. 
 
4.5.2.3. TEM Assay and Imaging142, 190, 207, 317 
 
In Costar 96-well, round-bottom plates were added 80 µL of 215 mM phosphate buffer, 20 µL of 10x 
test compound dilutions (250 µM – prepared in the same way as for the ThT assay) and 100 µL of 50 µM 
Aβ40 or Aβ42 respectively.  For the control wells, 2 µL of DMSO and 18 µL of phosphate buffer was 
added. Final Aβ: test compound ratio was 1:1 (25 µM). Plates were incubated on a Fisher plate incubator 
set to 37 °C and the contents were shaken at 730 cpm for 24 h. To prepare the TEM grids, ~ 20 µL droplet 
was added using a disposable Pasteur pipette over the formvar-coated copper grids (400 mesh). Grids were 
air-dried for about 3 h before adding two droplets (~ 40 µL, using a disposable Pasteur pipette) of ultra-
pure water and using small pieces of filter paper to wash out precipitated buffer salts. After air-drying for ~ 
15-20 min, the grids were negatively stained by adding a droplet (~ 20 µL, using a disposable Pasteur 
pipette) of 2% phosphotungstic acid (PTA) and immediately after the grids were dried using small pieces of 
filter paper. Grids were further air-dried overnight. The scanning was carried out using a Philips CM 10 
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transmission electron microscope at 60 kV (Department of Biology, University of Waterloo) and 
micrographs were obtained using a 14-megapixel AMT camera. 
 
 
 
Figure 60: Principles of the TEM imaging setup for assessing amyloid morphology with or without select derivatives. 
 
 
 
4.5.2.4. DPPH Scavenging Assay324 
 
The ability of select quinazolines to scavenge the DPPH radical was utilized as a measure of 
antioxidant capacity. Quinazoline stock solutions were prepared in anhydrous methanol (500 µM) and the 
DPPH solution was also prepared in anhydrous methanol (56 µM). The addition sequence was carried out 
in a 96-well clear, flat bottom plate as follows: 90 µL DPPH, 10 µL test compound solution (50 µΜ) final 
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concentration. Control solutions contained 90 µL anhydrous methanol and 10 µL test compound whereas 
DPPH control contained 90 µL of DPPH, and 10 µL anhydrous methanol. This readings were taken initially 
at 517 nm with 30 sec. shaking (double orbital at 530 cpm) prior to the 1 h, light restrictive, incubation 
period at room temperature after which readings were taken again at 517 nm after another round of 30 sec 
shaking (double orbital at 530 cpm) using a BioTek Synergy H1 microplate reader. The results were 
expressed as percentage inhibition and the data presented was average of triplicate reading (for two 
independent experiments). 
 
4.5.3. Computational Chemistry299, 313, 317, 324 
 
The molecular docking studies were conducted using Discovery Studio 4.0 (Structure-Based-Design 
program) from BIOVIA Inc. San Diego, USA. Select quinazolines derivatives were built and minimized 
using the small molecules module in Discovery Studio. X-ray coordinates of human cholinesterases were 
obtained from the protein data bank (hAChE PBD ID: 1B41 and hBuChE PDB ID: 1P0I) and prepared 
using the macromolecules module in Discovery Studio. Ligand binding sites were defined by selecting a 12 
Å radius sphere for AChE and 15 Å radius sphere for BuChE. The molecular docking was performed using 
the receptor-ligand interactions module in Discovery Studio. The LibDock algorithm was used to find the 
most appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. For amyloid-β docking studies, the NMR solution structure of Aβ fibrils were 
obtained from the protein data bank (PDB ID: 2LMN). Aβ dimer and Aβ fibril assemblies were built using 
the macromolecules module in Discovery Studio. Ligand binding site was defined by selecting a 15 Å 
radius sphere for both Aβ assemblies. Molecular docking was performed using the receptor-ligand 
interactions module in Discovery Studio, where the LibDock algorithm was used to find the most 
appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. 
 	   117 
CHAPTER 5 
  Development and Evaluation of N-(3,4-dimethoxyphenethyl)quinazolin-4-amines 
as Dual ChE and Aβ Aggregation Inhibitors   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Chapter banner   
  
5.1. Introduction 
 
The dimethoxybenzyl series (Chapter 3) provided good insight into the requirements and restrictions 
toward the dual targeting of the ChEs and Aβ aggregation. The introduction of the dimethoxyphenethyl 
series was a direct comparison to the Chapter 3 counterparts. A regioisomeric assessment was also included 
with this Chapter comparing N-(3,4-dimethoxyphenethyl)-quinazolin-4-amine vs. N-(3,4-dimethoxy 
phenethyl)-quinazolin-2-amine, and as observed in Chapter 4, interesting SAR was projected from this 
assessment. An optimization phase is also presented in this Chapter, where select C2-groups, including the 
previously unutilized dimethylamine group, were applied to various chloroquinazoline scaffolds to acquire 
additional SAR data.  
This chapter highlights the synthesis and development of target derivatives (refer to the chapter 
banner above) along with the acquisition and assessment of the SAR data. For the most part, the synthetic 
approaches and mechanisms here have been previously discussed in Chapter 3 and 4. A brief summary is 
provided prior to the listing of experimental data and methodology. 
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5.2. Hypothesis 
 
With respect to this series, the re-introduction of the 3,4-dimethoxy moiety, with the additional 
methylene unit in the linker chain, should regain some benefit with respect to AChE targeting, while 
offering an additional point of rotation to enhance binding conformations. 
On the other hand, continuing with the existing selection of C2-groups offers an opportunity to 
evaluate and compare the impact of the 3,4-dimethoxybenzyl (Chapter 3) vs. the 3,4-dimethoxyphenethyl 
moieties at the C4-position. Previous predications hold true with entities like the azide and carbonyl-based 
groups with respect to their inability to target BuChE. The increased free-rotation potential at the C4-
position, combined with alkylamines at the C2-posiiton, are predicted to aid with BuChE inhibition, while 
effectively targeting AChE and modulating amyloid aggregation. As observed in Chapter 4, the 
introduction of a regioisomer provided good insight into the roles of the C2- and C4-groups with respect to 
dual ChE and dual amyloid targeting.  
Lastly, the introduction of the chloroquinazoline scaffolds, as part of the optimization process, are 
predicted to significantly influence ChE binding and amyloid modulation. The new introduction of the 
dimethylamine group at the C2-position, as part of the optimization process, would present the only tertiary 
amine based quinazolines in the collective chemical library. The SAR obtained from these derivatives 
should provide critical insight. 
 
5.3. Results and Discussions 
 
The proceeding sub-chapter discusses new synthetic methodology, while briefly highlighting 
previously-established routes to desired derivatives. Biological assessments in the cholinesterase and 
amyloid-β aggregation assay (to obtain IC50 values and/or investigation aggregation kinetics) are conducted. 
Aggregate load is corroborated via transmission electron microscopy in amyloid morphology screening and 
select derivatives are assessed for ROS scavenging in the DPPH assay. Computational studies are 
performed in the ChE X-ray structures and amyloid models to evaluate the acquisitioned SAR data.  
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5.3.1. Synthesis 
 
As previously described in Chapters 3 and 4, initial coupling in this series utilized 2,4-DCQ (4) to add 
the 3,4-dimethoxyphenethylamine group to the C4-position of the quinazoline scaffold, via a NAS reaction, 
to yield 2-chloro-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (32, Scheme 13, 80–85% yield).299, 303 
The C2-unsubstituted derivative (N-(3,4-dimethoxyphenethyl)quinazolin-4-amine, 33, Scheme 13, ~ 45% 
yield) was also attained via the Pd/C and hydrazine-driven dehalogenation reaction.304 The regioisomer of 
33 was generated by heating 2-chloroquinazoline and 3,4-dimethoxyphenethylamine, under high 
temperature and pressure conditions, to yield N-(3,4-dimethoxyphenethyl)quinazolin-2-amine, 33-iso, 
Scheme 13, ~ 55% yield). 
 
Scheme 13a  
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 32, 33 and 33-iso. (a) 3,4-
dimethoxyphenethylamine, DIPEA, EtOH, reflux, 4 h; (b) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h; (c) 3,4-
dimethoxyphenethylamine, DIPEA, 1,4-dioxane, pressure vial, 150–155 °C, 2 h. 
 
 
Synthesis of 2-azido-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (34, Scheme 14, ~ 90% yield) 
was accomplished as previously described utilizing sodium azide,305, 306 while the generation of the C2-
amino derivative (35, Scheme 14, N4-(3,4-dimethoxyphenethyl)quinazoline-2,4-diamine) was primarily 
conducted using the azide reduction approach via Pd/C and hydrazine.305 The effective formate/formic acid 
approach was utilized to generate 36 (4-(3,4-dimethoxyphenethyl)amino)quinazolin-2-ol, Scheme 14, yield 
~ 65%).  
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Scheme 14a  
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 34–36. (a) Sodium azide, EtOH, 
acetic acid, 90–95 °C, 2 h; (b) Cu2O, K2CO3, DMEDA, ethylene glycol, ammonium hydroxide, pressure vial, oil bath, 
105 °C, 24 h; (c) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h; (d) HCl, sodium nitrite, sodium azide, 0 °C–r.t., 1 h; (e) 
potassium formate, formic acid, 120–125 °C, 14–16 h. 
 
 
Scheme 15a  
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 37–44. (a) Urea, 1,4-dioxane, 
pressure vial, 160–165 °C, 24 h.; (b) glycinamide, DBU, 1,4-dioxane, pressure vial, 150–155 °C, 4 h.; (c) acetyl 
chloride, acetic acid, 1,4-dioxane, 120 °C, 24 h. (d) Primary amine (R1 = Me, Et, n-Pr, i-Pr or c-Pr), DIPEA, 1,4-
dioxane, pressure vial 150–155 °C, 2 h. 
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The development of both the C2-carbonyl based derivatives 37 (C2 = urea), 38 (C2 = glycinamide), 
39 (C2 = acetamide) and the C2-alkylamine based derivatives (40–44) was accomplished as previously 
described in Chapter 3 and 4 (Scheme 15).  
The development of the dimethoxyphenethyl-based chloroquinazolines with various alkylamines at 
the C2-position (45–59) was accomplished using previously described methodologies in Chapter 3 and 4 
(Scheme 16). 
 
Scheme 16a  
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 45–59. (a) Primary amine (R1 = n-
Pr, i-Pr or c-Pr) or dimethylamine, DIPEA, 1,4-dioxane, pressure vial 150–155 °C, 2 h. 
 
 
5.3.2. Cholinesterase 
 
The ability of 2-substituted-N-(3,4-dimethoxyphenethyl)quinazolin-4-amines (32–44) and the C4-
unsubstituted regiosiomer (33-iso) to target the cholinesterases (hAChE/hBuChE) was assessed using the 
DTNB method as described in Chapter 3 (Table 5). ChE data for phase-2 or optimization candidates (45-
59) is showcased in Table 6.  
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Examination of Table 5 generally pointed to the overall inability of most derivatives within this series 
to target BuChE. When comparing the anti-BuChE activity of the alkylamine-based derivatives here (40–
44) versus those in Chapter 3 (dimethoxybenzyl series, 14–18), the addition of the second methylene linker 
at the C4-position significantly enhanced the biological activity with respect to BuChE, for the most part. 
With respect to AChE targeting, IC50 values ranged from 3 to 13 µM and that closely matched the 3 to 9 
µM range seen with the dimethoxybenzyl counterparts (Chapter 3, Table 1). 
 
Table 5: Cholinesterase inhibition data for 2-substituted-N-(3,4-dimethoxyphenethyl)quinazolin-4-amines (32–44) and 
the C4-unsubstituted regiosiomer (33-iso). 
 
 
 
 
 
 
Derivative R-Grp 
ChE IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
hAChE hBuChE 
32 Cl 2.8 ± 0.3 > 50 – 4.40 225.3 1:5 
33 H 2.8 ± 0.2 > 50 – 3.64 210.9 1:5 
33-iso – 8.4 ± 0.9 > 50 – 3.64 252.1 1:5 
34 N3 9.5 ± 1.0 > 50 – 5.05 271.3 1:7  
35 H 2.5 ± 0.2 > 50 – 2.98 209.5 3:6  
36 OH 7.6 ± 0.5 > 50 – 4.26 259.9 2:6 
37 CONH2 8.7 ± 0.7 > 50 – 3.65 287.0 4:8 
38 CH2CONH2 12.5 ± 1.5 > 50 – 3.08 304.2 4:8 
39 COMe 7.4 ± 0.6 > 50 – 3.18 294.6 2:7 
40 Me 8.5 ± 0.5 4.5 ± 0.3 1.89 4.45 229.4 2:6 
41 Et 7.5 ± 0.4 14.0 ± 1.8 0.54 4.98 245.9 2:6 
42 n-Pr 7.0 ± 0.6 24.9 ± 3.0 0.28 5.51 258.6 2:6 
43 i-Pr 7.6 ± 0.7 7.8 ± 0.9 0.97 5.29 259.9 2:6 
44 c-Pr 7.2 ± 0.8 5.6 ± 0.4 1.29 5.03 252.7 2:6 
Donepezil – 0.03 ± 0.002 3.6 ± 0.4 0.01 4.59 321.7 0:4 
Tacrine – 0.16 ± 0.01 0.04 ± 0.001 4.00 3.27 165.6 2:2 
Galantamine – 2.6 ± 0.6 > 50 – 1.18 239.4 1:4 
Rivastigmine – 6.5 ± 0.5 > 10 – 2.10 226.3 0:4 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. 
bSelectivity index is calculated as (hAChE IC50)  ÷ (hBuChE IC50). cClogP values were determined using ChemDraw 
Professional 15.0. dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design 
software, BIOVIA Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding 
acceptors. 
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Interestingly, both 32 (C2 = Cl) and 33 (C2 = H) showcased equipotent activity in AChE (IC50 = 2.8 
µM) matching that of galantamine, while 33’s regiosiomer was 3-fold less potent (33-iso, IC50 = 8.4 µM). 
The azide functionality in this series (34, IC50 = 9.5 µM) was comparable to its dimethoxybenzyl 
counterpart in Chapter 3 (8, IC50 = 8.3 µM, Table 1). That observation carried over to the C2-amino 
derivative (35, IC50 = 2.6 µM), which was roughly 4-fold more potent compared to the azide derivative and 
equipotent to 9 (Chapter 3, Table 1). More so, the decreased potency with a C2-hydroxy group observed in 
Chapter 3 with the dimethoxybenzyl series (9 vs. 10) was also seen here, where derivative 36 was 3-fold 
less potent compared to 35 but also equipotent to 10 (Chapter 3, Table 1). 
With respect to the carbonyl-based derivatives, similar to those in Chapter 3, derivatives 37–39 
exhibited similar activity toward AChE (IC50 ~ 8 µM); however, the glycinamide derivative here (38) was 
less potent compared to its dimethoxybenzyl counterpart in Chapter 3 (IC50 ~ 13 µM vs. 7 µM). All 
derivatives discussed thus far within this series were inactive toward BuChE, a similar observation with 
those dimethoxybenzyl counterparts in Chapter 3.  
The introduction of alkylamines at the C2-position (derivatives 40–44, Table 5) established 
comparable activity toward AChE (IC50 ~ 7.6 µM) as seen with the dimethoxybenzyl counterpart (14–18, 
Chapter 3, IC50 ~ 6.6 µM). That said, the alkylamine-based derivatives in this series were anywhere from 
1.2 to 6.8-fold more effective at targeting BuChE compared to derivatives 14–18, with C2-propylamine 
showing the least improvement. Another interesting note, while 14–18 (Chapter 3) exhibited BuChE 
activity ranging from 25–30 µM the dimethoxyphenethyl counterparts (40–44) exhibited a wider range of 
BuChE activity (4.5–24.9 µM). More so, derivatives 40 and 44 were the first amongst all series discussed 
thus far to exhibit selective inhibition of BuChE. Those were also the most potent BuChEIs in this series 
(close in activity with donepezil IC50 ~ 4 µM), suggesting that smaller, hydrophobic groups were needed to 
accommodate the larger C4-dimethoxy phenethylamine group to achieve desirable inhibition. The ranking 
of the alkyl side chains, with respect to BuChE inhibition, were: Me > c-Pr > i-Pr > Et > n-Pr. 
Considering the general advantage of placing alkylamines at the C2-position, along with the 
dimethoxyphenethylamine group at the C4-position, the optimization of 42–44 (C2 = n-Pr, i-Pr and c-Pr) 
was investigated on chloroquinazoline scaffolds (6-, 7- or 8-chloroquinazoline). The introduction of the 
new C2-group (dimethylamine, –N(Me)2) was meant to correlate with the isopropylamine functionality. As 
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seen in Table 6, the chloroquinazoline derivatives (45–59) showcased an activity range of 6.2–13.4 µM 
(IC50) toward AChE and 3.9– >50 µM (IC50) toward BuChE. When compared to non-chloroquinazoline 
counterparts in Table 5, a general decrease in potency was observed suggesting that the chlorine addition 
was not as successful in enhancing ChE binding.  
 
Table 6: Cholinesterase inhibition data for 2-substituted-N-(3,4-dimethoxyphenethyl)chloroquinazolin-4-amines (45-
59). 
 
 
 
Derivative R-Grp 
ChE IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
hAChE hBuChE 
45 Cl 8.3 ± 0.9 > 50 – 5.13 281.6 1:5 
46 Cl 9.0 ± 0.8 > 50 – 5.13 284.7 1:5 
47 Cl 10.0 ± 0.9 > 50 – 5.13 280.9 1:5 
48 n-Pr 6.2 ± 0.6 > 50 – 6.26 325.8 2:6 
49 i-Pr 6.8 ± 0.7 20.34 0.34 6.04 320.4 2:6  
50 c-Pr 8.0 ± 0.7 > 50 – 5.79 320.4 2:6 
51 N(Me)2 7.2 ± 0.7 31.27 0.23 5.29 311.1 1:6 
52 n-Pr 7.2 ± 0.7 > 50 – 6.26 320.7 2:6 
53 i-Pr 7.9 ± 0.8 3.94 2.01 6.04 324.5 2:6  
54 c-Pr 8.7 ± 0.8 > 50 – 5.79 318.3 2:6 
55 N(Me)2 13.4 ± 1.1 > 50 – 5.29 311.8 1:6 
56 n-Pr 6.5 ± 0.5 > 50 – 6.26 324.8 2:6 
57 i-Pr 6.8 ± 0.7 19.29 0.35 6.04 324.5 2:6  
58 c-Pr 6.6 ± 0.7 > 50 – 5.79 315.2 2:6 
59 N(Me)2 8.1 ± 0.8 > 50 – 5.29 310.4 1:6 
Donepezil – 0.03 ± 0.002 3.6 ± 0.4 0.01 4.59 321.7 0:4 
Tacrine – 0.16 ± 0.01 0.04 ± 0.001 4.00 3.27 165.6 2:2 
Galantamine – 2.6 ± 0.6 > 50 – 1.18 239.4 1:4 
Rivastigmine – 6.5 ± 0.5 > 10 – 2.10 226.3 0:4 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. 
bSelectivity index is calculated as (hAChE IC50)  ÷ (hBuChE IC50). cClogP values were determined using ChemDraw 
Professional 15.0. dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design 
software, BIOVIA Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding 
acceptors. 
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Starting out with the C2-chlorine based derivatives, 45–47 were roughly three to four times less potent 
toward AChE (IC50 ~ 8-10 µM) compared to 32. Placement of the chlorine atom from position 6 to 7 to 8 
progressively reduced potency in AChE. Similar to 32, none of these derivatives targeted BuChE.  
When compared to 42–44, the impact of chlorine placement at position 6 of the quinazoline scaffold 
in 48–50 had negligible impact on AChE inhibition (average IC50 ~ 7.0 vs. 7.3 µM) but significantly 
hindered BuChE inhibition, with the cyclopropyl-based derivative (50) suffering a 10-fold minimum 
decrease in BuChE potency (IC50 ~ 6 vs. > 50 µM). With the dimethylamine functionality at the C2-
position (51), no significant impact on AChE inhibition was observed, while BuChE inhibition dropped 
1.5-fold compared to the isopropylamine-based derivative (49) (IC50 ~ 31 vs. 20 µM). 
Moving on, when compared to 42–44 and 48–50, the impact of chlorine placement at position 7 in 
52–54 had minor impact on AChE inhibition (average IC50 ~ 7.0 vs. 7.3 vs. 7.9 µM; respectively).  In 
BuChE, chlorine placement (6 or 7 position) had no impact on inhibition with the propyl- and cyclopropyl-
based derivatives (52 and 54), while the isopropyl-based derivative (53) displayed a 4-fold increase in 
potency compared to the 6-chloro isomer (49) (IC50 ~ 4 vs. 20 µM; respectively).  In addition, 53 was also 
2-fold more potent toward BuChE than the non-chlorinated counterpart (43) (IC50 ~ 4 vs. 8 µM; 
respectively).  With the dimethylamine functionality however, (55) exhibited potency losses with both 
ChEs compared to 51 – AChE IC50 ~ 13 vs. 7 µM and BuChE IC50 > 50 vs. 30 µM; respectively.  
Lastly, the impact of chlorine placement at position 8 in 56-58 elicited null or minor improvements on 
AChE inhibition (average IC50 ~ 6.6 µM) compared to other placements (52-54 and 48-50) and non-
chlorinated (42-44) counterparts  (average IC50 ~ 7.9 vs. 7.0 vs. 7.3 µM; respectively).  In BuChE, chlorine 
placement at 8 position showcased comparable results as those observed with chlorine placement at 
position 6 and 7, with the exception of 53. With the dimethylamine functionality, 59 exhibited similar 
potency to 51 in AChE (IC50 ~ 8 vs. 7 µM; respectively), while its inactivity toward BuChE matched that of 
55. 
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Figure 61: Cholinesterase metrics for fourteen 2-substituted-N-(3,4-dimethoxyphenethyl)quinazolin-4-amines (32-44) 
and 15 2-substituted-N-(3,4-dimethoxyphenethyl)chloroquinazolin-4-amines (45-59). 
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In summary, 29 derivatives were assessed for dual cholinesterase activity, of which derivative 35 (N4-
(3,4-dimethoxyphenethyl)quinazoline-2,4-diamine) was identified as the most active AChEI (IC50 = 2.6 
µM), while derivative 53 (7-chloro-N4-(3,4-dimethoxyphenethyl)-N2-isopropylquinazoline-2,4-diamine) 
was identified as the most active BuChEI (IC50 ~ 4 µM) matching the activity level of donepezil. Generally, 
this series proved to be more or less as effective toward AChE as the dimethoxybenzyl series (Chapter 3). 
Activity toward BuChE was improved overall, while the introduction of the chloroquinazoline scaffolds 
and the dimethylamine functionality at the C2-position offered mixed outcomes, specifically with BuChE 
inhibition (Figure 61). 
 
 
5.3.3. Amyloid-β Aggregation 
 
The ability of 2-substituted-N-(3,4-dimethoxyphenethyl)quinazolin-4-amines (32–44) and the C4-
unsubstituted regiosiomer (33-iso) to modulate the aggregation kinetics of amyloid-β was assessed using 
the ThT-binding method described earlier in Chapter 3 (Table 7). Amyloid-β inhibitory data for phase-2 or 
optimization candidates (45–59) is showcased in Table 8.  
Examination of Table 7 demonstrated the overall ability of this series to dually target Aβ aggregation 
(11 out of 14 derivatives as dual inhibitors). When compared to their dimethoxybenzyl counterparts in 
Chapter 3, inhibitory activity toward Aβ42 was improved across the board, while inhibitory activity toward 
Aβ40 was more of a mixed bag. Of noteworthy mention, derivatives 35 (C2 = NH2) and 41 (C2 = NHEt) 
exhibited strong inhibitory activity toward Aβ40 that placed them between the activities of resveratrol and 
curcumin.  
Starting out with the C2-chlorine derivative, 32 was significantly more active toward both Aβ40/42 
(IC50 ~ 8 and 13 µM; respectively) as compared to its dimethoxybenzyl counterpart (5, Table 2). It was also 
the most active Aβ42 inhibitor in this sub-series. The dechlorination of 32 hindered Aβ42 activity 
significantly and also reduced Aβ40 activity by 1.5-fold. That said, 33 was still more active toward both 
Aβ40/42 as compared to its dimethoxybenzyl counterpart (7, Table 2). On the other hand, 33’s regioisomer 
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was completely inactive toward both Aβ40/42, suggesting that the increased linearity of 33-iso prevented 
the necessary destabilizing interactions with the amyloid structures.  
 
 
Table 7: Amyloid-β (Aβ40/42) inhibition data for 2-substituted-N-(3,4-dimethoxyphenethyl)quinazolin-4-amines (32–
44) and the C4-unsubstituted regiosiomer (33-iso). 
 
 
 
 
 
 
 
 
Derivative R-Grp 
Amyloid-β IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
Aβ40 Aβ42 
32 Cl 8.2 ± 1.5  13.0 ± 1.9 0.63 4.40 225.3 1:5 
33 H 12.0 ± 2.4 36% – 3.64 210.9 1:5 
33-iso – NA NA – 3.64 252.1 1:5 
34 N3 40% 14% – 5.05 271.3 1:7  
35 H  2.7 ± 0.8 45% – 2.98 209.5 3:6  
36 OH 10.4 ± 1.2 32% – 4.26 259.9 2:6 
37 CONH2 14.4 ± 2.9 33% – 3.65 287.0 4:8 
38 CH2CONH2 NA NA – 3.08 304.2 4:8 
39 COMe 29% 22% – 3.18 294.6 2:7 
40 Me 6.6 ± 1.3 23.1 ± 2.5 – 4.45 229.4 2:6 
41 Et 2.9 ± 0.5 41% – 4.98 245.9 2:6 
42 n-Pr  4.3 ± 0.9 14% – 5.51 258.6 2:6 
43 i-Pr 32% 10% – 5.29 259.9 2:6 
44 c-Pr 4.9 ± 1.0 25% – 5.03 252.7 2:6 
Curcumin – 3.3 ± 0.45 9.9 ± 0.4 0.33 4.59 302.1 2:6 
Resveratrol – 1.1 ± 0.1 15.3 ± 1.9 0.07 2.83 187.2 3:3 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). bSelectivity 
index is calculated as (Aβ40 IC50)  ÷ (Aβ42 IC50). cClogP values were determined using ChemDraw Professional 15.0. 
dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design software, BIOVIA 
Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding acceptors. 
 
Compared to the outcome of the azide functionality in 9 (Chapter 3), 34 exhibited at least a 4-fold 
decline in activity toward Aβ40, while gaining some level of inhibition toward Aβ42. Reduction of that 
azide to the amino group (35, IC50 ~ 3 and ~ 31 µM; respectively) caused an approximate 9-fold increase in 
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Aβ40 activity, a 3-fold increase in Aβ42 activity, while surpassing the activity levels observed with its 
dimethoxybenzyl counter (10, Chapter 3) and curcumin. Replacement of the amino group in 35 with a 
hydroxyl group in 36 resulted in an approximate 4-fold decline in Aβ40 activity and an approximate 1.5-
fold decline in Aβ42 activity. Compared to 10 (Chapter 3), 36 was roughly 1.3 fold less active toward 
Aβ40 but it engaged in Aβ42 activity by providing 32% inhibition at 25 µM. 
With respect to the carbonyl-based derivatives, C2-urea-containing derivative 37 was the most active 
amongst the three, although it was 1.7-fold and 1.2-fold less active toward Aβ40/42; respectively. Similar 
to the other glycinamide-containing derivatives (Chapter 3 – 12 and Chapter 4 – 25), 38 was inactive 
toward Aβ40/42. The acetamide-based derivative was roughly equipotent toward both Aβ40/42 (P.I at 25 
µM was ~ 26%) and while that was a gain in activity with respect to Aβ42, it was a significant decline in 
activity toward Aβ40 when compared to the dimethoxybenzyl counterpart (13, Chapter 3). 
The introduction of alkylamines at the C2-position (40-44) established some interesting SAR. With 
the exception of the isopropyl-containing derivative (43, Aβ40 P.I at 25 µM was 32%), others exhibited 
good activity toward Aβ40 (IC50 ~ 3–7 µM) with 41 (C2 = NHEt) being the most potent, 42/44 (C2 = NHn-
Pr and NHc-Pr; respectively) being roughly equipotent at IC50 ~ 4.6 µM, while 40  (C2 = NHMe) provided 
an IC50 value of ~ 7 µM. When compared to their dimethoxybenzyl counterparts in Chapter 3, all were 
more potent toward both Aβ40/42, with the exception of 42, which was roughly 2.5-fold less potent toward 
Aβ40 compared to 16. 
With the introduction of the chloroquinazoline scaffolds, amyloid targeting (Aβ40/42) transitioned 
favourably, as showcased in Table 8, with almost all derivatives (45-59) surpassing their respective 
counterparts from Table 7. Activities toward Aβ40 ranged from 1.5-10.5 µM, while Aβ42 activities ranged 
from 1.3 µM to 33% inhibition at 25 µM. Compared to 32 (Table 7), derivatives 45-47 were anywhere from 
2.3 to 5.5-fold more potent toward Aβ40, while also being 5 to 10-fold more potent toward Aβ42. Chlorine 
placement was generally in the ranking of 7-Cl > 6-Cl ~ 8-Cl. An interesting observation came out with 47 
and carried on to the other derivatives in this sub-series – The placement of a C8-chlorine enabled dual Aβ 
targeting but with selectivity toward Aβ42 (Table 8). 
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Table 8: Amyloid-β (Aβ40/42) inhibition data for 2-substituted-N-(3,4-dimethoxyphenethyl)chloroquinazolin-4-
amines (45–59). 
 
 
Derivative R-Grp 
Amyloid-β IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
Aβ40 Aβ42 
45 Cl 2.6 ± 0.3 2.6 ± 0.2 0.99 5.13 281.6 1:5 
46 Cl 1.5 ± 0.2 1.9 ± 0.2 0.81 5.13 284.7 1:5 
47 Cl 3.5 ± 0.4 1.3 ± 0.8 2.76 5.13 280.9 1:5 
48 n-Pr 4.9 ± 0.5 10.7 ± 1.1 0.46 6.26 325.8 2:6 
49 i-Pr 5.8 ± 0.7 7.7 ± 0.8 0.76 6.04 320.4 2:6  
50 c-Pr 8.9 ± 0.9 9.8 ± 0.8 0.91 5.79 320.4 2:6 
51 N(Me)2 2.5 ± 0.3 5.6 ± 0.7 0.44 5.29 311.1 1:6 
52 n-Pr 3.1 ± 0.3 12.4 ± 1.1 0.25 6.26 320.7 2:6 
53 i-Pr 10.6 ± 0.9 33% – 6.04 324.5 2:6  
54 c-Pr 5.2 ± 0.6 22.5 ± 1.9 0.23 5.79 318.3 2:6 
55 N(Me)2 4.3 ± 0.4 9.4 ± 0.9 0.45 5.29 311.8 1:6 
56 n-Pr 4.9 ± 0.5 2.3 ± 0.3 2.17 6.26 324.8 2:6 
57 i-Pr 4.0 ± 0.4 1.5 ± 0.2 2.73 6.04 324.5 2:6  
58 c-Pr 4.6 ± 0.5 2.2 ± 0.2 2.08 5.79 315.2 2:6 
59 N(Me)2 2.3 ± 0.2 1.8 ± 0.3 1.27 5.29 310.4 1:6 
Curcumin – 3.3 ± 0.45 9.9 ± 0.4 0.33 4.59 302.1 2:6 
Resveratrol – 1.1 ± 0.1 15.3 ± 1.9 0.07 2.83 187.2 3:3 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). bSelectivity 
index is calculated as (Aβ40 IC50)  ÷ (Aβ42 IC50). cClogP values were determined using ChemDraw Professional 15.0. 
dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design software, BIOVIA 
Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding acceptors. 
 
 
With respect to Aβ40 inhibition, chlorine placement at position 6 of the quinazoline scaffold in 48–50, 
when compared to 42–44, had a positive impact with an isopropylamine at the C2 position group  (IC50 ~ 6 
vs. ~ 40+ µM) but a negative outcome with the cyclopropylamine group  (IC50 ~ 9 vs. 5 µM), while the 
propylamine-based derivatives remained equipotent (IC50 ~ 4-5 µM). With Aβ42, derivatives 48–50 
significantly surpassed the inhibition levels of 42–44, with 49 (C2 = NHi-Pr) being the most active of the 
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three (IC50 ~ 8 µM). Comparing the dimethylamine-based derivative (51) to 49, activity toward Aβ40/42 
improved by 2.3- and 1.4-fold; respectively.  
Moving on, when compared to 42–44 and 48–50, the impact of chlorine placement at position 7 in 
52–54 placed inhibitory activity toward Aβ42 between derivatives 42–44 and 48–50 (IC50’s were better 
than non-chlorinated counterparts but worse than those with chlorine placement at position 6). With respect 
to Aβ40, minor improvements came with the propylamine group  (52, IC50 ~ 3 vs. 4 vs. 5 µM; 
respectively), while middle ground placements came with the isopropyl- (53, IC50 ~ 11 vs. 40+ vs. 6 µM; 
respectively) and cyclopropylamine (54, IC50 ~ 5 vs. 5 vs. 9 µM; respectively) groups. Similar to 51, with 
respect to 48–50, derivative 55 was more potent toward both Aβ40/42 when compared to 52–54. That said, 
55 was roughly 1.7-fold less potent toward Aβ40/42 compared to 51. 
Lastly, the impact of chlorine placement at position 8 in 56–58 elicited major improvements with 
respect to Aβ42 inhibition and anywhere from minor setback to minor improvements with respect to Aβ40 
inhibition, when compared to 42–44, 48–51 and 52–55. As mentioned earlier, derivatives 56–58 where 
strong, dual Aβ inhibitors with selectivity geared toward Aβ42. With these 15 chloroquinazoline 
derivatives, 8 surpassed the Aβ42 activity levels of resveratrol, while 5 met or surpassed the Aβ40 activity 
levels of curcumin.  
In summary, 29 derivatives were assessed for dual Aβ activity, of which derivative 46 (2,7-dichloro-
N-(3,4-dimethoxyphenethyl)quinazolin-4-amine) was identified as the most potent and dual Aβ inhibitor 
(Aβ40 IC50 = 1.5 µM; Aβ42 IC50 = 1.9 µM), while derivative 47 (2,8-dichloro-N-(3,4-dimethoxyphenethyl) 
quinazolin-4-amine) was identified as the most potent Aβ42 inhibitor (IC50 = 1.3 µM). Generally, this series 
proved to be more effective at dual Aβ targeting as compared to the dimethoxybenzyl series (Chapter 3). 
The introduction of the chloroquinazoline scaffolds and the dimethylamine functionality at the C2-position, 
offered potency improvements overall when compared to the non-chlorinated counterparts (Figure 62). 
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Figure 62: Amyloid-β metrics for fourteen 2-substituted-N-(3,4-dimethoxyphenethyl)quinazolin-4-amines (32–44) and 
15 2-substituted-N-(3,4-dimethoxyphenethyl)chloroquinazolin-4-amines (45–59). 
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The aggregation kinetic assessment of Aβ40 with or without leading derivatives from this chapter is 
showcased in Figure 63. As observed in Panels A–D, derivatives 45, 46, 51 and 59 exhibited concentration-
dependent inhibition of Aβ40 aggregation; however they showcased various modes of aggregation. With 
the dichloro-based derivatives (45 and 46), no monomeric structure stabilization was observed (at the 1 and 
5 µM concentrations), although both managed to completely halt the aggregation process at 25 µM. 
Nonetheless, at 1 and 5 µM concentrations, 45 and 46 managed to reduce the rate of aggregation and the 
overall aggregate load after the 24 hour incubation period. On the other hand, derivatives 51 and 59 
managed to showcase all three-modes of inhibition. Across all tested concentrations (1, 5 and 25 µM), both 
derivatives managed to systematically stabilize the monomeric peptide structures with increasing 
compound concentrations, although 51 was more effective compared to 59. In addition, both derivatives 
managed to reduce the rate of aggregation as well as the total aggregate load after the 24 hour incubation 
period.  
The aggregation kinetic assessment of Aβ42 with or series-leading derivatives is showcased in Figure 
64. As observed in Panels A–D, derivatives 46, 47, 57 and 59 exhibited concentration-dependent and multi-
mode inhibition of Aβ42 aggregation. At 1 and 5 µM concentrations, all derivatives managed to reduce the 
rate of fibrillation and overall aggregate load at the end of the 24 hour incubation period. Those capabilities 
extended to the 25 µM concentrations for 46 and 57, while derivatives 47 and 59 managed to completely 
block the aggregation process at the 5:1 test ratio (compound: Aβ42).  
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Figure 63: ThT-monitored kinetics of Aβ40 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of 2,6-dichloro-N-(3,4-
dimethoxyphenethyl)quinazolin-4-amine (45) on the aggregation kinetics of 5 µM Aβ40. Panel (B): Impact of 1, 5 or 
25 µM of 2,7-dichloro-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (46) on the aggregation kinetics of 5 µM Aβ40. 
Panel (C): Impact of 1, 5 or 25 µM of 6-chloro-N4-(3,4-dimethoxyphenethyl)-N2,N2-dimethylquinazoline-2,4-diamine 
(51) on the aggregation kinetics of 5 µM Aβ40. Panel (D): Impact of 1, 5 or 25 µM of 8-chloro-N4-(3,4-
dimethoxyphenethyl)-N2,N2-dimethylquinazoline-2,4-diamine (59) on the aggregation kinetics of 5 µM Aβ40.  
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Figure 64: ThT-monitored kinetics of Aβ42 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of 2,7-dichloro-N-(3,4-
dimethoxyphenethyl)quinazolin-4-amine (46) on the aggregation kinetics of 5 µM Aβ42. Panel (B): Impact of 1, 5 or 
25 µM of 2,8-dichloro-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (47) on the aggregation kinetics of 5 µM Aβ42. 
Panel (C): Impact of 1, 5 or 25 µM of 8-chloro-N4-(3,4-dimethoxyphenethyl)-N2-isopropylquinazoline-2,4-diamine (57) 
on the aggregation kinetics of 5 µM Aβ42. Panel (D): Impact of 1, 5 or 25 µM of 8-chloro-N4-(3,4-
dimethoxyphenethyl)-N2,N2-dimethylquinazoline-2,4-diamine (59) on the aggregation kinetics of 5 µM Aβ42.  
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5.3.4. Transmission Electron Microscopy (TEM) 
 
The assessment of amyloid morphology at the conclusion of a 24-hour incubation period at 37 °C was 
conducted on leading derivatives. This commonly employed, qualitative technique is used to corroborate 
the quantitative results from the ThT-binding assay.207, 317 Experimental setup included the incubations of 
control and test samples, at 1:1 ratios of 25 µM, in triplicate at 37 °C (with shaking) over a 24-hour 
timeline. Triplicate samples were combined after the incubation period and applied to the copper-mesh 
grids prior to imaging in the TEM. 
As observed in Figure 65, resveratrol was effective at reducing total amyloid load (Panels B and E) 
compared to control samples (Panels A and D). That said, derivative 46 (Panel C) surpassed the inhibitory 
potential of resveratrol against Aβ40, while derivative 47 was more effective against Aβ42, compared to 
resveratrol.  
 
 
Figure 65: TEM assessment of Aβ40/42 morphology with or without test compounds at the end of a 24 h, 37 °C 
incubation period at pH 7.4. Panel (A–C): 25 µM Aβ40 alone or at a 1:1 ratio with resveratrol or 2,7-dichloro-N-(3,4-
dimethoxyphenethyl)quinazolin-4-amine (46); respectively. Panel (D–F): 25 µM Aβ42 alone or at a 1:1 ratio with 
resveratrol or 2,8-dichloro-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (47); respectively. White/black bars 
represent 500 nm. 
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5.3.5. Antioxidant Capacity 
 
The ability of 4-((3,4-dimethoxyphenethyl)amino)quinazolin-2-ol (36) to scavenge ROS was assessed 
using the previously described DPPH-scavenging assay.216, 319-321  
 
 
 
 
 
 
 
 
 
Figure 66: Standards utilized in the DPPH-scavenging along with the data for 4-((3,4-dimethoxyphenethyl)amino) 
quinazolin-2-ol (36). 
 
 
While a conjugated phenolic, it was no surprise to observe the weaker (~ 1.9-fold) scavenging 
potential of 36 in the DPPH assay, compared to 10 (Figure 66). The benefits of the additional methylene 
linker at the C4-position that served ChE and amyloid inhibition (compared to 10, Chapter 3) turned 
negatively with respect to antioxidant capacity. The overall, and likely hindered, conformation of 36 
attributed to the restricted access to the C2-hydroxyl group, thus impacting radical scavenging potential.  
 
 
5.3.6. Molecular Modeling 
 
The utilization of computational software is not only useful in structure-based drug design, it is also 
employed to understand and corroborate the acquired SAR data. The assessment of ligand-receptor 
interactions was conducted between leading (or comparable) derivatives from the 2-substituted-N-(3,4-
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dimethoxyphenethyl)quinazolin-4-amine series (32–44) or the 2-substituted-N-(3,4-dimethoxyphenethyl) 
chloroquinazolin-4-amine series (45–59) and the cholinesterase or amyloid targets of interest.  
 
 
5.3.6.1. Cholinesterase 
 
Based on the acquired anti-ChE data, presented in Tables 5 and 6, the docking interactions of 32 and 
35 were investigated in hAChE (PBD: 1B41) and superimposed in Figure 67, along with the docking 
interactions of 40 and 40 or 43 and 53 in hBuChE (PBD: 1P0I). 
 
 
 
 
 
Figure 67: Superimposition of docking structures. Panel (A): Binding modes of 32 (red) and 35 (purple) in the active 
site of hAChE (PDB ID: 1B41). Panel (B): Binding modes of 40 (green) and 44 (magenta) in the active sites of 
hBuChE (PDB ID: 1P0I). Panel (C): Binding modes of 43 (blue) and 53 (gold) in the active sites of hBuChE (PDB ID: 
1P0I). Hydrogens removed to enhance visibility. Black-dashed lines indicate hydrogen-bonding interactions.  
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As observed in Panel A, despite their equipotent profiles toward hAChE, derivatives 32 and 35 
showcased vastly different binding modes. With 32, the quinazoline scaffold was stacked against W286, 
roughly at 5–6 Å, while the dimethoxyphenyl group extended deep into the active site with a parallel 
stacking to S203 and H447. This orientation allowed for the para-methoxy group to undergo hydrogen-
bonding interactions with S203’s OH (~ 2.8 Å). In contrast, 35’s quinazoline scaffold was aligned 
perpendicular to W86 (~ 6 Å), while the C4-dimethoxyphenethyl group ran parallel to the acyl pocket, 
directed toward the PAS where the dimethoxyphenyl ring was parallel to W286 (~ 6–7 Å). The ligand’s 
C2-amino group underwent hydrogen-bonding interactions with S203 and H447 (~ 2.5–3.3 Å). 
In BuChE, derivative 40 and 44 exhibited similar binding modes, where the quinazoline scaffold was 
stacked perpendicular between W82 and the acyl pocket (~ 6 Å) and measured roughly 15 Å from A277. 
This allowed for hydrogen-bonding interactions between the quinazolines’ N1 and S203’s hydroxyl group 
(~ 3.0 Å). With both derivatives, the C4-dimethoxyphenethyl group bent toward W82 (in a perpendicular 
arrangement to the quinazoline scaffolds) allowing for the para-methoxy group to undergo hydrogen-
bonding interactions with W82’s NH (~ 3.3 Å). The C2-alkylamines were also pointed perpendicularly 
toward W82, allowing for hydrogen-bonding interactions between the C2-NH and S203’s hydroxyl group 
(~ 3.1 Å).  
Considering the approximate 2-fold difference in potency, the impact of chlorine placement at 
position 7 of the quinazoline scaffold was assessed by comparing 43 and 53 in BuChE. As seen in Panel C, 
the quinazoline scaffolds were stacked perpendicular between W82 and the acyl pocket (~ 6 Å) and 
measured roughly 15 Å from A277. This allowed for hydrogen-bonding interactions between the 
quinazolines’ N1 and S203’s hydroxyl group (~ 3.0 Å). Similar to 40 and 44, derivative 43’s C4-
dimethoxyphenethyl group was bent toward W82 (in a perpendicular arrangement to the quinazoline 
scaffolds) allowing for the para-methoxy group to undergo hydrogen-bonding interactions with W82’s NH 
(~ 3.3 Å). The C2-isopropylamine was also pointed perpendicularly toward W82, allowing for hydrogen-
bonding interactions between the C2-NH and S203’s hydroxyl group (~ 3.3 Å). In 53, the C2-
isopropylamine possessed the same binding modes, but the C4-dimethoxyphenethyl group was directed 
linearly toward A277, while its C7-chlorine was directly interacting with the hydrophobic acyl pocket 
(L286–V288) at roughly 4–5 Å. 
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5.3.6.2. Amyloid-β 
 
Based on the acquired anti-Aβ data, presented in Table 8, the docking interactions of 45, 46 and 47 
were investigated in both a dimeric and fibril model of Aβ (Aβ9-40 – PDB 2LMN)322 with superimpositions 
showcased in Figure 68. 
 
 
 
 
 
 
 
 
 
Figure 68: Superimposition of docking structures. Panels (A and B): Binding modes of 45 (gold), 46 (red) and 47 
(turquoise) in the Aβ (Aβ9-40 – PDB 2LMN) dimer model or fibril model; respectively. Hydrogens removed to enhance 
visibility. Amino acid labels to be used as a general guide as space restrictions limited complete and accurate labeling 
of all peptide structures. 
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8–9 Å). In contrast, 47 exhibited a reverse orientation where the quinazoline scaffold was stacked parallel 
over G25–S26 at roughly 7 Å. Its C4-functionality ran parallel over G22–V24 and toward F19/F20 at 
roughly 7–8 Å, while the C8-chlorine was stacked over D23 (~ 7 Å).  
In the fibril model, derivatives 46 and 47 provided perfectly superimposed binding interactions, as 
showcased in Panel B. All three dichloroquinazolines (45-47) had their C4-functional groups intercalated 
within the steric zipper domain, where the dimethoxyphenyl rings ran parallel to the peptide backbone (~ 
5–6 Å from the two pairs of M35 residues). While the quinazoline scaffold of 45 was stacked perpendicular 
to the peptide backbone, those of 46 and 47 were superimposed and stacked parallel to the peptide 
backbone (A30–I32, ~ 5 Å). All three derivatives underwent hydrogen-bonding interactions between their 
C4-NH and I32’s and G33’s backbone carbonyls and amine (~ 2.5–3.3 Å). 
 
 
5.4. Summary 
 
 
Figure 69: Cumulative chapter summary of 2-substituted-N-(3,4-dimethoxyphenethyl)quinazolin-4-amines (32-44) and 
2-substituted-N-(3,4-dimethoxyphenethyl)chloroquinazolin-4-amines (45-59). 
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With this dimethoxyphenethylamine-based series, an overall improvement in BuChE targeting was 
observed, without significant losses on AChE potency. When compared to their dimethoxybenzyl 
counterparts, the derivatives in this series were generally more capable of targeting Aβ40/42, while the 
investigation into the cholorquinazoline scaffolds significantly improved dual Aβ targeting. Unlike the 
amino regioisomer explored in Chapter 4 (22 vs. 22-iso), the unsubstituted regioisomer in this series was 
not effective on any target of interest (33 vs. 33-iso). In addition, the antioxidant capacity of 36 was 2-fold 
weaker compared to 10 (Chapter 3), suggesting a steric hindrance concern at the C2-hydroxyl site. 
Nonetheless, the series was the first to showcase selective BuChEIs (40, 44 and 53) and selective 
Aβ42 aggregation inhibitors (47, 56–59). While there was no clear “series leader(s)”, 8-chloro-N4-(3,4-
dimethoxyphenethyl)-N2-isopropylquinazoline-2,4-diamine (57) was identified was the best, overall, due to 
its potent and dual Aβ aggregation inhibition in addition to providing moderate but dual ChE inhibition 
(Figure 69).  
 
 
5.5. Experimental 
 
Please note that this subsection includes new and re-listed methodologies from Chapter 3 and 4. For 
schematic representation of re-listed methodologies, if applicable, please refer to Chapter 3 and 4 – Section 
3.5 or 4.5. 
 
5.5.1. Chemistry 
 
General Information. All the reagents and solvents were reagent grade purchased from various vendors 
(Acros Organics, Sigma-Aldrich, and Alfa Aesar, USA) with a minimum purity of 95% and were used 
without further purification. Melting points (mp) were determined using a Fisher-Johns apparatus and are 
uncorrected. Reaction progress was monitored by UV using thin-layer chromatography (TLC) using Merck 
60F254 silica gel plates. Column chromatography was performed with Merck silica gel 60 (230−400 mesh) 
with 5:1 EtOAc:MeOH as the solvent system unless otherwise specified. Proton (1H NMR) and carbon (13C 
NMR) spectra were performed on a Bruker Avance (at 300 and 75 MHz; respectively) spectrometer using 
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DMSO-d6. Coupling constants (J values) were recorded in hertz (Hz) and the following abbreviations were 
used to represent multiplets of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. 
Carbon multiplicities (C, CH, CH2 and CH3) were assigned by DEPT 90/135 experiments. High-resolution 
mass spectrometry (HRMS) was determined using a Thermo Scientific Q-Exactive Orbitrap mass 
spectrometer (positive mode, ESI), Department of Chemistry, University of Waterloo. Compound purity 
(roughly 95% or over) was determined using an Agilent 1100 series HPLC equipped with an analytical 
column (Agilent Zorbax Eclipse XDB-C8 column, 4.6 x 150 mm, 5 µm particle size) running 50:50 
Water:ACN with 0.1% TFA at a flow rate of 1.0-1.5 mL/min or an Agilent 6100 series single quad LCMS 
equipped with an Agilent 1.8 µm Zorbax Eclipse Plus C18 (2.1 x 50 mm) running 50:50 Water:ACN with 
0.1% FA with a flow rate of 0.5mL/min. All the final compounds exhibited ≥ 95% purity. 
 
General procedure for the synthesis of 2,4,6-, 2,4,7- or 2,4,8-trichloroquinazolines.289, 323 In a 250 
mL RBF, 5 g of 2-amino-5-chloro, 4-chloro, or 3-chlorobenzoic acid (29.24 mmol) was suspended in 25 
mL of anhydrous toluene and allowed to stir on an ice bath. To this, 5 eq. of POCl3 (146.20 mmol) was 
added in small aliquots followed by the slow addition of 5 eq. of DEA (146.20 mmol). The solution was 
kept on the ice bath for 10 min before moving to room temperature and allowed to stir for 1 h prior to 
refluxing at 105–110 °C for 14–16 h. Upon cooling to room temperature, the reaction mixture was added in 
small aliquots to a double-ice-water bath while stirring. The quenching solution was left stirring at room 
temperature for 5 h before vacuum filtering the yellowish-grey precipitate. The precipitate was stirred for 1 
h in a saturated NaHCO3 solution and then was re-filtered. This neutralization process was carried out 2–3 
times until the bicarbonate solution maintains a neutral to slight basic pH. The final precipitate was 
dissolved in DCM and purified by a silica gel column chromatography using 100% DCM as the eluent to 
afford white to light grey solid. 
 
2,4,6-Trichloroquinazoline. Yield: 75% (4.43 g, 19.12 mmol); mp 126–128 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 8.31 (s, 1H), δ 8.15 (d, J = 9.0 Hz, 1H), δ 8.04 (d, J = 8.9 Hz, 1H). LRMS (ESI) m/z calcd for 
C8H4Cl3N2 [M + H]+ 232.93, found 232.92. 
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2,4,7-Trichloroquinazoline.  Yield: 80% (4.73 g, 20.41 mmol); mp 137–139 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 8.30 (d, J = 9.0 Hz, 1H), δ 8.20 (s, 1H), δ 7.88 (d, J = 8.7 Hz, 1H). LRMS (ESI) m/z calcd for 
C8H4Cl3N2 [M + H]+ 232.93, found 232.92. 
 
2,4,8-Trichloroquinazoline. Yield: 65% (3.84 g, 16.56 mmol); mp 135–137 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 8.31 (d, J = 7.7 Hz, 1H), δ 8.25 (d, J = 8.5 Hz, 1H), δ 7.78 (t, J = 7.4 Hz, 1H). LRMS (ESI) 
m/z calcd for C8H4Cl3N2 [M + H]+ 232.93, found 232.92. 
 
 
 
General procedure for the synthesis of 2-chloro-, 2,6-dichloro-, 2,7-dichloro- or 2,8-dichloro-N-
substituted-quinazolin-4-amines.303, 305 To a 30 mL solution of ethanol in a 100 mL round-bottom flask 
on ice, 5 g of 4 or a trichloroquinazoline (21.46–25.13 mmol) was added followed by slow addition of 1.3 
eq. (27.90–32.66 mmol) of the corresponding primary amine. Contents were stirred on an ice bath while 2.0 
eq. of diisopropyl-ethylamine (DIPEA, 42.92–50.25 mmol) was added in drop wise fashion. The solution 
was then heated at 80-85 °C under reflux for 3–4 h. The reaction contents were cooled to room temperature 
and precipitated residues were vacuum-filtered with ethyl acetate (EtOAc) rinses. The organic supernatant 
was concentrated in vacuo followed by two rounds of liquid-liquid extraction using EtOAc and saturated 
brine solution (40–50 mL each respectively). The combined organic layers were dried over MgSO4, 
evaporated in vacuo and purified (1-2 times) using silica gel column chromatography with 5:1 
EtOAc:MeOH as the elution solvent. Final compounds were white to beige solids with yields ranging from 
70-90%.  
 
2-Chloro-N-(3,4-dimethoxyphenethyl)-quinazolin-4-amine (32). Yield: 80% yield (6.89 g, 20.10 mmol). 
Mp: 182–184 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.76 (br s, 1H), δ 8.21 (d, J = 8.3 Hz, 1H), δ 7.72 (t, J 
= 7.5 Hz, 1H), δ 7.56 (d, J = 8.2 Hz, 1H), δ 7.45 (t, J = 7.6 Hz, 1H), δ 6.83-6.71 (m, 3H), δ 3.72-3.66 (m, 
8H), δ 2.84 (t, J = 6.9 Hz, 2H). HRMS (ESI) m/z calcd for C18H18ClN3O2 [M + H]+ 344.1088, found 
344.1707. Purity: 97.4% 
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2,6-Dichloro-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (45). Yield: 80% (1.31 g, 3.45 mmol); mp 
143–145 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.82 (br s, 1H), δ 8.39 (s, 1H), δ 7.77 (dd, J = 8.9, 2.2 Hz, 
1H), δ 7.60 (d, J = 8.7 Hz, 1H), δ 6.85–6.73 (m, 3H), δ 3.71–3.65 (m, 8H), δ 2.83 (t, J = 7.4 Hz, 2H). 
LRMS (ESI) m/z calcd for C18H18Cl2N3O2 [M + H]+ 378.06, found 378.09. 
 
2,7-Dichloro-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (46). Yield: 77% (1.26 g, 3.34 mmol); mp 
147–149 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.92 (br s, 1H), δ 8.24 (d, J = 8.6 Hz, 1H), δ 7.66 (s, 1H), δ 
7.57 (d, J = 8.9 Hz, 1H), δ 6.85–6.72 (m, 3H), δ 3.71–3.65 (m, 8H), δ 2.83 (t, J = 7.4 Hz, 2H). LRMS (ESI) 
m/z calcd for C18H18Cl2N3O2 [M + H]+ 378.06, found 378.10. 
 
2,8-Dichloro-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (47). Yield: 87% (1.39 g, 3.67 mmol); mp 
145–147 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.97 (br s, 1H), δ 8.18 (d, J = 8.6 Hz, 1H), δ 7.92 (d, J = 8.9 
Hz, 1H), δ 7.45 (t, J = 8.4 Hz, 1H), δ 6.85–6.71 (m, 3H), δ 3.71–3.65 (m, 8H), δ 2.83 (t, J = 7.4 Hz, 2H). 
LRMS (ESI) m/z calcd for C18H18Cl2N3O2 [M + H]+ 378.06, found 378.04. 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-4-amines. In a 50 mL round 
bottom flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was dissolved 
in 20 mL of anhydrous ethanol. While stirring on ice, 10 mol. % of 10% Pd/C was added to reaction 
mixture followed by the drop-wise addition of 1.3 eq. of hydrazine hydrate. Solution was stirred on ice for 
5 min before refluxing for 2 h at 80–85 °C. Upon completion and cooling to room temperature, the reaction 
mixture was passed through a tightly-packed cotton-filled syringe that has been pre-rinsed with ethanol, to 
remove the Pd/C catalyst. A 30 mL aliquot of ethanol was used to rinse the syringe. The combined ethanol 
solutions were evaporated in vacuo, diluted in EtOAc (20 mL) and washed 25 mL x 2 with equal volumes 
of brine solution. The combined aqueous layers were washed with 15 mL of EtOAc. The combined EtOAc 
layers were dried over MgSO4, before removing the EtOAc in vacuo to yield a solid or semi-solid crude 
product that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH solvent system. 
Final compounds were white to pale yellow solids with yields ranging from 40–47%. 
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N-(3,4-Dimethoxyphenethyl)quinazolin-4-amine (33). Yield: 40% (0.18 g, 0.58 mmol); Mp 155–157 °C. 
1H NMR (300 MHz, DMSO-d6): δ 8.44 (s, 1H), δ 8.28 (br s, 1H), δ 8.16 (d, J = 6.0 Hz, 1H), δ 7.71–7.62 
(m, 2H), δ 7.46 (t, J = 9.0 Hz, 1H), δ 6.83–6.72 (m, 3H), δ 3.70 (d, J = 6.0 Hz, 2H), δ 3.67 (s, 3H), δ 3.66 
(s, 3H), δ 2.84 (t, J = 9.0 Hz, 2H). HRMS (ESI) m/z calcd for C18H20N3O2 [M + H]+ 310.1477, found 
310.1549. Purity: 98.6%  
 
 
 
General procedure for the synthesis of N2-substituted-quinazolin-2-amines. In a 50 mL pressure 
vial (PV), 0.25 g of 2-chloroquinazoline (1.52 mmol) was dissolved in 5 mL of 1,4-dioxane followed by the 
addition of 3 eq. (4.56 mmol) of the appropriate primary amine and 5 eq. of DIPEA (7.60 mmol). Pressure 
vial was sealed and stirred in an oil bath at 155–160 °C for 5 h. Upon completion and cooling to room 
temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and washed 25 mL x 3 times with 
equal volumes of brine solution. The combined aqueous layers were washed with ~ 25 mL of EtOAc. The 
combined EtOAc layers were dried over MgSO4 before removing the EtOAc in vacuo to yield a solid crude 
product that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the solvent 
system. Final compounds were pale yellow to pale brown solids with yields ranging from 47–52%. 
 
 
N-(3,4-Dimethoxyphenethyl)quinazolin-2-amine (33-iso). Yield: 52% (0.18 g, 0.58 mmol); Mp 144–146 
°C. 1H NMR (300 MHz, DMSO-d6): δ 9.09 (s, 1H), δ 7.72 (d, J = 8.0 Hz, 1H), δ 7.72–7.63 (m, 2H), δ 
7.45–7.33 (m, 1H), δ 7.32–7.20 (m, 2H), δ 6.84–6.69 (m, 3H), δ 3.70 (s, 3H), δ 3.67 (s, 3H), δ 3.62 (q, J = 
8.2 Hz, 2H), δ 2.75 (t, J = 7.6 Hz, 2H). HRMS (ESI) m/z calcd for C18H20N3O2 [M + H]+ 310.1477, found 
310.1549. Purity: 99.6%  
 
 
 
General procedure for the synthesis of 2-azido-N-substituted-quinazolin-4-amine.305 In a 50 mL 
RBF, 2-chloro-N-substituted-quinazolin-4-amine (~1.86 mmol), 1.1 eq. NaN3 (2.05 mmol), 4:1 EtOH (20 
mL) and glacial acetic acid (5 mL) were combined and refluxed at 90–95 °C for 2 h with stirring. After 
cooling, the solution was vacuum-filtered to afford white solids at yields ranging from 80–85%. 
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2-Azido-N-(3,4-dimethoxyphenethyl)quinazolin-4-amine (13c). Yield: 82% (0.42 g, 1.20 mmol); Mp 
259–261 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.91 (br s, 1H), δ 8.42 (d, J = 8.2 Hz, 1H), δ 8.31 (d, J = 
8.3 Hz, 1H), δ 7.96 (t, J = 8.0 Hz, 1H), δ 7.71 (t, J = 8.0 Hz, 1H), δ 6.86–6.78 (m, 3H), δ 3.78–3.76 (m, 
2H), δ 3.67 (s, 6H), δ 2.91 (t, J = 7.2 Hz, 2H). 13C NMR (100 MHz, DMSO-d6): δ 157.43, δ 153.90, δ 
148.61, δ 147.28, δ 134.48, δ 132.33, δ 131.74, δ 127.72, δ 124.87, δ 120.54, δ 115.88, δ 112.61, δ 112.22, 
δ 111.90, δ 55.48, δ 55.32, δ 42.85, δ 33.46. HRMS (ESI) m/z calcd for C18H19N6O2 [M + H]+ 351.1491, 
found 351.1564. Purity: 94.9% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2,4-diamine.305  
 
Method 1A: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was added along with 20 mol. % of CuI. To that, a mixture of 1,4-dioxane (5 mL) and 30% aqueous 
ammonia (15 mL) was added at room temperature. The pressure vial was sealed tightly and partially 
submerged in silicone oil heating at 130–135 °C. Contents were stirred in the pressure vial for 24 h (Note: 
in the event of pressure leakage, the contents were cooled to room temperature and additional aqueous 
ammonia, (10 mL) was added, sealed and heating was carried on through the 24 h period). The reaction 
contents were cooled to room temperature and the solution was diluted with 25 mL EtOAc, washed with 
saturated brine solution (10 mL x 3), and the aqueous layer was neutralized with dilute HCl, and then re-
extracted with 15 mL EtOAc. The organic layers were combined, dried over MgSO4, evaporated in vacuo 
and purified using silica gel column chromatography with 5:1 EtOAc:MeOH as an initial elution solvent 
followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine). Final compounds were obtained as 
white to beige solids with final yields ranging from 20–25%.  
 
Method 1B: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was dissolved and gently heated in 5 mL ethylene glycol. To that, 20 mol. % of Cu2O and DMEDA 
were added followed by 20 eq. K2CO3 and finally, 40 eq. of 30% aqueous ammonia solution (~15–20 mL). 
The pressure vial was sealed tightly, partially submerged in silicone oil and heated at 100–105 °C. Contents 
were stirred in the pressure vial for 24 h. After the reaction contents were cooled to room temperature, the 
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solution was diluted with 50 mL EtOAc, washed with saturated brine solution (25 mL x 3) and the aqueous 
layer was neutralized with dilute HCl, and then re-extracted with 25 mL EtOAc. The residue formed was 
dissolved in methanol (20–25 mL). The EtOAc layers were dried over MgSO4 and evaporated in vacuo. 
The methanol fraction was dried with molecular sieves before evaporating the methanol in vacuo. Both 
EtOAc and methanol fractions were combined and purified using silica gel column chromatography with 
5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH with 1% TEA 
(triethylamine). Final compounds were obtained as white to beige solids with yields ranging from 35–40%.  
 
Method 2: In a 50 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) 
was combined with 6 eq. urea (22.32 mmol) and diluted with 10 mL of anhydrous 1,4-dioxane. The 
pressure vial was sealed tightly and partially submerged in silicone oil heating at 160–165 °C. Contents 
were stirred in the pressure vial for 24 h. Once the reaction contents were cooled to room temperature, the 
solution was diluted with 20–25 mL EtOAc. The contents were washed three times with 20 mL saturated 
brine solution and the aqueous layers were re-extracted twice with 20 mL EtOAc. The organic layers were 
combined, dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography 
with 5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA 
(triethylamine). Final compounds were obtained as white to light beige solids with yields ranging from 50–
55%. 
 
Method 3: In a 50 mL round-bottom flask, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) was 
combined with 1.1 eq. NaN3 (4.09 mmol), before diluting with 4:1 EtOH (20 mL) and glacial acetic acid (5 
mL). Flask contents were stirred under reflux at 90–95 °C for 2 h. After cooling the reaction mixture, 10 
mol. % of Pd/C (10%) was added followed by slow addition of 1.5 eq. of hydrazine hydrate (5.58 mmol). 
Flask contents were stirred under reflux at 90–95 °C for an additional two hrs. Once complete, the warm 
solution was passed through a large, tightly packed cotton syringe with the aid of additional EtOH washes 
(2 x 20 mL). The ethanolic mixture was evaporated in vacuo. Final compounds were obtained as white to 
beige solids with yields ranging from 80–85%. 
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N4-(3,4-Dimethoxyphenethyl)quinazolin-2,4-diamine (35). Yield: 80% (0.76 g, 2.33 mmol); Mp: 179-
181 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.92–7.86 (m, 2H), δ 7.42 (t, J = 8.0 Hz, 1H), δ 7.15 (d, J = 8.0 
Hz, 1H), δ 6.97 (t, J = 7.5 Hz, 1H), δ 6.84–6.73 (m, 3H), δ 6.05 (br s, 2H), 3.67 (s, 6H), δ 3.60-3.64 (m, 
2H), δ), δ 2.83 (t, J = 6.9 Hz, 2H). HRMS (ESI) m/z calcd for C18H20N4O2 [M + H]+ 325.1664, found: 
325.1657. 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-ols. In a 50 mL round bottom 
flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was combined with 1.3 
eq. of potassium formate (1.89–2.41 mmol) then dissolved in 20 mL of formic acid. Solution was refluxed 
for 14–16 h at 120–125 °C. Upon completion and cooling to room temperature, the reaction mixture was 
diluted with ~ 30 mL of brine solution, ~ 50 mL of saturated NaHCO3 solution before extracting with ~ 25 
mL (x 3) of EtOAc and washed with 25 mL (x 3) parts of brine solution. The combined aqueous layers 
were washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 before 
removing the EtOAc in vacuo to yield a solid product that generally did not require additional purification. 
Additional purification as required, was accomplished by silica gel column chromatography using 5:1 
EtOAc:MeOH as the eluent. The compounds were obtained as white solids with yields ranging from 58–
70%. 
 
4-((3,4-Dimethoxyphenethyl)amino)quinazolin-2-ol (36). Yield: 62% (0.29 g, 0.90 mmol); Mp 210–212 
°C. 1H NMR (300 MHz, DMSO-d6): δ 10.60 (br s, 1H), δ 8.40 (br s, 1H), δ 8.02 (d, J = 8.1 Hz, 1H), δ 7.47 
(t, J = 7.5 Hz, 1H), δ 7.12–7.02 (m, 2H), δ 6.83–6.71 (m, 3H), δ 3.70–3.60 (m, 8H), δ 2.82 (t, J = 7.1 Hz, 
2H). HRMS (ESI) m/z calcd for C18H20N3O3 [M + H]+ 326.1426, found 326.1499. Purity: 97.3% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-urea.305 In a pressure vial, 0.5 
g of 2-chloro-N-substituted-quinazolin-4-amine (~1.85 mmol) was mixed with 6 eq. urea (~11.2 mmol) and 
10 mL of anhydrous 1,4-dioxane, sealed tightly and heated at 160–165 °C in an oil bath for 24 h. After 
cooling to room temperature, the solution was diluted with 20 mL EtOAc, washed three times with 20 mL 
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brine solution; the aqueous layers were extracted twice with 20 mL EtOAc. The combined organic layers 
were dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography using a 
combination of 5:1 EtOAc:MeOH and 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine) to afford target 
compounds as white solids with yields ranging from 45–50% and the hydrolyzed amine compounds as off 
white solids with yields ranging from 50–55%.  
 
1-(4-((3,4-Dimethoxyphenethyl)amino)quinazolin-2-yl)urea (37). Yield: 47% (0.25 g, 0.68 mmol); Mp 
246–248 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.10 (br s, 1H), δ 8.76 (br s, 1H), δ 8.35 (br s, 1H), δ 8.03 
(d, J = 8.2 Hz, 1H), δ 7.46 (t, J = 7.6 Hz, 1H), δ 7.44 (d, J = 8.2 Hz, 1H), δ 7.28 (t, J = 7.6 Hz, 1H), δ 6.90–
6.78 (m, 4H), δ 3.70–3.67 (m, 8H), δ 2.86 (t, J = 7.5 Hz, 2H). HRMS (ESI) m/z calcd for C19H22N5O3 [M + 
H]+ 368.1644, found 368.1718. Purity: 95.7% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-glycinamide.299 In a 50 mL 
pressure vial, 0.25 g of 2-chloro-N-substituted-quinazolin-4-amine (~ 0.83 mmol) was combined with 3 eq. 
(~ 2.50-mmol) of glycinamide.HCl then dissolved in 5 mL of 1,4-dioxane followed by the addition of 5 eq. 
of DBU (~ 4.15 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 4 h. Upon 
completion and cooling to room temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and 
washed 25 mL (x 3) brine solution. The combined aqueous layers were washed with ~ 25 mL of EtOAc. 
The combined EtOAc layers were dried over MgSO4 and EtOAc was removed in vacuo to yield solid that 
was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the eluent to afford target 
compounds as pale yellow to brown solids with yields ranging between 52–58%. 
 
2-((4-((3,4-Dimethoxyphenethyl)amino)quinazolin-2-yl)amino)acetamide (38). Yield: 52% (0.14 g, 
0.38 mmol); Mp 159–161 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.13 (br s, 1H), δ 7.93 (d, J = 8.2 Hz, 1H), 
δ 7.45 (t, J = 7.5 Hz, 1H), δ 7.21 (d, J = 8.4 Hz, 2H), δ 7.01 (t, J = 7.5 Hz, 1H), δ 6.97 (br s, 1H), δ 6.84–
6.74 (m, 3H), δ 6.42 (br s, 1H), δ 3.86 (d, J = 7.1 Hz, 2H), δ 3.68 (s, 3H), δ 3.67 (s, 3H), δ 3.64–3.59 (m, 
 	   151 
2H), δ 2.82 (t, J = 7.1 Hz, 2H). HRMS (ESI) m/z calcd for C20H24N5O3 [M + H]+ 382.1801, found 
382.1873. Purity: 99.6% 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-acetamide.312 In a 50 mL 
round bottom flask (RBF), 0.5 g of N4-substituted-quinazolin-2,4-diamine (1.54–2.00 mmol) was dissolved 
in 15 mL of 1,4-dioxane and 10 mL of glacial acetic acid/acetyl chloride combination (4:1 ratio). Solution 
was refluxed for 24 h at 90–95 °C. Upon completion and cooling to room temperature, the reaction mixture 
was diluted with ~ 30 mL of brine solution, ~ 30 mL of concentrated NaHCO3 solution before extracting 
with ~ 25 mL (x 3) of EtOAc and washed with 25 mL (x 2) brine solution. The combined aqueous layers 
were washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 and the 
organic solvent was removed in vacuo to yield a solid product that generally did not require additional 
purification. Purification was carried out as required, by silica gel column chromatography using 5:1 
EtOAc:MeOH as the eluent to afford target compounds as white solids with yields ranging from 35–42%. 
 
 
N-(4-((3,4-Dimethoxyphenethyl)amino)quinazolin-2-yl)acetamide (39).  Yield: 57% (0.33 g, 0.90 
mmol); Mp 241–243 °C. 1H NMR (300 MHz, DMSO-d6): δ 9.83 (br s, 1H), δ 8.47 (br s, 1H), δ 8.07 (d, J = 
8.0 Hz, 1H), δ 7.60 (t, J = 7.2 Hz, 1H), δ 7.43 (d, J = 8.2 Hz, 1H), δ 7.26 (t, J = 6.0 Hz, 1H), δ 6.87-6.76 
(m, 3H), δ 3.66–3.63 (m, 8H), δ 2.84 (t, J = 7.5 Hz, 2H), δ 2.52 (s, 3H). HRMS (ESI) m/z calcd for 
C20H23N4O3 [M + H]+ 367.1692, found 367.1766. Purity: 96.8% 
 
 
General procedure for the synthesis of N4-substituted-N2-alkyl-quinazolin-2,4-diamine.299, 313 In a 
50 mL pressure vial (PV), 0.25 g of 2-chloro, 2,6-dichloro, 2,7-dichloro or 2,8-dichloro-N-substituted-
quinazolin-4-amine (~ 0.66–0.83 mmol) was combined with 2 eq. (~ 1.32–1.66 mmol) of primary amine 
(methyl-, ethyl-, n-propyl-, isopropyl- or cyclopropylamine) or dimethylamine then dissolved in 5 mL of 
1,4-dioxane followed by the addition of 3 eq. of DIPEA (~ 1.98–2.40 mmol). Pressure vial was sealed and 
stirred in an oil bath at 150–155 °C for 2 h. Upon completion and cooling to room temperature, the reaction 
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mixture was diluted with ~ 40 mL of EtOAc and washed with brine solution (25 mL x 2). The combined 
aqueous layer was washed with ~ 25 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 
before removing EtOAc in vacuo to yield a solid product that was purified by silica gel column 
chromatography using 5:1 EtOAc:MeOH as the eluent to afford pale yellow to brown solids yielding at 55–
70%. 
 
N4-(3,4-Dimethoxyphenethyl)-N2-methylquinazoline-2,4-diamine (40). Yield: 70% (0.34 g, 1.01 mmol); 
Mp 153–155 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.87 (d, J = 8.0 Hz, 2H), δ 7.40 (t, J = 7.2 Hz, 1H), δ 
7.19 (d, J = 9.0 Hz, 1H), δ 6.94 (t, J = 6.0 Hz, 1H), δ 6.83–6.72 (m, 3H), δ 6.42 (br s, 1H), δ 3.66 (s, 6H), δ 
3.63–3.60 (m, 2H), δ 2.86–2.79 (m, 2H), δ 2.80 (d, J = 4.5 Hz, 3H). HRMS (ESI) m/z calcd for C19H23N4O2 
[M + H]+ 339.1743, found 339.1816. Purity: 97.8%  
 
N4-(3,4-Dimethoxyphenethyl)-N2-ethylquinazoline-2,4-diamine (41). Yield: 70% (0.33 g, 0.94 mmol); 
Mp 157–159 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.86 (d, J = 8.0 Hz, 2H), δ 7.41 (t, J = 7.2 Hz, 1H), δ 
7.19 (d, J = 9.0 Hz, 1H), δ 6.96 (t, J = 6.0 Hz, 1H), δ 6.84-6.75 (m, 3H), δ 6.40 (br s, 1H), δ 3.67 (s, 6H), δ 
3.63–3.60 (m, 2H), δ 3.34–3.32 (m, 2H), δ 2.82 (t, J = 7.2 Hz, 2H), δ 1.08 (t, J = 7.0 Hz, 3H). HRMS (ESI) 
m/z calcd for C20H24N4O2 [M + H]+ 353.1899, found 353.1971. Purity: 98.6%  
 
N4-(3,4-Dimethoxyphenethyl)-N2-propylquinazoline-2,4-diamine (42). Yield: 68% (0.36 g, 0.98 mmol); 
Mp 127–129 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.87 (d, J = 8.0 Hz, 2H), δ 7.39 (t, J = 7.2 Hz, 1H), δ 
7.16 (d, J = 9.0 Hz, 1H), δ 6.94 (t, J = 6.0 Hz, 1H), δ 6.83-6.72 (m, 3H), δ 6.52 (br s, 1H), δ 3.63 (s, 6H), δ 
3.63–3.60 (m, 2H), δ 3.34–3.32 (m, 2H), δ 2.82 (t, J = 7.2 Hz, 2H), δ 1.59–1.46 (m, 2H), 0.83 (t, J = 7.0 
Hz, 3H). HRMS (ESI) m/z calcd for C21H27N4O2 [M + H]+ 367.2056, found 367.2132. Purity: 99.0%  
 
N4-(3,4-Dimethoxyphenethyl)-N2-isopropylquinazoline-2,4-diamine (43). Yield: 67% (0.35 g, 0.96 
mmol); Mp 134–136 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.90 (d, J = 8.0 Hz, 2H), δ 7.45 (t, J = 7.2 Hz, 
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1H), δ 7.18 (d, J = 9.0 Hz, 1H), δ 7.00 (t, J = 6.0 Hz, 1H), δ 6.84–6.72 (m, 3H), δ 6.55 (br s, 1H), δ 4.02–
3.95 (m, 1H), δ 3.66 (s, 6H), δ 3.63–3.60 (m, 2H), δ 2.82 (t, J = 7.2 Hz, 2H), δ 1.13 (d, J = 6.0 Hz, 6H). 
HRMS (ESI) m/z calcd for C21H27N4O2 [M + H]+ 367.2056, found 367.2131. Purity: 97.5%  
 
N2-Cyclopropyl-N4-(3,4-dimethoxyphenethyl)quinazoline-2,4-diamine (44). Yield: 67% (0.35 g, 0.96 
mmol); Mp 166–168 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.90 (d, J = 8.0 Hz, 2H), δ 7.40 (t, J = 7.2 Hz, 
1H), δ 7.20 (d, J = 9.0 Hz, 1H), δ 7.00 (t, J = 6.0 Hz, 1H), δ 6.85–6.72 (m, 3H), δ 6.48 (br s, 1H), δ 3.68–
3.65 (m, 8H), δ 2.85–2.80 (m, 3H), δ 0.63–0.55 (m, 2H), δ 0.48-0.40 (m, 2H). HRMS (ESI) m/z calcd for 
C21H25N4O2 [M + H]+ 365.1899, found 365.1975. Purity: 95.8%  
 
6-Chloro-N4-(3,4-dimethoxyphenethyl)-N2-propylquinazoline-2,4-diamine (48). Yield: 71% (0.37 g, 
0.93 mmol); Mp 107–109 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.08–8.03 (m, 2H), δ 7.40 (dd, J = 8.9, 2.3 
Hz, 1H), δ 7.17 (d, J = 8.8 Hz, 1H), δ 6.84–6.71 (m, 4H), δ 3.67–3.59 (m, 8H), δ 3.27–3.23 (m, 2H), δ 2.81 
(t, J = 7.3 Hz, 2H), δ 1.48 (sextet, J = 7.2 Hz, 2H), δ 0.84 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z calcd for 
C21H26ClN4O2 [M + H]+ 401.1666, found 401.1740. Purity: 99.4% 
 
6-Chloro-N4-(3,4-dimethoxyphenethyl)-N2-isopropylquinazoline-2,4-diamine (49). Yield: 75% (0.40 g, 
0.99 mmol); Mp 109–111 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.09–8.05 (m, 2H), δ 7.43 (dd, J = 8.9, 2.2 
Hz, 1H), δ 7.18 (d, J = 9.0 Hz, 1H), δ 6.84–6.72 (m, 3H), δ 6.71 (br s, 1H), δ 4.16–4.09 (m, 1H), δ 3.67–
3.59 (m, 8H), δ 2.82 (t, J = 7.3 Hz, 2H), δ 1.12 (d, J = 6.5 Hz, 6H). HRMS (ESI) m/z calcd for 
C21H26ClN4O2 [M + H]+ 401.1666, found 401.1740. Purity: 98.3% 
 
6-Chloro-N2-cyclopropyl-N4-(3,4-dimethoxyphenethyl)quinazoline-2,4-diamine (50). Yield: 72% (0.38 
g, 0.95 mmol); Mp 104–106 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.07 (d, J = 2.2 Hz, 1H), δ 8.00 (br s, 
1H), δ 7.42 (dd, J = 8.9, 2.3 Hz, 1H), δ 7.22 (d, J = 8.9 Hz, 1H), δ 6.86–6.71 (m, 4H), δ 3.67–3.59 (m, 8H), 
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δ 2.87–2.75 (m, 3H), δ 0.64–0.58 (m, 2H), δ 0.48–0.43 (m, 2H). HRMS (ESI) m/z calcd for C21H24ClN4O2 
[M + H]+ 399.1510, found 399.1582. Purity: 98.5% 
 
6-Chloro-N4-(3,4-dimethoxyphenethyl)-N2,N2-dimethylquinazoline-2,4-diamine (51). Yield: 70% (0.36 
g, 0.93 mmol); Mp 124–126 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.08–8.05 (m, 2H), δ 7.40 (dd, J = 8.9, 
2.3 Hz, 1H), δ 7.20 (d, J = 8.9 Hz, 1H), δ 6.84–6.70 (m, 3H), δ 3.67–3.58 (m, 8H), δ 3.12 (s, 6H), δ 2.82 (t, 
J = 7.2 Hz, 2H). 13C NMR (75 MHz, DMSO-d6) δ 159.45, δ 158.72, δ 150.76, δ 148.62, δ 147.22, δ 
132.28, δ 132.06, δ 126.85, δ 123.40, δ 121.95, δ 120.43, δ 112.49, δ 111.94, δ 110.86, δ 55.47, δ 55.20, δ 
42.48, δ 36.44, δ 34.00. HRMS (ESI) m/z calcd for C20H24ClN4O2 [M + H]+ 387.1510, found 387.1581. 
Purity: 96.5% 
 
7-Chloro-N4-(3,4-dimethoxyphenethyl)-N2-propylquinazoline-2,4-diamine (52). Yield: 71% (0.37 g, 
0.93 mmol); Mp 105–107 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.96–7.90 (m, 2H), δ 7.20–7.15 (m, 1H), δ 
6.97 (dd, J = 8.6, 2.1 Hz, 1H), δ 6.84–6.72 (m, 4H), δ 3.67–3.59 (m, 8H), δ 2.81 (t, J = 7.3 Hz, 2H), δ 1.46 
(sextet, J = 7.2 Hz, 2H), δ 0.78 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z calcd for C21H26ClN4O2 [M + H]+ 
401.1666, found 401.1738. Purity: 99.6% 
 
7-Chloro-N4-(3,4-dimethoxyphenethyl)-N2-isopropylquinazoline-2,4-diamine (53). Yield: 71% (0.37 g, 
0.93 mmol); Mp 111–113 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.97–7.93 (m, 2H), δ 7.19–7.14 (m, 1H), δ 
6.99 (dd, J = 8.7, 2.1 Hz, 1H), δ 6.84–6.72 (m, 4H), δ 4.17–4.10 (m, 1H), δ 3.67–3.59 (m, 8H), δ 2.82 (t, J 
= 7.3 Hz, 2H), δ 1.12 (d, J = 6.5 Hz, 6H). HRMS (ESI) m/z calcd for C21H26ClN4O2 [M + H]+ 401.1666, 
found 401.1738. Purity: 95.2% 
 
7-Chloro-N2-cyclopropyl-N4-(3,4-dimethoxyphenethyl)quinazoline-2,4-diamine (54). Yield: 72% (0.38 
g, 0.95 mmol); Mp 108–110 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.02 (br s, 1H), δ 7.93 (d, J = 8.9 Hz, 
1H), δ 7.21–7.19 (m, 1H), δ 6.99 (dd, J = 8.9, 2.3 Hz, 1H), δ 6.91 (br s, 1H), δ 6.80–6.71 (m, 3H), δ 3.67–
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3.59 (m, 8H), δ 2.88–2.78 (m, 3H), δ 0.64–0.58 (m, 2H), δ 0.48–0.43 (m, 2H). HRMS (ESI) m/z calcd for 
C21H24ClN4O2 [M + H]+ 399.1510, found 399.1581. Purity: 99.2% 
 
7-Chloro-N4-(3,4-dimethoxyphenethyl)-N2,N2-dimethylquinazoline-2,4-diamine (55). Yield: 70% (0.36 
g, 0.93 mmol); Mp 128–130 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.09 (br s, 1H), δ 7.90 (d, J = 8.7 Hz, 
1H), δ 7.20 (d, J = 2.1 Hz, 1H), δ 6.97 (dd, J = 8.7, 2.1 Hz, 1H), δ 6.84–6.69 (m, 3H), δ 3.71–3.58 (m, 8H), 
δ 3.13 (s, 6H), δ 2.82 (t, J = 7.2 Hz, 2H). HRMS (ESI) m/z calcd for C20H24ClN4O2 [M + H]+ 387.1510, 
found 387.1580. Purity: 98.4% 
 
8-Chloro-N4-(3,4-dimethoxyphenethyl)-N2-propylquinazoline-2,4-diamine (56). Yield: 71% (0.37 g, 
0.93 mmol); Mp 101–103 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.92–7.86 (m, 2H), δ 7.57 (d, J = 7.0 Hz, 
1H), δ 6.94–6.72 (m, 5H), δ 3.59–3.67 (m, 8H), δ 3.37–3.33 (m, 2H), δ 2.83 (t, J = 7.3 Hz, 2H), δ 1.51 
(sextet, J = 7.2 Hz, 2H), δ 0.76 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z calcd for C21H26ClN4O2 [M + H]+ 
401.1666, found 401.1738. Purity: 98.3% 
 
8-Chloro-N4-(3,4-dimethoxyphenethyl)-N2-isopropylquinazoline-2,4-diamine (57). Yield: 76% (0.39 g, 
0.97 mmol); Mp 104–106 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.92–7.86 (m, 2H), δ 7.57 (d, J = 7.0 Hz, 
1H), δ 6.94–6.72 (m, 5H), δ 4.19–4.08 (m, 1H), δ 3.67–3.59 (m, 8H), δ 2.82 (t, J = 7.3 Hz, 2H), δ 1.13 (d, J 
= 6.5 Hz, 6H). HRMS (ESI) m/z calcd for C21H26ClN4O2 [M + H]+ 401.1666, found 401.1737. Purity: 
98.6% 
 
8-Chloro-N2-cyclopropyl-N4-(3,4-dimethoxyphenethyl)quinazoline-2,4-diamine (58). Yield: 71% (0.37 
g, 0.94 mmol); Mp 102–104 °C. 1H NMR (300 MHz, DMSO-d6) δ 7.92–7.86 (m, 2H), δ 7.57 (d, J = 7.0 
Hz, 1H), δ 6.94–6.72 (m, 5H), δ 3.67–3.59 (m, 8H), δ 2.88–2.78 (m, 3H), δ 0.64–0.58 (m, 2H), δ 0.48–0.43 
(m, 2H). HRMS (ESI) m/z calcd for C21H24ClN4O2 [M + H]+ 399.1510, found 399.1581 Purity: 98.4% 
 
 	   156 
8-Chloro-N4-(3,4-dimethoxyphenethyl)-N2,N2-dimethylquinazoline-2,4-diamine (59). Yield: 68% (0.35 
g, 0.91 mmol); Mp 121–123 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.10 (br s, 1H), δ 7.87 (d, J = 7.6 Hz, 
1H), δ 7.59 (d, J = 7.5 Hz, 1H), δ 6.90 (t, J = 7.8 Hz, 1H), δ 6.84–6.70 (m, 3H), δ 3.70–3.60 (m, 8H), δ 
3.17 (s, 6H), δ 2.83 (t, J = 7.2 Hz, 2H). HRMS (ESI) m/z calcd for C20H24ClN4O2 [M + H]+ 387.1510, 
found 387.1581. Purity: 99.0% 
 
 
5.5.2. Biological Screening 
 
5.5.2.1. Human Cholinesterase (hChE) Assay299, 313 
 
The inhibition profile of quinazoline derivatives was evaluated using the Ellman (DTNB) reagent.315 
Human AChE and BuChE enzymes were obtained from Sigma-Aldrich, St. Louis, MO, USA (AChE 
product number C0663 and BuChE product number B4186 respectively). The cholinesterase inhibitors 
tacrine (item number 70240, Cayman Chemical Company, Ann Arbor, MI), donepezil (product number 
D6821, Sigma-Aldrich, St. Louis, MO), galantamine (product number G1660, Sigma-Aldrich, St. Louis, 
MO) and rivastigmine (product number SML0881, Sigma-Aldrich, St. Louis, MO) were used as reference 
agents. Quinazoline derivative stock solutions were prepared in DMSO (maximum 1% v/v in final wells) 
and diluted in buffer solution (50 mM Tris.HCl, pH 8.0, 0.1 M NaCl, 0.02 M MgCl2.6H2O). Then 160 µL 
of 5,5’-dithiobis(2-nitrobenzoic acid) (1.5 mm DTNB), 50 µL of hAChE (0.22 U/mL in 50 mM Tris.HCl, 
pH 8.0, 0.1% w/v bovine serum albumin, BSA) or 50 µL of hBuChE (0.12 U/mL in 50 mM Tris.HCl, pH 
8.0, 0.1% w/v BSA) were added to 96-well plates after which 10 µL each of quinazoline derivatives (final 
concentration range 0.1–50 µM) were added and incubated for 5 min. Then 30 µL of either 
acetylthiocholine iodide (15 mM AThCl prepared in ultra pure water) or S-butyrylthiocholine iodide (15 
mM BThCI prepared in ultra pure water) were added. The absorbance was measured at different time 
intervals (0, 60, 120, 180, 240 and 300 s) using a wavelength of 412 nm. The inhibitory concentration (IC50 
values) was calculated from the concentration–inhibition dose response curve on a logarithmic scale. The 
results were expressed as average values based on two to three independent experiments run in triplicate 
measurements. 
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5.5.2.2. Amyloid-β (Aβ) Aggregation Assay317 
 
The ability of quinazoline-based derivatives to inhibit Aβ-aggregation kinetics was determined using a 
ThT-binding fluorescence assay. These assays were conducted in Costar, black-surround, clear-bottom 
384-well plates with frequent shaking (30 sec. of linear shaking at 730 cpm every 5 minutes) and constant 
heating at 37 °C for 24 h. The ThT excitation/emission was measured at 440 nm/490 nm and readings were 
taken every 5 minutes using a BioTek Synergy H1 microplate reader. Quinazoline stock solutions were 
prepared in DMSO and diluted to 10x in 215 mM phosphate buffer at pH 7.4. Abeta.HFIP samples (Aβ40 
or Aβ42, rPeptide, Bogart, USA) were dissolved in 1% ammonium hydroxide, sonicated at room 
temperature for 5 minutes then diluted to 50 µM in 215 mM phosphate buffer (pH 7.4). A 15 µM ThT stock 
solution was prepared with 50 mM glycine and adjusted to pH 7.4. The assay was carried out by adding 44 
µL ThT, 20–35 µL buffer, 1 µL DMSO (for background and controls only) followed by the addition of 8 
µL of 10x compound dilutions (1–25 µM concentration range). An end point reading was conducted to 
evaluate potential test compound interference with ThT-fluorescence before adding 8 µL of Aβ40 or Aβ42 
stock solutions (5 µM final concentration). Plates were sealed with a transparent plate film before initiating 
the assay. RFU values were corrected for ThT-interference before calculating end point percent inhibitions 
or IC50 values and obtaining the aggregation kinetic plots. Data presented was an average of triplicate 
reading for two-three independent experiments. 
 
5.5.2.3. TEM Assay and Imaging142, 190, 207, 317 
 
In Costar 96-well, round-bottom plates were added 80 µL of 215 mM phosphate buffer, 20 µL of 10x 
test compound dilutions (250 µM – prepared in the same way as for the ThT assay) and 100 µL of 50 µM 
Aβ40 or Aβ42 respectively.  For the control wells, 2 µL of DMSO and 18 µL of phosphate buffer was 
added. Final Aβ: test compound ratio was 1:1 (25 µM). Plates were incubated on a Fisher plate incubator 
set to 37 °C and the contents were shaken at 730 cpm for 24 h. To prepare the TEM grids, ~ 20 µL droplet 
was added using a disposable Pasteur pipette over the formvar-coated copper grids (400 mesh). Grids were 
air-dried for about 3 h before adding two droplets (~ 40 µL, using a disposable Pasteur pipette) of ultra-
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pure water and using small pieces of filter paper to wash out precipitated buffer salts. After air-drying for ~ 
15-20 min, the grids were negatively stained by adding a droplet (~ 20 µL, using a disposable Pasteur 
pipette) of 2% phosphotungstic acid (PTA) and immediately after the grids were dried using small pieces of 
filter paper. Grids were further air-dried overnight. The scanning was carried out using a Philips CM 10 
transmission electron microscope at 60 kV (Department of Biology, University of Waterloo) and 
micrographs were obtained using a 14-megapixel AMT camera. 
 
5.5.2.4. DPPH Scavenging Assay324 
 
The ability of select quinazolines to scavenge the DPPH radical was utilized as a measure of 
antioxidant capacity. Quinazoline stock solutions were prepared in anhydrous methanol (500 µM) and the 
DPPH solution was also prepared in anhydrous methanol (56 µM). The addition sequence was carried out 
in a 96-well clear, flat bottom plate as follows: 90 µL DPPH, 10 µL test compound solution (50 µΜ) final 
concentration. Control solutions contained 90 µL anhydrous methanol and 10 µL test compound whereas 
DPPH control contained 90 µL of DPPH, and 10 µL anhydrous methanol. This readings were taken initially 
at 517 nm with 30 sec. shaking (double orbital at 530 cpm) prior to the 1 h, light restrictive, incubation 
period at room temperature after which readings were taken again at 517 nm after another round of 30 sec 
shaking (double orbital at 530 cpm) using a BioTek Synergy H1 microplate reader. The results were 
expressed as percentage inhibition and the data presented was average of triplicate reading (for two 
independent experiments). 
 
5.5.3. Computational Chemistry299, 313, 317, 324 
 
The molecular docking studies were conducted using Discovery Studio 4.0 (Structure-Based-Design 
program) from BIOVIA Inc. San Diego, USA. Select quinazolines derivatives were built and minimized 
using the small molecules module in Discovery Studio. X-ray coordinates of human cholinesterases were 
obtained from the protein data bank (hAChE PBD ID: 1B41 and hBuChE PDB ID: 1P0I) and prepared 
using the macromolecules module in Discovery Studio. Ligand binding sites were defined by selecting a 12 
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Å radius sphere for AChE and 15 Å radius sphere for BuChE. The molecular docking was performed using 
the receptor-ligand interactions module in Discovery Studio. The LibDock algorithm was used to find the 
most appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. For Amyloid-β docking studies, the NMR solution structure of Aβ fibrils were 
obtained from the protein data bank (PDB ID: 2LMN). Aβ dimer and Aβ fibril assemblies were built using 
the macromolecules module in Discovery Studio. Ligand binding site was defined by selecting a 15 Å 
radius sphere for both Aβ assemblies. Molecular docking was performed using the receptor-ligand 
interactions module in Discovery Studio, where the LibDock algorithm was used to find the most 
appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. 
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CHAPTER 6 
  Development and Evaluation of N-phenethylquinazolin-4-amines as Dual ChE and 
Aβ Aggregation Inhibitors   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Chapter banner   
  
6.1. Introduction 
 
The preceding chapters (3–5) showcased the SAR data from 56 quinazoline and cholorquinazoline 
derivatives, including two regioisomeric structures. The acquired data thus far highlighted the advantages 
and disadvantages of introducing a dimethoxyphenyl moiety or an additional methylene linker at the C4-
positon of the quinazoline scaffold, while providing clear indications of the biological outcomes based on 
the nature of the C2-groups. The assessment of regioisomeric structures and the impact of chlorine 
placements provided valuable SAR for the optimization (Phase 2) stage.  
This chapter sets to further expand on the acquired SAR data by developing and assessing 30 
derivatives that continue to explore the collection of the C2-groups introduced since Chapter 3. The 
examination of two regioisomers and chlorine placement at position 6, 7 or 8 on the quinazoline scaffold 
are also investigated. Highlights of the synthetic routes to target derivatives (refer to the chapter banner 
above) along with the acquisition and assessment of the SAR data are provided.  
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Generally, all synthetic approaches and mechanisms here have been previously discussed in Chapters 
3–5. A brief summary is provided prior to the listing of experimental data and methodology. 
 
 
6.2. Hypothesis 
 
With respect to this series, the absence of the 3,4-dimethoxy moiety, with the additional methylene 
unit in the linker chain, should enhance BuChE targeting, while offering an additional point of rotation to 
enhance binding conformations in AChE and amongst amyloid structures. 
On the other hand, continuing with the existing selection of C2-groups offers an opportunity to 
evaluate and compare the impact of the phenethyl moiety vs. the benzyl (Chapter 4) and the 3,4-
dimethoxyphenethyl (Chapter 5) at the C4-position. Previous predications hold true with entities like the 
azide and carbonyl-based groups with respect to their inability to target BuChE. The increased free-rotation 
potential at the C4-position, combined with alkylamines at the C2-position, are predicted to aid with 
BuChE inhibition, while effectively targeting AChE and modulating amyloid aggregation. As these 
derivatives lack the dimethoxy moiety, it is predicated that their binding conformation within AChE should 
be primarily based at the catalytic site, with little PAS interactions.  
As observed in Chapters 4 and 5, the introduction of a regioisomer provided good insight into the 
roles of the C2- and C4-groups with respect to dual ChE and dual amyloid targeting and here, two isomers 
are evaluated. 
Lastly, as seen in Chapter 5, the introduction of the chloroquinazoline scaffolds, as part of the 
optimization process, are predicted to significantly influence ChE binding and amyloid modulation. The 
dimethylamine group at the C2-position, as part of the optimization process, would present the only tertiary 
amine based quinazolines in the collective chemical library. The SAR obtained from these derivatives 
should provide critical insight. 
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6.3. Results and Discussions 
 
The proceeding sub-chapter briefly highlights previously-established routes to target derivatives. 
Biological assessments in the cholinesterase and amyloid-β aggregation assay (to obtain IC50 values and/or 
investigation aggregation kinetics) are conducted. Aggregate load is corroborated via transmission electron 
microscopy in amyloid morphology screening and select derivatives are assessed for ROS scavenging in 
the DPPH assay. Computational studies are performed in the ChE X-ray structures and amyloid models to 
evaluate the acquisitioned SAR data.  
 
6.3.1. Synthesis 
 
As previously described in Chapters 3–5, initial coupling in this series utilized 2,4-DCQ (4) to add the 
phenethylamine group to the C4-position of the quinazoline scaffold, via a NAS reaction, to yield 2-chloro-
N-phenethylquinazolin-4-amine (60, Scheme 17, 80–85% yield).299, 303 The C2-unsubstituted derivative (N-
phenethylquinazolin-4-amine, 61, Scheme 17, ~ 45% yield) was also synthesized via the Pd/C and 
hydrazine-driven dehalogenation reaction.304 The regioisomer of 61 was generated by heating 2-
chloroquinazoline and phenethylamine, under high temperature and pressure conditions, to yield N-
phenethylquinazolin-2-amine, 61-iso, Scheme 17, ~ 55% yield). 
 
Scheme 17a  
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 60, 61 and 61-iso.(a) 
Phenethylamine, DIPEA, EtOH, reflux, 4 h; (b) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h; (c) Phenethylamine, 
DIPEA, 1,4-dioxane, pressure vial, 150–155 °C, 2 h. 
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Synthesis of 2-azido-N-phenethylquinazolin-4-amine (62, Scheme 18, ~ 90% yield) was accomplished 
as previously described utilizing sodium azide,305, 306 while the generation of the C2-amino derivative (63, 
Scheme 18, N4-phenethylquinazoline-2,4-diamine) was primarily conducted using the azide reduction 
approach via Pd/C and hydrazine.305 The synthesis of 63-iso was accomplished from the previously 
described method using 2,4-diaminoquinazoline (DAQ).317 The effective formate/formic acid approach was 
utilized to generate 64 (4-(phenethylamino)quinazolin-2-ol, Scheme 18, yield ~ 65%).  
 
Scheme 18a  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 62–64 and 63-iso. (a) Sodium azide, 
EtOH, acetic acid, 90–95 °C, 2 h; (b) Cu2O, K2CO3, DMEDA, ethylene glycol, ammonium hydroxide, pressure vial, oil 
bath, 105 °C, 24 h; (c) Pd/C, hydrazine hydrate, EtOH, reflux, 2 h; (d) HCl, sodium nitrite, sodium azide, 0 °C–r.t., 1 h; 
(e) Sodium hydride, DMSO, benzyl bromide, 0 °C–r.t., 14 h; (f) DMA, potassium or cesium carbonate, benzyl bromide 
80–85 °C, 5 h.; (g) Potassium formate, formic acid, 120–125 °C, 14–16 h. 
 
 
The synthesis of both the C2-carbonyl based derivatives 65 (C2 = urea), 66 (C2 = glycinamide), 67 
(C2 = acetamide) and the C2-alkylamine based derivatives (68–72) was accomplished as previously 
described in Chapters 3–5 (Scheme 19). As previously outlined in Chapter 5, the synthesis of the 
phenethyl-based chloroquinazolines with various alkylamines at the C2-position (73–87) was accomplished 
using previously described methodologies based on N.A.S (Scheme 20). 
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Scheme 19a  
 
 
 
 
 
 
 
 
 
 
 
 	  	  
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 65–72. (a) Urea, 1,4-dioxane, 
pressure vial, 160–165 °C, 24 h.; (b) glycinamide, DBU, 1,4-dioxane, pressure vial, 150–155 °C, 4 h.; (c) acetyl 
chloride, acetic acid, 1,4-dioxane, 120 °C, 24 h. (d) Primary amine (R1 = Me, Et, n-Pr, i-Pr or c-Pr), DIPEA, 1,4-
dioxane, pressure vial 150–155 °C, 2 h. 
 
 
 
Scheme 20a  
 
 
 
aReagents and conditions: Synthetic routes toward quinazoline-based derivatives 73–87.(a) Primary amine (R1 = n-Pr, 
i-Pr or c-Pr) or dimethylamine, DIPEA, 1,4-dioxane, pressure vial 150–155 °C, 2 h. 
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6.3.2. Cholinesterase 
 
The ability of 2-substituted-N-phenethylquinazolin-4-amines (60–72) and the related regiosiomers (61-
iso and 63-iso) to target the cholinesterases (hAChE/hBuChE) was assessed using the DTNB method as 
described in Chapter 3 (Table 9). ChE data for phase-2 candidates (73–87) are showcased in Table 10.  
 
Table 9: Cholinesterase inhibition data for 2-substituted-N-phenethylquinazolin-4-amines (60–72) and the related 
regiosiomers (61-iso and 63-iso). 
 
 
 
 
 
 
Derivative R-Grp 
ChE IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
hAChE hBuChE 
60 Cl 7.7 ± 0.5 > 50 – 4.74 182.1 1:3 
61 H 6.2 ± 0.7 14.1 ± 1.2 0.44 3.98 168.7 1:3 
61-iso – 7.6 ± 0.5 > 50 – 3.98 197.7 1:3 
62 N3 9.7 ± 0.8 > 50 – 5.39 221.5 1:7  
63 H 5.7 ± 0.7 4.9 ± 0.6 1.16 3.97 176.6 3:4 
63-iso – 7.1 ± 0.7 2.4 ± 0.1 2.96 3.97 209.2 3:4 
64 OH 8.1 ± 0.6 > 50 – 4.61 208.5 2:4 
65 CONH2 7.9 ± 0.6 > 50 – 3.99 232.8 4:6 
66 CH2CONH2 7.3 ± 0.9 3.5 ± 0.2 2.09 3.59 247.9 4:6 
67 COMe 7.0 ± 0.5 > 50 – 3.52 245.5 2:5 
68 Me 8.7 ± 1.0 5.0 ± 0.3 1.74 4.79 187.6 2:4 
69 Et 7.6 ± 0.5 3.2 ± 0.3 2.38 5.32 199.2 2:4 
70 n-Pr 7.2 ± 0.6 5.0 ± 0.4 1.44 5.85 212.3 2:4 
71 i-Pr 7.2 ± 0.4 1.6 ± 0.05 4.51 5.63 214.3 2:4 
72 c-Pr 8.6 ± 0.6 11.4 ± 0.9 0.75 5.38 208.5 2:4 
Donepezil – 0.03 ± 0.002 3.6 ± 0.4 0.01 4.59 321.7 0:4 
Tacrine – 0.16 ± 0.01 0.04 ± 0.001 4.00 3.27 165.6 2:2 
Galantamine – 2.6 ± 0.6 > 50 – 1.18 239.4 1:4 
Rivastigmine – 6.5 ± 0.5 > 10 – 2.10 226.3 0:4 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. 
bSelectivity index is calculated as (hAChE IC50)  ÷ (hBuChE IC50). cClogP values were determined using ChemDraw 
Professional 15.0. dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design 
software, BIOVIA Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding 
acceptors. 
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When considered against Table 3 (Chapter 4) and Table 5 (Chapter 5), the data presented in Table 9 
generally pointed to the superior ability of most derivatives within this series to target BuChE. With respect 
to AChE targeting, IC50 values ranged from 6 to 10 µM, which was a narrower range of inhibitory activity 
when compared to the 5–14 µM range seen with the benzyl counterparts (Chapter 4, Table 3) and the 3–13 
µM range seen with the dimethoxyphenethyl counterparts (Chapter 5, Table 5).  
Interestingly, both 60 (C2 = Cl; IC50 = 7.7 µM) and 61 (C2 = H; IC50 = 6.2 µM) showcased equipotent 
activity in AChE when compared with their C4-benzyl counterparts (19 and 20; respectively). While both 
were roughly 2.5-fold less potent in AChE compared with their C4-dimethoxyphenethyl counterparts (32 
and 33; respectively), 61 became the first C2-substituted derivative to display moderate activity toward 
BuChE (IC50 ~ 14 µM). This was one of the initial pointers toward the favorability of the C4-
phenethylamine group to target BuChE. That said, 61-iso showcased the same pattern as seen with 33-iso 
(Chapter 5) where AChE activity was reduced roughly 1.2-fold and a loss of BuChE inhibition was 
observed.  
The azide functionality in this series (62, IC50 = 9.7 µM) was comparable to its dimethoxyphenethyl 
counterpart in Chapter 5 (34, IC50 = 8.5 µM, Table 5) and roughly 1.4-fold more potent than its benzyl 
counterpart in Chapter 4 (21, IC50 = 14.0 µM). That said, 62 was the least potent AChEI in this series and 
as with other azide-based derivatives, it was inactive toward BuChE. With a C2-amino group, 63 was 
equipotent to 22 with respect to AChE but, thanks to its additional methylene linker, an enhanced binding 
conformation was observed in BuChE yielding a 6-fold improvement in the IC50 (5 vs. 30 µM). The 
relevance of the dimethoxy moiety is showcased when comparing 63 and 35 (Chapter 5), where a 2.2-fold 
decline in AChE potency was observed with the absence of the 3,4-dimethoxy group. Similar to what was 
observed with 22 and 22-iso in Chapter 4, 63-iso lost some AChE potency (~ 1.2-fold) in favour of a 2-fold 
improvement in BuChE inhibition, with respect to 63. When compared directly to 22-iso, no differences 
were observed in AChE activity but an approximate 5-fold improvement was observed with BuChE 
targeting. The introduction of the C2-hydroxy group in 64 yielded comparable results to those observed in 
Chapter 4 (benzyl series) and Chapter 5 (dimethoxyphenethyl series) with AChE IC50 at roughly 8 µM and 
no activity toward BuChE. 
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With respect to the carbonyl-based derivatives, derivatives 65–67 exhibited activity toward AChE at 
IC50 values of 7–8 µM, which closely resemble those of 24–26 (Chapter 4, benzyl series) and 37/39 
(Chapter 5, dimethoxyphenethyl series). While carbonyl-based derivatives have been a write-off with 
respect to BuChE targeting, it was a pleasant surprise to observe that 66 (C2 = glycinamide) was not only 
active toward BuChE, but also equipotent to donepezil (IC50 = 3.5 µM). As hypothesized with 61, the 
additional methylene linker at the C4-position in 66 must have facilitated a substantially favourable binding 
conformation within BuChE to yield the 14-fold+ improvement in inhibition. 
The introduction of alkylamines at the C2-position (derivatives 68–72, Table 8) established 
comparable activity toward AChE (IC50 ~ 7.9 µM) as seen with both the benzyl (27–31, Chapter 4, IC50 ~ 
7.3 µM) and the dimethoxyphenethyl counterparts (40–44, Chapter 5, IC50 ~ 7.6 µM). With respect to 
BuChE on the other hand, inhibition was generally improved with C2-Et, nPr and iPr derivatives (69-71) 
surpassing both benzyl (28–30) and dimethoxyphenethyl (41–43) counterparts. While 72 (C2-cPr) was the 
least favourable amongst the alkylamine-based derivatives, derivative 71 (AChE IC50 = 7.2 µM, BuChE 
IC50 = 1.6 µM) exhibited strong AChE inhibition and was the most potent BuChE inhibitor (surpassing 
donepezil by 2.3- fold) amongst the subgroup. 
Considering the general advantage of placing alkylamines at the C2-position, along with the benefits 
of a phenethylamine group at the C4-position, the optimization of 70–72 (C2 = n-Pr, i-Pr and c-Pr) was 
investigated on chloroquinazoline scaffolds (6-, 7- or 8-chloroquinazoline). The use of the dimethylamine 
group was meant to correlate with the isopropylamine functionality. As seen in Table 10, the 
chloroquinazoline derivatives (73–87) showcased an activity range of 5.8–8.9 µM (IC50) toward AChE and 
0.1–50+ µM (IC50) toward BuChE. When compared to non-chloroquinazoline counterparts in Table 5, 
general improvements are seen in both AChE and BuChE, which was expected considering the additional 
hydrophobicity and electrostatic changes. This was an interesting observation considering that chlorine 
placement did not necessarily benefit ChE binding with the dimethoxyphenethyl series (Chapter 5).  
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Table 10: Cholinesterase inhibition data for 2-substituted-N-phenethylchloroquinazolin-4-amines (73–87). 
 
 
 
 
 
 
Derivative R-Grp 
ChE IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
hAChE hBuChE 
73 Cl 8.3 ± 0.8 > 50 – 5.47 231.18 1:3 
74 Cl 7.6 ± 0.8 43.0 ± 3.9 0.18 5.47 234.26 1:3 
75 Cl 8.9 ± 0.9 14.3 ± 1.5 0.62 5.47 232.89 1:3 
76 n-Pr 8.9 ± 0.6 4.8 ± 0.3 1.84 6.60 275.08 2:4 
77 i-Pr 8.7 ± 0.5  1.5  ± 0.1 5.64 6.38 274.39 2:4  
78 c-Pr 8.7 ± 0.9 9.1 ± 0.7 0.95 6.13 266.16 2:4 
79 N(Me)2 7.7 ± 0.8 5.4 ± 0.6 1.41 5.63 261.02 1:4 
80 n-Pr 7.2 ± 0.7 4.4 ± 0.4 1.66 6.6 270.96 2:4 
81 i-Pr 6.6 ± 0.6 0.1 ± 0.02 73.3 6.38 273.37 2:4  
82 c-Pr 7.3 ± 0.6 3.5 ± 0.4 2.09 6.13 264.1 2:4 
83 N(Me)2 5.8 ± 0.7 1.5 ± 0.1 3.92 5.63 258.96 1:4 
84 n-Pr 7.7 ± 0.7 6.0 ± 0.6 1.28 6.6 272.68 2:4 
85 i-Pr 8.6 ± 0.9 2.6 ± 0.2 3.26 6.38 275.08 2:4  
86 c-Pr 7.6 ± 0.7 10.9 ± 0.9 0.69 6.13 265.48 2:4 
87 N(Me)2 7.5 ± 0.8 > 50 – 5.63 263.08 1:4 
Donepezil – 0.03 ± 0.002 3.6 ± 0.4 0.01 4.59 321.7 0:4 
Tacrine – 0.16 ± 0.01 0.04 ± 0.001 4.00 3.27 165.6 2:2 
Galantamine – 2.6 ± 0.6 > 50 – 1.18 239.4 1:4 
Rivastigmine – 6.5 ± 0.5 > 10 – 2.10 226.3 0:4 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. 
bSelectivity index is calculated as (hAChE IC50)  ÷ (hBuChE IC50). cClogP values were determined using ChemDraw 
Professional 15.0. dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design 
software, BIOVIA Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding 
acceptors. 
 
 
Starting out with the C2-chlorine based derivatives, 73–75 were roughly equipotent to 60 toward 
AChE (IC50 ~ 8–9 µM), with chlorine placement ranking as C7, C6 then C8. Interestingly, chlorine 
placement had significant impact on BuChE targeting considering that 73 (C6-Cl) was inactive, 74 (C7-Cl) 
was very weakly active, while 75 (C8-Cl) showcased moderate inhibition (IC50 ~ 14 µM). When compared 
to dimethoxyphenethyl counterparts (45–47), derivatives 73–75 were generally more effective or on par.  
 	   169 
When compared to 70–72, the impact of chlorine placement at position 6 of the quinazoline scaffold 
in 76–78 had negligible or minor impact on AChE inhibition (average IC50 ~ 7.7 vs. 8.8 µM), with C2-cPr 
being the least impacted (derivative 72 vs. 78). On the other hand, in BuChE, only the C2-cPr derivative 
(78) showcased slight improvement (~ 1.3-fold) compared 72, while others remain unchanged. With the 
dimethylamine functionality at the C2-position (79), an approximate 1.1-fold improvement in AChE was 
observed (when compared to 76–78), while BuChE activity was comparable to 76, while being roughly 4-
fold less potent compared to the isopropyl-based relative, 77. When compared to dimethoxyphenethyl 
counterparts (48–51), derivatives 76–79 were slightly less effective against AChE but much more effective 
toward BuChE. 
Moving on, when compared to 76–79, the impact of chlorine placement at position 7 in 80–83 had 
positive impact on all the derivatives (not just in a general sense) with respect to both AChE and BuChE 
inhibition. Most significant was the 15-fold increase in BuChE potency between 77 and 81. As a matter of 
fact, derivative 81 was 40-fold more potent toward BuChE compared to donepezil and only 2-fold less 
potent compared to tacrine. When compared to dimethoxyphenethyl counterparts (52–55), derivatives 80–
83 were either on par or more effective against AChE, while exhibiting superior inhibition toward BuChE. 
Lastly, the impact of chlorine placement at position 8 in 84–87 elicited null or minor changes toward 
AChE inhibition (average IC50 ~ 7.9 µM) compared to other placements (76–79 and 80–83) and non-
chlorinated (70–72) counterparts  (average IC50 ~ 8.5 vs. 6.7 vs. 7.7 µM; respectively).  In BuChE, chlorine 
placement at 8 position generally worsened or severely hindered inhibition when compared to other 
placements and non-chlorinated counterparts. Of greatest interest was the complete loss of BuChE 
inhibition with derivative 87. That said, the isopropyl group at C2-position was always ranked in first place 
with respect to BuChE, while the dimethylamine group was ranked first with respect to AChE. When 
compared to dimethoxyphenethyl counterparts (56–59), derivatives 80–83 were generally as effective or 
slightly less effective against AChE, while BuChE activity was better (overall) but some derivatives were 
just as ineffective as observed in 56–59. 
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Figure 70: Cholinesterase metrics for fifteen 2-substituted-N-phenethylquinazolin-4-amines (60–72) and 15 2-
substituted-N-phenethylchloroquinazolin-4-amines (73–87). 
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In summary, 30 derivatives were assessed for dual cholinesterase activity, of which derivative 63 (N4-
phenethylquinazoline-2,4-diamine) was identified as the most active and non-selective AChEI (Dual IC50 ~ 
5.3 µM), while derivative 81 (7-chloro-N2-isopropyl- N4-phenethylquinazoline-2,4-diamine) was identified 
as the most active BuChEI (IC50 = 95 nM) surpassing the activity level of donepezil by 4-fold. Generally, 
this series proved to be more or less as effective toward AChE as the benzyl and dimethoxyphenethyl series 
(Chapter 4 and Chapter 5). Activity toward BuChE was significantly improved overall, while the 
introduction of the chloroquinazoline scaffolds and the dimethylamine functionality at the C2-position 
further improved biological activity, specifically with BuChE inhibition (Figure 70). 
 
 
 
6.3.3. Amyloid-β Aggregation 
 
The ability of 2-substituted-N-phenethylquinazolin-4-amines (60–72) and the related regiosiomer (61-
iso and 63-iso) to modulate the aggregation kinetics of amyloid-β was assessed using the ThT-binding 
method described earlier in Chapter 3 (Table 11). Amyloid-β inhibitory data for optimization candidates 
(73–87) is showcased in Table 12.  
When compared to benzyl (Table 4) and dimethoxyphenethyl (Table 7) counterparts in Chapters 4 and 
5, respectively, the examination of Table 11 demonstrated a higher number of inactive or weakly active 
derivatives toward Aβ aggregation (4 out of 15 derivatives were inactive toward both Aβ species, in 
addition to 2 that were inactive toward Aβ42). Overall, none of the derivatives here were considered as 
potent inhibitors of Aβ42 (most active had an IC50 ~ 25 µM); however, some were quite effective toward 
Aβ40 (7 out of 15 had an IC50 < 5 µM). Of noteworthy mention, derivatives 65 (C2 = urea), 69 (C2 = 
NHEt) and 72 (C2 = NHcPr) exhibited strong inhibitory activity toward Aβ40 (IC50 0.8–1.4 µM) that 
placed them on par with the activity of resveratrol.  
Starting out with the C2-chlorine derivative, 60 (IC50 = 5 µM) was more active toward Aβ40 compared 
to both benzyl (19, IC50 ~ 17 µM ) and dimethoxyphenethyl (32, IC50 ~ 8 µM) counterparts; however, it 
was only moderately active toward Aβ42 (P.I at 25 µM was ~ 36%, compared to 22% for 19). 
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Table 11: Amyloid-β (Aβ40/42) inhibition data for 2-substituted-N-phenethylquinazolin-4-amines (60–72) and the 
related regiosiomers (61-iso and 63-iso). 
 
 
 
 
 
 
 
Derivative R-Grp 
Amyloid-β IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
Aβ40 Aβ42 
60 Cl 5.0 ± 0.8 36% – 4.74 182.1 1:3 
61 H 11.9 ± 2.5 32% – 3.98 168.7 1:3 
61-iso – NA NA  – 3.98 197.7 1:3 
62 N3 NA NA  – 5.39 221.5 1:7  
63 H 8.2 ± 2.0 37% – 3.97 176.6 3:4 
63-iso – 14.9 ± 1.9 50% – 3.97 209.2 3:4 
64 OH 11.2 ± 1.4 NA – 4.61 208.5 2:4 
65 CONH2 1.0 ± 0.1 46% – 3.99 232.8 4:6 
66 CH2CONH2 NA NA  – 3.59 247.9 4:6 
67 COMe NA NA  – 3.52 245.5 2:5 
68 Me 2.0 ± 0.4 40% 1.74 4.79 187.6 2:4 
69 Et 1.4 ± 0.3 47% 2.38 5.32 199.2 2:4 
70 n-Pr 4.4 ± 0.6 33% 1.44 5.85 212.3 2:4 
71 i-Pr 3.8 ± 0.7 NA 4.51 5.63 214.3 2:4 
72 c-Pr 0.8 ± 0.03 22% 0.75 5.38 208.5 2:4 
Curcumin – 3.3 ± 0.45 9.9 ± 0.4 0.33 4.59 302.1 2:6 
Resveratrol – 1.1 ± 0.1 15.3 ± 1.9 0.07 2.83 187.2 3:3 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). bSelectivity 
index is calculated as (Aβ40 IC50)  ÷ (Aβ42 IC50). cClogP values were determined using ChemDraw Professional 15.0. 
dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design software, BIOVIA 
Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding acceptors. 
 
 
The dechlorination of 60 hindered Aβ40 activity nearly 2.5-fold with no impact on Aβ42 activity and 
derivative 61 became equipotent to its dimethoxyphenethyl counterpart (33). When compared to the benzyl 
counterpart (20), 61 was much more effective toward Aβ40 activity and demonstrated mild improvements 
toward Aβ42 activity. Its regioisomer (61-iso) was just as inactive toward both Aβ40/42 as 33-iso in 
Chapter 5, suggesting that the lack of a functional group at the C4-position is detrimental to Aβ targeting.  
Compared to the outcome of the azide functionality in 21 (Chapter 4) and 34 (Chapter 5), it was 
interesting to observe the abolished activity of 62 toward both Aβ40/42. This further strengthens the 
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incompatibility of the azide group with these quinazoline scaffolds. Reduction of that azide to the amino 
group (63, IC50 ~ 8 and ~ 35 µM; Aβ40/42 respectively) led to enhanced biological activity; however, it 
was a weaker inhibitor of Aβ40/42 compared to 35 (dimethoxyphenethyl counterpart, IC50 ~ 3 and ~ 28 
µM; Aβ40/42 respectively). Compared to its benzyl counterpart (22, IC50 ~ 5 µM and not active; Aβ40/42 
respectively), 63 was less effective toward Aβ40 only. Its regioisomer (63-iso) on the other hand, was less 
potent toward Aβ40 (~ 1.8-fold), while improving inhibitory potential toward Aβ42 by 13%. That said, 
direct comparison of 22-iso and 63-iso showcased significant hindrances in anti-Aβ40/42 activity with the 
additional methylene linker at the C2-position. Replacement of the C2-amino group in 63 with a hydroxyl 
group in 64 (IC50 ~ 11 µM and not active; Aβ40/42 respectively) resulted in an approximate 1.4-fold 
improvement in Aβ40 activity but with a total loss of Aβ42 activity. Compared to its benzyl counterpart 
(23), 64 was far less effective toward Aβ40 (~ 37-fold), while being equipotent to 36 (the 
dimethoxyphenethyl counterpart) with respect to Aβ40. 
With respect to the carbonyl-based derivatives, the C2-urea-containing derivative (65) was the only 
dually active derivative in this sub-group. While no activity was anticipated for the glycinamide-based 
derivative (66), the inactivity observed with 67 was a bit unexpected considering the mild, yet dual 
inhibition within the dimethoxyphenethyl series (39) and the potent activity seen with 26 (Aβ40 IC50 ~ 2 
µM). Compared to its benzyl and dimethoxyphenethyl counterparts (24 and 37; respectively), 65 was a 
superior inhibitor of Aβ40 (IC50 ~ 1 µM)., while showcasing comparable Aβ42 activity as 24.  
The introduction of alkylamines at the C2-position (68–72) provided more potent inhibitory activity 
toward Aβ40 (average IC50 ~ 2.5 µM), across the board, when compared to both benzyl (27–31, average 
IC50 ~ 5.5 µM – excluding 27) and dimethoxyphenethyl (40–44, average IC50 ~ 4.8 µM – excluding 43) 
counterparts. The effectiveness of alkyl chains was ranked as c-Pr > Et > Me > i-Pr > n-Pr, with derivative 
72 being approximately 1.4-fold more potent than resveratrol (Aβ40 IC50 = 790 nM) and roughly 7-fold 
more potent compared to both benzyl and dimethoxyphenethyl counterparts (31 and 44; respectively). 
With respect to Aβ42, C2-iPr or cPr derivatives (71 and 72) were ranked lower in terms of inhibitory 
activity, while both C2-Et or nPr derivatives (69 and 70) were slightly more effective compared to both 
benzyl and dimethoxyphenethyl counterparts. With the C2-Me derivative, 68 was ranked in between 27 and 
40. 
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With the introduction of the chloroquinazoline scaffolds, Aβ42 potency was enhanced overall, while 
activity toward Aβ40 was more of a mixed outcome, as showcased in Table 12. Compared to 60 (Table 11), 
only derivative 73 was 1.8-fold less potent toward Aβ40, while 74 and 75 were roughly 2.5-fold more 
effective. These derivatives were either 4-fold (73) or 20-fold (74 and 75) more potent toward Aβ42, 
compared to 60. Chlorine placement was generally in the ranking of 7-Cl > 8-Cl > 6-Cl and interestingly, 
both 74 and 75 were classified as dual, non-selective inhibitors of Aβ40/42 (IC50 ~ 1.9 µM). When 
compared to dimethoxylphenethyl counterparts (45–47), 73–75 were either on par or slightly less effective.  
 
Table 12: Amyloid-β (Aβ40/42) inhibition data for 2-substituted-N-phenethylquinazolin-4-amines (73–87). 
 
 
 
 
 
 
 
 
 
Derivative R-Grp 
Amyloid-β IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
Aβ40 Aβ42 
73 Cl 9.3 ± 0.8 7.7 ± 0.8 1.21 5.47 231.18 1:3 
74 Cl 1.7 ± 0.2 1.7 ± 0.2 1.00 5.47 234.26 1:3 
75 Cl 2.3 ± 0.3 2.0 ± 0.4 1.15 5.47 232.89 1:3 
76 n-Pr 44% 23% – 6.60 275.08 2:4 
77 i-Pr 8.6 ± 0.7 36% – 6.38 274.39 2:4  
78 c-Pr 8.7 ± 0.9 19% – 6.13 266.16 2:4 
79 N(Me)2 6.5 ± 0.7 20% – 5.63 261.02 1:4 
80 n-Pr 6.9 ± 1.4 4.6 ± 0.9 1.50 6.6 270.96 2:4 
81 i-Pr 6.1 ± 1.3 7.2 ± 1.6 0.85 6.38 273.37 2:4  
82 c-Pr 4.8 ± 1.0 11.7 ± 2.0 0.41 6.13 264.1 2:4 
83 N(Me)2 5.1 ± 1.7 29% – 5.63 258.96 1:4 
84 n-Pr 3.7 ± 0.5 6.5 ± 0.4 0.57 6.6 272.68 2:4 
85 i-Pr 0.9 ± 0.1 3.9 ± 0.5 0.23 6.38 275.08 2:4  
86 c-Pr 1.3 ± 0.2 6.8 ± 1.3 0.19 6.13 265.48 2:4 
87 N(Me)2 1.9 ± 0.3 5.8 ± 0.7 0.33 5.63 263.08 1:4 
Curcumin – 3.3 ± 0.45 9.9 ± 0.4 0.33 4.59 302.1 2:6 
Resveratrol – 1.1 ± 0.1 15.3 ± 1.9 0.07 2.83 187.2 3:3 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). bSelectivity 
index is calculated as (Aβ40 IC50)  ÷ (Aβ42 IC50). cClogP values were determined using ChemDraw Professional 15.0. 
dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design software, BIOVIA 
Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding acceptors. 
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With respect to Aβ40 inhibition, chlorine placement at position 6 of the quinazoline scaffold in 76–78, 
when compared to 70–72, had a significantly negative impact on inhibitory activity with 76 being the least 
active derivative in the sub-group. While both 77 and 78 were equipotent, they suffered a 2.3-fold and a 
10.9-fold decline in Aβ40 potency; respectively, compared to 71 and 72. With respect to Aβ42, and 
compared to 70–72, derivative 76 lost 10% of inhibitory activity, derivative 77 gained 36%, while 
derivative 78 was on par with its non-chlorinated counterpart. Comparing the dimethylamine-based 
derivative (79) to 77, activity toward Aβ40 improved by 1.4-fold, while Aβ42 inhibition was backtracked 
by 16%. Collective comparison to their dimethoxyphenethyl counterparts (48–51, Chapter 5), 76–78 were 
less potent across the board, although 50 and 78 were on par with respect to Aβ40. 
Moving on, when compared to 76–79, the impact of chlorine placement at position 7 in 80–83 
enhanced both Aβ40/42 inhibitory activity across the board. Least impact was observed with the 
dimethylamine C2-group, where Aβ40 inhibition was improved 1.3-fold, while activity toward Aβ42 
increased by 9%. Derivatives 82 (C2 = NHc-Pr) and 83 (C2 = NMe2) were equipotent toward Aβ40 at IC50 
~ 5 µM, while 80 (C2 = NHn-Pr) and 81 (C2 = NHn-Pr) were also equipotent toward Aβ40 at IC50 ~ 6.5 
µM. For Aβ42 inhibition, C2-groups ranked as NHn-Pr > NHi-Pr > NHc-Pr >> NMe2. When compared to 
70-72 (non-chlorinated counterparts), derivatives 80–82 were weaker toward Aβ40 but much more 
effective toward Aβ42. When compared to their dimethoxyphenethyl counterparts (52–55) with respect to 
Aβ40, derivative 80 was less potent (~ 2.2-fold), derivative 81 was more potent (~ 1.7-fold), while 82 and 
83 were equipotent to 54 and 55; respectively (IC50 ~ 4.9 µM). With respect to Aβ42, 80–82 were more 
potent compared to 52–54, while 55 was more active compared to 83. 
Lastly, the impact of chlorine placement at position 8 in 84–87 elicited varying levels of improvement, 
toward Aβ40 inhibition compared to non-chlorinated counterparts (70–72), C6- (76–79) and C7-cholinated 
counterparts (80–83) and more so, their dimethoxyphenethyl counterparts (56–59). Most significant was 
the improvement of the C2 = NHi-Pr derivative (85 – Aβ40, IC50 = 0.9 µM) considering the overall average 
Aβ40 IC50 of ~ 6 µM for other related counterparts. In addition, 85 was the most active Aβ42 aggregation 
inhibitor  (IC50 = 3.9 µM), amongst the alkylamine-based derivatives (70–72 and 76–87). Overall, 
derivatives 84–87 were more effective toward Aβ42 compared to 70–72, 76–79 and 81–83. 
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Figure 71: Amyloid-β metrics for fifteen 2-substituted-N-phenethylquinazolin-4-amines (60–72) and 15 2-substituted-
N-phenethylchloroquinazolin-4-amines (73–87). 
 
 
In summary, 30 derivatives were assessed for dual Aβ activity, of which derivatives 65 (1-(4-
(phenethylamino)quinazolin-2-yl)urea),  72  (N2-cyclopropyl-N4-phenethylquinazoline-2,4-diamine) and 85 
(8-chloro-N2-isopropyl-N4-phenethylquinazoline-2,4-diamine) were identified as comparably potent Aβ40 
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inhibitors (IC50 ~ 0.8–1.0 µM), while derivative 74  (2,7-dichloro-N-phenethylquinazolin-4-amine) was 
identified as the most potent, non-selective Aβ42 inhibitor (Aβ40/42 IC50 = 1.7 µM). 
 Generally, this series proved to be less effective at Aβ42 targeting as compared to the benzyl and 
dimethoxyphenethyl series (Chapter 4–5), while Aβ40 activity had mixed outcomes. The introduction of 
the chloroquinazoline scaffolds and the dimethylamine functionality at the C2-position, offered a mix of 
potency improvements and setbacks when compared to the non-chlorinated counterparts (Figure 71). 
The aggregation kinetic assessment of Aβ40 with or without series-leading derivatives is showcased 
in Figure 72. As observed in Panels A–D, derivatives 65, 72, 85 and 86 exhibited concentration-dependent 
inhibition of Aβ40 aggregation; however they showcased various modes of aggregation. Starting with the 
urea-based derivative, 65 managed to induce similar levels of monomeric structure stabilization throughout 
the concentration range (roughly a 2 hour delay in the aggregation process). While the rate and total 
aggregate load differences between each concentration level was not very large, the starting out (with 1 
µM) was effective enough to elicit a strong inhibitory profile. On the other hand, derivative 72 showcased 
all three modes of inhibitory activity, with increased potency, across all tested concentrations. Significant 
reductions in the start-time of the aggregation process, its rate and overall fibril load were observed with 25 
µM almost halting aggregation processes completely. With the dichloro-based derivatives (85 and 86), no 
monomeric structure stabilization was observed (at the 1 and 5 µM concentrations), although both managed 
to completely halt the aggregation process at 25 µM. Nonetheless, at 1 and 5 µM concentrations, 85 and 86 
managed to reduce the rate of aggregation and the overall aggregate load after the 24 hour incubation 
period. It was interesting to observe the how the 1.3-fold difference in potency between 72 and 86 
manifested in the aggregation kinetics (Panel B vs. Panel D). 
The aggregation kinetic assessment of Aβ42 with or series-leading derivatives is showcased in Figure 
73. As observed in Panels A–B, derivatives 74 and 75 exhibited concentration-dependent and multi-mode 
inhibition of Aβ42 aggregation. At 1 and 5 µM concentrations, both derivatives managed to reduce the rate 
of fibrillation and overall aggregate load at the end of the 24 hour incubation period, with 74 almost 
abolishing aggregation processes all together at 1:1 ratios with Aβ42. At 25 µM concentrations, both 
derivatives managed to completely block the aggregation process at the 5:1 test ration (compound: Aβ42).  
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Figure 72: ThT-monitored kinetics of Aβ40 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of 1-(4-(phenethylamino)quinazolin-2-yl)urea (65) 
on the aggregation kinetics of 5 µM Aβ40. Panel (B): Impact of 1, 5 or 25 µM of N2-cyclopropyl-N4-
phenethylquinazoline-2,4-diamine (72) on the aggregation kinetics of 5 µM Aβ40. Panel (C): Impact of 1, 5 or 25 µM 
of 8-chloro-N2-isopropyl-N4-phenethylquinazoline-2,4-diamine (85) on the aggregation kinetics of 5 µM Aβ40. Panel 
(D): Impact of 1, 5 or 25 µM of 8-chloro-N2-cyclopropyl-N4-phenethylquinazoline-2,4-diamine (86) on the aggregation 
kinetics of 5 µM Aβ40.  
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Figure 73: ThT-monitored kinetics of Aβ42 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of 2,7-dichloro-N-phenethylquinazolin-4-amine (74) 
on the aggregation kinetics of 5 µM Aβ42. Panel (B): Impact of 1, 5 or 25 µM of 2,8-dichloro-N-phenethyl)quinazolin-
4-amine (75) on the aggregation kinetics of 5 µM Aβ42. 
 
 
6.3.4. Transmission Electron Microscopy (TEM) 
 
The assessment of amyloid morphology at the conclusion of a 24-hour incubation period at 37 °C was 
conducted on series-leading derivatives. This commonly employed, qualitative technique is used to 
corroborate the quantitative results from the ThT-binding assay. Experimental setup included the 
incubations of control and test samples, at 1:1 ratios of 25 µM, in triplicate at 37 °C (with shaking) over a 
24-hour timeline. Triplicate samples were combined after the incubation period and applied to the copper-
mesh grids prior to imaging in the TEM. 
As observed in Figure 74, resveratrol was effective at reducing total amyloid load (Panels B and E) 
compared to control samples (Panels A and D). That said, derivative 85 (Panel C) was more effective 
against Aβ40, while derivative 74 was significantly more potent toward Aβ42, compared to resveratrol.  
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Figure 74: TEM assessment of Aβ40/42 morphology with or without test compounds at the end of a 24 h, 37 °C 
incubation period at pH 7.4. Panel (A–C): 25 µM Aβ40 alone or at a 1:1 ratio with resveratrol or 8-chloro-N2-
isopropyl-N4-phenethylquinazoline-2,4-diamine (85); respectively. Panel (D–F): 25 µM Aβ42 alone or at a 1:1 ratio 
with resveratrol or 2,7-dichloro-N-phenethylquinazolin-4-amine (74); respectively. White/black bars represent 500 nm. 
 
 
 
6.3.5. Antioxidant Capacity 
 
The ability of 4-(phenethylamino)quinazolin-2-ol (64) to neutralize ROS was assessed using the 
previously described DPPH-scavenging assay. 
As a conjugated, and less sterically hindered, phenolic compound, it was no surprise to observe the 
stronger (~1.5-fold) scavenging potential of 64 in the DPPH assay, compared to both its 
dimethoxyphenethyl counterpart (36, Figure 75). The increased flexibility of 64 also enabled it to slightly 
out-perform 23 by 1.1-fold. Derivative 64 was also 2-fold less potent than trolox but was 1.2-fold more 
effective compared to resveratrol. 
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Figure 75: Standards utilized in the DPPH-scavenging along with the data for 4-(phenethylamino)quinazolin-2-ol (64). 
 
 
6.3.6. Molecular Modeling 
 
The utilization of computational software is not only useful in structure-based drug design, it is also 
employed to understand and corroborate the acquired SAR data. The assessment of ligand-receptor 
interactions was conducted between leading (or comparable) derivatives from the 2-substituted-N-
phenethylquinazolin-4-amine series (60–72) or the 2-substituted-N-phenethylchloroquinazolin-4-amine 
series (73–87) and the cholinesterase or amyloid targets of interest.  
 
 
6.3.6.1. Cholinesterase 
 
Based on the acquired anti-ChE data, presented in Tables 9 and 10, the docking interactions of 63 
with 63-iso and 81 with 83 were investigated in hAChE (PBD: 1B41) and superimposed in Figure 76, 
along with the docking interactions of 63 with 63-iso and 71/77/81/85 in hBuChE (PBD: 1P0I). 
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Figure 76: Superimposition of docking structures. Panel (A–B): Binding modes of 63 (orange) and 63-iso (magenta) or 
81 (red) and 83 (olive) in the active site of hAChE (PDB ID: 1B41); respectively. Panel (C): Binding modes of 63 
(orange) and 63-iso (magenta) in the active sites of hBuChE (PDB ID: 1P0I). Panel (D): Binding modes of 71 (green), 
77 (gold), 81 (red) and 85 (blue) in the active sites of hBuChE (PDB ID: 1P0I). Hydrogens removed to enhance 
visibility. Black-dashed lines indicate hydrogen-bonding interactions.  
 
 
As observed in Panel A, despite their isomeric structures, both quinazoline scaffolds of 63 and 63-iso 
were stacked parallel over W86 at roughly 4–5 Å, orienting their C2- and C4-amino groups; respectively, 
to undergo hydrogen-bonding interactions with W86’s indole ring (~ 3.5 Å) and H447’s backbone carbonyl 
(~ 2.6 Å). Both ligands were localized within the active site, where the quinazoline scaffolds measured 
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roughly 14 Å from W286. Both ligands had their phenethylamine groups running parallel to W86 and 
measuring ~ 10 Å from W286.  
In Panel B, very close superimpositions were observed with 81 and 83, where the quinazoline 
scaffolds were roughly 11 Å from W286 and stacked perpendicular to across W86 (4–5 Å). Both ligands 
oriented their C7-chlorines and C2-isopropylamine or dimethylamine groups; respectively, over the indole 
and backbone structures of W86 (~ 4 Å). The C4-phenethylamine groups were directed, perpendicularly, 
toward the acyl pocket (~ 7 Å) and the phenyl rings were roughly 6 Å from the PAS. This alignment of the 
C4-groups allowed for hydrogen-bonding interactions (~ 3.3 Å) between the NH ’s and the S203’s 
hydroxyl group. 
In BuChE (Panel C), the isomeric ligands (63 and 63-iso) exhibited unique but also similar binding 
modes, where the quinazoline scaffolds were primarily interacting with W82 – 63’s quinazoline was 
stacked perpendicular between W82 and the catalytic triad’s H437 (~ 5 Å), while 63-iso’s quinazoline was 
more parallel over W82 (~ 5 Å). Both quinazolines measured roughly 18 Å from A277 and the ligands had 
their phenethylamines superimpose while directed toward the acyl pocket (~ 6 Å). This alignment of the 
phenethylamines allowed for hydrogen-bonding interactions (~ 2.3–3.5 Å) between the NH ’s and the 
S198’s hydroxyl group/H438’s imidazole ring. With both ligands, the C2- and C4-amino groups; 
respectively, were directed toward the backbone of H438, but no hydrogen-bonding interactions were 
observed.  
Lastly, in Panel D, we investigated the impact of chlorine presence and placement in 71 vs. 77, 81 and 
85. While 81, with C7-chlorine, was significantly more potent (~ 20-fold) compared to the other three, it 
was quite surprising to observe the near-perfect superimposition of all four ligands in BuChE. All took on a 
wide-C-shaped conformation, where the quinazoline scaffolds were stacked over the catalytic triad (~ 4 Å), 
placed between W82 and the acyl pocket (~ 6 Å), while the phenethylamine and isopropyl groups were 
oriented toward W82 in a perpendicular fashion (~ 4 Å). All ligand C2-NHs’ underwent hydrogen-bonding 
with S198’s hydroxyl group and H438’s imidazole ring (~ 2.6 Å). The superior potency of 81 is therefore 
attributed to both the placement and likely binding kinetics attributed to the C7-chlorine. 
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6.3.6.2. Amyloid-β 
 
Based on the acquired anti-Aβ data, presented in Table 12, the docking interactions of 85 and 86 were 
investigated in both a dimeric and fibril model of Aβ (Aβ9-40 – PDB 2LMN) with superimpositions 
showcased in Figure 77. 
 
 
 
 
 
 
 
 
 
Figure 77: Superimposition of docking structures. Panels (A and B): Binding modes of 85 (olive) and 86 (magenta) in 
the Aβ (Aβ9-40 – PDB 2LMN) dimer model or fibril model; respectively. Hydrogens removed to enhance visibility. 
Amino acid labels to be used as a general guide as space restrictions limited complete and accurate labeling of all 
peptide structures. 
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6 Å. The quinazoline scaffold of 85 was perpendicularly stacked within the hairpin loop domain, measuring 
roughly 4 Å from I32. The ligand’s C4-NH was undergoing hydrogen-bonding interactions with A30’s 
backbone carbonyl (3.3 Å). On the other hand, 86’s quinazoline scaffold was stacked parallel to D23-V24 
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at roughly 5 Å, allowing for hydrogen-bonding interactions between its C4-NH and D23’s carboxyl group 
(~ 2.9 Å) and V24’s backbone carbonyl and amine (~ 3.5 Å). Overall, both ligands oriented their C2-
alkylamines toward F19/F20 and measured roughly 7 Å from the amino acid phenyl rings. 
In the fibril model, both ligands oriented their C4-phenethylamine groups within the steric zipper 
domain, measuring roughly 5–6 Å from the quad M35 residues. Their quinazoline scaffolds were stacked 
perpendicular to M35 (with respect to the peptide backbone) at roughly 4–5 Å. This collective orientation 
allowed for both ligands’ C4-NH to undergo hydrogen-bonding with G33’s backbone carbonyl (2.7 Å). 
Ligand 85’s isopropylamine was stacked parallel to I31-I32, allowing its C2-NH to undergo hydrogen-
bonding with I31’s backbone carbonyl (3.3 Å), while 86’s cyclopropylamine group was positioned between 
L34-V36 at roughly 5–6 Å. 
 
 
6.4. Summary 
 
Figure 78: Cumulative chapter summary of 2-substituted-N-phenethylquinazolin-4-amines (60-72) and 2-substituted-
N-phenethylchloroquinazolin-4-amines (73-87). 
 
 
With this phenethylamine-based series, an overall improvement in BuChE targeting was observed, 
without significant losses in AChE potency. When compared to their benzyl and dimethoxyphenethyl 
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counterparts, the derivatives in this series were generally not as capable of targeting Aβ42, while the 
investigation into the cholorquinazoline scaffolds significantly improved dual Aβ targeting. The 
regioisomer investigations here yielded similar observations as to those observed in Chapters 4 and 5, 
where C4-unsubstituted derivative (61-iso) was not effective at either ChE or amyloid targeting, while C4-
amino-based isomer (63-iso), enhanced BuChE binding and Aβ42 compared to 63 (which was more potent 
toward AChE and Aβ40). In addition, the antioxidant capacity of 64 exceeded that of both benzyl (23) and 
dimethoxyphenethyl (36) counterparts and resveratrol as well. 
Nonetheless, the series also demonstrated a number of selective BuChEIs (63-iso, 66, 68–71, 76, 77, 
79–85), one selective Aβ42 aggregation inhibitor (80) and three non-selective Aβ inhibitors (74, 75 and 81). 
It also had the most “inactive” derivatives toward Aβ42 aggregation, compared to previous series. Overall, 
a series leader was identified in 7-chloro-N2-isopropyl-N4-phenethylquinazoline-2,4-diamine (81) due to its 
potent activity toward BuChE (~ 95 nM, highest in entire drug library) and multi-targeting capacity toward 
AChE and Aβ40/42 at the equipotent concentration of ~ 7 µM (Figure 78).  
 
 
6.5. Experimental 
 
Please note that this subsection includes re-listed methodologies from Chapter 3–5. For schematic 
representation of re-listed methodologies, if applicable, please refer to Chapter 3 and 4 – Section 3.5 or 4.5. 
 
6.5.1. Chemistry 
 
General Information. All the reagents and solvents were reagent grade purchased from various vendors 
(Acros Organics, Sigma-Aldrich, and Alfa Aesar, USA) with a minimum purity of 95% and were used 
without further purification. Melting points (mp) were determined using a Fisher-Johns apparatus and are 
uncorrected. Reaction progress was monitored by UV using thin-layer chromatography (TLC) using Merck 
60F254 silica gel plates. Column chromatography was performed with Merck silica gel 60 (230−400 mesh) 
with 5:1 EtOAc:MeOH as the solvent system unless otherwise specified. Proton (1H NMR) and carbon (13C 
NMR) spectra were performed on a Bruker Avance (at 300 and 75 MHz; respectively) spectrometer using 
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DMSO-d6. Coupling constants (J values) were recorded in hertz (Hz) and the following abbreviations were 
used to represent multiplets of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. 
Carbon multiplicities (C, CH, CH2 and CH3) were assigned by DEPT 90/135 experiments. High-resolution 
mass spectrometry (HRMS) was determined using a Thermo Scientific Q-Exactive Orbitrap mass 
spectrometer (positive mode, ESI), Department of Chemistry, University of Waterloo. Compound purity 
(roughly 95% or over) was determined using an Agilent 1100 series HPLC equipped with an analytical 
column (Agilent Zorbax Eclipse XDB-C8 column, 4.6 x 150 mm, 5 µm particle size) running 50:50 
Water:ACN with 0.1% TFA at a flow rate of 1.0-1.5 mL/min or an Agilent 6100 series single quad LCMS 
equipped with an Agilent 1.8 µm Zorbax Eclipse Plus C18 (2.1 x 50 mm) running 50:50 Water:ACN with 
0.1% FA with a flow rate of 0.5mL/min. All the final compounds exhibited ≥ 95% purity. 
 
General procedure for the synthesis of 2,4,6-, 2,4,7- or 2,4,8-trichloroquinazolines.289, 323 In a 250 
mL RBF, 5 g of 6-, 7- or 8-chloroquinazolin,2-4-diol (25.51 mmol) was suspended in 25 mL of anhydrous 
toluene and allowed to stir on an ice bath. To this, 5 eq. of POCl3 (127.55 mmol) was added in small 
aliquots followed by the slow addition of 5 eq. of DEA (127.55 mmol). The solution was kept on the ice 
bath for 10 min before moving to room temperature and allowed to stir for 1 h prior to refluxing at 105–110 
°C for 14–16 h. Upon cooling to room temperature, the reaction mixture was added in small aliquots to a 
double-ice-water bath while stirring. The quenching solution was left stirring at room temperature for 5 h 
before vacuum filtering the yellowish-grey precipitate. The precipitate was stirred for 1 h in a saturated 
NaHCO3 solution and then was re-filtered. This neutralization process was carried out 2–3 times until the 
bicarbonate solution maintains a neutral to slight basic pH. The final precipitate was dissolved in DCM and 
purified by a silica gel column chromatography using 100% DCM as the eluent to afford white to light grey 
solid. 
 
2,4,6-Trichloroquinazoline. Yield: 75% (4.43 g, 19.12 mmol); Mp 126–128 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 8.31 (s, 1H), δ 8.15 (d, J = 9.0 Hz, 1H), δ 8.04 (d, J = 8.9 Hz, 1H). LRMS (ESI) m/z calcd for 
C8H4Cl3N2 [M + H]+ 232.93, found 232.92. 
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2,4,7-Trichloroquinazoline.  Yield: 80% (4.73 g, 20.41 mmol); Mp 137–139 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 8.30 (d, J = 9.0 Hz, 1H), δ 8.20 (s, 1H), δ 7.88 (d, J = 8.7 Hz, 1H). LRMS (ESI) m/z calcd for 
C8H4Cl3N2 [M + H]+ 232.93, found 232.92. 
 
2,4,8-Trichloroquinazoline. Yield: 65% (3.84 g, 16.56 mmol); Mp 135–137 °C. 1H NMR (300 MHz, 
DMSO-d6) δ 8.31 (d, J = 7.7 Hz, 1H), δ 8.25 (d, J = 8.5 Hz, 1H), δ 7.78 (t, J = 7.4 Hz, 1H). LRMS (ESI) 
m/z calcd for C8H4Cl3N2 [M + H]+ 232.93, found 232.92. 
 
 
General procedure for the synthesis of 2-chloro-, 2,6-dichloro-, 2,7-dichloro- or 2,8-dichloro-N-
substituted-quinazolin-4-amines.303, 305 To a 30 mL solution of ethanol in a 100 mL round-bottom flask 
on ice, 5 g of 4 or a trichloroquinazoline (21.46–25.13 mmol) was added followed by slow addition of 1.3 
eq. (27.90–32.66 mmol) of the corresponding primary amine. Contents were stirred on an ice bath while 2.0 
eq. of diisopropyl-ethylamine (DIPEA, 42.92–50.25 mmol) was added in drop wise fashion. The solution 
was then heated at 80-85 °C under reflux for 3–4 h. The reaction contents were cooled to room temperature 
and precipitated residues were vacuum-filtered with ethyl acetate (EtOAc) rinses. The organic supernatant 
was concentrated in vacuo followed by two rounds of liquid-liquid extraction using EtOAc and saturated 
brine solution (40–50 mL each respectively). The combined organic layers were dried over MgSO4, 
evaporated in vacuo and purified (1–2 times) using silica gel column chromatography with 5:1 
EtOAc:MeOH as the elution solvent. Final compounds were white to beige solids with yields ranging from 
70–90%.  
 
2-Chloro-N-(phenethyl)-quinazolin-4-amine (60). Yield: 70% (4.98 g, 17.79 mmol); Mp: 145–147 °C. 
1H NMR (300 MHz, DMSO-d6) δ 8.81 (br s, 1H), δ 8.18 (d, J = 8.0 Hz, 1H), δ 7.73 (t, J = 7.6 Hz, 1H), δ 
7.57 (d, J = 8.0 Hz, 1H), δ 7.47 (t, J = 7.6 Hz, 1H), δ 7.27–7.16 (m, 5H), δ 3.66 (q, J = 6.2 Hz, 2H), δ 2.91 
(t, J = 7.2 Hz, 2H). HRMS (ESI) m/z calcd for C16H14ClN3 [M + H]+  284.0876, found 284.1332. Purity: 
96.9% 
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2,6-Dichloro-N-phenethylquinazolin-4-amine (71). Yield: 75% (1.03 g, 3.25 mmol); Mp 133–135 °C. 1H 
NMR (300 MHz, DMSO-d6) δ 8.88 (br s, 1H), δ 8.38 (d, J = 2.2 Hz, 1H), δ 7.77 (dd, J = 8.9, 2.2 Hz, 1H), 
δ 7.59 (d, J = 8.9 Hz, 1H), δ 7.30–7.16 (m, 5H), δ 3.65 (q, J = 6.1 Hz, 2H), δ 2.90 (t, J = 7.2 Hz, 2H). 
LRMS (ESI) m/z calcd for C16H14Cl2N3 [M + H]+ 318.04, found 318.00. 
 
2,7-Dichloro-N-phenethylquinazolin-4-amine (72). Yield: 75% (1.03 g, 3.25 mmol); Mp 137–139 °C. 1H 
NMR (300 MHz, DMSO-d6) δ 8.94 (br s, 1H), δ 8.22 (d, J = 8.8 Hz, 1H), δ 7.65 (s, 1H), δ 7.58 (d, J = 8.7 
Hz, 1H), δ 7.28–7.17 (m, 5H), δ 3.65 (q, J = 6.1 Hz, 2H), δ 2.90 (t, J = 7.2 Hz, 2H). LRMS (ESI) m/z calcd 
for C16H14Cl2N3 [M + H]+ 318.04, found 318.06. 
 
2,8-Dichloro-N-phenethylquinazolin-4-amine (73). Yield: 90% (1.24 g, 3.90 mmol); Mp 136–138 °C. 1H 
NMR (300 MHz, DMSO-d6) δ 9.01 (br s, 1H), δ 8.16 (d, J = 8.8 Hz, 1H), δ 7.91 (d, J = 8.7 Hz, 1H), δ 7.45 
(t, J = 8.0 Hz, 1H), δ 7.29–7.15 (m, 5H), δ 3.68 (q, J = 6.1 Hz, 2H), δ 2.92 (t, J = 7.2 Hz, 2H). LRMS (ESI) 
m/z calcd for C16H14Cl2N3 [M + H]+ 318.04, found 318.03. 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-4-amines. In a 50 mL round 
bottom flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was dissolved 
in 20 mL of anhydrous ethanol. While stirring on ice, 10 mol. % of 10% Pd/C was added to reaction 
mixture followed by the drop-wise addition of 1.3 eq. of hydrazine hydrate. Solution was stirred on ice for 
5 min before refluxing for 2 h at 80–85 °C. Upon completion and cooling to room temperature, the reaction 
mixture was passed through a tightly-packed cotton-filled syringe that has been pre-rinsed with ethanol, to 
remove the Pd/C catalyst. A 30 mL aliquot of ethanol was used to rinse the syringe. The combined ethanol 
solutions were evaporated in vacuo, diluted in EtOAc (20 mL) and washed 25 mL x 2 with equal volumes 
of brine solution. The combined aqueous layers were washed with 15 mL of EtOAc. The combined EtOAc 
layers were dried over MgSO4, before removing the EtOAc in vacuo to yield a solid or semi-solid crude 
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product that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH solvent system. 
Final compounds were white to pale yellow solids with yields ranging from 40–47%. 
 
N-Phenethylquinazolin-4-amine (61).  Yield: 42% (0.19 g, 0.76 mmol); Mp 137–139 °C. 1H NMR (300 
MHz, DMSO-d6): δ 8.44 (s, 1H), δ 8.33 (t, J = 9.0 Hz, 1H), δ 8.16 (d, J = 6.0 Hz, 1H), δ 7.71–7.62 (m, 
2H), δ 7.43 (t, J = 9.0 Hz, 1H), δ 7.26–7.16 (m, 5H), δ 3.69 (d, J = 6.0 Hz, 2H), δ 2.91 (t, J = 9.0 Hz, 2H). 
13C NMR (100 MHz, DMSO-d6): δ 159.25, δ 155.12, δ 149.05, δ 139.52, δ 132.42, δ 128.65, δ 128.33, δ 
127.47, δ 126.07, δ 125.51, δ 122.54, δ 114.94, δ 42.06, δ 34.46. HRMS (ESI) m/z calcd for C16H16N3 [M 
+ H]+ 250.1266, found 250.1338. Purity: 96.6% 
 
 
 
General procedure for the synthesis of N2-substituted-quinazolin-2-amines. In a 50 mL pressure 
vial (PV), 0.25 g of 2-chloroquinazoline (1.52 mmol) was dissolved in 5 mL of 1,4-dioxane followed by the 
addition of 3 eq. (4.56 mmol) of the appropriate primary amine and 5 eq. of DIPEA (7.60 mmol). Pressure 
vial was sealed and stirred in an oil bath at 155–160 °C for 5 h. Upon completion and cooling to room 
temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and washed 25 mL x 3 times with 
equal volumes of brine solution. The combined aqueous layers were washed with ~ 25 mL of EtOAc. The 
combined EtOAc layers were dried over MgSO4 before removing the EtOAc in vacuo to yield a solid crude 
product that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the solvent 
system. Final compounds were pale yellow to pale brown solids with yields ranging from 47–52%. 
 
 
N-Phenethylquinazolin-2-amine (61-iso): Yield: 47% (0.19 g, 0.76 mmol); Mp 133–135 °C. 1H NMR 
(300 MHz, DMSO-d6) δ 9.06 (s, 1H), δ 7.74 (dd, J = 0.9, 8.0 Hz, 1H), δ 7.70–7.62 (m, 1H), δ 7.47–7.32 
(m, 2H), δ 7.27–7.16 (m, 6H), δ 3.54 (q, J = 8.2 Hz, 2H), δ 2.88 (t, J = 7.6 Hz, 2H). HRMS (ESI) m/z calcd 
for C16H16N3 [M + H]+ 250.1266, found 250.1338. Purity: 98.0% 
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General procedure for the synthesis of 2-azido-N-substituted-quinazolin-4-amine.305 In a 50 mL 
RBF, 2-chloro-N-substituted-quinazolin-4-amine (~1.86 mmol), 1.1 eq. NaN3 (2.05 mmol), 4:1 EtOH (20 
mL) and glacial acetic acid (5 mL) were combined and refluxed at 90–95 °C for 2 h with stirring. After 
cooling, the solution was vacuum-filtered to afford white solids at yields ranging from 80–85%. 
 
2-Azido-N-phenethylquinazolin-4-amine (62). Yield: 83% (0.42 g, 1.46 mmol); Mp 233–235 °C. 1H 
NMR (300 MHz, DMSO-d6): δ 8.96 (br s, 1H), δ 8.40 (d, J = 8.2 Hz, 1H), δ 8.30 (d, J = 8.3 Hz, 1H), δ 
7.97 (t, J = 8.0 Hz, 1H), δ 7.71 (t, J = 8.0 Hz, 1H), δ 7.27–7.16 (m, 5H), δ 3.76 (q, J = 6.6 Hz, 2H), δ 2.97 
(t, J = 7.3 Hz, 2H). HRMS (ESI) m/z calcd for C16H15N6 [M + H]+ 291.1280, found 291.1351. Purity: 
97.8% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2,4-diamine.305  
 
Method 1A: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was added along with 20 mol. % of CuI. To that, a mixture of 1,4-dioxane (5 mL) and 30% aqueous 
ammonia (15 mL) was added at room temperature. The pressure vial was sealed tightly and partially 
submerged in silicone oil heating at 130–135 °C. Contents were stirred in the pressure vial for 24 h (Note: 
in the event of pressure leakage, the contents were cooled to room temperature and additional aqueous 
ammonia, (10 mL) was added, sealed and heating was carried on through the 24 h period). The reaction 
contents were cooled to room temperature and the solution was diluted with 25 mL EtOAc, washed with 
saturated brine solution (10 mL x 3), and the aqueous layer was neutralized with dilute HCl, and then re-
extracted with 15 mL EtOAc. The organic layers were combined, dried over MgSO4, evaporated in vacuo 
and purified using silica gel column chromatography with 5:1 EtOAc:MeOH as an initial elution solvent 
followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine). Final compounds were obtained as 
white to beige solids with final yields ranging from 20–25%.  
 
Method 1B: In a 100 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 
mmol) was dissolved and gently heated in 5 mL ethylene glycol. To that, 20 mol. % of Cu2O and DMEDA 
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were added followed by 20 eq. K2CO3 and finally, 40 eq. of 30% aqueous ammonia solution (~15–20 mL). 
The pressure vial was sealed tightly, partially submerged in silicone oil and heated at 100–105 °C. Contents 
were stirred in the pressure vial for 24 h. After the reaction contents were cooled to room temperature, the 
solution was diluted with 50 mL EtOAc, washed with saturated brine solution (25 mL x 3) and the aqueous 
layer was neutralized with dilute HCl, and then re-extracted with 25 mL EtOAc. The residue formed was 
dissolved in methanol (20–25 mL). The EtOAc layers were dried over MgSO4 and evaporated in vacuo. 
The methanol fraction was dried with molecular sieves before evaporating the methanol in vacuo. Both 
EtOAc and methanol fractions were combined and purified using silica gel column chromatography with 
5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH with 1% TEA 
(triethylamine). Final compounds were obtained as white to beige solids with yields ranging from 35–40%.  
 
Method 2: In a 50 mL round-bottom pressure vial, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) 
was combined with 6 eq. urea (22.32 mmol) and diluted with 10 mL of anhydrous 1,4-dioxane. The 
pressure vial was sealed tightly and partially submerged in silicone oil heating at 160–165 °C. Contents 
were stirred in the pressure vial for 24 h. Once the reaction contents were cooled to room temperature, the 
solution was diluted with 20–25 mL EtOAc. The contents were washed three times with 20 mL saturated 
brine solution and the aqueous layers were re-extracted twice with 20 mL EtOAc. The organic layers were 
combined, dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography 
with 5:1 EtOAc:MeOH as an initial elution solvent followed by transition to 5:1 EtOAc:MeOH w/ 1% TEA 
(triethylamine). Final compounds were obtained as white to light beige solids with yields ranging from 50–
55%. 
 
Method 3: In a 50 mL round-bottom flask, 2-chloro-N-substituted-quinazolin-4-amine (3.72 mmol) was 
combined with 1.1 eq. NaN3 (4.09 mmol), before diluting with 4:1 EtOH (20 mL) and glacial acetic acid (5 
mL). Flask contents were stirred under reflux at 90–95 °C for 2 h. After cooling the reaction mixture, 10 
mol. % of Pd/C (10%) was added followed by slow addition of 1.5 eq. of hydrazine hydrate (5.58 mmol). 
Flask contents were stirred under reflux at 90–95 °C for an additional two hrs. Once complete, the warm 
solution was passed through a large, tightly packed cotton syringe with the aid of additional EtOH washes 
(2 x 20 mL). The ethanolic mixture was evaporated in vacuo. Final compounds were obtained as white to 
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beige solids with yields ranging from 80–85%. 
 
Method 4: In a 50 mL round-bottom flask, 2,4-diaminoquinazoline* (1 g, 6.24 mmol) was dissolved in 3 
mL DMSO. With stirring and periodic cooling over ice-water, NaH (60%, 0.25 g, 6.24 mmol) was added 
over a 10–15 min. period. After complete addition of NaH, flask was stirred at room temperature with slow, 
dropwise addition of the appropriate alkyl/aryl halide (6.24 mmol) dissolved in 3 mL DMSO. Contents are 
allowed to stir at room temperature overnight (~14 h) before diluting with 20 mL of water and stirring at 
room temperature for 15 min. The mixture is extracted thrice with diethyl ether (40 mL x 3). The combined 
organic layers are washed twice with brine (20 mL x 2). Combined organic layer was dried with MgSO4 
and concentrated in vacuo before purifying with silica gel column chromatography using 5:1 EtOAc/MeOH 
to afford beige to off-white solids at 20-31% yield.  
 
*General procedure for synthesis of 2,4-diaminoquinazoline.291, 317 In a 250 mL round-bottom 
pressure flask, 2-fluorobenzonitrile (4.6 mL, 42.32 mmol) or 2-aminobenzonitrile (5 g, 42.32 mmol) was 
combined with guanidine carbonate (11.43 g, 126.96 mmol) and diluted in 30 mL dimethylacetaminde 
(DMA). Contents are heated in an oil bath at 150 °C for overnight (~ 14 h) then diluted with 50mL of water 
before extracting thrice with EtOAc (50 mL x 3) and washing with brine (2 x 20 mL). Combined organic 
layer was dried with MgSO4 and concentrated in vacuo before purifying with silica gel column 
chromatography using 5:1 EtOAc/MeOH to afford an off-white solid at 80% yield. 1H NMR (300 MHz, 
DMSO- d6) δ 7.91 (d, 7.8 Hz, 1H), δ 7.41 (t, J = 7.8 Hz, 1H), δ 7.21 (br s, 2H), δ 7.15 (d, J = 8.1 Hz, 1H), δ 
6.95 (t, J = 7.2 Hz, 1H), δ 5.91 (br s, 2H). 13C NMR (100 MHz, DMSO- d6) δ 162.45, δ 160.75, δ 152.52, δ 
132.30, δ 124.22, δ 123.52, δ 119.73, δ 110.34. 
 
N4-Phenethylquinazolin-2,4-diamine (63). Yield: 80% (0.75 g, 2.84 mmol); Mp: 168-170 °C. 1H NMR 
(300 MHz, DMSO-d6), δ 8.30 (br s, 1H), 7.97 (d, J = 8.0 Hz, 1H), δ 7.48 (t, J = 9.0 Hz, 1H), δ 7.28–7.07 
(m, 6H), δ 7.05 (t, J = 6.0 Hz, 1H), δ 6.48 (br s, 2H), δ 3.63 (q, J = 6.5 Hz, 2H), δ 2.90 (t, J = 7.4 Hz, 2H). 
HRMS (ESI) m/z calcd for C16H16N4 [M + H]+ 265.1453, found: 265.1446. 
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General procedure for synthesis of N2-substituted-quinazoline-2,4-diamines.317 In a 50 mL round-
bottom flask, 2,4-diaminoquinazoline (1 g, 6.24 mmol) was dissolved in 20 mL DMA followed by the 
addition of potassium carbonate (0.85 g, 6.24 mmol) and the appropriate alkyl/aryl halide (6.24 mmol) at 
room temperature. Contents are refluxed at 85 °C for 5 h before diluting with 30 mL of water and stirring at 
R.T for 15 min. The mixture is extracted thrice with EtOAc (50 mL x 3). The combined organic layers are 
washed twice with brine (20 mL x 2). Combined organic layer was dried with MgSO4 and concentrated in 
vacuo before purifying with silica gel column chromatography using 5:1 EtOAc/MeOH to afford beige to 
off-white solids at 14–26% yield. 
 
N2-Phenethylquinazoline-2,4-diamine (22-iso). Yield 19% (0.31 g, 1.17 mmol); Mp: 151–153 °C; 1H 
NMR (300 MHz, DMSO-d6): δ 8.11 (d, J = 8.2 Hz, 1H), δ 7.67 (s, 1H), δ 7.40 (d, J = 8.0 Hz, 1H), δ 7.32 – 
7.11 (m, 9H), δ 3.59 (d, J = 7.0 Hz, 2H), δ 2.88 (d, J = 7.4 Hz, 2H). HRMS (ESI) m/z calcd for C16H16N4 
[M + H]+ 265.1448, observed 265.1447. 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-ols. In a 50 mL round bottom 
flask (RBF), 0.5 g of 2-chloro-N-substituted-quinazolin-4-amine (1.45–1.85 mmol) was combined with 1.3 
eq. of potassium formate (1.89–2.41 mmol) then dissolved in 20 mL of formic acid. Solution was refluxed 
for 14–16 h at 120–125 °C. Upon completion and cooling to room temperature, the reaction mixture was 
diluted with ~ 30 mL of brine solution, ~ 50 mL of saturated NaHCO3 solution before extracting with ~ 25 
mL (x 3) of EtOAc and washed with 25 mL (x 3) parts of brine solution. The combined aqueous layers 
were washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 before 
removing the EtOAc in vacuo to yield a solid product that generally did not require additional purification. 
Additional purification as required, was accomplished by silica gel column chromatography using 5:1 
EtOAc:MeOH as the eluent. The compounds were obtained as white solids with yields ranging from 58–
70%. 
 
4-(Phenethylamino)quinazolin-2-ol (64). Yield: 58% (0.27 g, 1.02 mmol); Mp 189–191 °C. 1H NMR 
(300 MHz, DMSO-d6): δ 10.60 (br s, 1H), δ 8.57 (br s, 1H), δ 8.06 (d, J = 8.1 Hz, 1H), δ 7.47 (t, J = 7.5 
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Hz, 1H), δ 7.29–7.02 (m, 7H), δ 3.60 (q, J = 7.6 Hz, 2H), δ 2.89 (t, J = 7.4 Hz, 2H).  HRMS (ESI) m/z 
calcd for C16H16N3O [M + H]+ 266.1215, found 266.1287. Purity: 96.9% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-urea.305 In a pressure vial, 0.5 
g of 2-chloro-N-substituted-quinazolin-4-amine (~1.85 mmol) was mixed with 6 eq. urea (~11.2 mmol) and 
10 mL of anhydrous 1,4-dioxane, sealed tightly and heated at 160–165 °C in an oil bath for 24 h. After 
cooling to room temperature, the solution was diluted with 20 mL EtOAc, washed three times with 20 mL 
brine solution; the aqueous layers were extracted twice with 20 mL EtOAc. The combined organic layers 
were dried over MgSO4, evaporated in vacuo and purified using silica gel column chromatography using a 
combination of 5:1 EtOAc:MeOH and 5:1 EtOAc:MeOH w/ 1% TEA (triethylamine) to afford target 
compounds as white solids with yields ranging from 45–50% and the hydrolyzed amine compounds as off 
white solids with yields ranging from 50–55%.  
 
1-(4-(Phenethylamino)quinazolin-2-yl)urea (65). Yield: 51% (0.27 g, 0.90 mmol); Mp 197–199 °C. 1H 
NMR (300 MHz, DMSO-d6): δ 9.08 (br s, 1H), δ 8.83 (br s, 1H), δ 8.45 (br s, 1H), δ 8.05 (d, J = 8.2 Hz, 
1H), δ 7.58 (t, J = 7.6 Hz, 1H), δ 7.44 (d, J = 8.2 Hz, 1H), δ 7.32–7.17 (m, 6H), δ 6.87 (br s, 1H), δ 3.67–
3.62 (m, 2H), δ 2.90 (t, J = 7.5 Hz, 2H). HRMS (ESI) m/z calcd for C17H18N5O [M + H]+ 308.1433, found 
308.1505. Purity: 95.9% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-glycinamide.299 In a 50 mL 
pressure vial, 0.25 g of 2-chloro-N-substituted-quinazolin-4-amine (~ 0.83 mmol) was combined with 3 eq. 
(~ 2.50 mmol) of glycinamide.HCl then dissolved in 5 mL of 1,4-dioxane followed by the addition of 5 eq. 
of DBU (~ 4.15 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 4 h. Upon 
completion and cooling to room temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and 
washed 25 mL (x 3) brine solution. The combined aqueous layers were washed with ~ 25 mL of EtOAc. 
The combined EtOAc layers were dried over MgSO4 and EtOAc was removed in vacuo to yield solid that 
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was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the eluent to afford target 
compounds as pale yellow to brown solids with yields ranging between 52–58%. 
 
2-((4-(Phenethylamino)quinazolin-2-yl)amino)acetamide (66). Yield: 55% (0.16 g, 0.48 mmol); Mp 
149–151 °C. 1H NMR (300 MHz, DMSO-d6): δ 8.06 (br s, 1H), δ 7.92 (d, J = 8.2 Hz, 1H), δ 7.45 (t, J = 
7.5 Hz, 1H), δ 7.28–7.16 (m, 7H), δ 7.01 (t, J = 7.5 Hz, 1H), δ 6.97 (br s, 1H), δ 6.37 (br s, 1H), δ 3.86 (d, J 
= 7.1 Hz, 2H), δ 3.61 (q, J = 5.9 Hz, 2H), δ 2.89 (t, J = 7.1 Hz, 2H). HRMS (ESI) m/z calcd for C18H20N5O 
[M + H]+ 322.1590, found 322.1662. Purity: 99.2% 
 
 
General procedure for the synthesis of N4-substituted-quinazolin-2-acetamide.312 In a 50 mL 
round bottom flask (RBF), 0.5 g of N4-substituted-quinazolin-2,4-diamine (1.54-2.00 mmol) was dissolved 
in 15 mL of 1,4-dioxane and 10 mL of glacial acetic acid/acetyl chloride combination (4:1 ratio). Solution 
was refluxed for 24 h at 90–95 °C. Upon completion and cooling to room temperature, the reaction mixture 
was diluted with ~ 30 mL of brine solution, ~ 30 mL of concentrated NaHCO3 solution before extracting 
with ~ 25 mL (x 3) of EtOAc and washed with 25 mL (x 2) brine solution. The combined aqueous layers 
were washed twice with 15 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 and the 
organic solvent was removed in vacuo to yield a solid product that generally did not require additional 
purification. Purification was carried out as required, by silica gel column chromatography using 5:1 
EtOAc:MeOH as the eluent to afford target compounds as white solids with yields ranging from 35–42%. 
 
 
N-(4-(Phenethylamino)quinazolin-2-yl)acetamide (67): Yield: 49% (0.28 g, 0.92 mmol); Mp 187–189 
°C. 1H NMR (300 MHz, DMSO-d6): δ 9.45 (br s, 1H), δ 7.86 (m, 2H), δ 7.39 (t, J = 9.0 Hz, 1H), δ 7.27–
7.16 (m, 6H), δ 6.93 (t, J = 6.0 Hz, 1H), δ 3.63 (q, J = 6.0 Hz, 2H), δ 2.92 (t, J = 7.5 Hz, 2H), δ 2.26 (s, 
3H). HRMS (ESI) m/z calcd for C18H19N4O [M + H]+ 307.1481, found 307.1553. Purity: 99.9% 
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General procedure for the synthesis of N4-substituted-N2-alkyl-quinazolin-2,4-diamine.299, 313 In a 
50 mL pressure vial (PV), 0.25 g of 2-chloro, 2,6-dichloro, 2,7-dichloro or 2,8-dichloro-N-substituted-
quinazolin-4-amine (~ 0.66–0.83 mmol) was combined with 2 eq. (~ 1.32–1.66 mmol) of primary amine 
(methyl-, ethyl-, n-propyl-, isopropyl- or cyclopropylamine) or dimethylamine then dissolved in 5 mL of 
1,4-dioxane followed by the addition of 3 eq. of DIPEA (~ 1.98–2.40 mmol). Pressure vial was sealed and 
stirred in an oil bath at 150–155 °C for 2 h. Upon completion and cooling to room temperature, the reaction 
mixture was diluted with ~ 40 mL of EtOAc and washed with brine solution (25 mL x 2). The combined 
aqueous layer was washed with ~ 25 mL of EtOAc. The combined EtOAc layers were dried over MgSO4 
before removing EtOAc in vacuo to yield a solid product that was purified by silica gel column 
chromatography using 5:1 EtOAc:MeOH as the eluent to afford pale yellow to brown solids yielding at 55–
70%. 
 
N2-Methyl-N4-(phenethyl)quinazoline-2,4-diamine (68). Yield: 65% (0.32 g, 1.15 mmol); Mp 121–123 
°C. 1H NMR (300 MHz, DMSO-d6): δ 7.97 (m, 2H), δ 7.42 (t, J = 9.0 Hz, 1H), δ 7.29–7.16 (m, 6H), δ 6.93 
(t, J = 6.0 Hz, 1H), δ 6.35 (br s, 1H), δ 3.60 (q, J = 6.0 Hz, 2H), δ 2.80 (t, J = 9.0 Hz, 2H), δ 2.70 (d, J = 3.0 
Hz, 3H). HRMS (ESI) m/z calcd for C17H19N4 [M + H]+ 279.1531, found 279.1603. Purity: 98.6% 
 
N2-Ethyl-N4-(phenethyl)quinazoline-2,4-diamine (69). Yield: 61% (0.31 g, 1.06 mmol); Mp 117–119 °C. 
1H NMR (300 MHz, DMSO-d6): δ 7.86 (m, 2H), δ 7.43 (t, J = 9.0 Hz, 1H), δ 7.30–7.16 (m, 6H), δ 6.97 (t, 
J = 6.0 Hz, 1H), δ 6.50 (br s, 1H), δ 3.61 (q, J = 6.0 Hz, 2H), δ 3.32 (d, J = 9.0 Hz, 2H), δ 2.92 (t, J = 9.0 
Hz, 2H), δ 1.09 (t, J = 6.0 Hz, 3H). HRMS (ESI) m/z calcd for C18H21N4 [M + H]+ 293.1688, found 
293.1795. Purity: 98.0% 
 
N4-(Phenethyl)-N2-propylquinazoline-2,4-diamine (70). Yield: 55% (0.30 g, 0.98 mmol); Mp 102–104 
°C. 1H NMR (300 MHz, DMSO-d6): δ 7.86 (m, 2H), δ 7.39 (t, J = 9.0 Hz, 1H), δ 7.27–7.16 (m, 6H), δ 6.93 
(t, J = 6.0 Hz, 1H), δ 6.40 (br s, 1H), δ 3.60 (q, J = 6.0 Hz, 2H), δ 3.30–3.24 (m, 2H), δ 2.89 (t, J = 7.5 Hz, 
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2H), δ 1.56–1.49 (sextet, J = 6.0 Hz, 2H), δ 0.84 (t, J = 7.5 Hz, 3H). HRMS (ESI) m/z calcd for C19H23N4 
[M + H]+ 307.1844, found 307.1916. Purity: 100.0% 
 
N2-Isopropyl-N4-(phenethyl)quinazoline-2,4-diamine (71). Yield: 58% (0.32 g, 1.06 mmol); Mp 112–
114 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.89 (m, 2H), δ 7.40 (t, J = 9.0 Hz, 1H), δ 7.27–7.17 (m, 6H), δ 
6.98 (t, J = 6.0 Hz, 1H), δ 6.30 (br s, 1H), δ 4.12 (m, 1H), δ 3.60 (q, J = 6.0 Hz, 2H), δ 2.91 (t, J = 7.5 Hz, 
2H), δ 1.12 (d, J = 6.0 Hz, 6H). HRMS (ESI) m/z calcd for C19H23N4 [M + H]+ 307.1844, found 307.1916. 
Purity: 98.5% 
 
N2-Cyclopropyl-N4-(phenethyl)quinazoline-2,4-diamine (72). Yield: 58% (0.32 g, 1.05 mmol); Mp 116–
118 °C. 1H NMR (300 MHz, DMSO-d6): δ 7.87 (m, 2H), δ 7.40 (t, J = 9.0 Hz, 1H), δ 7.30–7.12 (m, 6H), δ 
6.90 (t, J = 6.0 Hz, 1H), δ 6.60 (br s, 1H), δ 3.63 (q, J = 6.0 Hz, 2H), δ 2.92 (t, J = 7.5 Hz, 2H), δ 2.82 (m, 
1H), δ 0.59 (d, J = 4.8 Hz, 2H), δ 0.44 (d, J = 4.8 Hz, 2H). HRMS (ESI) m/z calcd for C19H21N4 [M + H]+ 
305.1688, found 305.1759. Purity: 100.0% 
 
6-Chloro-N4-phenethyl-N2-propylquinazoline-2,4-diamine (76). Yield: 71% (0.38 g, 1.12 mmol); Mp 
107–109 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.09–8.02 (m, 2H), δ 7.41 (dd, J = 8.9, 2.3 Hz, 1H), δ 7.30–
7.14 (m, 6H), δ 6.72 (br s, 1H), δ 3.60 (q, J = 7.5 Hz, 2H), δ 3.23–3.20 (m, 2H), δ 2.89 (t, J = 7.3 Hz, 2H), 
δ 1.47 (sextet, J = 7.2 Hz, 2H), δ 0.84 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z calcd for C19H22ClN4 [M + H]+ 
341.1455, found 341.1527. Purity: 99.7% 
 
6-Chloro-N2-isopropyl-N4-phenethylquinazoline-2,4-diamine (77). Yield: 75% (0.40 g, 1.18 mmol); Mp 
104–106 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.10–8.04 (m, 2H), δ 7.44 (dd, J = 8.9, 2.3 Hz, 1H), δ 7.30–
7.15 (m, 6H), δ 6.65 (br s, 1H), δ 4.18–4.07 (m, 1H), δ 3.60 (q, J = 7.5 Hz, 2H), δ 2.89 (t, J = 7.3 Hz, 2H), 
δ 1.13 (d, J = 6.5 Hz, 6H). HRMS (ESI) m/z calcd for C19H22ClN4 [M + H]+ 341.1455, found 341.1527. 
Purity: 98.6% 
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6-Chloro-N2-cyclopropyl-N4-phenethylquinazoline-2,4-diamine (78). Yield: 73% (0.39 g, 1.15 mmol); 
Mp 108–110 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.07–8.04 (m, 2H), δ 7.43 (dd, J = 8.9, 2.3 Hz, 1H), δ 
7.29–7.14 (m, 6H), δ 6.87 (br s, 1H), 3.67–3.60 (m, 2H), δ 2.89 (t, J = 7.6 Hz, 2H), δ 2.81–2.75 (m, 1H), δ 
0.65–0.58 (m, 2H), δ 0.48–0.43 (m, 2H). HRMS (ESI) m/z calcd for C19H20ClN4 [M + H]+ 338.1298, found 
339.1371. Purity: 99.6%  
 
6-Chloro-N2,N2-dimethyl-N4-phenethylquinazoline-2,4-diamine (79). Yield: 76% (0.39 g, 1.20 mmol); 
Mp 122–124 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.11 (br s, 1H), δ 8.04 (d, J = 2.3 Hz, 1H), δ 7.41 (dd, J 
= 8.9, 2.3 Hz, 1H), δ 7.28–7.16 (m, 6H), δ 3.61 (q, J = 5.6 Hz, 2H), δ 3.12 (s, 6H), δ 2.90 (t, J = 7.2 Hz, 
2H). HRMS (ESI) m/z calcd for C18H20ClN4 [M + H]+ 327.1298, found 327.1370. Purity: 99.5% 
 
7-Chloro-N4-phenethyl-N2-propylquinazoline-2,4-diamine (80). Yield: 70% (0.37 g, 1.10 mmol); Mp 
105–107 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.03 (br s, 1H), δ 7.89 (d, J = 8.7 Hz, 1H), δ 7.30–7.15 (m, 
6H), δ 6.96 (dd, J = 8.9, 2.3 Hz, 1H), δ 6.71 (br s, 1H), δ 3.60 (q, J = 7.5 Hz, 2H), δ 3.23–3.20 (m, 2H), δ 
2.89 (t, J = 7.3 Hz, 2H), δ 1.46 (sextet, J = 7.2 Hz, 2H), δ 0.84 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z calcd 
for C19H22ClN4 [M + H]+ 341.1455, found 341.1528. Purity: 99.4% 
 
7-Chloro-N2-isopropyl-N4-phenethylquinazoline-2,4-diamine (81). Yield: 75% (0.40 g, 1.18 mmol); Mp 
106–108 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.07 (br s, 1H), δ 7.91 (d, J = 8.7 Hz, 1H), δ 7.30–7.15 (m, 
6H), δ 6.98 (dd, J = 8.9, 2.3 Hz, 1H), δ 6.62 (br s, 1H), δ 4.16–4.09 (m, 1H), δ 3.60 (q, J = 7.5 Hz, 2H), δ 
2.89 (t, J = 7.3 Hz, 2H), δ 1.13 (d, J = 6.5 Hz, 6H). HRMS (ESI) m/z calcd for C19H22ClN4 [M + H]+ 
341.1455, found 341.1528. Purity: 99.6% 
 
7-Chloro-N2-cyclopropyl-N4-phenethylquinazoline-2,4-diamine (82). Yield: 73% (0.39 g, 1.15 mmol); 
Mp 111–113 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.07 (br s, 1H), δ 7.92 (d, J = 8.7 Hz, 1H), δ 7.29–7.14 
(m, 6H), δ 6.99 (dd, J = 8.7, 2.0 Hz, 1H), δ 6.92 (br s, 1H), δ 3.67–3.60 (m, 2H), δ 2.89 (t, J = 7.6 Hz, 2H), 
δ 2.85–2.77 (m, 1H), δ 0.65–0.59 (m, 2H), δ 0.48–0.45 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 160.94, 
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δ 159.43, δ 152.96, δ 139.64, δ 136.75, δ 128.65, δ 128.29, δ 126.03, δ 124.75, δ 123.14, δ 122.43, δ 
119.97, δ 109.87, δ 42.14, δ 34.53, δ 23.85, δ 6.37. HRMS (ESI) m/z calcd for C19H20ClN4 [M + H]+ 
338.1298, found 339.1371. Purity: 98.5%  
 
7-Chloro-N2,N2-dimethyl-N4-phenethylquinazoline-2,4-diamine (83). Yield: 72% (0.37 g, 1.15 mmol); 
Mp 127–129 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.12 (br s, 1H), δ 7.90 (d, J = 8.7 Hz, 1H), δ 7.29–7.14 
(m, 6H), δ 6.97 (dd, J = 8.9, 2.3 Hz, 1H), δ 3.60 (q, J = 5.6 Hz, 2H), δ 3.12 (s, 6H), δ 2.89 (t, J = 7.2 Hz, 
2H). HRMS (ESI) m/z calcd for C18H20ClN4 [M + H]+ 327.1298, found 327.1371. Purity: 94.5% 
 
8-Chloro-N4-phenethyl-N2-propylquinazoline-2,4-diamine (84).  Yield: 70% (0.37 g, 1.10 mmol); Mp 
102–104 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.03 (br s, 1H), δ 7.85 (d, J = 8.6 Hz, 1H), δ 7.57 (d, J = 8.6 
Hz, 1H), δ 7.30–7.15 (m, 5H), δ 6.89 (t, J = 7.9 Hz, 1H), δ 6.79 (br s, 1H), δ 3.61 (q, J = 7.5 Hz, 2H), δ 
3.23–3.20 (m, 2H), δ 2.89 (t, J = 7.3 Hz, 2H), δ 1.50 (sextet, J = 7.2 Hz, 2H), δ 0.84 (t, J = 7.4 Hz, 3H). 
HRMS (ESI) m/z calcd for C19H22ClN4 [M + H]+ 341.1455, found 341.1528. Purity: 98.8% 
 
8-Chloro-N2-isopropyl-N4-phenethylquinazoline-2,4-diamine (85). Yield: 70% (0.37 g, 1.10 mmol); Mp 
107–109 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.99 (br s, 1H), δ 8.16 (d, J = 8.6 Hz, 1H), δ 7.88 (d, J = 8.6 
Hz, 1H), δ 7.44 (t, J = 7.9 Hz, 1H), δ 7.30-7.09 (m, 5H), δ 6.97 (br s, 1H), δ 4.25-4.14 (m, 1H), δ 3.67 (q, J 
= 7.5 Hz, 2H), δ 2.89 (t, J = 7.3 Hz, 2H), δ 1.16 (d, J = 6.5 Hz, 6H). HRMS (ESI) m/z calcd for C19H22ClN4 
[M + H]+ 341.1455, found 341.1527. Purity: 100.0% 
 
8-Chloro-N2-cyclopropyl-N4-phenethylquinazoline-2,4-diamine (86). Yield: 69% (0.37 g, 1.09 mmol); 
Mp 111–113 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.17–8.15 (m, 1H), δ 7.92–7.87 (m, 1H), δ 7.63–7.59 
(m, 1H), δ 7.31–7.04 (m, 5H), δ 6.98–6.92 (m, 2H), δ 3.75–3.64 (m, 2H), δ 2.97–2.88 (m, 3H), δ 0.65–0.59 
(m, 2H), δ 0.48–0.45 (m, 2H). HRMS (ESI) m/z calcd for C19H20ClN4 [M + H]+ 338.1298, found 338.1372. 
Purity: 98.7% 
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8-Chloro-N2,N2-dimethyl-N4-phenethylquinazoline-2,4-diamine (87). Yield: 72% (0.37 g, 1.15 mmol); 
Mp 122–124 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.15 (br s, 1H), δ 7.86 (d, J = 8.7 Hz, 1H), δ 7.60 (d, J 
= 8.7 Hz, 1H), δ 7.30–7.15 (m, 5H), δ 6.91 (t, J = 9.0 Hz, 1H), δ 3.63 (q, J = 5.6 Hz, 2H), δ 3.18 (s, 6H), δ 
2.91 (t, J = 7.2 Hz, 2H). HRMS (ESI) m/z calcd for C18H19ClN4 [M + H]+ 327.1298, found 327.1371. 
Purity: 96.3% 
 
 
6.5.2. Biological Screening 
 
6.5.2.1. Human Cholinesterase (hChE) Assay299, 313 
 
The inhibition profile of quinazoline derivatives was evaluated using the Ellman (DTNB) reagent.315 
Human AChE and BuChE enzymes were obtained from Sigma-Aldrich, St. Louis, MO, USA (AChE 
product number C0663 and BuChE product number B4186 respectively). The cholinesterase inhibitors 
tacrine (item number 70240, Cayman Chemical Company, Ann Arbor, MI), donepezil (product number 
D6821, Sigma-Aldrich, St. Louis, MO), galantamine (product number G1660, Sigma-Aldrich, St. Louis, 
MO) and rivastigmine (product number SML0881, Sigma-Aldrich, St. Louis, MO) were used as reference 
agents. Quinazoline derivative stock solutions were prepared in DMSO (maximum 1% v/v in final wells) 
and diluted in buffer solution (50 mM Tris.HCl, pH 8.0, 0.1 M NaCl, 0.02 M MgCl2.6H2O). Then 160 µL 
of 5,5’-dithiobis(2-nitrobenzoic acid) (1.5 mm DTNB), 50 µL of hAChE (0.22 U/mL in 50 mM Tris.HCl, 
pH 8.0, 0.1% w/v bovine serum albumin, BSA) or 50 µL of hBuChE (0.12 U/mL in 50 mM Tris.HCl, pH 
8.0, 0.1% w/v BSA) were added to 96-well plates after which 10 µL each of quinazoline derivatives (final 
concentration range 0.1–50 µM) were added and incubated for 5 min. Then 30 µL of either 
acetylthiocholine iodide (15 mM AThCl prepared in ultra pure water) or S-butyrylthiocholine iodide (15 
mM BThCI prepared in ultra pure water) were added. The absorbance was measured at different time 
intervals (0, 60, 120, 180, 240 and 300 s) using a wavelength of 412 nm. The inhibitory concentration (IC50 
values) was calculated from the concentration–inhibition dose response curve on a logarithmic scale. The 
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results were expressed as average values based on two to three independent experiments run in triplicate 
measurements. 
 
6.5.2.2. Amyloid-β (Aβ) Aggregation Assay317 
 
The ability of quinazoline-based derivatives to inhibit Aβ-aggregation kinetics was determined using a 
ThT-binding fluorescence assay. These assays were conducted in Costar, black-surround, clear-bottom 
384-well plates with frequent shaking (30 sec. of linear shaking at 730 cpm every 5 minutes) and constant 
heating at 37 °C for 24 h. The ThT excitation/emission was measured at 440 nm/490 nm and readings were 
taken every 5 minutes using a BioTek Synergy H1 microplate reader. Quinazoline stock solutions were 
prepared in DMSO and diluted to 10x in 215 mM phosphate buffer at pH 7.4. Abeta.HFIP samples (Aβ40 
or Aβ42, rPeptide, Bogart, USA) were dissolved in 1% ammonium hydroxide, sonicated at room 
temperature for 5 minutes then diluted to 50 µM in 215 mM phosphate buffer (pH 7.4). A 15 µM ThT stock 
solution was prepared with 50 mM glycine and adjusted to pH 7.4. The assay was carried out by adding 44 
µL ThT, 20–35 µL buffer, 1 µL DMSO (for background and controls only) followed by the addition of 8 
µL of 10x compound dilutions (1–25 µM concentration range). An end point reading was conducted to 
evaluate potential test compound interference with ThT-fluorescence before adding 8 µL of Aβ40 or Aβ42 
stock solutions (5 µM final concentration). Plates were sealed with a transparent plate film before initiating 
the assay. RFU values were corrected for ThT-interference before calculating end point percent inhibitions 
or IC50 values and obtaining the aggregation kinetic plots. Data presented was an average of triplicate 
reading for two-three independent experiments. 
 
6.5.2.3. TEM Assay and Imaging142, 190, 207, 317 
 
In Costar 96-well, round-bottom plates were added 80 µL of 215 mM phosphate buffer, 20 µL of 10x 
test compound dilutions (250 µM – prepared in the same way as for the ThT assay) and 100 µL of 50 µM 
Aβ40 or Aβ42 respectively.  For the control wells, 2 µL of DMSO and 18 µL of phosphate buffer was 
added. Final Aβ: test compound ratio was 1:1 (25 µM). Plates were incubated on a Fisher plate incubator 
 	   203 
set to 37 °C and the contents were shaken at 730 cpm for 24 h. To prepare the TEM grids, ~ 20 µL droplet 
was added using a disposable Pasteur pipette over the formvar-coated copper grids (400 mesh). Grids were 
air-dried for about 3 h before adding two droplets (~ 40 µL, using a disposable Pasteur pipette) of ultra-
pure water and using small pieces of filter paper to wash out precipitated buffer salts. After air-drying for ~ 
15-20 min, the grids were negatively stained by adding a droplet (~ 20 µL, using a disposable Pasteur 
pipette) of 2% phosphotungstic acid (PTA) and immediately after the grids were dried using small pieces of 
filter paper. Grids were further air-dried overnight. The scanning was carried out using a Philips CM 10 
transmission electron microscope at 60 kV (Department of Biology, University of Waterloo) and 
micrographs were obtained using a 14-megapixel AMT camera. 
 
6.5.2.4. DPPH Scavenging Assay324 
 
The ability of select quinazolines to scavenge the DPPH radical was utilized as a measure of 
antioxidant capacity. Quinazoline stock solutions were prepared in anhydrous methanol (500 µM) and the 
DPPH solution was also prepared in anhydrous methanol (56 µM). The addition sequence was carried out 
in a 96-well clear, flat bottom plate as follows: 90 µL DPPH, 10 µL test compound solution (50 µΜ) final 
concentration. Control solutions contained 90 µL anhydrous methanol and 10 µL test compound whereas 
DPPH control contained 90 µL of DPPH, and 10 µL anhydrous methanol. This readings were taken initially 
at 517 nm with 30 sec. shaking (double orbital at 530 cpm) prior to the 1 h, light restrictive, incubation 
period at room temperature after which readings were taken again at 517 nm after another round of 30 sec 
shaking (double orbital at 530 cpm) using a BioTek Synergy H1 microplate reader. The results were 
expressed as percentage inhibition and the data presented was average of triplicate reading (for two 
independent experiments). 
 
6.5.3. Computational Chemistry299, 313, 317, 324 
 
The molecular docking studies were conducted using Discovery Studio 4.0 (Structure-Based-Design 
program) from BIOVIA Inc. San Diego, USA. Select quinazolines derivatives were built and minimized 
 	   204 
using the small molecules module in Discovery Studio. X-ray coordinates of human cholinesterases were 
obtained from the protein data bank (hAChE PBD ID: 1B41 and hBuChE PDB ID: 1P0I) and prepared 
using the macromolecules module in Discovery Studio. Ligand binding sites were defined by selecting a 12 
Å radius sphere for AChE and 15 Å radius sphere for BuChE. The molecular docking was performed using 
the receptor-ligand interactions module in Discovery Studio. The LibDock algorithm was used to find the 
most appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. For Amyloid-β docking studies, the NMR solution structure of Aβ fibrils were 
obtained from the protein data bank (PDB ID: 2LMN). Aβ dimer and Aβ fibril assemblies were built using 
the macromolecules module in Discovery Studio. Ligand binding site was defined by selecting a 15 Å 
radius sphere for both Aβ assemblies. Molecular docking was performed using the receptor-ligand 
interactions module in Discovery Studio, where the LibDock algorithm was used to find the most 
appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. 
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CHAPTER 7 
  Development and Evaluation of 2,4-Disubstituted Pyridopyrimidines as Dual ChE 
and Aβ Aggregation Inhibitors with Chelation Capacity   
 
 
 
 
 
 
 
 
 
* Chapter banner   
  
 
7.1. Introduction 
 
The preceding chapters (3–6) showcased the SAR data from 86 quinazoline and cholorquinazoline 
derivatives, including four regioisomeric structures. The acquired data thus far highlighted the advantages 
and disadvantages of introducing a dimethoxyphenyl moiety or an additional methylene linker at the C4-
positon of the quinazoline scaffold, while providing clear indications of the biological outcomes based on 
the nature of the C2-groups. The assessment of regioisomeric structures and the impact of chlorine 
placements provided valuable SAR for the optimization (Phase 2) stage.  
This chapter sets to further expand on the acquired SAR data, of the C4-dimethoxypheneyl and C4-
phenethylamine series, by developing and assessing 10 derivatives based on the quinazoline-related 
scaffold – pyridopyrimidine (Ppd). From the cumulative assessment of the C2-groups utilized throughout 
the project, the following alkylamines (n-propyl, i-proply, c-propyl and dimethylamines) were utilized in 
this chapter. 
Generally, all synthetic approaches and mechanisms here have been previously discussed in Chapters 
3–6. A brief summary is provided prior to the listing of experimental data and methodology. 
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7.2. Hypothesis 
 
With respect to this series, the focus on the dimethoxyphenethyl and phenethyl moieties at C4-
position was based on the overall benefits observed with the additional methylene unit in the linker chain. 
While the 3,4-dimethoxy groups were more suitable for AChE targeting, their absence proved more 
effective at BuChE targeting, so these observations are likely to carry forward here. On the other hand, 
honing in on the aliphatic alkylamines was based on their superior ability to generate dual ChE inhibitors, 
while offering strong potentials toward dual Aβ targeting.  
The strategy behind the pyridopyrimidine scaffold is established on the introduction of a chelation 
center within the scaffold (pyridine nitrogen and C4-NH) and decreasing the overall hydrophobicity of the 
derivatives. While the chelation center would enhance the overall multi-targeting capacity of the 
derivatives, the reduced hydrophobicity associated with the more polar scaffold is predicated to deter 
BuChE activity. The SAR obtained from these derivatives should provide critical insight, especially when 
compared to their non-chlorinated, quinazoline-based counterparts in Chapters 5 and 6. 
 
 
7.3. Results and Discussions 
 
The proceeding sub-chapter briefly highlights previously-established routes to target derivatives. 
Biological assessments in the cholinesterase and amyloid-β aggregation assay (to obtain IC50 values and/or 
investigation aggregation kinetics) are conducted. Aggregate load is corroborated via transmission electron 
microscopy in amyloid morphology screening and derivatives are assessed for iron chelation potential in 
the competition-based ferrozine assay. Computational studies are performed in the ChE X-ray structures 
and amyloid models to evaluate the acquisitioned SAR data.  
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7.3.1. Synthesis 
 
As previously described, initial coupling in this series utilized 2,4-dichloropyridopyrimidine (2,4-
DCP) to add the 3,4-dimethoxyphenethylamine or the phenethylamine group to the C4-position of the 
pyrido[3,2-d]pyrimidine (Ppd) scaffold, via a NAS reaction, to yield 2-chloro-N-(3,4-dimethoxyphenethyl) 
pyrido[3,2-d]pyrimidin-4-amine or 2-chloro-N-phenethylpyrido[3,2-d]pyrimidin-4-amine (88–89, Scheme 
21). The coupling of the alkylamines at the C2-position to 88 or 89 was accomplished using previously 
described methodologies based on N.A.S (90–97, Scheme 22). 
 
Scheme 21a  
 
 
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward pyridopyrimidine-based derivatives 88 and 89. (a) 3,4-
dimethoxyphenethylamine or phenethylamine, DIPEA, EtOH, reflux, 4 h. 
 
 
Scheme 22a  
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  
aReagents and conditions: Synthetic routes toward pyridopyrimidine-based derivatives 90–97.(a) Primary amine (R1 = 
n-Pr, i-Pr or c-Pr) or dimethylamine, DIPEA, 1,4-dioxane, pressure vial 150–155 °C, 2 h. 
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7.3.2. Cholinesterase 
 
The ability of 2,4-disubstituted pyridopyrimidines (88–97) to target the cholinesterases (hAChE/ 
hBuChE) was assessed using the DTNB method as described in Chapter 3 (Table 13). 
 
 
Table 13: Cholinesterase inhibition data for 2,4-disubstituted pyridopyrimidines (88–97). 
 
 
 
 
 
 
Derivative R-Grp 
ChE IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
hAChE hBuChE 
88 Cl 9.0 ± 0.9 > 50 – 3.59 267.53 1:6 
89 Cl 7.2 ± 0.7 > 50 – 3.93 209.57 1:4 
90 n-Pr 7.2 ± 0.8 > 50 – 4.81 308.35 2:7 
91 i-Pr 7.4 ± 0.7 > 50 – 4.59 303.21 2:7 
92 c-Pr 7.2 ± 0.5 > 50 – 4.34 299.09 2:7 
93 N(Me)2 6.7 ± 0.5 > 50 – 3.81 290.52 1:7 
94 n-Pr 8.1± 0.8 30.3 ± 2.8 0.27 5.16 251.41 2:5 
95 i-Pr 7.8 ± 0.8 29.3 ± 2.1 0.27 4.94 255.87 2:5 
96 c-Pr 7.6 ± 0.6 > 50 – 4.68 244.21 2:5 
97 N(Me)2 6.8 ± 0.7 > 50 – 4.15 242.84 1:5 
Donepezil – 0.03 ± 0.002 3.6 ± 0.4 0.01 4.59 321.7 0:4 
Tacrine – 0.16 ± 0.01 0.04 ± 0.001 4.00 3.27 165.6 2:2 
Galantamine – 2.6 ± 0.6 > 50 – 1.18 239.4 1:4 
Rivastigmine – 6.5 ± 0.5 > 10 – 2.10 226.3 0:4 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. 
bSelectivity index is calculated as (hAChE IC50)  ÷ (hBuChE IC50). cClogP values were determined using ChemDraw 
Professional 15.0. dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design 
software, BIOVIA Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding 
acceptors. 
 
When considered against non-chlorinated quinazoline counterparts in Table 5 (Chapter 5) and Table 9 
(Chapter 6), the data presented in Table 13 generally pointed to the significant inability of the derivatives 
within this pyridopyrimidine series to target BuChE. With respect to AChE targeting, IC50 values remained 
static at ~ 7.5 µM, compared to ~ 6.2 µM for dimethoxyphenethylamine-based quinazolines and ~ 7.7 for 
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phenethylamine-based quinazolines counterparts. Starting with the C2-chlorine-based derivatives, 88 was 
roughly 3-fold less potent toward AChE compared to its quinazoline counterpart (32, IC50 ~ 3 µM) and 
roughly 1.3-fold less potent compared to its phenethylamine counterpart (89, IC50 ~ 7 µM). Interestingly, 
89 was equipotent to its quinazoline counterpart (60) toward AChE. 
The introduction of secondary alkylamines at the C2-position of the dimethoxyphenethylamine-based 
pyridopyrimidines (90–92, Table 13) established equipotent activity toward AChE (IC50 ~ 7.3 µM) as seen 
with their quinazoline counterparts (42–44); however, BuChE activity was totally suppressed with the 
pyridopyrimidine scaffold. The tertiary dimethylamine-based derivative (93) was also inactive toward 
BuChE and was more or less comparable to 90–92 toward AChE. Compared to 90–93, the phenethylamine-
based pyridopyrimidines (94–97) were also equipotent toward AChE (although 94 was slightly less potent 
compared to 90), while BuChE was either very weak (94 and 95, IC50 ~ 30 µM) to non-existent (96 and 97). 
When extending the comparison to their quinazoline counterparts (70–72), the pyridopyrimidine-based 
derivatives were no match on the BuChE front and, yet again, were roughly equivalent in their activity 
toward AChE (IC50 7.7 µM vs. 7.8 µM).  
In summary, the investigation into the impact of the pyridopyrimidine scaffold on dual ChE inhibition 
simply revealed that while AChE targeting potential was not impacted, these derivatives (88–97) were not 
suitable for BuChE targeting, based on their polar ring scaffold. Overall, AChE targeting was based on an 
average IC50 value of 7.5 µM. 
 
 
7.3.3. Amyloid-β Aggregation 
 
The ability of 2,4-disubstituted pyridopyrimidines (88–97) to modulate the aggregation kinetics of 
amyloid-β was assessed using the ThT-binding method described earlier in Chapter 3 (Table 14).  
When considered against non-chlorinated quinazoline counterparts in Table 7 (Chapter 5) and Table 11 
(Chapter 6), the data presented in Table 14 generally pointed to the reduced capacity of 88–97 to target 
Aβ40 (with the exception of 95 being ~ 4-fold more potent compared to 71), while also demonstrating 
enhanced capacity to inhibit Aβ42. 
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Starting with the C2-chlorine-based derivatives, 88 was roughly 4-fold less potent toward Aβ40 
compared to its quinazoline counterpart (32, IC50 ~ 8 µM), but was roughly 5-fold more potent toward 
Aβ42 (IC50 ~ 3 µM). The phenethylamine counterpart (89) was 18% less potent toward Aβ40, while also 
being ~ 10-fold less potent toward Aβ42. Interestingly, 89 was roughly 10-fold less potent toward Aβ40 
and ~ 1.5-fold more potent toward Aβ42 compared to its quinazoline counterpart (60). 
 
 
Table 14: Amyloid-β (Aβ40/42) inhibition data for 2,4-disubstituted pyridopyrimidines (88–97). 
 
 
 
 
 
 
 
 
 
Derivative R-Grp 
Amyloid-β IC50 (µM) a SI b ClogP c MV (Å3) d HBD:HBA e 
Aβ40 Aβ42 
88 Cl 44% 2.7 ± 0.3 – 3.59 267.53 1:6 
89 Cl 26% 22.6 ± 2.8 – 3.93 209.57 1:4 
90 n-Pr NA 41% – 4.81 308.35 2:7 
91 i-Pr NA 33% – 4.59 303.21 2:7 
92 c-Pr NA 46% – 4.34 299.09 2:7 
93 N(Me)2 23% 38% – 3.81 290.52 1:7 
94 n-Pr NA 13.7 ± 2.0 – 5.16 251.41 2:5 
95 i-Pr 1.1 ± 0.1 50% – 4.94 255.87 2:5 
96 c-Pr 6.8 ± 1.0 11.5 ± 1.5 – 4.68 244.21 2:5 
97 N(Me)2 NA 12.7 ± 2.0 – 4.15 242.84 1:5 
Curcumin – 3.3 ± 0.45 9.9 ± 0.4 0.33 4.59 302.1 2:6 
Resveratrol – 1.1 ± 0.1 15.3 ± 1.9 0.07 2.83 187.2 3:3 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). bSelectivity 
index is calculated as (Aβ40 IC50)  ÷ (Aβ42 IC50). cClogP values were determined using ChemDraw Professional 15.0. 
dMolecular volumes in Å3 units were determined using Discovery Studio, Structure-Based Design software, BIOVIA 
Inc., USA. eShowcasing the ratio of HBD = hydrogen-bonding donors to HBA = hydrogen-bonding acceptors. 
 
 
The introduction of secondary alkylamines at the C2-position of the dimethoxyphenethylamine-based 
pyridopyrimidines (90–92, Table 13) demonstrated a total loss of Aβ40 activity (compared to IC50 ~ 4–39 
µM, 42–44) while exhibiting an estimated 40% inhibition toward Aβ42 (compared to ~ 16% inhibition at 
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25 µM). The tertiary dimethylamine-based derivative (93) was weakly active toward Aβ40 (P.I ~ 23% at 25 
µM), while exhibiting P.I of Aβ42 similar to 90–92 (38% vs. ~ 40% at 25 µM). Compared to 90–93, the 
phenethylamine-based pyridopyrimidines (94–97) were more active toward Aβ42 (IC50 ~ 16 µM), while 
only 95 and 96 exhibited potent to moderate (IC50 ~ 1 and 7 µM; respectively) inhibition of Aβ40. When 
extending the comparison to their quinazoline counterparts (70–72), the pyridopyrimidine-based derivatives 
were more active toward Aβ42 (IC50 ~ 48 vs. ~ 16 µM; respectively), while activity toward Aβ40 was of 
mixed outcomes. While the quinazoline scaffold favoured the n-Pr (70, IC50 ~ 4 µM) and c-Pr (72, IC50 ~ 1 
µM) C2-groups, the pyridopyrimidine favoured the i-Pr group (95, IC50 ~ 1 µM). 
In summary, the investigation into the impact of the pyridopyrimidine scaffold on dual Aβ targeting 
simply revealed that while the pyridopyrimidine scaffold was not as effective toward Aβ40, it generally 
enhanced Aβ42 targeting potential. Overall, derivative 95 (N2-isopropyl-N4-phenethylpyrido[3,2-
d]pyrimidine-2,4-diamine) was identified as the leading Aβ40 aggregation inhibitor (IC50 ~ 1 µM, 
equipotent to resveratrol), while 88 (2-chloro-N-(3,4-dimethoxyphenethyl)pyrido[3,2-d]pyrimidin-4-amine) 
was identified as the leading Aβ42 aggregation inhibitor (IC50 ~ 3 µM). 
 The aggregation kinetic assessment of Aβ40/42 with or without series-leading derivatives is 
showcased in Figure 79. As observed in Panel A, derivative 95 exhibited concentration-dependent 
inhibition of Aβ40 aggregation while showcasing multi-mode anti-aggregation characteristics. Starting with 
1 µM test concentration, 95 managed to induce some level of monomeric structure stabilization (roughly a 
1–2 hour delay in the aggregation process), while reducing both the rate and total aggregate load to roughly 
50%. These patterns were extended to both the 5 and 25 µM test concentrations, but at higher levels 
exemplified by the 4–5 delay in the aggregation process. 
In Panel B, derivative 88 exhibited concentration-dependent inhibition of Aβ42 aggregation, with both   
5 and 25 µM test concentrations halting the aggregation processes completely. At the 1 µM test 
concentration, the only observable impact was focused on slight reductions of the total aggregate load at the 
end of the 24 hour incubation process. 
 
 
 
 
 
 
 	   212 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79: ThT-monitored kinetics of Aβ40/42 aggregation at 37 °C over a 24 h incubation period at pH 7.4 
(Excitation = 440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of N2-isopropyl-N4-
phenethylpyrido[3,2-d]pyrimidine-2,4-diamine (95) on the aggregation kinetics of 5 µM Aβ40. Panel (B): Impact of 1, 
5 or 25 µM of 2-chloro-N-(3,4-dimethoxyphenethyl) pyrido[3,2-d]pyrimidin-4-amine (88) on the aggregation kinetics 
of 5 µM Aβ42. 
 
 
 
7.3.4. Transmission Electron Microscopy (TEM) 
 
The assessment of amyloid morphology at the conclusion of a 24-hour incubation period at 37 °C was 
conducted on leading derivatives. This commonly employed, qualitative technique is used to corroborate 
the quantitative results from the ThT-binding assay. Experimental setup included the incubations of control 
and test samples, at 1:1 ratios of 25 µM, in triplicate at 37 °C (with shaking) over a 24-hour timeline. 
Triplicate samples were combined after the incubation period and applied to the copper-mesh grids prior to 
imaging in the TEM. 
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As observed in Figure 80, resveratrol was effective at reducing total amyloid load (Panels B and E) 
compared to control samples (Panels A and D). That said, derivative 95 (Panel C) was similarly effective 
against Aβ40, while derivative 88 was significantly more potent toward Aβ42, compared to resveratrol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80: TEM assessment of Aβ40/42 morphology with or without test compounds at the end of a 24-hour, 37 °C 
incubation period at pH 7.4. Panel (A–C): 25 µM Aβ40 alone or at a 1:1 ratio with resveratrol or N2-isopropyl-N4-
phenethylpyrido[3,2-d]pyrimidine-2,4-diamine (95); respectively. Panel (D–F): 25 µM Aβ42 alone or at a 1:1 ratio 
with resveratrol or 2-chloro-N-(3,4-dimethoxyphenethyl)pyrido[3,2-d]pyrimidin-4-amine (88); respectively. White/ 
black bars represent 500 nm. 
 
 
7.3.5. Iron Chelation Capacity 
 
The ability of these 2,4-disubstituted pyridopyrimidines to chelate iron (Fe2+) was conducted in 
comparison to their respective quinazoline counterparts, as part of the initial chelation center hypothesis, 
using the competition-based ferrozine assay (Table 15).319 This commonly employed assay is based on the 
observed ferrozine absorbance shift upon iron-binding (562 nm) and the reduction in ferrozine-iron 
complex absorbance with a competitive chelator (such as a pyridopyrimidine-based derivative). 
Experimental setup included the incubations of ferrozine and iron-(II)-sulphate (at 2.5:1 ratio – 100 µM: 40 
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µM) at room temperature followed by the addition of assay controls (clioquinol and deferoxamine) or test 
samples (90–97) at 50 µM, in triplicate. The 96-well plates were covered and incubated, with shaking, for 
15-30 minutes prior to reading at 562 nm. 
 
 
 
Table 15: Iron (Fe2+) chelation capacity for 2,4-disubstituted pyridopyrimidines (90–97) in relation to quinazoline 
counterparts (42–44 and 70–72). 
 
 
 
 
 
 
 
 
 
 
 
Derivative R-Grp 
% Fe2+ 
Chelation a 
% Fe2+ 
Chelation a 
R-Grp 
Qnz- 
Counterpart 
90 n-Pr 24% 3% n-Pr 42 
91 i-Pr 22% 2% i-Pr 43 
92 c-Pr 27% NA c-Pr 44 
93 N(Me)2 23% – – – 
94 n-Pr 29% 4% n-Pr 70 
95 i-Pr 24% 2% i-Pr 71 
96 c-Pr 37% 3% c-Pr 72 
97 N(Me)2 23% – – – 
Clioquinol – 39%    
Deferroxamine – 88%    
 
 
Notes: a Percent inhibition values are an average of triplicate readings based on two independent experiments. NA = 
Not active. 
 
 
 
As observed in Table 15, the pyridopyrimidines managed to inflict an average 26% chelating capacity 
for iron. When compared to their quinazoline counterparts, the pyridopyrimidine-chelating hypothesis was 
supported considering the inability of the quinazoline-based derivatives to chelate iron. That said, the only 
potential chelating quinazolines were those featuring the urea moiety at the C2-position (11, 24, 37 and 65) 
and in fact, those demonstrated an average of 15% chelating capacity (Figure 81). Overall, 96 (N2-
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cyclopropyl-N4-phenethylpyrido[3,2-d]pyrimidine-2,4-diamine) was identified as the most active iron 
chelator, equipotent to clioquinol (37% vs. 39%; respectively). 
 
 
 
 
 
 
 
 
 
Figure 81: Overall summary of the scaffold evaluation toward iron chelation capacity. 
 
 
7.3.6. Molecular Modeling 
 
The utilization of computational software is not only useful in structure-based drug design, it is also 
employed to understand and corroborate the acquired SAR data. The assessment of ligand-receptor 
interactions was conducted between leading (or comparable) derivatives from the 2,4-disubstituted 
pyridopyrimidine series (88–97) and the cholinesterase or amyloid targets of interest.  
 
 
7.3.6.1. Cholinesterase 
 
Based on the acquired anti-ChE data, presented in Table 13, the docking interactions of 93 and 97 
were investigated in hAChE (PBD: 1B41) and superimposed in Figure 82. While both derivatives are 
equipotent, they exhibited opposite binding interactions within AChE. With 93, the pyridopyrimidine 
scaffold was dominantly PAS localized (~ 5–6 Å from W286), allowing for the C4-dimethoxy 
phenethylamine to extend deep toward the active site. This orientation facilitated the para-methoxy group 
to undergo hydrogen-bonding interactions with W86’s indole NH (~ 3.3 Å). In contrast, 97 exhibited 
stronger active site binding interactions with its pyridopyrimidine scaffold stacked semi-parallel over W86 
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(~ 5 Å) and the pyridine ring oriented toward the catalytic triad, facilitating hydrogen-bonding interactions 
between the pyridine nitrogen and S203’s OH (~ 3.4 Å). The C4-phenethylamine ran parallel to the acyl 
pocket and was pointed toward W286 (~ 6–7 Å). With both derivatives, no hydrogen-bonding interactions 
were observed with dimethylamine groups, but it was interesting to observe the orientation of these groups 
with respect to the pyridopyrimidine scaffold – In 93, the dimethylamine group was oriented in a planar 
manner, while 97 was running anti-planar with the pyridopyrimidine scaffold. 
 
 
 
 
 
 
 
 
 
 
Figure 82: Superimposition of docking structures of 93 (gold) and 97 (turquoise) in the active site of hAChE (PDB ID: 
1B41). Hydrogens removed to enhance visibility. Black-dashed lines indicate hydrogen-bonding interactions.  
 
 
 
7.3.6.2. Amyloid-β 
 
Based on the acquired anti-Aβ data, presented in Table 14, the docking interactions of 95 and 96 were 
investigated in both a dimeric and fibril model of Aβ (Aβ9-40 – PDB 2LMN) with superimpositions 
showcased in Figure 83.  
Considering the approximate 7-fold gap in potency toward Aβ40, the unique binding interactions of 
95 (C2 = i-Pr) and 96 (C2 = c-Pr) explain the potency gap. In a general sense, ligand 95 exhibited close 
interactions at three regions of the dimeric structure, compared to just two regions with ligand 96. The 
pyridopyrimidine scaffold of 95 was equidistantly placed between the V24 and I32 (~ 5–6 Å), allowing the 
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C4-phenethlyamine group to interact within the hairpin loop domain, where the phenyl ring was roughly 4 
Å from S26–N27 and the C4–NH was ~ 3.4 Å from E22’s carboxyl group (hydrogen-bonding interaction). 
The ligand’s isopropyl group was directed toward the aliphatic regions L34 (~ 4–5 Å), allowing for 
hydrogen-bonding interactions between the C2-NH and the backbone carbonyl of I32 (~ 3.5 Å). In contrast, 
the pyridopyrimidine scaffold of 96 was perpendicularly stacked against I31 (~ 4–5 Å), while the C2-
cyclopropylamine group was suspended over I32, allowing for hydrogen-bonding interactions between the 
C2-NH and the backbone carbonyl of I32 (~ 2.9 Å). The ligand’s C4-phenethylamine was running parallel 
along A30-I31 with the phenyl ring oriented toward the backbones of N27-K28 (~ 3–4 Å). 
 
 
 
 
 
Figure 83: Superimposition of docking structures. Binding modes of 95 (red) and 96 (green) in the Aβ (Aβ9-40 – PDB 
2LMN) dimer model. Hydrogens removed to enhance visibility. Amino acid labels to be used as a general guide as 
space restrictions limited complete and accurate labeling of all peptide structures. 
 
 
7.4. Summary 
 
With this collection of 2,4-disubstituted pyrido[3,2-d]pyrimidines, AChE targeting potential was not 
impacted while BuChE inhibition was basically non-existent, as initially anticipated. When compared to 
their non-chlorinated quinazoline counterparts, the pyridopyrimidines demonstrated improvements in Aβ42 
targeting, while inhibitory activity toward Aβ40 revealed more of a mixed outcome. In addition, the 
pyridopyrimidine scaffold itself enabled the derivatives within this series to impose anywhere from 22–
37% iron chelating capacity.  
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Overall, a series leader was identified in N2-cyclopropyl-N4-phenethylpyrido[3,2-d]pyrimidine-2,4-
diamine (96) due to its greater chelating capacity (~ 37% at 50 µM) and multi-targeting capacity toward 
AChE and Aβ40 at the equipotent concentration of ~ 7 µM (Figure 84). That said, 96 was capable of 
targeting Aβ42 (IC50 ~ 12 µM), but not BuChE. 
 
 
 
Figure 84: Cumulative chapter summary of 2,4-disubstituted pyridopyrimidines (88–97). 
 
 
7.5. Experimental 
 
Please note that this subsection includes re-listed methodologies from Chapter 3–5 and one new 
method (iron chelation) with a schematic representation. For schematic representation of re-listed 
methodologies, if applicable, please refer to Chapter 3 and 4 – Section 3.5 or 4.5. 
 
7.5.1. Chemistry 
 
General Information. All the reagents and solvents were reagent grade purchased from various vendors 
(Acros Organics, Sigma-Aldrich, and Alfa Aesar, USA) with a minimum purity of 95% and were used 
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without further purification. Melting points (mp) were determined using a Fisher-Johns apparatus and are 
uncorrected. Reaction progress was monitored by UV using thin-layer chromatography (TLC) using Merck 
60F254 silica gel plates. Column chromatography was performed with Merck silica gel 60 (230−400 mesh) 
with 5:1 EtOAc:MeOH as the solvent system unless otherwise specified. Proton (1H NMR) and carbon (13C 
NMR) spectra were performed on a Bruker Avance (at 300 and 75 MHz; respectively) spectrometer using 
DMSO-d6. Coupling constants (J values) were recorded in hertz (Hz) and the following abbreviations were 
used to represent multiplets of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. 
Carbon multiplicities (C, CH, CH2 and CH3) were assigned by DEPT 90/135 experiments. High-resolution 
mass spectrometry (HRMS) was determined using a Thermo Scientific Q-Exactive Orbitrap mass 
spectrometer (positive mode, ESI), Department of Chemistry, University of Waterloo. Compound purity 
(roughly 95% or over) was determined using an Agilent 1100 series HPLC equipped with an analytical 
column (Agilent Zorbax Eclipse XDB-C8 column, 4.6 x 150 mm, 5 µm particle size) running 50:50 
Water:ACN with 0.1% TFA at a flow rate of 1.0-1.5 mL/min or an Agilent 6100 series single quad LCMS 
equipped with an Agilent 1.8 µm Zorbax Eclipse Plus C18 (2.1 x 50 mm) running 50:50 Water:ACN with 
0.1% FA with a flow rate of 0.5mL/min. All the final compounds exhibited ≥ 95% purity. 
 
General procedure for the synthesis of 2,4-dichloro[3,2-d]pyriopyrimidine.289, 323 In a 250 mL 
RBF, 5 g of pyrido[3,2d]pyrimidin-2,4-diol (30.67 mmol) was suspended in 25 mL of anhydrous toluene 
and allowed to stir on an ice bath. To this, 5 eq. of POCl3 (153.37 mmol) was added in small aliquots 
followed by the slow addition of 5 eq. of DEA (153.37 mmol). The solution was kept on the ice bath for 10 
min before moving to room temperature and allowed to stir for 1 h prior to refluxing at 105–110 °C for 14–
16 h. Upon cooling to room temperature, the reaction mixture was added in small aliquots to a double-ice-
water bath while stirring. The quenching solution was left stirring at room temperature for 5 h before 
vacuum filtering the yellowish-grey precipitate. The precipitate was stirred for 1 h in a saturated NaHCO3 
solution and then was re-filtered. This neutralization process was carried out 2–3 times until the 
bicarbonate solution maintains a neutral to slight basic pH. The final precipitate was dissolved in DCM and 
purified by a silica gel column chromatography using 100% DCM as the eluent to afford white to light grey 
solid. 
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2,4-Dichloropyrido[3,2-d]pyrimidine. Yield: 65% (3.97 g, 19.94 mmol); Mp 197–199 °C. 1H NMR (300 
MHz, DMSO-d6) δ 9.17 (d, J = 4.1 Hz, 1H), δ 8.44 (d, J = 8.4 Hz, 1H), δ 8.10 (dd, J = 8.6, 4.1 Hz, 1H). 
LRMS (ESI) m/z calcd for C7H4Cl2N3 [M + H]+ 199.97, found 199.96. 
 
 
General procedure for the synthesis of 2-chloro-N-substituted-pyrido[3,2-d]pyrimidin-4-
amines.303, 305 To a 30 mL solution of ethanol in a 100 mL round-bottom flask on ice, 5 g of 2,4-
dichloropyrido[3,2-d]pyrimidine (25.13 mmol) was added followed by slow addition of 1.3 eq. (32.66 
mmol) of the corresponding primary amine. Contents were stirred on an ice bath while 2.0 eq. of 
diisopropylethylamine (DIPEA, 50.25 mmol) was added in drop wise fashion. The solution was then heated 
at 80–85 °C under reflux for 3–4 h. The reaction contents were cooled to room temperature and precipitated 
residues were vacuum-filtered with ethyl acetate (EtOAc) rinses. The organic supernatant was concentrated 
in vacuo followed by two rounds of liquid-liquid extraction using EtOAc and saturated brine solution (40–
50 mL each respectively). The combined organic layers were dried over MgSO4, evaporated in vacuo and 
purified (1–2 times) using silica gel column chromatography with 5:1 EtOAc:MeOH as the elution solvent. 
Final compounds were white to beige solids with yields ranging from 82–84%.  
 
 
2-Chloro-N-(3,4-dimethoxyphenethyl)pyrido[3,2-d]pyrimidin-4-amine (88). Yield: 84% (1.45 g, 4.22 
mmol); Mp 156–158 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.96 (br s, 1H), δ 8.73 (s, 1H), δ 7.99 (d, J = 
8.6 Hz, 1H), δ 7.78 (dd, J = 8.6, 4.3 Hz, 1H), δ 6.83–6.71 (m, 3H), δ 3.74–3.67 (m, 8H), δ 2.84 (t, J = 7.4 
Hz, 2H). LRMS (ESI) m/z calcd for C17H18ClN4O2 [M + H]+ 345.10, found 345.11. 
 
2-Chloro-N-phenethylpyrido[3,2-d]pyrimidin-4-amine (89). Yield: 82% (1.17 g, 4.12 mmol). 1H NMR 
(300 MHz, DMSO-d6) δ 9.02 (br s, 1H), δ 8.74 (s, 1H),, δ 7.99 (d, J = 8.8 Hz, 1H), δ 7.78 (dd, J = 8.5, 4.2 
Hz, 1H), δ 7.28–7.13 (m, 5H), δ 3.68 (q, J = 6.1 Hz, 2H), δ 2.91 (t, J = 7.2 Hz, 2H). LRMS (ESI) m/z calcd 
for C15H14ClN4 [M + H]+ 285.08, found 285.09. 
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General procedure for the synthesis of N4-substituted-N2-alkyl-pyrido[3,2-d]pyrimidin-2,4-
diamines.299, 313 In a 50 mL pressure vial (PV), 0.25 g of 2-chloro-N-(3,4-dimethoxyphenethyl)pyrido[3,2-
d]pyrimidin-4-amine or 2-chloro-N-phenethylpyrido[3,2-d]pyrimidin-4-amine (~ 0.73–0.88 mmol) was 
combined with 2 eq. (~ 1.46–1.76 mmol) of primary amine (n-propyl-, isopropyl- or cyclopropylamine) or 
dimethylamine then dissolved in 5 mL of 1,4-dioxane followed by the addition of 3 eq. of DIPEA (~ 2.19–
2.64 mmol). Pressure vial was sealed and stirred in an oil bath at 150–155 °C for 2 h. Upon completion and 
cooling to room temperature, the reaction mixture was diluted with ~ 40 mL of EtOAc and washed with 
brine solution (25 mL x 2). The combined aqueous layer was washed with ~ 25 mL of EtOAc. The 
combined EtOAc layers were dried over MgSO4 before removing EtOAc in vacuo to yield a solid product 
that was purified by silica gel column chromatography using 5:1 EtOAc:MeOH as the eluent to afford pale 
yellow to brown solids yielding at 71–78%. 
 
 
N4-(3,4-Dimethoxyphenethyl)-N2-propylpyrido[3,2-d]pyrimidine-2,4-diamine (90). Yield: 76% (0.40 g, 
1.10 mmol); mp 121–123 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.22 (dd, J = 4.8, 1.2 Hz, 1H), δ 7.85 (br s, 
1H), δ 7.53 (br s, 1H), δ 7.43 (dd, J = 8.4, 4.1 Hz, 1H), δ δ 6.84–6.72 (m, 4H), δ 3.67–3.61 (m, 8H), δ 
3.30–3.24 (m, 2H), δ 2.82 (t, J = 7.3 Hz, 2H), δ 1.46 (sextet, J = 7.2 Hz, 2H), δ 0.84 (t, J = 7.4 Hz, 3H). 
HRMS (ESI) m/z calcd for C20H26N5O2 [M + H]+ 368.2008, found 368.2081. Purity: 99.6% 
 
N4-(3,4-Dimethoxyphenethyl)-N2-isopropylpyrido[3,2-d]pyrimidine-2,4-diamine (91). Yield: 73% 
(0.39 g, 1.06 mmol); mp 127–129 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.22 (dd, J = 4.8, 1.2 Hz, 1H), δ 
7.86 (brs, 1H), δ 7.53 (br s, 1H), δ 7.44 (dd, J = 8.4, 4.1 Hz, 1H), δ 6.84–6.72 (m, 3H), δ 6.57 (br s, 1H), 
4.16–4.09 (m, 1H), δ 3.67–3.61 (m, 8H), δ 2.82 (t, J = 7.3 Hz, 2H), δ 1.12 (d, J = 6.5 Hz, 6H). HRMS 
(ESI) m/z calcd for C20H26N5O2 [M + H]+ 368.2008, found 368.2081. Purity: 98.4%  
 
N2-Cyclopropyl-N4-(3,4-dimethoxyphenethyl)pyrido[3,2-d]pyrimidine-2,4-diamine (92). Yield: 71% 
(0.38 g, 1.03 mmol); mp 117–119 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.25 (dd, J = 4.8, 1.2 Hz, 1H), δ 
7.94 (br s, 1H), δ 7.59 (br s, 1H), δ 7.45 (dd, J = 8.4, 4.1 Hz, 1H), δ 6.94 (br s, 1H), δ 6.84–6.72 (m, 3H), δ 
3.68–3.65 (m, 8H), δ 2.88–2.80 (m, 3H), δ 0.63–0.59 (m, 2H), δ 0.48–0.46 (m, 2H). HRMS (ESI) m/z 
calcd for C20H24N5O2 [M + H]+ 366.1852, found 366.1927. Purity: 99.4% 
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N4-(3,4-Dimethoxyphenethyl)-N2,N2-dimethylpyrido[3,2-d]pyrimidine-2,4-diamine (93). Yield: 77% 
(0.40 g, 1.12 mmol). 1H NMR (300 MHz, DMSO-d6) δ 8.24 (dd, J = 4.2, 1.5 Hz, 1H), δ 8.03 (br s, 1H), δ 
7.57 (dd, J = 8.5, 1.5 Hz, 1H), δ 7.44 (dd, J = 8.5, 4.2 Hz, 1H), δ 6.83–6.70 (m, 3H), δ 3.67–3.62 (m, 8H), δ 
3.14 (s, 6H), δ 2.82 (t, J = 7.2 Hz, 2H). HRMS (ESI) m/z calcd for C19H24N5O2 [M + H]+ 354.1852, found 
354.1924. Purity: 97.3% 
 
N4-Phenethyl-N2-propylpyrido[3,2-d]pyrimidine-2,4-diamine (94). Yield: 76% (0.41 g, 1.34 mmol); Mp 
132–134 °C. 1H NMR (300 MHz, DMSO-d6) δ 8.22 (dd, J = 4.1, 1.6 Hz, 1H), δ 7.95 (br s, 1H), δ 7.54 (br 
s, 1H), δ 7.44 (dd, J = 8.4, 4.1 Hz, 1H), δ 7.29–7.14 (m, 5H), δ 6.78 (br s, 1H), δ 3.62 (q, J = 7.5 Hz, 2H), δ 
3.23–3.20 (m, 2H), δ 2.89 (t, J = 7.3 Hz, 2H), δ 1.48 (sextet, J = 7.2 Hz, 2H), δ 0.84 (t, J = 7.4 Hz, 3H). 13C 
NMR (75 MHz, DMSO-d6) δ 159.32, δ 146.53, δ 142.32, δ 141.98, δ 139.52, δ 131.99, δ 131.41, δ 128.60, 
δ 128.30, δ 127.53, δ 126.4, δ 42.67, δ 41.39, δ 34.63, δ 22.34, δ 11.53. HRMS (ESI) m/z calcd for 
C18H22N5 [M + H]+ 308.1797, found 308.1869. Purity: 99.4% 
 
N2-Isopropyl-N4-phenethylpyrido[3,2-d]pyrimidine-2,4-diamine (95). Yield: 76% (0.41 g, 1.34 mmol). 
1H NMR (300 MHz, DMSO-d6) δ 8.23 (dd, J = 4.1, 1.6 Hz, 1H), δ 7.99 (br s, 1H), δ 7.55 (br s, 1H), δ 7.44 
(dd, J = 8.4, 4.1 Hz, 1H), δ 7.30–7.14 (m, 5H), δ 6.60 (br s, 1H), δ 4.19–4.08 (m, 1H), δ 3.63 (q, J = 7.5 
Hz, 2H), δ 2.89 (t, J = 7.3 Hz, 2H), δ 1.13 (d, J = 6.5 Hz, 6H). HRMS (ESI) m/z calcd for C18H22N5 [M + 
H]+ 308.1797, found 308.1869. Purity: 99.7% 
 
N2-Cyclopropyl-N4-phenethylpyrido[3,2-d]pyrimidine-2,4-diamine (96). Yield: 72% (0.39 g, 1.27 
mmol). 1H NMR (300 MHz, DMSO-d6) δ 8.26 (dd, J = 4.1, 1.6 Hz, 1H), δ 8.02 (br s, 1H), δ 7.55 (br s, 
1H), δ 7.46 (dd, J = 8.4, 4.1 Hz, 1H), δ 7.27–7.16 (m, 5H), δ 6.93 (br s, 1H), δ 3.63 (q, J = 7.5 Hz, 2H), δ 
2.89 (t, J = 7.3 Hz, 2H), δ 2.81–2.77 (m, 1H), δ 0.63–0.59 (m, 2H), δ 0.49–0.46 (m, 2H). HRMS (ESI) m/z 
calcd for C18H20N5 [M + H]+ 306.1640, found 306.1711. Purity: 99.8% 
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N2,N2-Dimethyl-N4-phenethylpyrido[3,2-d]pyrimidine-2,4-diamine (97). Yield: 78% (0.40 g, 1.37 
mmol). 1H NMR (300 MHz, DMSO-d6) δ 8.25 (dd, J = 4.2, 1.5 Hz, 1H), δ 8.09 (br s, 1H), δ 7.57 (dd, J = 
8.5, 1.5 Hz, 1H), δ 7.44 (dd, J = 8.5, 4.2 Hz, 1H), δ 7.26–7.16 (m, 5H), δ 3.63 (q, J = 5.6 Hz, 2H), δ 3.14 
(s, 6H), δ 2.90 (t, J = 7.2 Hz, 2H). HRMS (ESI) m/z calcd for C17H20N5 [M + H]+ 294.1640, found 
294.1712. Purity: 99.8% 
 
 
7.5.2. Biological Screening 
 
7.5.2.1. Human Cholinesterase (hChE) Assay299, 313 
 
The inhibition profile of quinazoline derivatives was evaluated using the Ellman (DTNB) reagent.315 
Human AChE and BuChE enzymes were obtained from Sigma-Aldrich, St. Louis, MO, USA (AChE 
product number C0663 and BuChE product number B4186 respectively). The cholinesterase inhibitors 
tacrine (item number 70240, Cayman Chemical Company, Ann Arbor, MI), donepezil (product number 
D6821, Sigma-Aldrich, St. Louis, MO), galantamine (product number G1660, Sigma-Aldrich, St. Louis, 
MO) and rivastigmine (product number SML0881, Sigma-Aldrich, St. Louis, MO) were used as reference 
agents. Quinazoline derivative stock solutions were prepared in DMSO (maximum 1% v/v in final wells) 
and diluted in buffer solution (50 mM Tris.HCl, pH 8.0, 0.1 M NaCl, 0.02 M MgCl2.6H2O). Then 160 µL 
of 5,5’-dithiobis(2-nitrobenzoic acid) (1.5 mm DTNB), 50 µL of hAChE (0.22 U/mL in 50 mM Tris.HCl, 
pH 8.0, 0.1% w/v bovine serum albumin, BSA) or 50 µL of hBuChE (0.12 U/mL in 50 mM Tris.HCl, pH 
8.0, 0.1% w/v BSA) were added to 96-well plates after which 10 µL each of quinazoline derivatives (final 
concentration range 0.1–50 µM) were added and incubated for 5 min. Then 30 µL of either 
acetylthiocholine iodide (15 mM AThCl prepared in ultra pure water) or S-butyrylthiocholine iodide (15 
mM BThCI prepared in ultra pure water) were added. The absorbance was measured at different time 
intervals (0, 60, 120, 180, 240 and 300 s) using a wavelength of 412 nm. The inhibitory concentration (IC50 
values) was calculated from the concentration–inhibition dose response curve on a logarithmic scale. The 
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results were expressed as average values based on two to three independent experiments run in triplicate 
measurements. 
 
 
7.5.2.2. Amyloid-β (Aβ) Aggregation Assay317 
 
The ability of quinazoline-based derivatives to inhibit Aβ-aggregation kinetics was determined using a 
ThT-binding fluorescence assay. These assays were conducted in Costar, black-surround, clear-bottom 
384-well plates with frequent shaking (30 sec. of linear shaking at 730 cpm every 5 minutes) and constant 
heating at 37 °C for 24 h. The ThT excitation/emission was measured at 440 nm/490 nm and readings were 
taken every 5 minutes using a BioTek Synergy H1 microplate reader. Quinazoline stock solutions were 
prepared in DMSO and diluted to 10x in 215 mM phosphate buffer at pH 7.4. Abeta.HFIP samples (Aβ40 
or Aβ42, rPeptide, Bogart, USA) were dissolved in 1% ammonium hydroxide, sonicated at room 
temperature for 5 minutes then diluted to 50 µM in 215 mM phosphate buffer (pH 7.4). A 15 µM ThT stock 
solution was prepared with 50 mM glycine and adjusted to pH 7.4. The assay was carried out by adding 44 
µL ThT, 20–35 µL buffer, 1 µL DMSO (for background and controls only) followed by the addition of 8 
µL of 10x compound dilutions (1–25 µM concentration range). An end point reading was conducted to 
evaluate potential test compound interference with ThT-fluorescence before adding 8 µL of Aβ40 or Aβ42 
stock solutions (5 µM final concentration). Plates were sealed with a transparent plate film before initiating 
the assay. RFU values were corrected for ThT-interference before calculating end point percent inhibitions 
or IC50 values and obtaining the aggregation kinetic plots. Data presented was an average of triplicate 
reading for two-three independent experiments. 
 
7.5.2.3. TEM Assay and Imaging142, 190, 207, 317 
 
In Costar 96-well, round-bottom plates were added 80 µL of 215 mM phosphate buffer, 20 µL of 10x 
test compound dilutions (250 µM – prepared in the same way as for the ThT assay) and 100 µL of 50 µM 
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Aβ40 or Aβ42 respectively.  For the control wells, 2 µL of DMSO and 18 µL of phosphate buffer was 
added. Final Aβ: test compound ratio was 1:1 (25 µM). Plates were incubated on a Fisher plate incubator 
set to 37 °C and the contents were shaken at 730 cpm for 24 h. To prepare the TEM grids, ~ 20 µL droplet 
was added using a disposable Pasteur pipette over the formvar-coated copper grids (400 mesh). Grids were 
air-dried for about 3 h before adding two droplets (~ 40 µL, using a disposable Pasteur pipette) of ultra-
pure water and using small pieces of filter paper to wash out precipitated buffer salts. After air-drying for ~ 
15-20 min, the grids were negatively stained by adding a droplet (~ 20 µL, using a disposable Pasteur 
pipette) of 2% phosphotungstic acid (PTA) and immediately after the grids were dried using small pieces of 
filter paper. Grids were further air-dried overnight. The scanning was carried out using a Philips CM 10 
transmission electron microscope at 60 kV (Department of Biology, University of Waterloo) and 
micrographs were obtained using a 14-megapixel AMT camera. 
 
 
7.5.2.4. Iron Chelation Assay319 
 
The ability of select pyridopyrimidines to chelate iron was utilized as a measure of overall chelation 
capacity and the effectiveness of the scaffold as a chelating center. This was determined using the ferrozine 
(Sigma-Aldrich, USA) based competitive colorimetic assay. Test compounds were initially dissolved in 
anhydrous methanol to 10 mM and diluted down to 105 µM using 100 mM tris buffer (pH 7.4). Then 95 µL 
of test compound solutions (50 µM final concentration) were added to clear 96-well plates, followed by a 
10 µL aliquot of iron-(II)-sulphate (FeSO4 •7H2O) stock solution (from 800 µM stock solution prepared in 
methanol). After a 5-minute incubation period at room temperature, 95 µL ferrozine solution (from 210 µM 
stock solution prepared in tris buffer) was added. After incubating at room temperature for 30 minutes the 
absorbance was measured at 562 nm and subtracted from compound blanks (95 µL of compound solutions 
+ 105 µL of tris buffer) and compared to the ferrozine-only positive control (95 µL of tris buffer + 10 µL of 
iron sulphate + 95 µL of ferrozine). The results obtained were compared with known iron chelators 
clioquinol (50 µM) and desferoxamine (50 µM). The results were reported as average % iron-chelation ± 
SD in triplicate measurements based on two independent experiments. 
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Figure 85: Principles of the ferrozine-based iron chelation assay. 
 
 
7.5.3. Computational Chemistry299, 313, 317, 324 
 
The molecular docking studies were conducted using Discovery Studio 4.0 (Structure-Based-Design 
program) from BIOVIA Inc. San Diego, USA. Select quinazolines derivatives were built and minimized 
using the small molecules module in Discovery Studio. X-ray coordinates of human cholinesterases were 
obtained from the protein data bank (hAChE PBD ID: 1B41 and hBuChE PDB ID: 1P0I) and prepared 
using the macromolecules module in Discovery Studio. Ligand binding sites were defined by selecting a 12 
Å radius sphere for AChE and 15 Å radius sphere for BuChE. The molecular docking was performed using 
the receptor-ligand interactions module in Discovery Studio. The LibDock algorithm was used to find the 
most appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. For Amyloid-β docking studies, the NMR solution structure of Aβ fibrils were 
obtained from the protein data bank (PDB ID: 2LMN). Aβ dimer and Aβ fibril assemblies were built using 
the macromolecules module in Discovery Studio. Ligand binding site was defined by selecting a 15 Å 
radius sphere for both Aβ assemblies. Molecular docking was performed using the receptor-ligand 
interactions module in Discovery Studio, where the LibDock algorithm was used to find the most 
appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interaction. 
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CHAPTER 8 
  Development and Evaluation of Isomeric Monosubstituted 2,4-
diaminoquinazolines as Aβ Aggregation Inhibitors   
 
 
 
* Chapter banner   
  
 
8.1. Introduction 
 
The notion of regioisomeric comparison was examined in Chapters 4, 5 and 6. The SAR data from 
these 4 isomer pairs (22 vs. 22-iso, 33 vs. 33-iso, 61 vs. 61-iso and 63 vs. 63-iso) showcased interesting 
activities and selectivities with respect to both ChE and Aβ targeting. 
With the enhanced value of the quinazolin-2,4-diamine scaffold in dual Aβ targeting , this Chapter 
sets to further expand on the acquired SAR data, of the C2-amino and C4-amino series, by developing and 
assessing 15 isomer pairs based on the quinazoline scaffold. While initial derivatives were based on 
unsubstituted benzyl or phenethyl moieties, the library within this Chapter explores three aliphatic moieties 
(n-propyl, i-proply, and cyclohexyl) and a collection of substituted benzyl groups (EDGs and EWGs) – see 
Chapter banner above. 
Generally, all synthetic approaches and mechanisms here have been previously discussed in Chapters 
3–6. A brief summary is provided prior to the listing of experimental data and methodology. 
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8.2. Hypothesis 
 
With respect to these series, the focus is on modulating Aβ aggregation by evaluating the selectivity 
factor regarding the placement of the amino (–NH2) group. With the benzyl moiety in Chapter 4, the amino 
placement at the C4-position (22-iso) benefited both Aβ40/42 targeting, while the phenethyl moiety in 
Chapter 6 only benefited Aβ40 targeting with a C2-amino placement (63) and benefited Aβ42 targeting 
with a C4-amino placement (63-iso). 
While no clear hypothesis can be outlined, the safe prediction is that the smaller derivatives (i.e 
featuring either the isopropyl or propyl chains) are likely to provide no inhibitory capacity toward Aβ40/42. 
In addition, past chapters showcased that chlorine could serve as an anti-fibrillation moiety, so it was 
proposed to observe the effect of the halogen-based benzyl groups here.  
 
8.3. Results and Discussions 
 
The proceeding sub-chapter briefly highlights previously-established routes to target derivatives. 
Biological assessments in the amyloid-β aggregation assay (to obtain IC50 values and/or investigation 
aggregation kinetics) were conducted. Aggregate load is corroborated via TEM in amyloid morphology 
screening. Computational studies are performed in the ChE X-ray structures and amyloid models to 
evaluate the acquisitioned SAR data.  
 
 
8.3.1. Synthesis 
 
As initially described in Chapter 4, the synthetic schemes pertaining to this chapter revolve around the 
DAQ starting material. The generation of DAQ was accomplished by condensing 2-fluorobenzonitrile with 
guanidine carbonate and the selective alkylation of DAQ at the C4-position, generating the C2-amino series, 
was accomplished by utilizing sodium hydride, at equal equivalence with DAQ, to selectively deprotonate 
the C4-amino group before nucleophilic attack on the aryl bromide. For selective alkylation at the C2-
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position on the other hand, an inorganic quenching base was used and the more nucleophilic C2-amino 
group acted upon the aryl bromide, without deprotonation, to displace the halogen (Scheme 23).291, 317 
 
Scheme 23a 
 
 
 
 
 
 
 
aReagents and conditions: Synthetic routes toward isomeric quinazoline-2,4-diamine derivatives 98–112. (a) 
Guanidine carbonate, DMA, 150–155 °C, 14–16 h; (b) Sodium hydride, DMSO, benzyl bromide, 0 °C–r.t., 14 h; (c) 
DMA, potassium or cesium carbonate, benzyl bromide 80–85 °C, 5 h. 
 
 
8.3.2. Amyloid-β Aggregation 
 
The ability of the 2,4-diaminoquinazolines (98–112 and their respective regioisomers) to modulate the 
aggregation kinetics of amyloid-β was assessed using the ThT-binding method described earlier in Chapter 
3 (Table 16).  
Quite interestingly, the data revealed that C2-amino quinazolines were more active toward Aβ40 
compared to their C4-amino regioisomers, while toward Aβ42, the observation shifted in favour of the C4-
amino quinazolines – regardless of the nature of the alkyl or aryl group attached. The sole deviant from 
these observations is the 22/22-iso pair, considering that 22-iso was more potent toward both Aβ40/42 
compared to 22. Overall, all derivatives were capable of targeting one or both Aβ species, with four 
surpassing curcumin’s inhibitory potential toward Aβ42 and nine equaling or surpassing resveratrol’s 
inhibitory potential toward Aβ40. 
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Table 16: Amyloid-β (Aβ40/42) inhibition data for 2,4-diaminoquinazolines (98–112) and their regioisomers. 
 
 
 
C2-amino 
Derivative 
Amyloid-β IC50 (µM) a R-Group 
Amyloid-β IC50 (µM) a C4-amino 
Derivative Aβ40 Aβ42 Aβ40 Aβ42 
98 15.0 ± 1.3 NA n-Pr 26% 10% 98-iso 
99 10.2 ± 1.0 NA i-Pr NA 15% 99-iso 
100 13.6 ± 1.3 37% Cyclohexylmethyl 18% 46% 100-iso 
101 3.7 ± 0.4 10% 3-Me 39% 48% 101-iso 
102 4.0 ± 0.4 41% 4-Me 13.1 ± 1.2 22.5 ± 2.3 102-iso 
103 20.6 ± 2.1 NA 3-OMe 20% 39% 103-iso 
104 1.1 ± 0.1 32% 4-OMe 6.8 ± 0.5 47% 104-iso 
105 3.6 ± 0.4 21.0 ± 1.8 3-CF3 12.5 ± 1.3 13.9 ± 1.5 105-iso 
106 2.0 ± 0.1 37% 4-CF3 2.3 ± 0.3 5.3 ± 0.4 106-iso 
107 1.9 ± 0.1 32% 3-Cl 5.9 ± 0.3 13.4 ± 1.2 107-iso 
108 0.6 ± 0.1 43% 4-Cl 0.9 ± 0.1 8.1 ± 0.9 108-iso 
109 0.6 ± 0.1 22.3 ± 2.2 3-Br 1.5 ± 0.2 2.8 ± 0.3 109-iso 
110 0.08 ± 0.01 14.8 ± 1.5 4-Br 1.7 ± 0.2 1.7 ± 0.2 110-iso 
111 2.9 ± 0.3 23% 3-F 11.3 ± 0.9 14.8 ± 1.5 111-iso 
112 3.1 ± 0.3 38% 4-F 37% 46% 112-iso 
  ê ê              – Previously reported –                                                           ê ê  
22 4.8 ± 1.1 NA Chapter 4 2.2 ± 0.5 8.4 ± 1.1 22-iso 
63 8.2 ± 2.0 37% Chapter 6 14.9 ± 1.9 50% 63-iso 
Curcumin 3.3 ± 0.45 9.9 ± 0.4 – 1.1 ± 0.1 15.3 ± 1.9 Resveratrol 
 
Notes: a IC50 values are an average ± SD of triplicate readings based on two to three independent experiments. NA = 
Not active. Percent inhibition (P.I) indicates level of inhibition at highest concentration tested (25 µM). 
 
 
Starting with the aliphatic additions to the DAQ scaffold, increasing the sterics and size (from n-Pr to 
i-Pr to cyclohexylmethyl) benefited Aβ42, regardless of placement, although C4-amino derivatives (98-iso 
– 100-iso) were more active.  Toward Aβ40, C2-amino derivatives (98–100) were roughly equipotent at an 
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IC50 of 13 µM, while their regioisomers were considerably weaker – maxing 26% inhibition at 25 µM for 
the n-Pr group. Compared to their aromatic counterparts (22/22-iso), 100/100-iso were generally less active 
toward Aβ40/42, with the exception of 100 demonstrating Aβ42 activity, when 22 did not. 
Transitioning to the substituted benzyl-based derivatives, the presence of either a para- or a meta-
methyl group on a C4-placed benzyl group (101–102, IC50 ~ 4 µM) did not impact Aβ40 inhibition, 
compared to the unsubstituted-benzyl derivative (22, IC50 ~ 5 µM). The addition; however, did impact 
Aβ42 inhibition, taking it from no activity with 22 to 10% with 101 and then to 41% with 102. When 
methyl addition was done on a C2-placed benzyl group, both Aβ40/42 activities dropped compared to 22-
iso, although the impact was greater seen with meta-methyl (101). Enhancing the EDG properties of the 
benzyl group with a methoxy group reduced the inhibitory profiles when placed at the meta-position, 
regardless of isomeric identity (i.e.: 103 < 101 and 22 in addition to 103-iso < 101-iso and 22-iso). 
However, para-placement of the methoxy group (104 and 104-iso) improved Aβ40 activity by 4-fold and 
2-fold; respectively, compared to para-methyl-based derivatives (102 and 102-iso). That observation did 
not extend to Aβ42 activity as 104 ranked between 22 (NA) and 102 (41%), while 104-iso (47%) was 
weaker than both 22-iso (IC50 ~ 8 µM) and 102-iso (IC50 ~ 23 µM). The change from methyl (101/101-iso 
and 102/102-iso) to trifluoromethyl (105/105-iso and 106/106-iso) was unanimously positive, or at least 
elicited similar inhibitory outcomes. Of notable mention, 106-iso was the first derivative to showcase dual 
potency toward Aβ40/42 with IC50’s of ~ 2 and 5 µM; respectively. These positive turnouts transitioned to 
the comparison with 22 and 22-iso, although that excluded 105-iso (meta-CF3) as it was less active 
compared to 22-iso.  
The introduction of meta- or para-positioned halides (bromo, chloro or fluoro) to the C4-placed 
benzyl moiety, as in 107–112, resulted in unanimous Aβ40/42 inhibitory improvements when compared to 
22. The regioisomers 107-iso – 112-iso, on the other hand, showcased mixed outcomes on both Aβ40/42 
fronts when compared to 22-iso. Focusing in on the C4-placed benzyl halides (107–112), with respect to 
both Aβ40/42, halide ranking was as follows: Br (para > meta) > Cl (para > meta) > F (para ~ meta). Of 
noteworthy mention, derivative 110 (para-Br) was the most potent Aβ40 inhibitor in not only this Chapter 
but amongst all derivatives tested. At 80 nM, it was 14-fold more potent compared to resveratrol and 60-
fold more potent compared to its unsubstituted counterpart (22). In addition, it was the most active Aβ40 
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inhibitor (IC50 ~ 15 µM) in the C2-amino series of derivatives (98-112) – Which in itself, points to the 
strong selectivity of these isomer for Aβ40 >> Aβ42. In second place, derivatives 108 (para-Cl) and 109 
(meta-Br) share an IC50 of 0.6 µM toward Aβ40, although both were almost as effective toward Aβ42 as 
well (IC50 ~ 22-29 µM). Shifting toward the C2-placed benzyl halides (107-iso – 112-iso), with respect to 
both Aβ40/42, halide ranking was almost similar: Br (para ~ meta) > Cl (para > meta) > F (para < meta). 
Of noteworthy mention, derivative 110-iso (para-Br) was the most potent and dual Aβ inhibitor (IC50 ~ 2 
µM), while 108-iso (para-Cl) was the most potent Aβ40 inhibitor (IC50 ~ 1 µM) in the C4-amino series. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 86: Amyloid-β metrics for thirty 2,4-diaminoquinazolines (98-112) including their regioisomers. 
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In summary, the expansion into the regioisomeric investigation with respect to Aβ inhibition was 
quite interesting. The initial data obtained from Chapter 4 (22/22-iso) and Chapter 6 (63/63-iso) led to the 
utilization of substituted benzyl (and not phenethyl) groups and the unanimous observation of preferred 
targeting (C2-amino derivatives preferably targeted Aβ40, while C4-amino derivatives preferably targeted 
Aβ42) was unexpected but intriguing. Overall, aliphatic groups were not favourable in terms of Aβ 
inhibition and in a very broad sense (with some expectations), para-substituted benzyl groups were more 
active compared to meta-substituted benzyl groups. Best results, on both Aβ40/42 fronts, were observed 
with 3- and 4-bromobenzyl groups (Figure 86). 
The aggregation kinetic assessment of Aβ40 with or without series-leading derivatives is showcased 
in Figure 87. As observed in Panel A–D, derivatives 109/109-iso and 110/110-iso exhibited concentration-
dependent inhibition of Aβ40 aggregation while showcasing multi-mode anti-aggregation characteristics. 
Both C2-amino derivatives (109 and 110; Panels A and C) managed to delay the onset of aggregation 2-
fold (t = 20 h. vs. 10 h for the Aβ40 control), while reducing the rate of aggregation. As very potent 
inhibitors, both kinetic plots showcased no plateau phase, which was indicative of ultra low fibril 
concentrations at the end of the 24 h incubation period. The C4-amino isomers (Panels B and D), on the 
other hand, did not showcase a delay in the aggregation process (at least at the 1 and 5 µM concentrations), 
but did showcase a reduction in the rates of aggregation and overall fibril load at the end of the 24 h 
incubation period. Interestingly, at the 5:1 ratio of 110-iso: Aβ40, the complete aggregation process was 
halted. Comparing 109-iso and 110-iso, it would appear that the placement of the bromine impacted the 
mode of inhibition across the concentration range – With a meta-bromine, monomeric stabilization was 
attainable with increasing concentration as seen by the time point of aggregation (10 h. vs. 12 h. vs. 15 h.), 
while para-bromine was more effective at reducing fibrillation. 
The aggregation kinetic assessment of Aβ42 with or without series-leading derivatives is showcased 
in Figure 88. As observed in Panel A–D, derivatives 109/109-iso and 110/110-iso exhibited concentration-
dependent inhibition of Aβ40 aggregation while showcasing multi-mode anti-aggregation characteristics. 
Both C2-amino derivatives (109 and 110; Panels A and C) managed to reduce the rate of aggregation and 
overall aggregate load. The kinetic plots demonstrate the greater ability of 110 to reduce Aβ42 fibrils 
compared to 109. 
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Figure 87: ThT-monitored kinetics of Aβ40 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of N4-(3-bromobenzyl)quinazoline-2,4-diamine (109) 
on the aggregation kinetics of 5 µM Aβ40. Panel (B): Impact of 1, 5 or 25 µM of N2-(3-bromobenzyl)quinazoline-2,4-
diamine (109-iso) on the aggregation kinetics of 5 µM Aβ40. Panel (C): Impact of 1, 5 or 25 µM of N4-(4-
bromobenzyl)quinazoline-2,4-diamine (110) on the aggregation kinetics of 5 µM Aβ40. Panel (D): Impact of 1, 5 or 25 
µM of N2-(4-bromobenzyl)quinazoline-2,4-diamine (110-iso) on the aggregation kinetics of 5 µM Aβ40. 
 
 
The C4-amino isomers (Panels B and D), on the other hand, did showcase minor delays in the 
aggregation process (roughly 1.5-2 h delay compared to control), but a reduction in the rates of aggregation 
was more dominant with 109-iso vs. 110-iso. While overall fibril load was reduced in a concentration-
Derivative 109-iso 
General Legend: 
 
!    ThT blank 
! Aβ40 alone  (5 µM) 
! Aβ40 + 1 µM compound (5:1 ratio)  
! Aβ40 + 5 µM compound (1:1 ratio) 
! Aβ40 + 25 µM compound (1:5 ratio) 
(B) (A) 
Derivative 109 
Derivative 110-iso Derivative 110 
0 
5 
10 
15 
20 
25 
0 5 10 15 20 25 
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e 
Time in h 
(D) (C) 
0 
5 
10 
15 
20 
25 
0 5 10 15 20 25 
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e 
Time in h 
0 
5 
10 
15 
20 
25 
0 5 10 15 20 25 
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e 
Time in h 
0 
5 
10 
15 
20 
25 
0 5 10 15 20 25 
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e 
Time in h 
N
N
HN
110
NH2
Br
N
N
HN
109
NH2
Br
N
N
NH2
N
H
Br
N
N
NH2
N
H
Br
109-iso
110-iso
 	   235 
dependent manner with both derivatives, 110-iso: managed to completely halt Aβ42 aggregation at the 5:1 
ratio tested (110-iso: Aβ42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 88: ThT-monitored kinetics of Aβ42 aggregation at 37 °C over a 24 h incubation period at pH 7.4 (Excitation = 
440 nm, Emission = 490 nm). Panel (A): Impact of 1, 5 or 25 µM of N4-(3-bromobenzyl)quinazoline-2,4-diamine (109) 
on the aggregation kinetics of 5 µM Aβ42. Panel (B): Impact of 1, 5 or 25 µM of N2-(3-bromobenzyl)quinazoline-2,4-
diamine (109-iso) on the aggregation kinetics of 5 µM Aβ42. Panel (C): Impact of 1, 5 or 25 µM of N4-(4-
bromobenzyl)quinazoline-2,4-diamine (110) on the aggregation kinetics of 5 µM Aβ42. Panel (D): Impact of 1, 5 or 25 
µM of N2-(4-bromobenzyl)quinazoline-2,4-diamine (110-iso) on the aggregation kinetics of 5 µM Aβ42. 
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8.3.3. Transmission Electron Microscopy (TEM) 
 
The assessment of amyloid morphology at the conclusion of a 24-hour incubation period at 37 °C was 
conducted on leading derivatives. This commonly employed, qualitative technique is used to corroborate 
the quantitative results from the ThT-binding assay.207, 317 Experimental setup included the incubations of 
control and test samples, at 1:1 ratios of 25 µM, in triplicate at 37 °C (with shaking) over a 24-hour 
timeline. Triplicate samples were combined after the incubation period and applied to the copper-mesh 
grids prior to imaging in the TEM. 
As observed in Figure 89, resveratrol was effective at reducing total amyloid load (Panels B and E) 
compared to control samples (Panels A and D). That said, derivative 110 (Panel C) abolished the 
aggregation process and far exceeded the inhibitory potential of resveratrol against Aβ40, while derivative 
110-iso was far more effective against Aβ42, compared to resveratrol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 89: TEM assessment of Aβ40/42 morphology with or without test compounds at the end of a 24 h, 37 °C 
incubation period at pH 7.4. Panel (A–C): 25 µM Aβ40 alone or at a 1:1 ratio with resveratrol or N4-(4-
bromobenzyl)quinazoline-2,4-diamine (110); respectively. Panel (D–F): 25 µM Aβ42 alone or at a 1:1 ratio with 
resveratrol or N2-(4-bromobenzyl)quinazoline-2,4-diamine (110-iso); respectively. White/black bars represent 500 nm. 
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8.3.4. Amyloid-β Molecular Modeling  
 
The utilization of computational software is not only useful in structure-based drug design, it is also 
employed to understand and corroborate the acquired SAR data. The assessment of ligand-receptor 
interactions was conducted between leading (or comparable) derivatives from the 2,4-diaminoquinazolines 
(98-112 and respective isomers) and the amyloid targets of interest. Based on the acquired anti-Aβ data, 
presented in Table 16, the docking interactions of 109/109-iso and 100/100-iso were investigated in both 
the dimeric and fibril model of Aβ (Aβ9-40 – PDB 2LMN) with superimpositions showcased in Figure 90.  
Considering the 2.5-fold gap in potency toward Aβ40, the unique binding interactions of 109 (C2-
amino) within the KLVFFA region (vs. 109-iso) explain the potency gap. The quinazoline scaffold of 109 
(Panel A) was stacked perpendicular over V18-F20 (~ 4–5 Å), with the 3-bromobenzyl moiety oriented 
toward the hairpin loop domain. The bromine was pointed toward the hydrophobic region of I32-L34 (~ 5–
7 Å). The ligand’s C2-amino was close to the carboxyl group of D23, but did not undergo hydrogen-
bonding interactions. In contrast, the regioisomer (109-iso, Panel A) was dominantly interacting within the 
hairpin loop domain, where the quinazoline scaffold was suspended parallel over the peptide chain, 
between D23 and K29 (~ 4–5 Å). The ligand’s C4-amino group was undergoing hydrogen-bonding 
interactions with D23’s carboxyl side chain (~ 3.2 Å), while the 3-bromobenzyl moiety was oriented over 
V24–S26 (~ 4–6 Å). Transitioning to Panel B, the observed 21-fold potency gap between 110 and 110-iso, 
along with the kinetic plot patterns in Figure 87, is corroborated in the dimer model docking. While both 
isomers are dominantly interacting within the hairpin loop domain, stronger interactions were demonstrated 
by 110 compared to 110-iso. Starting with the quinazoline scaffold, that of 110 is stacked semi-parallel 
over the S26-K28 region (~ 4–5 Å), with the C2-amino group directed toward D23-G25, although no 
hydrogen-bonding interactions were observed. The ligand’s 4-bromobenzyl moiety extends outward from 
the hairpin loop domain, running parallel to the peptide backbone with the bromophenyl ring equidistantly 
placed between D23-G25 and I31-G33 (~ 6–7 Å). On the other hand, the quinazoline scaffold of 110-iso 
was perpendicularly stacked over I31-I32 (~ 4–5 Å), allowing the C4-amino group to hydrogen-bond with 
carbonyl backbone of G33 (~ 3.1 Å), while the 4-bromobenzyl moiety extended perpendicularly toward 
N27-K28 (~ 4–6 Å). 
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Figure 90: Superimposition of docking structures. Panel (A, C): Binding modes of 109 (pink) and 109-iso (green) in 
the Aβ (Aβ9-40 – PDB 2LMN) dimer or fibril model; respectively. Panel (B, D): Binding modes of 110 (red) and 110-
iso (gold) in the Aβ (Aβ9-40 – PDB 2LMN) dimer or fibril model; respectively Hydrogens removed to enhance 
visibility. Amino acid labels to be used as a general guide as space restrictions limited complete and accurate labeling 
of all peptide structures. 
 
 
The collective comparison of both isomeric pairs in the fibril model (Figure 90, Panel C and D) 
revealed one particularly interesting observation. With a 3-bromobenzyl moiety, regardless of C2- or C4-
placement, the quinazoline scaffolds were directly intercalated within the steric zipper domain, while with a 
4-bromobenzyl moiety, it was the 4-bromophenyl rings that were directly intercalated within the steric 
zipper domain. 
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8.4. Summary 
 
With this collection of 2,4-diaminoquinazolines, Aβ targeting preferences emerged with the C2-amino 
derivatives surpassing the activity of their regioisomers against Aβ40, while the C4-amino derivatives 
surpassed the activity of their regioisomers against Aβ42.  
Overall, leading candidates were identified in N4-(4-bromobenzyl)quinazoline-2,4-diamine (100) due 
to its superior inhibitory potential toward Aβ40 (IC50 ~ 80 nM), while its regioisomer was the most potent 
and dual, non-selective Aβ inhibitor (IC50 ~ 2 µM). While bromo-based quinazolin-diamines were most 
potent overall, chloro-based bioisosteres were ranked in second place (Figure 91).  
 
 
 
Figure 91: Cumulative chapter summary of 2,4-diaminoquinazolines (98–112) and their respective regioisomers. 
 
 
 
8.5. Experimental 
 
Please note that this subsection includes re-listed methodologies from Chapter 3–7. For schematic 
representation of re-listed methodologies, if applicable, please refer to Chapter 3 and 4 – Section 3.5 or 4.5. 
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8.5.1. Chemistry 
 
General Information. All the reagents and solvents were reagent grade purchased from various vendors 
(Acros Organics, Sigma-Aldrich, and Alfa Aesar, USA) with a minimum purity of 95% and were used 
without further purification. Melting points (mp) were determined using a Fisher-Johns apparatus and are 
uncorrected. Reaction progress was monitored by UV using thin-layer chromatography (TLC) using Merck 
60F254 silica gel plates. Column chromatography was performed with Merck silica gel 60 (230−400 mesh) 
with 5:1 EtOAc:MeOH as the solvent system unless otherwise specified. Proton (1H NMR) and carbon (13C 
NMR) spectra were performed on a Bruker Avance (at 300 and 75 MHz; respectively) spectrometer using 
DMSO-d6. Coupling constants (J values) were recorded in hertz (Hz) and the following abbreviations were 
used to represent multiplets of NMR signals: s = singlet, d = doublet, t = triplet, m = multiplet, br = broad. 
Carbon multiplicities (C, CH, CH2 and CH3) were assigned by DEPT 90/135 experiments. High-resolution 
mass spectrometry (HRMS) was determined using a Thermo Scientific Q-Exactive Orbitrap mass 
spectrometer (positive mode, ESI), Department of Chemistry, University of Waterloo. Compound purity 
(roughly 95% or over) was determined using an Agilent 1100 series HPLC equipped with an analytical 
column (Agilent Zorbax Eclipse XDB-C8 column, 4.6 x 150 mm, 5 µm particle size) running 50:50 
Water:ACN with 0.1% TFA at a flow rate of 1.0-1.5 mL/min or an Agilent 6100 series single quad LCMS 
equipped with an Agilent 1.8 µm Zorbax Eclipse Plus C18 (2.1 x 50 mm) running 50:50 Water:ACN with 
0.1% FA with a flow rate of 0.5mL/min. All the final compounds exhibited ≥ 95% purity. 
 
General procedure for synthesis of 2,4-diaminoquinazoline.291, 317 In a 250 mL round-bottom 
pressure flask, 2-fluorobenzonitrile (4.6 mL, 42.32 mmol) or 2-aminobenzonitrile (5 g, 42.32 mmol) was 
combined with guanidine carbonate (11.43 g, 126.96 mmol) and diluted in 30 mL dimethylacetaminde 
(DMA). Contents are heated in an oil bath at 150 °C for overnight (~14 h) then diluted with 50mL of water 
before extracting thrice with EtOAc (50 mL x 3) and washing with brine (2x 20 mL). Combined organic 
layer was dried with MgSO4 and concentrated in vacuo before purifying with silica gel column 
chromatography using 5:1 EtOAc/MeOH to afford an off-white solid at 80% yield. 1H NMR (300 MHz, 
DMSO- d6) δ 7.91 (d, 7.8 Hz, 1H), δ 7.41 (t, J = 7.8 Hz, 1H), δ 7.21 (br s, 2H), δ 7.15 (d, J = 8.1 Hz, 1H), δ 
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6.95 (t, J = 7.2 Hz, 1H), δ 5.91 (br s, 2H). 13C NMR (100 MHz, DMSO- d6) δ 162.45, δ 160.75, δ 152.52, δ 
132.30, δ 124.22, δ 123.52, δ 119.73, δ 110.34. 
 
General procedure for synthesis of N4-substituted-quinazoline-2,4-diamines.317 In a 50 mL round-
bottom flask, 2,4-diaminoquinazoline* (1 g, 6.24 mmol) was dissolved in 3 mL DMSO. With stirring and 
periodic cooling over ice-water, NaH (60%, 0.25 g, 6.24 mmol) was added over a 10–15 min. period. After 
complete addition of NaH, flask was stirred at room temperature with slow, dropwise addition of the 
appropriate alkyl/aryl halide (6.24 mmol) dissolved in 3 mL DMSO. Contents are allowed to stir at room 
temperature overnight (~14 h) before diluting with 20 mL of water and stirring at room temperature for 15 
min. The mixture is extracted thrice with diethyl ether (40 mL x 3). The combined organic layers are 
washed twice with brine (20 mL x 2). Combined organic layer was dried with MgSO4 and concentrated in 
vacuo before purifying with silica gel column chromatography using 5:1 EtOAc/MeOH to afford beige to 
off-white solids at 20-31% yield.  
 
N4-Propylquinazoline-2,4-diamine (98). Yield: 20% (0.25 g, 1.24 mmol); Mp: 121–123 °C; 1H NMR 
(300 MHz, DMSO- d6): δ 8.09–7.95 (m, 2H), δ 7.47 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), δ 7.19 (dd, J = 8.4, 1.2 
Hz, 1H), δ 7.03 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), δ 6.28 (s, 2H), δ 3.43–3.36 (m, 2H), δ 1.61 (h, J = 7.4 Hz, 
2H), δ 0.89 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z calcd for C11H14N4 [M+1]+ 203.12912, observed 
203.12911.  
 
N4-Isopropylquinazoline-2,4-diamine (99). Yield: 19% (0.24 g, 1.19 mmol); Mp: 131–133 °C; 1H NMR 
(300 MHz, DMSO- d6): δ 8.25–8.02 (m, 2H), δ 7.54 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), δ 7.24 (dd, J = 8.4, 1.1 
Hz, 1H), δ 7.12 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), δ 6.72 (s, 2H), δ 4.47 (h, J = 6.7 Hz, 1H), δ 1.22 (d, J = 6.6 
Hz, 6H). HRMS (ESI) m/z calcd for C11H14N4 [M+1]+ 203.12912, observed 203.12908.  
 
N4-(Cyclohexylmethyl)quinazoline-2,4-diamine (100). Yield: 20% (0.32 g, 1.25 mmol); Mp: 108–110 
°C; 1H NMR (300 MHz, DMSO-d6): δ 8.48 (s, 1H), δ 8.12 (d, J = 8.2 Hz, 1H), δ 7.57 (t, J = 7.7 Hz, 1H), δ 
7.27 (d, J = 8.3 Hz, 1H), δ 7.15 (t, J = 7.6 Hz, 1H), δ 6.82 (s, 2H), δ 1.74 – 1.56 (m, 7H), δ 1.16 (t, J = 10.6 
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Hz, 4H), δ 0.94 (t, J = 11.3 Hz, 2H). HRMS (ESI) m/z calcd for C15H20N4 [M+1]+ 257.17607, observed 
257.17589. 
 
N4-(3-Methylbenzyl)quinazoline-2,4-diamine (101). Yield: 24% (0.39 g, 1.48 mmol); Mp: 117–119 °C; 
1H NMR (300 MHz, DMSO-d6): δ 8.80 (s, 1H), δ 8.09 (d, J = 8.2 Hz, 1H), δ 7.53 (ddd, J = 8.3, 7.0, 1.3 Hz, 
1H), δ 7.25 (dd, J = 8.4, 1.1 Hz, 1H), δ 7.21–7.05 (m, 4H), δ 7.02 (dd, J = 5.5, 3.3 Hz, 1H), δ 6.56 (s, 2H), 
δ 4.69 (d, J = 5.7 Hz, 2H), δ 2.25 (s, 3H). HRMS (ESI) m/z calcd for C16H16N4 [M+1]+ 265.14477, 
observed 265.14469. 
 
N4-(4-Methylbenzyl)quinazoline-2,4-diamine (102). Yield: 21% (0.35 g, 1.33 mmol); Mp: 113-115 °C; 
1H NMR (300 MHz, DMSO-d6): δ 8.95 (s, 1H), δ 8.11 (d, J = 8.0 Hz, 1H), δ 7.56 (ddd, J = 8.4, 7.0, 1.3 Hz, 
1H), δ 7.24 (d, J = 8.3 Hz, 3H), δ 7.11 (t, J = 8.9 Hz, 3H), δ 6.74 (s, 2H), δ 4.68 (d, J = 5.8 Hz, 2H), δ 2.24 
(s, 3H). HRMS (ESI) m/z calcd for C16H16N4 [M+1]+ 265.14477, observed 265.14467. 
 
N4-(3-Methoxybenzyl)quinazoline-2,4-diamine (103). Yield: 20% (0.35 g, 1.25 mmol); Mp: 132–134 °C; 
1H NMR (300 MHz, DMSO-d6): δ 8.89 (s, 1H), δ 8.11 (d, J = 8.2 Hz, 1H), δ 7.55 (ddd, J = 8.4, 6.9, 1.3 Hz, 
1H), δ 7.31–7.06 (m, 3H), δ 6.97–6.87 (m, 2H), δ 6.78 (ddd, J = 8.2, 2.5, 1.2 Hz, 1H), δ 6.64 (s, 2H), δ 4.70 
(d, J = 5.6 Hz, 2H), δ 3.69 (s, 3H). HRMS (ESI) m/z calcd for C16H16N4O [M+1]+ 281.13969, observed 
281.13964. 
 
N4-(4-Methoxybenzyl)quinazoline-2,4-diamine (104). Yield: 25% (0.44 g, 1.57 mmol); Mp: 140–142 °C; 
1H NMR (300 MHz, DMSO-d6): δ 9.77 (d, J = 6.2 Hz, 1H), δ 8.29 (d, J = 8.2 Hz, 1H), δ 7.69 (t, J = 7.7 Hz, 
1H), δ 7.62 (s, 1H), δ 7.44–7.23 (m, 5H), δ 6.86 (d, J = 8.3 Hz, 2H), δ 4.68 (d, J = 5.7 Hz, 2H), 3.69 (s, 
3H). HRMS (ESI) m/z calcd for C16H16N4O [M+1]+ 281.13969, observed 281.13963. 
 
N4-(3-(Trifluoromethyl)benzyl)quinazoline-2,4-diamine (105). Yield: 19% (0.37 g, 1.16 mmol); Mp: 
104–106 °C; 1H NMR (300 MHz, DMSO-d6): δ 9.00 (d, J = 6.5 Hz, 1H), δ 8.10 (d, J = 8.1 Hz, 1H), δ 7.75–
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7.64 (m, 2H), δ 7.61–7.49 (m, 3H), δ 7.27 (d, J = 8.2 Hz, 1H), δ 7.14 (t, J = 7.5 Hz, 1H), δ 6.69 (s, 2H), δ 
4.80 (d, J = 5.6 Hz, 2H). HRMS (ESI) m/z calcd for C16H13F3N4 [M+1]+ 319.11651, observed 319.11637. 
 
N4-(4-(Trifluoromethyl)benzyl)quinazoline-2,4-diamine (106). Yield: 20% (0.40 g, 1.26 mmol); Mp: 
110–112 °C; 1H NMR (300 MHz, DMSO-d6): δ 8.51 (s, 1H), δ 8.00 (d, J = 8.1 Hz, 1H), δ 7.65 (d, J = 8.1 
Hz, 2H), δ 7.59–7.37 (m, 3H), δ 7.19 (d, J = 8.0 Hz, 1H), δ 7.03 (t, J = 7.6 Hz, 1H), δ 6.07 (s, 2H), δ 4.77 
(d, J = 5.9 Hz, 2H). HRMS (ESI) m/z calcd for C16H13F3N4 [M+1]+ 319.11651, observed 319.11647. 
 
N4-(3-Chlorobenzyl)quinazoline-2,4-diamine (107). Yield: 23% (0.41 g, 1.44 mmol); Mp: 117-119 °C; 
1H NMR (300 MHz, DMSO-d6): δ 9.12 (s, 1H), δ 8.14 (dd, J = 8.3, 1.3 Hz, 1H), δ 7.59 (ddd, J = 8.4, 7.1, 
1.3 Hz, 1H), δ 7.42 (d, J = 1.9 Hz, 1H), δ 7.35 – 7.28 (m, 4H), δ 7.23 – 7.11 (m, 1H), δ 6.86 (s, 2H), δ 4.73 
(d, J = 5.4 Hz, 2H). HRMS (ESI) m/z calcd for C15H13ClN4 [M+1]+ 285.09015, observed 285.09006.  
 
N4-(4-Chlorobenzyl)quinazoline-2,4-diamine (108). Yield: 26% (0.46 g, 1.62 mmol); Mp: 132–134 °C; 
1H NMR (300 MHz, DMSO-d6): δ 9.11 (t, J = 6.0 Hz, 1H), δ 8.13 (dd, J = 8.3, 1.3 Hz, 1H), δ 7.58 (ddd, J 
= 8.3, 7.0, 1.2 Hz, 1H), δ 7.44–7.31 (m, 4H), δ 7.28 (d, J = 8.3 Hz, 1H), δ 7.24–7.10 (m, 1H), δ 6.81 (s, 
2H), δ 4.70 (d, J = 5.5 Hz, 2H). HRMS (ESI) m/z calcd for C15H13ClN4 [M+1]+ 285.09015, observed 
285.09005.  
 
N4-(3-Bromobenzyl)quinazoline-2,4-diamine (109). Yield: 24% (0.49 g, 1.49 mmol); Mp: 127-129 °C; 
1H NMR (300 MHz, DMSO-d6): δ 8.99 (s, 1H), δ 8.10 (dd, J = 8.2, 1.4 Hz, 1H), δ 7.60–7.51 (m, 2H), δ 
7.44–7.33 (m, 2H), δ 7.27 (d, J = 7.9 Hz, 2H), δ 7.15 (s, 1H), δ 6.72 (s, 2H), δ 4.71 (d, J = 5.7 Hz, 2H). 
HRMS (ESI) m/z calcd for C15H13BrN4 [M+1]+ 329.03964, observed 329.03968. 
 
N4-(4-Bromobenzyl)quinazoline-2,4-diamine (110). Yield: 29% (0.60 g, 1.83 mmol); Mp: 116–118 °C; 
1H NMR (300 MHz, DMSO-d6): δ 7.95 (d, J = 8.1 Hz, 1H), δ 7.46 (q, J = 12.2, 10.0 Hz, 2H), δ 7.36–7.10 
(m, 7H), δ 7.02 (t, J = 7.5 Hz, 1H), δ 4.54 (d, J = 6.3 Hz, 2H). HRMS (ESI) m/z calcd for C15H13BrN4 
[M+1]+ 329.03964, observed 329.03965. 
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N4-(3-Fluorobenzyl)quinazoline-2,4-diamine (111). Yield: 24% (0.40 g, 1.49 mmol); Mp: 118–120 °C; 
1H NMR (300 MHz, DMSO-d6): δ 8.92 (t, J = 5.9 Hz, 1H), δ 8.10 (dd, J = 8.3, 1.3 Hz, 1H), δ 7.55 (ddd, J = 
8.3, 6.9, 1.3 Hz, 1H), δ 7.40–6.97 (m, 6H), δ 6.62 (s, 2H), δ 4.72 (d, J = 5.6 Hz, 2H). HRMS (ESI) m/z 
calcd for C15H13FN4 [M+1]+ 269.11970, observed 269.11956. 
 
N4-(4-Fluorobenzyl)quinazoline-2,4-diamine (112). Yield: 28% (0.47 g, 1.75 mmol); Mp: 123–125 °C; 
1H NMR (300 MHz, DMSO-d6): δ 9.08 (d, J = 7.0 Hz, 1H), δ 8.12 (d, J = 8.1 Hz, 1H), δ 7.58 (t, J = 7.6 Hz, 
1H), δ 7.45–7.37 (m, 2H), δ 7.28 (d, J = 8.3 Hz, 1H), δ 7.17–7.08 (m, 3H), δ 6.85 (s, 2H), δ 4.70 (d, J = 5.7 
Hz, 2H). HRMS (ESI) m/z calcd for C15H13FN4 [M+1]+ 269.11970, observed 269.11958.  
 
 
General procedure for synthesis of N2-substituted-quinazoline-2,4-diamines.317 In a 50 mL round-
bottom flask, 2,4-diaminoquinazoline (1 g, 6.24 mmol) was dissolved in 20 mL DMA followed by the 
addition of potassium carbonate (0.85 g, 6.24 mmol) and the appropriate alkyl/aryl halide (6.24 mmol) at 
room temperature. Contents are refluxed at 80–85 °C for 5 h before diluting with 30 mL of water and 
stirring at R.T for 15 min. The mixture is extracted thrice with EtOAc (50 mL x 3). The combined organic 
layers are washed twice with brine (20 mL x 2). Combined organic layer was dried with MgSO4 and 
concentrated in vacuo before purifying with silica gel column chromatography using 5:1 EtOAc/MeOH to 
afford beige to off-white solids at 14–26% yield. 
 
N2-Propylquinazoline-2,4-diamine (98-iso). Yield: 16% (0.20 g, 0.99 mmol); Mp: 159–161 °C; 1H NMR 
(300 MHz, DMSO-d6): δ 8.05 (d, J = 8.2 Hz, 1H), δ 7.57 (d, J = 7.9 Hz, 1H), δ 7.35 (d, J = 8.4 Hz, 1H), δ 
7.14 (s, 1H), δ 3.32–3.26 (m, 2H), δ 1.53 (h, J = 7.4 Hz, 2H), δ 0.87 (t, J = 7.4 Hz, 3H). HRMS (ESI) m/z 
calcd for C11H14N4 [M+1]+ 203.12912, observed 203.12912.  
 
N2-Isopropylquinazoline-2,4-diamine (99-iso). Yield: 14% (0.18 g, 0.89 mmol); Mp: 127–129 °C; 1H 
NMR (300 MHz, DMSO-d6): δ 8.07 (d, J = 8.1 Hz, 1H), δ 7.60 (t, J = 7.7 Hz, 1H), δ 7.35 (d, J = 8.4 Hz, 
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1H), δ 7.16 (t, J = 7.7 Hz, 1H), δ 4.16 (h, J = 6.7 Hz, 1H), δ 1.15 (d, J = 6.5 Hz, 6H). HRMS (ESI) m/z 
calcd for C11H14N4 [M+1]+ 203.12912, observed 203.12912.  
 
N2-(Cyclohexylmethyl)quinazoline-2,4-diamine (100-iso). Yield: 25% (0.40 g, 1.56 mmol); Mp: 193–
195 °C; 1H NMR (300 MHz, DMSO-d6): δ 9.00 (d, J = 31.9 Hz, 1H), δ 8.17 (d, J = 8.1 Hz, 1H), δ 7.76 (t, J 
= 7.7 Hz, 1H), δ 7.36 (t, J = 7.7 Hz, 1H), δ 1.63 (dd, J = 22.6, 10.7 Hz, 6H), δ 1.18 (d, J = 12.5 Hz, 5H), δ 
0.93 (q, J = 10.7, 10.1 Hz, 2H). HRMS (ESI) m/z calcd for C15H20N4 [M+1]+ 257.17607, observed 
257.17598. 
 
N2-(3-Methylbenzyl)quinazoline-2,4-diamine (101-iso). Yield: 18% (0.30 g, 1.14 mmol); Mp: 104-106 
°C; 1H NMR (300 MHz, DMSO-d6): δ 8.03 (d, J = 8.2 Hz, 1H), 7.57 (s, 1H), 7.31 (d, J = 8.3 Hz, 1H), 
7.19–7.08 (m, 4H), 7.00 (d, J = 7.3 Hz, 1H), 4.54 (d, J = 6.2 Hz, 2H), 2.24 (s, 3H). HRMS (ESI) m/z calcd 
for C16H16N4 [M+1]+ 265.14477, observed 265.14465. 
 
N2-(4-Methylbenzyl)quinazoline-2,4-diamine (102-iso). Yield: 20% (0.33 g, 1.25 mmol); Mp: 109–111 
°C; 1H NMR (300 MHz, DMSO-d6): δ 7.96 (d, J = 8.1 Hz, 1H), δ 7.48 (t, J = 7.7 Hz, 1H), δ 7.27–7.15 (m, 
3H), δ 7.10–6.97 (m, 4H), δ 4.49 (d, J = 6.2 Hz, 2H), δ 2.22 (s, 3H). HRMS (ESI) m/z calcd for C16H16N4 
[M+1]+ 265.14477, observed 265.14465. 
 
N2-(3-Methoxybenzyl)quinazoline-2,4-diamine (103-iso). Yield: 17% (0.29 g, 1.04 mmol); Mp: 147–149 
°C; 1H NMR (300 MHz, DMSO-d6): δ 7.97 (d, J = 8.1 Hz, 1H), δ 7.50 (t, J = 7.8 Hz, 1H), δ 7.28–7.12 (m, 
2H), δ 7.05 (t, J = 7.5 Hz, 1H), δ 6.93–6.78 (m, 2H), δ 6.78–6.69 (m, 1H), δ 4.51 (d, J = 6.3 Hz, 2H), δ 3.68 
(s, 3H). HRMS (ESI) m/z calcd for C16H16N4O [M+1]+ 281.13969, observed 281.13964. 
 
N2-(4-Methoxybenzyl)quinazoline-2,4-diamine (104-iso). Yield: 21% (0.36 g, 1.29 mmol); Mp: 139–141 
°C; 1H NMR (300 MHz, DMSO-d6): δ 8.01 (d, J = 8.1 Hz, 1H), δ 7.81–6.92 (m, 7H), δ 6.89–6.77 (m, 2H), 
δ 4.48 (d, J = 6.0 Hz, 2H), δ 3.68 (d, J = 1.3 Hz, 3H). HRMS (ESI) m/z calcd for C16H16N4O [M+1]+ 
281.13969, observed 281.13961. 
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N2-(3-(Trifluoromethyl)benzyl)quinazoline-2,4-diamine (105-iso). Yield: 15% (0.30 g, 0.94 mmol); Mp: 
118–120 °C; 1H NMR (300 MHz, DMSO-d6): δ 7.99 (d, J = 8.1 Hz, 1H), δ 7.69 – 7.62 (m, 3H), δ 7.55–
7.47 (m, 5H), δ 7.24 (d, J = 8.3 Hz, 1H), δ 7.05 (d, J = 7.6 Hz, 1H), δ 4.62 (d, J = 6.2 Hz, 2H). HRMS 
(ESI) m/z calcd for C16H13F3N4 [M+1]+ 319.11651, observed 319.11638. 
 
N2-(4-(Trifluoromethyl)benzyl)quinazoline-2,4-diamine (106-iso). Yield: 16% (0.32 g, 1.00 mmol); Mp: 
124–126 °C; 1H NMR (300 MHz, DMSO-d6): δ 7.98 (d, J = 8.2 Hz, 1H), δ 7.63 (d, J = 8.1 Hz, 2H), δ 7.53 
(d, J = 8.2 Hz, 4H), δ 7.24 (d, J = 8.3 Hz, 1H), δ 7.08 (d, J = 8.2 Hz, 1H), δ 4.62 (d, J = 6.2 Hz, 2H). 
HRMS (ESI) m/z calcd for C16H13F3N4 [M+1]+ 319.11651, observed 319.11647. 
 
N2-(3-Chlorobenzyl)quinazoline-2,4-diamine (107-iso). Yield: 16% (0.28 g, 0.99 mmol); Mp: 121–123 
°C; 1H NMR (300 MHz, DMSO-d6): δ 7.95 (s, 1H), δ 7.49 (s, 1H), δ 7.36 (s, 1H), δ 7.28–7.21 (m, 6H), δ 
7.03 (t, J = 7.5 Hz, 2H), δ 4.52 (s, 2H). HRMS (ESI) m/z calcd for C15H13ClN4 [M+1]+ 285.09015, 
observed 285.09008.  
 
N2-(4-Chlorobenzyl)quinazoline-2,4-diamine (108-iso). Yield: 19% (0.34 g, 1.20 mmol); Mp: 128-130 
°C; 1H NMR (300 MHz, DMSO-d6): δ 7.97 (d, J = 8.1 Hz, 1H), δ 7.49 (t, J = 7.9 Hz, 1H), δ 7.42 – 7.13 (m, 
7H), δ 7.04 (t, J = 7.5 Hz, 2H), δ 4.51 (d, J = 6.3 Hz, 2H). HRMS (ESI) m/z calcd for C15H13ClN4 [M+1]+ 
285.09015, observed 285.09007.  
 
N2-(3-Bromobenzyl)quinazoline-2,4-diamine (109-iso). Yield: 21% (0.43 g, 1.31 mmol); Mp: 108–110 
°C; 1H NMR (300 MHz, DMSO-d6): δ 7.95 (d, J = 8.1 Hz, 1H), δ 7.49 (d, J = 6.0 Hz, 2H), δ 7.34 (dd, J = 
12.6, 7.6 Hz, 3H), δ 7.27–7.19 (m, 3H), δ 7.03 (t, J = 7.5 Hz, 2H), δ 4.52 (d, J = 6.4 Hz, 2H). HRMS (ESI) 
m/z calcd for C15H13BrN4 [M+1]+ 329.03964, observed 329.03958. 
 
N2-(4-Bromobenzyl)quinazoline-2,4-diamine (110-iso). Yield: 22% (0.46 g, 1.40 mmol); Mp: 119–121 
°C; 1H NMR (300 MHz, DMSO-d6): δ 7.98 (d, J = 8.2 Hz, 1H), δ 7.58–7.18 (m, 8H), δ 7.14–7.00 (m, 2H), 
δ 4.50 (d, J = 6.3 Hz, 2H). HRMS (ESI) m/z calcd for C15H13BrN4 [M+1]+ 329.03964, observed 329.03952. 
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N2-(3-Fluorobenzyl)quinazoline-2,4-diamine (111-iso). Yield: 20% (0.33 g, 1.23 mmol); Mp: 138–140 
°C; 1H NMR (300 MHz, DMSO-d6): δ 8.01–7.91 (m, 1H), δ 7.48 (t, J = 7.7 Hz, 1H), δ 7.30 (td, J = 7.9, 6.1 
Hz, 1H), δ 7.27–6.93 (m, 6H), δ 4.54 (d, J = 6.3 Hz, 2H). HRMS (ESI) m/z calcd for C15H13FN4 [M+1]+  
269.11970, observed 269.11954. 
 
N2-(4-Fluorobenzyl)quinazoline-2,4-diamine (112-iso). Yield: 20% (0.34 g, 1.27 mmol); Mp: 144–146 
°C; 1H NMR (300 MHz, DMSO-d6): δ 7.97 (d, J = 8.1 Hz, 1H), δ 7.49 (t, J = 7.7 Hz, 1H), δ 7.35 (dd, J = 
8.3, 5.6 Hz, 2H), δ 7.23 (d, J = 8.4 Hz, 1H), δ 7.07 (dd, J = 10.4, 7.5 Hz, 3H), δ 4.51 (d, J = 6.1 Hz, 2H). 
HRMS (ESI) m/z calcd for C15H13FN4 [M+1]+ 269.11970, observed 269.11953. 
 
 
8.5.2. Biological Screening 
 
8.5.2.1. Amyloid-β (Aβ) Aggregation Assay317 
 
The ability of quinazoline-based derivatives to inhibit Aβ-aggregation kinetics was determined using a 
ThT-binding fluorescence assay. These assays were conducted in Costar, black-surround, clear-bottom 
384-well plates with frequent shaking (30 sec. of linear shaking at 730 cpm every 5 minutes) and constant 
heating at 37 °C for 24 h. The ThT excitation/emission was measured at 440 nm/490 nm and readings were 
taken every 5 minutes using a BioTek Synergy H1 microplate reader. Quinazoline stock solutions were 
prepared in DMSO and diluted to 10x in 215 mM phosphate buffer at pH 7.4. Abeta.HFIP samples (Aβ40 
or Aβ42, rPeptide, Bogart, USA) were dissolved in 1% ammonium hydroxide, sonicated at room 
temperature for 5 minutes then diluted to 50 µM in 215 mM phosphate buffer (pH 7.4). A 15 µM ThT stock 
solution was prepared with 50 mM glycine and adjusted to pH 7.4. The assay was carried out by adding 44 
µL ThT, 20–35 µL buffer, 1 µL DMSO (for background and controls only) followed by the addition of 8 
µL of 10x compound dilutions (1–25 µM concentration range). An end point reading was conducted to 
evaluate potential test compound interference with ThT-fluorescence before adding 8 µL of Aβ40 or Aβ42 
stock solutions (5 µM final concentration). Plates were sealed with a transparent plate film before initiating 
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the assay. RFU values were corrected for ThT-interference before calculating end point percent inhibitions 
or IC50 values and obtaining the aggregation kinetic plots. Data presented was an average of triplicate 
reading for two-three independent experiments. 
 
 
8.5.2.2. TEM Assay and Imaging142, 190, 207, 317 
 
In Costar 96-well, round-bottom plates were added 80 µL of 215 mM phosphate buffer, 20 µL of 10x 
test compound dilutions (250 µM – prepared in the same way as for the ThT assay) and 100 µL of 50 µM 
Aβ40 or Aβ42 respectively.  For the control wells, 2 µL of DMSO and 18 µL of phosphate buffer was 
added. Final Aβ: test compound ratio was 1:1 (25 µM). Plates were incubated on a Fisher plate incubator 
set to 37 °C and the contents were shaken at 730 cpm for 24 h. To prepare the TEM grids, ~ 20 µL droplet 
was added using a disposable Pasteur pipette over the formvar-coated copper grids (400 mesh). Grids were 
air-dried for about 3 h before adding two droplets (~ 40 µL, using a disposable Pasteur pipette) of ultra-
pure water and using small pieces of filter paper to wash out precipitated buffer salts. After air-drying for ~ 
15-20 min, the grids were negatively stained by adding a droplet (~ 20 µL, using a disposable Pasteur 
pipette) of 2% phosphotungstic acid (PTA) and immediately after the grids were dried using small pieces of 
filter paper. Grids were further air-dried overnight. The scanning was carried out using a Philips CM 10 
transmission electron microscope at 60 kV (Department of Biology, University of Waterloo) and 
micrographs were obtained using a 14-megapixel AMT camera. 
 
 
8.5.3. Computational Chemistry299, 313, 317, 324 
 
The molecular docking studies were conducted using Discovery Studio 4.0 (Structure-Based-Design 
program) from BIOVIA Inc. San Diego, USA. Select quinazolines derivatives were built and minimized 
using the small molecules module in Discovery Studio. X-ray coordinates of human cholinesterases were 
obtained from the protein data bank (hAChE PBD ID: 1B41 and hBuChE PDB ID: 1P0I) and prepared 
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using the macromolecules module in Discovery Studio. Ligand binding sites were defined by selecting a 12 
Å radius sphere for AChE and 15 Å radius sphere for BuChE. The molecular docking was performed using 
the receptor-ligand interactions module in Discovery Studio. The LibDock algorithm was used to find the 
most appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. For Amyloid-β docking studies, the NMR solution structure of Aβ fibrils were 
obtained from the protein data bank (PDB ID: 2LMN). Aβ dimer and Aβ fibril assemblies were built using 
the macromolecules module in Discovery Studio. Ligand binding site was defined by selecting a 15 Å 
radius sphere for both Aβ assemblies. Molecular docking was performed using the receptor-ligand 
interactions module in Discovery Studio, where the LibDock algorithm was used to find the most 
appropriate binding modes for select quinazoline derivatives using CHARMm force field. The docked 
poses obtained were ranked based on the LibDock scores and were analyzed by evaluating all the polar and 
nonpolar interactions. 
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CHAPTER 9 
  Conclusions and Future Outlook   
 
Over its hundred plus years of research history, the field of dementia sciences has accomplished 
numerous milestones in furthering our knowledge of neurodegenerative disease. That history is also 
flagged with countless setbacks with respect to diagnosis and therapeutic interventions.  As with many 
aspects of life, one grows stronger when acknowledging and learning from any given setbacks or failures. 
The dementia research community has seen a paradigm-shift with respect to developing therapeutic 
interventions for Alzheimer’s disease. As our understanding of disease pathology continues to grow, it has 
become more relevant to develop multi-targeting therapeutics considering their higher probability of 
demonstrating disease-modifying effects. 
Over the course of the research program, a chemical library of 127 derivatives based on the 
quinazoline ring scaffold (and related templates) were developed and screened against multiple targets 
associated with AD pathology (AChE, BuChE, Aβ40/42 aggregation, ROS species and metal ions such as 
Fe2+).  
The design strategy was influenced by the diversity and vast utility of quinazoline and quinazoline-
related scaffolds in medicinal chemistry, along with previously reported studies on the smaller pyrimidine 
ring scaffold. Synthetic methodology was N.A.S-dominant, but included some cyclization reactions, 
catalyst-dependent reductions and hydrolysis steps). By far the most challenging aspect of the synthetic 
scheme was the POCl3-based chlorination step that yielded the critical di- or tri-chloroquinazoline 
intermediates. Biological assessments were accomplished using previously established or refurbished 
methods to obtain the necessary SAR data. Molecular modeling studies were conducted to investigate the 
docking of lead derivatives within the target enzymes and to corroborate their biological profiles. A 
collective summary of the various parameters for library characterization is presented below: 
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–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
o Molecular Weights (MWs): 202.3 – 483.6 gmol-1 
o Molecular Volumes: 132.9 – 400.3 Å3 
o Partition Coefficients (ClogPs): 1.8 – 6.6 
o hAChE Inhibition Range (IC50): 2.1 µM – 15.0 µM  
o hBuChE Inhibition Range (IC50): 90 nM – 50+ µM  
o Aβ40 Aggregation Inhibition: 80 nM – Not active 
o Aβ42 Aggregation Inhibition: 1.3 µM – Not active 
o Antioxidant Capacity: 33% – 63% at 50 µM  
o Iron Chelating Capacity: 15% – 37% at 50 µM  
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
While appropriate chapters included their particular metrics with respect to cholinesterase and/or 
amyloid-β data, the cumulative metrics are displayed below to assist in the identification of lead candidates 
from the collective library (Figure 92). 
  
As indicated through the cumulative metrics, no single derivative (out of the 97) exhibited IC50 values 
within the 0–5 µM range across the four primary targets. In addition, derivatives showcasing antioxidant or 
iron chelating capacities were moderate to weak AChE inhibitors, inactive toward BuChE and moderate to 
weakAβ40/42 aggregation inhibitors. That said, 4 of the 5 leading candidates in Figure 92 were derived 
from Chapter 7 – the phenethylamine-based series. Of those 4 top leading candidates, 85 (8-chloro-N2-
isopropyl-N4-phenethylquinazoline-2,4-diamine) exhibited IC50 values within the 0–5 µMrange for 
Aβ40/42 and BuChE, while the AChE IC50 was ~ 9 µM. While the quinazoline library contained 35–40 
candidates (~ 30% of library size) with nanomolar to low micromolar IC50 values toward Aβ40 
aggregation, it was essential to recall the primary goal of identifying multi-targeting derivatives. 
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Figure 92: Collective metrics for complete quinazoline-based library. Selections were based on good to moderate 
activity against all 4 primary targets. (Notes: As Chapter 8 diaminoquinazolines were only assessed for Aβ aggregation, 
they were included in the Aβ pie charts but not considered during leading candidate selection. Derivatives screened for 
antioxidant and chelation capacities were not identified as complete multi-targeting candidates; hence those metrics 
were not included here). 
 
 
è   In terms of general observations: 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
o While placement of an azide moiety at the C2-position of the quinazoline scaffold was not particularly 
favourable toward ChE inhibition, few derivatives showed good activity toward Aβ aggregation 
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inhibition. It is plausible that, they may offer a more desirable outcome if placed elsewhere in the 
molecule. 
o While placement of carbonyl moieties (at least amides) at the C2-position of the quinazoline scaffold 
was not useful against BuChE, they did provide valuable SAR toward other targets of interest.  
o The 3,4-dimethoxy moiety at the C4-position was favoured for enhancing AChE targeting but that 
usually came at the cost of BuChE inhibition.  
o The additional methylene linker at the C4-position yielded more positive outcomes compared its 
absence. 
o The transition from the quinazoline scaffold to the chlorinated quinazoline scaffolds yielded more 
positive outcomes, especially toward Aβ targeting.  
o The transition from the quinazoline scaffold to the pyridopyrimidine scaffold was not effective 
considering the null effects on AChE, loss of BuChE activity and reduced activities toward Aβ40. 
While they did provide moderate levels of Fe2+ chelation, further optimization with that scaffold is 
required. 
o Regioisomeric investigations highlighted the preference/selectivity of C2-alkylated derivatives toward 
more hydrophobic targets, like BuChE and Aβ42 (compared to their C4-alkylated isomers). 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
 
èWith respect to future studies regarding this research program, some short/mid-term goals include: 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
o Cholinesterase assessment of diaminoquinazolines (from Chapter 8) as that could alter existing leading 
candidate selections. Halogen-based derivatives, in particular, would be of keen interest considering 
their strong anti-Aβ activities.  
o Establishing MTT toxicity profiles for leading candidates, especially considering their higher ClogP 
values. Furthermore, establishing co-incubation toxicity profiles with Aβ and leading derivatives would 
provide key insight into their anti-Aβ-induced toxicity potential. 
o Assessment of top candidates toward tau aggregation as a 5th primary target. 
o Establishing some pharmacokinetic profiles for leading candidates to assess preclinical eligibility. 
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o Potential re-purposing of weaker candidates toward oncology targets. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
 
è On the other hand, further optimization and/or project expansion could incorporate: 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
o Assessments of other quinazoline-related scaffolds, such as quinoline or tetrahydroquinazoline. 
o Expansions to the nature and size of the alkylamines utilized at the C2-position. Small cyclic amines 
would be worthy of assessment. 
o Off-scaffold chelation centers and/or phenolic moieties for antioxidant capacity. 
o Comparisons of quinazoline-2,4-diols or quinazoline-2,4-dithiols to the quinazoline-2,4-diamines. 
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
 
It was interesting to observe the narrower inhibitory window of these derivatives toward AChE (as 
compared to BuChE) and perhaps performing some molecular dynamic studies or competitive-binding 
assays would help explain these observations. With respect to Aβ activity, a wide range of inhibitory 
activity was observed., indicating that these quinazoline scaffolds can be further explored and utilized in 
anti-Aβ research programs. 
In summary, the SAR data obtained for the quinazoline libraries (3,4-dimethoxybenzyl, benzyl, 3,4-
dimethoxyphenethyl and phenethyl series) yielded several interesting findings and validated the hypothesis 
that a quinazoline-scaffold is a versatile ring system that can be modified to design small molecules as 
potential multi-targeting agents to treat AD. In addition, these quinazoline based small molecules have the 
potential to be used as pharmacological tools to investigate and understand the mechanisms of protein 
aggregation. With current evidence strongly supporting the mandate to develop multi-pronged approaches 
to achieve the desired disease-modifying effects, the results discussed here could aid in the formulation of 
new drug development strategies to the deviate from the “one drug, one target” approach and yield newer 
generation therapies for AD patients.  
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  Appendices   
 
Appendix I: Sample spectra for Chapter 2  
 
Section A: NMR 
 
 
 
* Spectra generated using ChemDraw Professional 15.0 
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Appendix II: Sample spectra for Chapter 3  
Section A: NMR 
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Section B: HRMS 
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Section C: HPLC 
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Appendix III: Sample spectra for Chapter 4  
Section A: NMR 
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Section B: HRMS 
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Section C: HPLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
N
NH
NH
25 O
NH2
N
N
OH
NH
23
 	   266 
Appendix IV: Sample spectra for Chapter 5 
 
Section A: NMR 
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Section B: HRMS 
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 Section C: HPLC 
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Appendix V: Sample spectra for Chapter 6 
 
Section A: NMR 
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Section B: HRMS 
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Section C: HPLC 
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Appendix VI: Sample spectra for Chapter 7 
 
Section A: NMR 
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Section B: HRMS 
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Section C: HPLC 
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Appendix VII: Sample spectra for Chapter 8  
 
Section A: NMR 
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Section B: HRMS 
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Section C: HPLC 
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